Final Program Programme Final - CANO-ACIO

Transcription

Final
Program
Programme
Final
Lundbeck
in oncology
We believe in being open to new knowledge. But even
more, our sense of humanity defines how we reach out
to another human being and the world around us.
We have created an animated video aimed at helping
children better understand cancer in the family and
help them cope with the situation. If you think that
this video could be helpful for your patient, it is located
at http://www.lundbeck.com/ca/en/therapeutic-areas/
oncology.
Lundbeck
en oncologie
Nous croyons en l’ouverture d’esprit face aux nouvelles
connaissances. En outre, ce qui nous définit le plus est
notre sens de l’humanité et la façon dont nous tendons
la main à ceux qui nous entourent.
Nous avons créé une vidéo d’animation dont l’objectif
est d’aider les enfants à mieux comprendre le cancer
lorsqu’il survient dans leur famille et à faire face à
la situation. Si vous pensez que cette vidéo pourrait
être utile à votre patient, voici l’adresse URL où elle
peut être visualisée : http://www.lundbeck.com/ca/fr/
les-maladies/oncologie.
We will change what a cancer diagnosis means.
Together.
At Janssen, we’re not about small steps. We’ve set our sights on making cancer
a preventable and curable disease.
This isn’t easy. That’s why we partner with the world’s top minds, from academic
institutions and patient advocates to companies large and small.
Together, we are working toward one goal: changing what a cancer diagnosis
means for patients and their loved ones.
We bring to life transformational cancer therapies – with a commitment to help
get them to the people who need them.
We are Janssen. We collaborate with the world for the health of everyone in it.
Learn more at www.janssen.ca
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
vx150001E
© 2015 Janssen Inc.
www.janssen.ca
The image depicted contains models and is
being used for illustrative purposes only.
g
n
i
ni z
O
I
C
A
/
O
N
A
C ArS
St
g
o
c
Re
We are pleased to announce
the third annual live webcast
of our awards ceremony!
The CANO/ACIO AwArds CeremONy Is sCheduled fOr
TuesdAy, OCTOber 6, 2015
9:15Am-10:00Am eT / 6:15Am – 7:00Am PT
In the Concert hall of the fairmont royal york.
The awards ceremony will be live webcast at:
WWW.CANO-ACIO.CA/2015-lIve-WebCASt
At the ceremony we will recognize the
extraordinary contributions of our members
to their profession, their patients, and their community.
the fOllOWINg AWArdS WIll be preSeNted:
boehringer Ingelheim Oncology Nurse of the Year Award
Pfizer Award for Excellence in Nursing Research
Pfizer Award for Excellence in Nursing Education
Pfizer Award for Excellence in Nursing Leadership
Pfizer Award for Excellence in Nursing
Clinical practice
Lymphoma Canada Award of Excellence
CANO/ACIO lifetime Achievement Award
CANO/ACIO Award of distinction
Our tWO leCtureShIp AWArdS WIll be preSeNted IN the fOllOWINg SeSSIONS*:
heleN hudSON leCture ANd AWArd preSeNtAtION
MerCk leCture ANd AWArd preSeNtAtION
sunday, October 4, 2015 from 11:30am – 12:30pm eT
monday, October 5, 2015 from 9:00am – 10:00am eT
sponsored by Amgen
sponsored by merck
the fOllOWINg AbStrACt AWArdS WIll be preSeNted At the ClOSINg CereMONY*,
WedNeSdAY, OCtOber 7, 2015 At 4:30pM IN the CONCert hAll.
Ovarian Cancer Canada Award for Excellence in Gynecology Oncology Nursing
CANO/ACIO Chapter poster Award
* The lectureships and closing ceremony are not live webcast.
we wish to thank members for the leadership shown in nominating one of their colleagues for an award.
And, we wish to thank the sponsors of the awards.
es
d
nce
a
s
is
a
n
on
Re c
e
d
S
e
O
l
I
N
O
A
t
C
/
é CIO
l’A
Il nous fait plaisir d’annoncer que nous
transmettrons en direct sur le Web notre
cérémonie de remise des prix et ce,
pour la troisième année consécutive !
lA CérémONIe de remIse des PrIx de l’ACIO/CANO AurA lIeu
le mardi 6 octobre 2015 de 9h15 à 10h (heure de l’est) /
de 6h15 à 7h (heure du Pacifique) dans la salle Concert Hall
du fairmont royal york.
la cérémonie de remise des prix sera retransmise en
direct sur le web à cette adresse :
WWW.CANO-ACIO.CA/2015-lIve-WebCASt
la cérémonie nous permet de reconnaître les
contributions hors pair de nos membres envers
leur profession, leurs patients et la collectivité.
NOuS Y préSeNterONS leS prIx SuIvANtS :
Prix Boehringer Ingelheim de l’infirmière en
oncologie de l’année
Prix d’excellence Pfizer en Pratique
Clinique infirmière
Prix d’excellence Pfizer en Recherche infirmière
Prix d’excellence de Lymphome Canada
Prix d’excellence Pfizer en Éducation infirmière
Prix œuvre de toute une vie de l’ACIO/CANO
Prix d’excellence Pfizer en Leadership infirmier
Prix distinction de l’ACIO/CANO
NOS deux CONféreNCeS de reMISeS de prIx SpéCIAux AurONt lIeu Aux heureS et dAteS SuIvANteS* :
préSeNtAtION du prIx de CONféreNCe à lA MéMOIre d’heleNe hudSON
dimanche 4 octobre 2015 de 11h30 à 12h30
préSeNtAtION du prIx de MerCk
lundi 5 octobre 2015 de 9h à 10h
Commanditée par Amgen
Commandité par merck
le prIx de préSeNtAtION deS AbrégéS SuIvANtS SerONt reMIS lOrS de lA CéréMONIe de Clôture*,
MerCredI 7 OCtObre 2015 à 16h30 dANS lA SAlle CONCert hAll.
Prix d’excellence des soins infirmiers oncologiques en gynécologie de Cancer de l’ovaire Canada
Prix de la meilleure affiche décerné par les sections de l’ACIO/CANO
* les conférences de remises de prix et la cérémonie de clôture ne seront pas retransmisent en
Nous tenons à remercier les personnes qui ont proposé la candidature d’un ou d’une de leurs collègues
pour leur initiative. Nous souhaitons également remercier tous les commanditaires des prix !
Congratulations to the Nominees of the
2015 Nurse of the Year Award!
Toutes nos félicitations aux candidat(e)s au prix
de l’infirmier(ère) de l’année pour 2015!
Valerie Burke, Port Moody, BC
Karen Cooper, Edmonton, AB
Tracey DasGupta, Toronto, ON
Gladys El-Helou, Montreal, QC
Wayne Enders, Edmonton, AB
Allison Filewich, Kelowna, BC
Jean Morrison-Kennedy, Lanark, NS
Christine Piescic, Toronto, ON
Juliana Roden, Vancouver, BC
Maureen Watt-Smit, Kitchener, ON
Karen Woodworth, Halifax, NS
The 2015 Nurse of the Year Award will be live webcast on
October 6, 9:15am – 10:00am EDT / 6:15am – 7:00am PDT at
La remise du prix de 2015 fera l’objet d’une webémission en direct
le 6 octobre, de 9 h 15 à 10 h (HAE) / de 6 h 15 à 7 h (HAP) à
WWWW.CANO-ACIO.CA/2015-LIVE-WEBCAST
Congratulations and best wishes to all nominees.
Encore une fois, toutes nos felicitations et nos meilleurs voeux à l’ensemble des candidates et candidats.
CANO/ACIO gratefully acknowledges the generous support of Boehringer Ingelheim (Canada) for this award.
L’ACIO/CANO tient à remercier Boehringer Ingelheim (Canada) du généreux soutien fourni envers ce prix.
MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB.
BUT THEY BEGIN IN THE HEART.
For more than 150 years, a very special passion has driven the people at Merck. Our goal is
to develop medicines, vaccines and animal health innovations that will improve the lives of
millions. Still, we know there is much more to be done. And we’re doing it, with a long-standing
commitment to research and development. We’re just as committed to expanding access
to healthcare and working with others who share our passion to create a healthier world.
Together, we’ll meet that challenge. With all our heart.
Copyright ©2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
One of a thousand reasons
to look for Astellas in oncology.
Astellas Pharma Canada is a proud sponsor of the
CANO/ACIO 2015 Conference
© 2015 Astellas Pharma Canada, Inc. All rights reserved.
Sponsor and Exhibitor Listing /
Liste des commanditaires et exposants
The 27th CANO/ACIO Annual Conference is made possible by the generous support of the following organizations:
La 27e conférence annuelle de l’ACIO/CANO est rendue possible grâce au généreux soutien des organisations suivantes:
Platinum / Platine
Gold / Or
Silver /
Argent
Bronze /
Bronze
App Sponsor / App de la conférence
Symposia / Symposiums
Amgen • Astellas • Boehringer Ingelheim • Janssen • Merck • Novartis • Pfizer Injectables • Roche
Focus Group / Panel de discussion
Gilead Sciences Canada Inc.
Award Sponsors / Commanditaires des récompenses
Amgen • Boehringer Ingelheim • CANO/ACIO BC, Ottawa, PEI, and Toronto Chapters • Merck •
Ovarian Cancer Canada • Kidney Cancer Canada • Lymphoma Canada • Pfizer Oncology
Exhibitors / Exposants
3M • Abbott Nutrition • Advanced Innovations Inc. • Alberta Health Services • Amgen • Astellas • Bayer •
Beauty Gives Back • Becton Dickinson (BD) • BioSyent • Boehringer Ingelheim • Bristol-Myers Squibb •
Calmoseptine • Canadian Nurses Association • Canadian Virtual Hospice • CANO/ACIO • Celgene •
Cold Comfort Canada Ltd • CSL Behring • de Souza Institute • Eisai Ltd. • Eli Lilly Canada Inc. • Gilead Sciences
Canada Inc. • Innovative OncoSolutions • Ipsen Biopharmaceuticals Canada • Janssen • Kidney Cancer Canada
• Lundbeck • Lymphoma Canada • Merck • Novartis • Oncology Nursing Society • Pfizer Injectables • Pfizer
Oncology • Rethink Breast Cancer • Roche • Takeda • Therakos • Trudel Medical Marketing Ltd. • Willow Breast
Cancer & Hereditary Cancer Support
Local Supporters / Commanditaires Locaux
Princess Margaret Cancer Foundation • Sunnybrook Foundation, Odette Cancer Program
10
CANO/ACIO Annual Conference 2015 | Toronto, Ontario
Conférence annuelle de l’ACIO/CANO 2015 | Toronto, Ontario
Table of contents
Table des matières
Sponsor and Exhibitor Listing /
Liste des commanditaires et exposants....................................................10
Welcome Notes / Mots de bienvenue.........................................................12
Letter from the President / Lettre de la Présidente ............................. 16
Greetings from Toronto! / Bonjour de Toronto ! .................................. 18
General Conference Information /
Informations sur la conférence .......................................................... 20
Committee Listing / Liste des membres des comités ......................... 21
About Toronto / Au sujet de Toronto ................................................... 22
Conference Floor Plan / Plan du centre de conférence .........................26
Exhibitor Floor Plan and Listing / Plan et liste des exposants ...............27
Conference Program-at-a-Glance /
Programme de la conférence d’un coup d’œil .................................. 28
Meeting Schedule / Horaire des réunions ................................................30
Day One / Jour Un ................................................................................ 31
Day Two / Jour Deux ............................................................................. 38
Day Three / Jour Trois .......................................................................... 45
Day Four / Jour Quatre ......................................................................... 37
Oral Abstract Listing / Abrégés des présentations orales ......................56
Poster Abstract Presentations and Listing /
Présentations des affiches ................................................................. 104
Toronto Map / Carte de Toronto ................................................................124
Sunday, October 4 - Wednesday, October 7, 2015 CANO/ACIO Annual Conference
Dimanche 4 octobre - mercredi 7 octobre, 2015 ACIO/CANO Conférence annuelle
11
Letter from the President
Dear Colleagues,
A highlight of our annual conference is the social event,
“Fire and Ice” on Tuesday, October 6, 2015. The planning
committee has re-created the 1980’s to provide you with
a fun-filled, nostalgic night of dancing, great music, and
food. The social will be held at the Fairmont Royal York
Hotel. I hope you join us for a very special evening.
On behalf of the CANO/ACIO Board, I welcome you to the
27th annual national CANO/ACIO conference in Toronto
from October 4 to 7, 2015.
This year CANO/ACIO is celebrating its 30th anniversary
as an association and we are celebrating with all of you
in one of the most multicultural and vibrant cities in
the country. The conference theme this year is ‘People,
Purpose, Passion/Communauté, Volonté, Passion’.
A special thank you to the conference co-chairs Karyn
Perry and Jeanne Robertson, the local planning chairs,
Charissa Cordon and Diana Incekol, the scientific
programming chair, Simonne Simon, the recognition of
excellence committee chair, Brenda Sabo, the
CANO/ACIO Head Office team, Ana Torres, Carole Perez,
Samantha Wale, and all of our volunteers and sponsors!
The health care system is changing in ways we can’t
foresee. Oncology nurses lead and affect new roles,
practice environments, care delivery models, and policy
decisions that contribute to the health and well-being
of cancer patients. This conference will bring together
an exceptional group of nurses from across Canada
and other parts of the world. Attending the conference
provides time to pause and reflect on the reasons you
chose to go into such a unique and rewarding specialty.
It is a time to reflect on the meaning that you represent
and hold for patients and their families.
The conference planning steering, local planning and
scientific programming committees have worked very
hard at creating a program that will stimulate you
to think in new and wonderful ways. It will inform
your work and your personal growth. The structure
includes oral/poster presentations, workshops, award
lectureships, CANO/ACIO award presentations and
our keynote addresses. We have six keynote speakers
this year: comedian and Registered Nurse Meg Soper,
Dr. Hans Messner, Dr. Mary Ferguson-Pare, Leslee
Thompson, Paul Alofs, and Annie Parker, who is a
patient and an advocate.
I want to thank all of you in advance for being a part of
this conference and supporting CANO/ACIO!
Sincerely,
Barbara Fitzgerald, RN, MScN
The annual general meeting scheduled on Tuesday,
October 6, 2015 from 8:00 a.m. to 9:15 a.m. is an
important meeting for all members to attend. It is
an occasion for the board to present and report on
the association’s achievements to our members. This
includes the president’s report, the treasurer’s report,
milestones and progress with our strategic plan over
the past year. There are challenges to be met as well as
opportunities for members to become involved. This
meeting provides an opportunity to engage with your
board of directors more deeply and directly.
16
President
Canadian Association of Nurses in Oncology
Lettre de la Présidente
Chers collègues,
Je me fais la porte-parole du conseil d’administration de
l’ACIO/CANO pour vous souhaiter la bienvenue à la 27e
conférence annuelle de l’ACIO/CANO, ayant lieu à Toronto
du 4 au 7 octobre 2015.
Cette année, l’ACIO/CANO célèbre son 30e anniversaire
et nous le célébrons en votre compagnie dans une des
villes les plus dynamiques et multiculturelles du pays. Le
thème de notre conférence annuelle est « Communauté,
Volonté, Passion / People, Purpose, Passion ».
Le système de soins de santé suit une évolution
qu’il nous est impossible de prévoir. Les infirmiers
et infirmières en oncologie assument et influencent
de nouveaux rôles, milieux de pratique, modèles
de prestations de soins et décisions politiques qui
contribuent à la santé et au bien-être des patients
atteints de cancer. Cette conférence rassemblera un
groupe exceptionnel d’infirmiers et infirmières d’un peu
partout au Canada et même d’autres régions du monde.
La participation à la conférence vous donne l’occasion de
marquer un temps d’arrêt et de réfléchir aux raisons pour
lesquelles vous avez choisi d’embrasser une spécialité
si enrichissante et originale. C’est le moment de songer
à ce que vous détenez et représentez pour les patients et
leurs proches.
Le comité directeur de la conférence, le comité de
planification local et le comité de planification
scientifique ont travaillé d’arrache-pied à la création
d’un programme qui vous amènera à penser autrement.
Tout cela guidera votre travail et votre croissance
personnelle. La structure inclut des présentations orales
et par affiches, des ateliers, des discours donnés dans le
cadre de prix de conférence, la remise des prix de l’ACIO/
CANO et enfin, les discours thème. Nous avons ainsi six
conférencières et conférenciers principaux cette année,
l’humoriste – et infirmière autorisée – Meg Soper, le
Dr Hans Messner, la Dre Mary Ferguson-Paré, Leslee
Thompson, Paul Alofs et Annie Parker, cette dernière
étant une patiente qui défend aussi la cause de ses pairs.
L’assemblée générale annuelle qui se déroulera de
8h à 9h15 le mardi 6 octobre 2015 est une réunion
importante à laquelle tous les membres devraient
assister. Elle fournit au CA une occasion de leur présenter
les réalisations de leur association. Elle comprend les
rapports de la présidente et de la trésorière, les jalons
et les progrès réalisés au cours de l’année écoulée
relativement au plan stratégique. Il y a des défis à
relever mais aussi des occasions de s’impliquer pour
les membres. L’assemblée vous donne l’opportunité
d’engager le dialogue avec votre CA et ce, de manière
directe et approfondie.
Un moment phare de notre conférence annuelle est
la soirée sociale baptisée “feu et glace”, le mardi 6
octobre. Le comité de planification local a décidé de
recréer les années 80 afin de vous faire profiter d’une
soirée dont les mets, la musique, la danse et les activités
divertissantes sauront vous plaire. Elle prendra place au
Fairmont Royal York Hotel. J’espère que célébrerez avec
nous cette soirée vraiment spéciale.
J’adresse tous mes remerciements aux co-présidentes
de la conférence Karyn Perry et Jeanne Robertson,
aux co-présidentes du comité de planification local
Charissa Cordon et Diana Incekol, à la présidente de la
planification scientifique Simonne Simon, à la présidente
du comité de reconnaissance de l’excellence Brenda
Sabo et, enfin, à l’équipe du bureau national de l’ACIO/
CANO – Ana Torres, Carole Perez, Samantha Wale, – et à
tous les bénévoles et commanditaires!
Je tiens à vous remercier à l’avance, tous et toutes, de
participer à cette conférence et de soutenir l’ACIO/CANO!
Bien à vous,
Barbara Fitzgerald, inf., M.Sc.inf.
Présidente
Association canadienne des infirmières en oncologie
Dimanche 4 octobre - mercredi 7 octobre 2015 Conférence annuelle de l’ACIO/CANO
17
Welcome to Toronto!
On behalf of the 2015 local planning committee, we welcome
you to Toronto for the 27th annual CANO/ACIO conference,
held at the Royal York Hotel from October 4 to 7, 2015.
The theme for this year’s conference is “People, Purpose,
Passion” and we are excited to host this year’s conference in
Canada’s most dynamic and diverse city, our city of Toronto!
In order to promote a balanced and healthy conference
that would not only satisfy the mind, but also the body, we
thought that it would be important to bring in a Zumba and
a yoga instructor. We are pleased to offer both a Zumba and
a yoga class to complement our scientific program at this
conference.
We have been very thoughtful in selecting various activities
for the conference, from the opening ceremony to the
social event and closing ceremony. We hope to make this
conference a memorable experience for everyone! In
planning for the conference, we wanted to specifically
focus on the important work of oncology nurses and the
impact of our work on patients and families. We created
our oncology nursing video to advertise for the conference,
to acknowledge the great work of our colleagues, and to
inspire others to continue to strive for excellence.
The workshops, oral and poster presentations, symposia,
and plenary sessions organized and selected by the
scientific program committee highlight the scholarly and
innovative work of oncology nurses across the country. Our
goal for this conference is for all of our participants to learn,
get inspired, network, and have fun. We hope that by the
end of the conference we not only have inspired you, but
that you have gained new knowledge and information that
you can share with others and apply in practice to optimize
the care of oncology patients and their families.
For our social event, we chose to have a 1980’s “Fire and Ice”
inspired theme. We feel that the 80’s is an era that many
of us can “jive” to. This night will be filled with great food,
music, dancing, fun, and nostalgic activities. We encourage
everyone to wear “red-hot” or “ice-bling” for this event.
We look forward to welcoming you to Toronto for the 27th
annual CANO/ACIO conference.
We are thrilled to have five keynote speakers who are leaders
in oncology and healthcare, with a passion for excellence
and innovation. This year, we have in a TED Talk-like format,
a series of innovative and inspirational speeches from two
strong leaders in nursing and oncology, and an oncology
patient who is also an advocate for genetic testing.
18
Sincerely,
Charissa Cordon, RN, BScN, MScN, CON(C)
Diana Incekol, RN, BScN, MScN, CON(C)
2015 Local Planning Committee Co-chairs
Conférence Annual
annuelle
CANO/ACIO
2014| |Toronto,
Ville de Ontario
Québec, Québec CANO/
CANO/ACIO
Conference
2015
ACIO Annualannuelle
Conference
2014 | Quebec
City,
Quebec Ontario
Conférence
de l’ACIO/CANO
2015
| Toronto,
Bienvenue à Toronto !
C’est au nom du comité de planification local 2015 que nous
vous souhaitons la bienvenue à Toronto à l’occasion de la 27e
conférence annuelle de l’ACIO/CANO, se déroulant au Royal
York Hotel du 4 au 7 octobre 2015. La conférence de cette
année a pour thème « Communauté, Volonté, Passion » et il
nous fait extrêmement plaisir d’accueillir la conférence dans
la ville la plus dynamique et diversifiée du Canada, notre
ville bien-aimée de Toronto !
Nous avons préparé une sélection mûrement réfléchie
d’activités pour la conférence, notamment pour les cérémonies
d’ouverture et de clôture et pour l’événement social, et nous
espérons qu’elles feront de la conférence de cette année une
expérience hautement mémorable pour toutes et tous! Lors
de la planification de la conférence, nous voulions concentrer
l’attention sur l’important travail que réalisent les infirmiers
et infirmières en oncologie et sur l’incidence de leur travail sur
les patients et leurs proches. Nous avons produit notre vidéo
sur les soins infirmiers en oncologie dans le but de faire de la
publicité pour la conférence, de reconnaître le superbe travail
de nos collègues et d’inspirer les autres à continuer d’aspirer à
l’excellence.
En ce qui concerne notre événement social, nous avons choisi le
thème feu et glace à la mode des années 80. Nous croyons que
les années 80 sont une décennie au son de laquelle beaucoup
d’entre nous pourrons nous déhancher. Cela sera une soirée
dont les mets, la musique, la danse et les amusantes activités
nostalgiques ne manqueront pas de vous plaire. Nous vous
encourageons tous et toutes à porter des vêtements « chauffés
au rouge » et/ou des accessoires ou paillettes « miroitant de
glace » lors de cet événement.
Pour faire en sorte que la conférence soit un événement
équilibré et sain qui satisfasse le mental mais aussi l’esprit
et le corps, nous estimons qu’il est important d’y faire venir
une instructrice de danse aérobique latine et une instructrice
de yoga. Nous sommes heureuses de pouvoir offrir une
séance de « Zumba » et une de yoga en plus de notre
programme scientifique.
Les ateliers, les présentations orales et d’affiches, les
symposiums et les séances plénières, sélectionnées et
organisées par le comité du programme scientifique, mettent
en valeur les travaux érudits et innovants des infirmiers
et infirmières en oncologie de l’ensemble du pays. Notre
but est que cette conférence soit, pour l’ensemble des
participants et participantes, une occasion d’apprendre,
de se sentir inspirés, de s’amuser ainsi qu’une plateforme
de réseautage. Nous espérons vivement qu’à la fin de la
conférence vous aurez été inspirés et surtout, que vous y
aurez acquis de nouvelles connaissances et informations que
vous pourrez partager avec autrui et mettre en œuvre dans
votre pratique afin d’optimiser les soins aux patients en
oncologie et à leurs proches.
Nous avons bien hâte de vous accueillir à Toronto à
l’occasion de la 27e conférence annuelle de l’ACIO/CANO.
Bien à vous,
Charissa Cordon, inf., M.Sc.inf., CSIO(C)
Diana Incekol, inf., M.Sc.inf., CSIO(C)
Association canadienne des infirmères en oncologie
Nous sommes ravies d’avoir cinq conférencières et
conférenciers d’honneur qui sont des chefs de file en oncologie
et en soins de santé et qui se passionnent pour l’excellence
et l’innovation. Cette année, nous adopterons un format basé
sur les TEDTalk, une série de discours novateurs et inspirants,
présentés par deux chefs de file de premier rang en soins
infirmiers et en oncologie ainsi que par une patiente en
oncologie qui défend la cause du dépistage génétique.
Dimanche 4 octobre - mercredi 7 octobre 2015 ACIO/CANO Conférence annuelle
19
General Conference Information/
Informations sur la conférence
Registration / Inscription
To register for the conference, go to the CANO/
ACIO website at www.cano-acio.ca and either
complete your registration online (pay by credit
card online and receive a $25 discount) or
download and submit by fax or mail a registration
form (cheque payment only). Once your
registration has been processed, a receipt will be
emailed to you.
On-site registration will be available. Cheque
and credit card payment will be accepted. The
registration desk is located in the Canadian
Room Foyer. The speaker services centre, located
in the Salon B, is equipped with PC laptops for
speakers to review their presentations before
their session. Speaker services and registration
hours are as follows:
Pour le comfort des délégués, un nombre limité Zumba
de chambres ont été réservées a l’hôtel Fairmont « Zumba Fitness » est la danse aérobique latine
qui fait appel à la musique et à des routines
Royal York à un tarif spécial.
chorégraphiées pour faire de l’exercice dans une
Veuillez contacter l’hôtel directement au
atmosphère enjouée. Pour favoriser l’aérobie, la
+1-416-368-2511 pour faire une réservation en
danse aérobique latine incorpore des routines
vous présentant en tant qu’ “Infirmières de
rapides et lentes. Dirigée par une instructrice agréée,
l’Association Canadienne d’Oncologie’ afin de
cette activité physique des plus amusantes vous
bénéficier du tarif spécial. Vous pouvez aussi
aidera à vous mettre en train et sera une excellente
réserver en ligne en suivant le lien sur la page de
façon de démarrer la journée! Pour y participer,
la conférence www.cano-acio.ca.
assurez-vous de porter des vêtements et souliers de
sport confortables.
Social Evening /
Soirée sociale
Yoga
Le terme « yoga » vient de la racine sanskrite
We want to continue to celebrate oncology nurses « yuj » qui signifie « atteler » ensemble l’esprit et
across Canada who are the driving forces in
le corps physique. Le yoga comprend une série
providing exemplary cancer care. The social event
de positions et de techniques de respiration
committee has prepared a very special night for the simples mais efficaces qui incorporent
delegates, entitled “fire and ice”. This is a themed également la méditation, pour assurer le bienSaturday, October 3 | 4:00 pm - 8:00 pm
event, filled with pop music from the 1980’s. We will être de l’esprit et d’autres éléments cachés de
Sunday, October 4 | 6:30 am - 7:00 pm
re-create the 1980’s to provide you with a fun-filled, l’existence humain. Dirigé par une instructrice de
Monday, October 5 | 6:30 am - 6:00 pm
nostalgic night of dancing, great music, and food!
yoga agréée, cela sera une merveilleuse manière
Tuesday, October 6 | 6:30 am - 7:00 pm
de calmer l’esprit et de terminer la journée! Pour
Please wear your best “red-hot ” or “ice-bling”
Wednesday, October 7 | 7:15 am - 4:30 pm
y participer, veuillez amener un tapis de yoga et
80’s costume.
porter des vêtements confortables.
Pour s’inscrire à la conférence, allez sur le site
Nous voulons continuer à célébrer les infirmières
internet de l’ACIO/CANO : www.cano-acio.ca et
en oncologie à travers le Canada qui prodiguent
complétez votre bulletin d’inscription en ligne
Lilly Oncology on Canvas Canada
(payez par carte de crédit et recevez $25 de remise) des soins oncologiques exemplaires. Le comité
Lilly Oncology on Canvas Canada (LOCC) a été
des événements sociaux a préparé une soirée
ou renvoyez votre bulletin par télécopieur ou par
créée pour aider ceux affectés par le cancer à
très spéciale pour les délégués, intitulée feu et
la poste (paiement par chèque uniquemement).
surmonter les effets emotionnels et physiques
glace. Placé sous ce thème, cet événement mettra de cette maladie, à travers la représentation
Vous recevrez un reçu par courriel lorsque votre
en vedette la musique pop des années 80. Nous
inscription aura été enregistrée.
artistique de leur parcours. Cette exposition se
allons recréer cette décennie afin de vous offrir
trouve dans la salle Ontario.
Pour avoir droit à l’escompte sur les frais
une soirée de danse, de bonne musique et de
d’inscription, votre paiement doit être soumis
cuisine pleine de plaisir et de nostalgie.
Simultaneous Translation/
en ligne ou posté au bureau l’ACIO/CANO avant
Traduction simultanée
le 15 août 2015.
Portez votre meilleur costume des années 80,
aux couleurs de feu ou aux reflets de glace.
Plenaries may be presented in English with
L’inscription sur place est possible par chèque ou
simultaneous translation into French.
carte crédit. Le bureau d’enregistrement se situe
Special Activities /
dans le Canadian Room Foyer. Le centre de services
Les conférences plènieres seront présentées en
aux conférenciers, situé dans le Salon B, est équipé Activités spéciales
anglais avec une traduction simultanée en français.
d’ordinateurs pour que les conférenciers puissent Zumba
revoir leur présentations avant leurs ateliers. Les
Scents / Parfums
Zumba Fitness is a Latin-inspired cardio-dance
heures du bureau d’inscription et du bureau des
workout that uses music and choreographed steps to Please note that the CANO/ACIO 2015 conference
services aux conférenciers sont les suivantes:
form a fitness party atmosphere. Zumba is an aerobic is a scent free environment. Please refrain from
activity, which incorporates alternating fast and
the use of perfumes or other strong scents during
Samedi 3 octobre | 4:00 pm - 8:00 pm
slow rhythms. Taught by a certified Zumba instructor, the conference.
Dimanche 4 octobre | 6:30 am - 7:00 pm
this fun-filled physical activity will get you moving
Lundi 5 octobre | 6:30 am - 6:00 pm
and is a great way to start your day! To participate, Veuillez noter que la conférence de l’ACIO/CANO
Mardi 6 octobre | 6:30 am - 7:00 pm
2015 est un environnement sans parfum. Par
wear comfortable work-out clothes and shoes.
Mercredi 7 octobre | 7:15 am - 4:30 pm
respect pour les autres participants, merci de ne
Yoga
pas utiliser de fragrances ou autres odeurs fortes
Accommodation /Logement The word “yoga” comes from the Sanskrit root
lors de la conférence.
“yuj”, which means “to yoke” the spirit and
For the convenience of conference attendees, a
physical body together. Yoga involves a series
Information
limited number of rooms have been reserved at the of simple, yet effective postures and breathing
Fairmont Royal York Hotel at a special rate.
techniques, and incorporates meditation for the
For further information contact the conference
well-being of mind and other hidden elements
We encourage all members to book at the
secretariat:
of human existence. Taught by a certified yoga
conference hotel. You can book online by
Pour plus d’informations, veuillez contacter le
following the link on the annual conference page instructor, this is an excellent way to calm the
mind and end the day! To participate, bring a yoga secrétariat de la conférence :
at www.cano-acio.ca or you can call the hotel
directly at +1-416-368-2511 to make reservations mat and wear comfortable clothes.
CANO/ACIO Management Office
and identify yourself as being with the “Canadian Lilly Oncology on Canvas Canada
570 West 7th Avenue, Suite 400,
Association of Nurses in Oncology”
Lilly Oncology on Canvas Canada (LOCC) was created
Vancouver, BC V5Z 1B3
to obtain the conference rate.
to help those affected by cancer cope with the
emotional and physical effects of this disease, through Tel: 604.874.4322 Fax: 604.874.4378
the artistic representation of their cancer journey. Email: cano@malachite–mgmt.com
www.cano–acio.ca
Their exhibition is located in the Ontario room.
20
Committee Listing
Liste des Membres des Comités
Local Planning Committee /
Comité de planification local
Charissa Cordon, RN, MN, CON(C) (Co-chair)
Scientific Program Committee/
Comité du programme
scientifique
Diana Incekol, RN, BScN, MScN, CON(C) (Co-chair)
Simonne Simon, RN, MN, BScN, CON(C) SPC chair
Philiz Goh, RN, BScN, CON(C), R.Kin, BSc Hons Kin, MN-HSLA(C)
Jennifer Anderson, RN, MN, CON(C) 2016 SPC co–chair
Christine Piescic, RN, BScN, CON(C)
Karine Bilodeau, inf., PhD, CON(C) 2014 SPC co–chair
Shawne Gray, RN, BScN, CON(C)
Virginia Lee, RN, MScA, PhD 2014 SPC co–chair
Sabrina Bennett, RN, BScN
Linda Watson, RN, PhD, CON(C) 2016 SPC co–chair
Rosemarie Rivera, RN, BScN, MN
Alice Chen, BSc
Janice Stewart, RN, BScN, MHS, CON(C)
Conference Planning
Steering Committee /
Comité d’organisation de
la conférence
Karyn Perry, RN, BSN, MBA, CON(C) CPSC co–chair
Jeanne Robertson, RN, BSc, BA, MBA CPSC co–chair
Jennifer Anderson, RN, MN, CON(C) 2016 SPC co–chair
Charissa Cordon, RN, BScN, MScN, CON(C) 2015 LPC co–chair
Sydney Farkas, RN, BN, CON(C) 2016 LPC co–chair
Diana Incekol, RN, BScN, MScN, CON(C) 2015 LPC co–chair
Elysa Meek, RN, BA, BN 2016 LPC co–chair
Simonne Simon, RN, BScN, MN, CON(C) SPC chair
Linda Watson, RN, PhD, CON(C) 2016 SPC co–chair
CANO Board of Directors /
Conseil d’administration de l’ACIO
Barbara Fitzgerald, RN, MScN
President
Tracy Truant, MScN, RN, PhD(c)
Vice–President
Jeanne Robertson, RN, BSc, BA, MBA
Treasurer
Lorna Roe, RN, MScN, BSc
Director–at–Large – Communications
Karyn Perry, RN, BSN, MBA, CON(C)
Director–at–Large – Education
Shari Moura, RN, MN, CON(C), CHPCN(C)
Director–at–Large – External Relations
Cindy McLennan, RN, BScN, MBA, CON(C)
Director–at–Large – Membership
Allyson Nowell, RN, BScN, MSc, CON(C)
Director–at–Large – Professional Practice
Dawn Stacey, RN, PhD, CON(C)
Director–at–Large – Research
Margaret Fitch, RN, PhD
Canadian Oncology Nursing Journal Editor–in–Chief
Philiz Goh, RN, CON(C), BScN, MN-HSLA(C)
Incoming Director–at–Large – Communications
Charissa Cordon, RN, BScN, MScN, CON(C)
Incoming Director–at–Large – Education
Linda Watson, RN, PhD, CON(C)
Incoming Vice-President
21
TORONTO,
a ‘PEOPLE, PURPOSE, PASSION’ city
Toronto is one of the most multicultural and diverse cities in the world
and is the capital city of Ontario. Located in southern Ontario, on the
northwestern shore of Lake Ontario, Toronto is Canada’s commercial
capital, and ranks fourth as the most populous cities in North America.
Diversity defines Toronto. In Toronto, there is a Little Italy, a Little India,
a Little Portugal, two Chinatowns and an area called “The Danforth”.
When it comes to food, Toronto has something for everyone. It houses
some of the top chefs in the world specializing in culinary delights that
can only be found in Toronto.
Toronto has a population of over 2.79 million people comprised of
diverse groups and cultures and more than 140 languages and dialects
spoken. 47% of Toronto’s population reported themselves as being part
of a visible minority. Toronto’s rich multicultural diversity is expressed
by its residents’ more than 200 distinct ethnic origins. The top five
visible minority groups in Toronto are: South Asian, Chinese, Black,
Filipino, and Latin American.
The conference will be held at Fairmont Royal York Hotel, which has a
very rich history that dates back to 1843 when Captain Thomas Dick first
built Ontario Terrace to what is now known as the Fairmont Royal York.
It has been said that this was the site where Sir John A. MacDonald met
with American Civil War sympathizers to plot the retaliation. In 1929,
the hotel had a complete demolition and developed into the largest
and tallest hotel in the British Commonwealth for its time with its hand
painted ceilings, own golf course and bank – also known as “a city
within a city”. With Fairmont Royal York’s elegance and reputation, it has
offered its gracious hospitality to over 40 million guests that include Her
Majesty Queen Elizabeth II and soon to the attendees of the 2015
CANO/ACIO conference.
22
16
16
CANO/ACIO Annual
Annual Conference
Conference 2015
2015 || Toronto,
Toronto, Ontario
Ontario
CANO/ACIO
Conférence annuelle
annuelle de
de l’ACIO/CANO
l’ACIO/CANO| 2015
| Toronto,
Ontario
Conférence
Toronto,
Ontario
Toronto,
ville sous le signe de ‘Communauté, Volonté, Passion’
Toronto, la capitale de l’Ontario, est l’une des villes les plus multiculturelles et les plus
diverses du monde. Située dans le sud de l’Ontario, sur la côte nord-ouest du lac Ontario,
Toronto est la capitale commerciale du Canada et la quatrième ville la plus peuplée
d’Amérique du Nord.
La diversité définit Toronto. À Toronto, il y a une Petite Italie, une Petite Inde, un Petit
Portugal, deux quartiers chinois et un quartier appelé « The Danforth ». Quand il s’agit de
cuisine, Toronto a de quoi satisfaire tout le monde. On y trouve des chefs parmi les meilleurs
au monde spécialisés dans des mets délicieux qui n’existent qu’à Toronto.
Toronto compte plus de 2,79 millions d’habitants qui comprennent toute une myriade de
groupes et de cultures et on y parle plus de 140 langues et dialectes. 47% de la population
de Toronto se dit provenir d’une minorité visible. La richesse de la diversité multiculturelle
s’exprime chez ses résidents par plus de 200 origines ethniques distinctes. Les minorités
visibles les plus représentées à Toronto sont les Asiatiques du sud, les Chinois, les Noirs, les
Philippins et les Latino-Américains.
La conférence aura lieu à l’Hôtel Fairmont Royal York, qui a une histoire très riche qui
commence en 1843, date à laquelle le capitaine Thomas Dick fit construire l’Ontario Terrace,
maintenant connue sous le nom d’Hôtel Fairmont Royal York. On dit que c’est là que Sir
John A. MacDonald rencontra des sympathisants de la guerre civile américaine pour tramer
une riposte. En 1929, l’hôtel fut complètement détruit avant de devenir le plus grand hôtel
(et le plus haut) du Commonwealth britannique de son temps, avec des plafonds peints à la
main, son propre terrain de golf et sa propre banque. On disait de lui qu ’il était « une ville à
l’intérieur d’une ville ». Avec son élégance et sa réputation, le Fairmont Royal York a offert
son hospitalité courtoise à plus de 40 millions d’hôtes, incluant sa Majesté la Reine
Elizabeth II et, bientôt, les participants à la conférence de l’ACIO/CANO de 2015.
Dimanche
Dimanche
4 octobre
4 octobre
- mercredi
- mercredi
7 octobre
7 octobre
2015 2015
Conférence
ACIO/CANO
annuelle
Conférence
de l’ACIO/CANO
annuelle
23
17
Introducing the CANO/ACIO 2015 Conference App!
Nous vous présentons l’App de la conférence de l'ACIO/CANO !
Did you know that there is a conference app that you can download that lists
all of the session information, speakers, speaker bios, abstracts, venue maps,
and other important conference information?
Event Directory
Saviez-vous qu’il y a une app de conférence que vous pouvez télécharger et qui
indique toutes les informations utiles : ateliers, présentateurs, abrégés, lieux,
cartes, et autres informations importantes ?
Download the app onto your iPhone, iPad, Android, or
Blackberry by scanning the QR code or searching for “ACIO” or
“CANO” in your phone’s app store.
Téléchargez l’app sur votre iPhone, iPad, Android, ou Blackberry en
scannant le code QR ou en recherchant “ACIO” ou “CANO” dans le
magasin d'applications de votre téléphone.
CANO/ACIO would like to thank the Canadian Cancer Society
for their exclusive sponsorship of the 2015 conference app
ACIO/CANO remercie la Société canadienne du cancer pour
son parrainage exclusif de l'app de la conférence 2015
We are pleased
to announce
the release of the
CANO/ACIO
Radiation Oncology
Nursing Practice Standards
and Competencies
Association canadienne des infirmières en oncologie
Visit the CANO/ACIO booth for more information or
visit www.cano-acio.ca to download.
MAIN MEZZANINE
CONFEDERATION 6
LADIES
TUDOR 7
Conference/ Workshop 3
TUDOR 8
MENS
CHECK
ROOM
PSAV
LADIES
SASKATCHEWAN
NOVA
SCOTIA
BRUNSWICK
PRINCE
EDWARD
ISLAND
MANITOBA
ALBERTA
GREAT
CANADIAN
NEWSSTAND
THE MEN’S
SALON
PENNY
LOAFERS
BOARDROOM
QUEBEC
TERRITORIES
AVENUES
RECEPTION
BRITISH COLUMBIA
ATM
LAVENDER
&
LACE
GAME TREK
YORK
LIBRARY
THE TICKET
HOUSE
MENS
DEMARCO
ALGONQUIN
Zumba/Yoga
PERPICH
LISA
CHAN MUST
HAVE
FINE
JEWELLERY
YORK
BY STATION
&
WATCH
T.K. BAR
CO. LTD
MAIN
MEZZANINE
Main Mezzanine
MODERN
LUGGAGE
NEWFOUNDLAND
ESCALATORS
TO ACCESS
THE P.A.T.H
CONFEDERATION 5
HUMAN Conference/ Workshop 2
RESOURCES
MENS
CONFEDERATION 3
PARKING
GARAGE
Conference Centre Floor Plan /
Plan du centre de conférences
LADIES
MENS
CONFEDERA
TION
5
AVENUES
RECEPTION
LADIES
CONFEDERA
TION
6
PSAV
TUDOR
7
CHECK
ROOM
PSAV
MODERN
LUGGAGE
CONCERT HALL
FOYER
YORK
LIBRARY
LADIES
SASKATCHEWAN
NOVA
SCOTIA
BRUNSWICK
PRINCE
EDWARD
ISLAND
MANITOBA
ALBERTA
GREAT
CANADIAN
NEWSSTAND
THE MEN’S
TUDOR SALON
KITCHEN
8
BOARDROOM
PENNY
LADIES
LOAFERS
SASKA
TCHEWAN
TERRITORIES
PRINCE
NEW
NOVA
EDWARD
QUEBEC
SCOTIA BRUNSWICK ISLAND
BRITISH COLUMBIA
MENS
ONTARIO
LISA ROOM
CHAN MUST
LAVENDER
HAVE
FINE
GAME TREK BOARDROOM
JEWELLERY
YORK
&
BY STATION
&
BAR
LACE
TERRITORIES
WATCH
T.K.
CO.
LTD
FOYER
NEWFOUNDLAND
ALBERTA
NEWFOUNDLAND
QUEBECROOM
CANADIAN
LADIES
BRITISH
COLUMBIA
MENS
ESCALATORS
CHECK
ROOM
SALON B
BALLROOM
LIBRARY
SALON A
ALGONQUIN
TORONTO
YORK
ROOM
STATION
ESCALATORS
THE TICKET
HOUSE
MENS
MANITOBA
DEMARCO
ALGONQUIN
Zumba/Yoga
PERPICH
ATM
CHECK
ROOM
CONFEDERA
STAGETION
3
TUDOR 8
ESCALATORS
TO ACCESS
THE P.A.T.H
TUDOR 7
MENS
CONFEDERATION 6
MENS
CONFEDERATION 5
HUMAN Conference/ Workshop 2
RESOURCES
PARKING
GARAGE
CONFEDERATION 3
PARKING
GARAGE
ESCALATORS
LADIES
LADIES
BAR
SALES & CATERING OFFICE
YORK
CONVENTION
FLOOR
convention floor
CONFEDERA
TION
5
LADIES
CONFEDERA
TION
6
CHECK
ROOM
FITNESS FACILITY
STAGE
CONCERT HALL
MASSAGE
ROOM
LADIES
Symposias / Plenaries
WADING
PSAV
POOL
HEALTH
CLUB
RECEPTION
FOYER
MEN
CONCERT HALL
TUDOR
7
SALON B
FOYER
LADIES
CONCERT HALL
Symposias / Plenaries
NEW
BRUNSWICK
PRINCE
EDWARD
ISLAND
ALBERTA
CHECK
ROOM
SALON A
ESCALATORS
BALCONY
BALCONY
BALLROOM
Exhibitors
SALES & CATERING OFFICE
EMPIRE CLUB
CHECK
ROOM
SALON A
ESCALATORS
TORONTO
ROOM
MENS
ALGONQUIN
CANADIAN ROOM
TORONTO
ROOM
ONTARIO ROOM
BOYLE
REAL
ESTATE
FOYER
E-POSTERS & INTERNET CENTRE
ROTARY
CLUB
MANITOBA
BRITISH
COLUMBIA
SWIMMING POOL
KITCHEN
WHIRL
POOL
NEWFOUNDLAND
QUEBECROOM
CANADIAN
MENS
OPEN TO FLOOR BELOW
26
ONTARIO ROOM
BOYLE
CHECK
ROOM
REAL
TORONTO
YORK
ROOM
ESTATE
STATION
SALON A
ESCALATORS
BAR
FOYER
E-POSTERS & INTERNET CENTRE
ROTARY
CLUB ESCALATORS
NOVA
SCOTIA
CONVENTION FLOOR
LADIES
SALON B
ONTARIO ROOM
KITCHEN
WHIRL BOARDROOM
EMPIRE
CLUB
POOL
TERRITORIES
FOYER
BALCONY
BALLROOM
HEALTH
CLUB
RECEPTION
FOYER
LADIES
MENS
SWIMMING POOL
LIBRARY
YORK
OPEN TO FLOOR BELOW
FITNESS FACILITY
STAGE
MASSAGE
ROOM
SASKATCHEWAN
MENS
WADING
POOL
MEN
8
BALLROOM
BALCONY
SALON B
LADIES
TUDOR
KITCHEN
MENS
CONFEDERA
STAGETION
3
PARKING
GARAGE
ESCALATORS
CANADIAN ROOM
Exhibitors
LADIES
Exhibitor Floor Plan and Listing /
Plan et liste des exposants
EXHIBIT HOURS :
Sunday, October 4, 9:30 am - 10:00 pm
Monday, October 5, 9:30 am - 6:00 pm
Tuesday, October 6, 9:30 am - 3:45 pm
201 300
203 302
EXHIBITOR NAME
3M
Abbott Nutrition
Advanced Innovations Inc. (Bio-Oil)
Amgen
Alberta Health Services
Astellas
Bayer
Beauty Gives Back
Becton Dickinson (BD) Canada
BioSyent Pharma Inc.
Boehringer Ingelheim
Bristol-Myers Squibb
BOOTH
309
321
405
212&214
305
221
308
317
318&320
203
310
311 &313
Calmoseptine
204
Canadian Nurses Association
Canadian Virtual Hospice
407
104
305
EXHIBITOR NAME
BOOTH
EXHIBITOR NAME
BOOTH
CANO/ACIO
222&224
Lundbeck Canada
209 & 211
Celgene
Cold Comfort Canada Ltd.
CSL Behring
223&322
Lymphoma Canada
Merck
Novartis
Oncology Nursing Society
Pfizer Injectables
Pfitzer Oncology
Rethink Breast Cancer
Takeda
Therakos
Trudell Medical Marketing Ltd.
Willow Breast & Hereditary
Cancer Support
205
316
de Souza Institute
106
Eisai Ltd
207
Eli Lilly Canada Inc.
Roche
201
314
Innovative OncoSolutions Inc.
Ipsen Biopharmaceuticals
Canada Inc.
Janssen
Kidney Cancer Canada
208 & 206
302
304
215&217
108
219
315
409
306
401
300
319
403
307
100
102
27
Conference Program-at-a-Glance /
Programme de la conférence d’un coup d’œil
Saturday, October 3, 2015 / Samedi 3 octobre 2015
4:00 pm – 8:00 pm
Registration / Inscription Canadian Room Foyer
7:00 pm – 9:00 pm
Merck Dinner Symposium / Souper éducatif Merck Concert Hall
Day One: Sunday, October 4, 2015 / Jour un: dimanche 4 octobre 2015
7:15 am – 8:30 am
Astellas Breakfast Symposium / Déjeuner éducatif Astellas Concert Hall
8:45 am – 9:30 am
Opening Ceremony / Cérémonie d’ouverture Concert Hall
9:30 am – 11:00 am
Workshop / Atelier
I–1 Confederation 3
Concurrent
Concurrent
Session/Session/
Concurrent Session/
Workshop
/ AtelierConcurrent
Session/Session/
Concurrent Session/
Concurrent
Workshop
/ Atelier
Atelier simultané
Atelier simultané
Atelier simultané
Atelier simultané Atelier simultané
I–2 Confederation 5Atelier
& 6 simultané
I–2 Confederation
5&6
8 Alberta
I–5 Alberta
I–3 TudorI–3
7 Tudor 7 I–4 Tudor 8 I–4 TudorI–5
11:00 am – 11:30 am
Health Break Sponsored by Bristol-Myers Squibb / Pause santé sponsorisée par Bristol-Myers Squibb Canadian Room
11:30 am – 12:30 pm
Helene Hudson Lectureship / Conférence Helene Hudson Concert Hall
12:45 pm – 2:15 pm
Janssen Lunch Symposium / Dîner éducatif Janssen Concert Hall
2:15 pm – 4:15 pm
CANO/ACIO’s
InternaConcurrent Session/Concurrent
Concurrent
ConcurrentConcurrentConcurrent
Concurrent
Concurrent Session/
Session/ Concurrent
Session/ CANO/ACIO’s
Concurrent Session/
International
StraStrategic DirecAtelier
simultané
Atelier Session/
simultanéAtelier tional
Atelier simultané
AtelierAtelier
simultanéSession/
Session/
Atelier Session/
Atelier
Session/ Atelier simultané
Session/ Atelier
tegic
Directions/
tions
– Roundtable
simultané
simultané
simultané
II–1 Confederation 3simultané
II–2 Confederation
II–3 Tudor 7 simultanéII–4 Tudorsimultané
8
II–5 Alberta
– Roundtable
/
Table
ronde : directions
II–1
II–25 & 6
II–3 Tudor 7
II–4 Tudor 8
II–5 Alberta
II–6 British
Table ronde
: direcstratégiques
interConfederation 3
Confederation
Columbia
tions stratégiques
nationales
de l’ACIO/
5&6
internationales
CANO
Quebec
de l’ACIO/CANO
Quebec
4:15 pm – 5:15 pm
Education Committee
Hematology/BMT SIG
Education Committee Hematology BMT
Researc
Confederation 3
Confederation 5 & 6
Research Committee
Surgical Oncolog
Tudor 7
Surgical Oncology SIG
Tudor 8
5:15 pm – 6:15 pm
Focus Group Gilead Sciences Canada Inc. / Panel de discussion Gilead Sciences Canada Inc. Alberta
6:15 pm – 7:15 pm
Keynote Presentation I Sponsored by Merck - Meg Soper / Conférence plénière I sponsorisée par Merck - Meg Soper Concert Hall
8:00 pm onward
Welcome Reception Sponsored by Janssen / Réception de bienvenue sponsorisée par Janssen Canadian Room
Day Two: Monday, October 5, 2015 / Jour deux: lundi 5 octobre 2015
6:15 am – 7:00 am
Zumba Session / Séance de zumba Algonquin
7:30 am – 8:45 am
Pfizer Injectables Breakfast Symposium / Déjeuner éducatif Pfizer Injectables Concert Hall
9:00 am – 10:00 am
Merck Lectureship and Award Presentation / Conférence Merck et remise de prix Concert Hall
10:00 am – 10:30 am
Health Break Sponsored by Roche / Pause santé sponsorisée par Roche Canadian Room Posters Group 1 Canadian Room Foyer
10:30 am – 11:45 am
Annual International Symposium: CANO/ACIO, ONS, ISNCC / Symposium international annuel : ACIO/CANO, ONS, ISNCC Concert Hall
11:45 pm– 1:15 pm
Boehringer Ingelheim Lunch Symposium / Dîner éducatif Boehringer Ingelheim Concert Hall
1:15 pm – 2:45 pm
2:45 pm – 3:15 pm
3:15 pm – 4:45 pm
Workshop / Atelier
III–1 Confederation 3
Workshop / Atelier
III–2 Confederation
5&6
Concurrent Session/
Atelier simultané
III–3 Tudor 7
Concurrent Session /
Atelier simultané
III–4 Tudor 8
Concurrent Session/
Atelier simultané
III–5 Alberta
Concurrent Session/
Atelier simultané
III–6 British
Columbia
Health Break Sponsored by Novartis / Pause santé sponsorisée par Novartis Canadian Room Posters Group 2 Canadian Room Foyer
Workshop / Atelier
IV–1 Confederation 3
Workshop / Atelier
IV–2 Confederation
5&6
Concurrent Session/
Atelier simultané
IV–3 Tudor 7
Concurrent Session/
Atelier simultané
IV–4 Tudor 8
Concurrent Session/
Atelier simultané
IV–5 Alberta
Concurrent Session/
Atelier simultané
IV–6 British
Columbia
4:45 pm – 6:00 pm
Keynote Presentation II Sponsored by Astellas – TED TEAM: Mary Ferguson-Paré, Leslee Thompson, Annie Parker /
Conférence plénière II sponsorisée par Astellas – TED TEAM : Mary Ferguson-Paré, Leslee Thompson, Annie Parker Concert Hall
6:00 pm – 7:00 pm
Council of Chapters Meeting / Rencontre du conseil des sections Confederation 3
7:00 pm – 9:00 pm
Roche Dinner Symposium / Souper éducatif Roche Concert Hall
9:10 pm – 10:00 pm
Yoga Session / Séance de yoga Algonquin
28
Webcast
Simultaneous interpretation into english
Simultaneous interpretation into french
Day Three: Tuesday, October 6, 2015 / Jour trois: mardi 6 octobre 2015
6:30 am – 7:45 am
Roche Breakfast Symposium / Déjeuner éducatif Roche Concert Hall
8:00 am – 9:15 am
CANO/ACIO AGM / AGA ACIO/CANO Concert Hall
9:15 am –10:00 am
CANO/ACIO Awards of Excellence Ceremony / Cérémonie des prix d’excellence de l’ACIO/CANO Concert Hall
10:00 am – 10:30 am
Health Break Sponsored by Janssen / Pause santé sponsorisée par Janssen Canadian Room Posters Group 3 Canadian Room Foyer
10:30 am – 12:00 pm
Workshop / Atelier
V–1 Confederation 3
Atelier simultané
V–2 Confederation
5&6
Concurrent Session/
Atelier simultané
V–3 Tudor 7
Atelier simultané
V–4 Tudor 8
Atelier simultané
V–5 Alberta
Concurrent Session/
Atelier simultané
V–6 British
Columbia
12:15 pm – 1:45 pm
Novartis Lunch Symposium / Dîner éducatif Novartis Concert Hall
2:00 pm – 3:00 pm
Keynote Presentation III – Paul Alofs / Conférence plénière III – Paul Alofs Concert Hall
3:00 pm – 3:30 pm
Health Break Sponsored by Lundbeck / Pause santé sponsorisée par Lundbeck Canadian Room Posters Group 4 Canadian Room Foyer
Workshop / Atelier
VI–1 Confederation 3
Workshop / Atelier
VI–2 Confederation
5&6
Atelier simultané
VI–3 Tudor 7
Atelier simultané
VI–4 Tudor 8
Atelier simultané
VI–5 Alberta
Concurrent Session/
Atelier simultané
VI–6 British
Columbia
5:15 pm – 6:15 pm
Radiation Oncology
SIG
Confederation 3
Gynecological
Oncology SIG
Confederation 5 & 6
Complementary
Medicine SIG
Tudor 7
Leadership
SIG
Tudor 8
Advanced Practice
Nursing SIG
Alberta
Cancer Survivorship
SIG
British Columbia
7:00 pm onward
Social Event / Soirée sociale Concert Hall
3:30 pm – 5:00 pm
Day Four: Wednesday, October 7, 2015 / Jour quatre: mercredi 7 octobre 2015
7:30 am – 8:45 am
Merck Breakfast Symposium / Déjeuner éducatif Merck Concert Hall
9:00 am – 10:00 am
Keynote Presentation IV – Hans Messner / Conférence plénière IV – Hans Messner Concert Hall
10:00 am – 10:30 am
Health Break Sponsored by Boehringer Ingelheim / Pause santé sponsorisée par Boehringer Ingelheim Canadian Room
10:30 am – 12:00 pm
Workshop / Atelier
VII–1
Confederation 3
12:15 pm – 1:45 pm
Amgen Lunch Symposium / Dîner éducatif Amgen Concert Hall
2:00 pm – 3:00 pm
Annual Canadian Cancer Society and CANO/ACIO Joint Symposium /
Symposium joint annuel de la société canadienne du cancer et de l’ACIO/CANO Concert Hall
3:00 pm – 4:30 pm
Workshop / Atelier
VIII–1
Confederation 3
4:30 pm – 5:00 pm
Closing Ceremony and Abstract Award Presentation / Cérémonie de clôture et remise de prix pour abrégés Concert Hall
Workshop / Atelier
VII–2 Confederation
5&6
Concurrent Session/
Atelier simultané
VII–3 Tudor 7
Concurrent Session/
Atelier simultané
VII–4 Tudor 8
Concurrent Session/
Atelier simultané
VII–5 Alberta
Concurrent Session/
Atelier simultané
VII–6 British
Columbia
Concurrent
Concurrent
Session/ Session/
Concurrent Session/
Workshop
/ AtelierConcurrent
Session/Session/
Concurrent Session/
Concurrent
Workshop
/ Atelier
Atelier simultané
Atelier simultané
VIII–2
Confederation
Atelier simultané
Atelier simultané
Atelier simultané Atelier simultané
VIII–2
Confederation
5 & 65 & 6
VIII–3
8 Alberta
VIII–5 Alberta
VIII–3 Tudor
7 Tudor 7 VIII–4 Tudor 8VIII–4 Tudor
VIII–5
Dimanche 4 octobre - mercredi 7 octobre 2015 ACIO/CANO Conférence annuelle
29
Meeting Schedule/
Horaires des réunions
Sunday, October 4 / Dimanche 4 octobre / 4:15pm - 5:15pm
Education Committee (Confederation 3)
Hematology/BMT Special Interest Group (Confederation 5 & 6)
Research Committee (Tudor 7)
Surgical Oncology Special Interest Group (Tudor 8)
Monday, October 5 / Lundi 5 octobre / 6:00 pm – 7:00 pm
Council of Chapters Meeting /
Rencontre du Conseil des sections (Confederation 3)
Tuesday, October 6 / Mardi 6 octobre / 8:00 am – 9:15 am
CANO/ACIO Annual General Meeting Assemblée Générale Annuelle de l’ACIO/CANO (Concert Hall)
CANO/ACIO Awards of Excellence Ceremony Cérémonie des prix de l’ACIO/CANO (Concert Hall)
Radiation Oncology Special Interest Group (Confederation 3)
Gynecological Oncology Special Interest Group (Confederation 5 & 6)
Complementary Medicine Special Interest Group (Tudor 7)
Leadership Special Interest Group (Tudor 8)
Advanced Practice Nursing Special Interest Group (Alberta)
Cancer Survivorship Special Interest Group (British Columbia)
Wednesday, October 7 / Mercredi 7 octobre / 4:30 pm – 5:00 pm
Closing Ceremony and Abstract Award Presentation /
Cérémonie de clôture et remise de prix pour abrégés (Concert Hall)
30
Merck Dinner Symposium /
Souper éducatif Merck 7:00 PM - 9:00 PM | Concert Hall
Targeting the PD-1-PD-L1 Axis: How
Immunotherapies are Changing the
Treatment of NSCLC
Day One / Jour un
Sunday, October 4, 2015
Dimanche 4 octobre 2015
Astellas Breakfast Symposium /
Déjeuner éducatif
Astellas | Concert Hall
7:15 AM - 8:30 AM
The Nurse’s Role in the CRPC Patient
Journey
Dr. Scott Berry, Sunnybrook Odette Cancer Centre.
Learning Objectives:
• Explain the mechanism of action of anti-PD-L1/anti-PD-1
immunotherapies
• List the anti-PD-L1/anti-PD-1 immunotherapies currently
being developed for the treatment of lung cancer
• Understand the relationship between PD-L1 expression,
testing, and efficacy of immunotherapy
• Feel confident managing of adverse events related to
anti-PD-L1/anti-PD-1 immunotherapies
Description:
Therapy which boosts the immune system’s natural antitumour response has become an area of great interest
in oncology. Anti-PD-1/PD-L1 immunotherapy was
recently approved for the treatment of melanoma and is
in development for the treatment of non-small cell lung
cancer (NSCLC). T-cell function is part of the body’s natural
anti-tumour response. Some tumours express the protein
PD-L1. When PD-L1 binds to the PD-1 receptor on T-cells it
interferes with T-cell function, thus allowing the tumour to
evade the immune system. Anti-PD-1/PD-L1 agents block the
interaction between T-cells and PD-L1 by binding to PD-1 or
PD-L1. This allows an anti-tumour immune response to be
generated. This symposium will review the immunotherapy
currently being developed for the treatment of NSCLC. It
will explore the relationship between PD-L1 expression on
tumour cells and the efficacy of these agents. Lastly, it will
provide guidance on patient counselling and management of
adverse events.
• Review new data for CRPC patient therapy
• Recognize the impact of the different treatments on patient
quality of life
• Differentiate the nurse’s role in the multidisciplinary team for
the management of CRPC patients
Opening Ceremony /
Cérémonie d’ouverture
8:45 AM - 9:30 AM | Concert Hall
Workshop / Atelier I-01
9:30 AM - 11:00 AM | Confederation 3
Designing a Small Manageable Qualitative
Study in Your Clinical Unit
Sally Thorne, RN, PhD, University of British Columbia,
Vancouver, British Columbia, Canada.
9:30 AM - 11:00 AM | Confederation 5&6
The CALM Intervention Workshop: Taking
the Passion for Psychosocial Care in
Nursing to the Next Level
Maurene McQuestion, RN, BScN, MSc, CON(C),
Patricia Murphy-Kane, RN, BScN, MN, CHPCN (C),
Kelly McGuigan, RN, BScN, MN, CON(C) CHPCN(C),
Carmine Malfitano, MSW, RSW, Gary Rodin, MD, FRCPC,
Sarah Hales, MD, PhD, FRCP(C), Princess Margaret Cancer
Centre, Toronto, Ontario, Canada.
31
Day One / Jour un
Saturday, October 3, 2015
Samedi 3 octobre 2015
Day One / Jour un
Concurrent Session / Atelier simultané Concurrent Session / Atelier simultané
I-03 9:30 AM - 11:00 AM | Tudor 7
I-04-B 10:00 AM - 10:30 AM
Concurrent Session / Atelier
simultané I-03-A 9:30 AM - 10:00 AM
Nurse-Led Model for Oncology Patient
Follow-Up
Rooted in Optimal Care-Licensed Practical
Nurses in Oncology
Kathy Coskey, RN, BScN, CON(C), CCRP1, Margaret
F. Forbes, RN(EC), MN, CON(C), BScN1,2, 1Hamilton Health
Sciences, Hamilton, Ontario, Canada, 2McMaster University,
Hamilton, Ontario, Canada.
Robin Moser, LPN, Tish Palfrey, LPN, Jackie Bergin, LPN,
Barbara Moore, LPN, Lizanne Clark, LPN, Tina S. Haayer, BScN,
LPN, Andrea Knox, BScN, CON(C), Allison P. Filewich, BScN,
CON(C), BC Cancer Agency, Kelowna, British Columbia, Canada.
Concurrent Session / Atelier simultané
I-04-C 10:30 AM - 11:00 AM
Concurrent Session / Atelier simultané Up Stream and Down the Road
Introducing a Mobile Cancer Screening
I-03-B 10:00 AM - 10:30 AM
Coach to Under- and Never-Screened
Cancer Survivorship Nurse Practitioner: Populations in an Urban Setting
Reflections on Implementation
Kristina Morrison, NP, Lisa McCune, MA, BC Cancer
Agency, Vancouver, British Columbia, Canada.
Patti-Ann Allen, RN, BScN, MScN, CON(C), Riley Crotta,
MHSc, Alyssa Higginson, BSc, MHSc, Britney Martin, BSc, MHSc,
Hamilton Health Sciences, Hamilton, Ontario, Canada.
I-03-C 10:30 AM - 11:00 AM
I-05 9:30 AM - 11:00 AM | Alberta
Adapting to Change: The Nurse’s Role in Concurrent Session / Atelier simultané
Oral Chemotherapy Administration
I-05-A 9:30 AM - 10:00 AM
Samantha Scime, BScN, RN, St. Michael’s Hospital,
Toronto, Ontario, Canada.
An Adaptation of a Purposeful
Nursing Framework to Understand
Interprofessional Patient-Centred
I-04 9:30 AM - 11:00 AM | Tudor 8
Practice in Oncology Teams: Usefulness
Concurrent Session / Atelier simultané and Limitations
Karine Bilodeau, RN, PhD, CON(C)1 2, Tremblay
I-04-A 9:30 AM - 10:00 AM
,
Usability and Acceptability of Nevasic
Audio Program in Management of
Chemotherapy-Induced Nausea
and Vomiting
Saeed Moradian, PhD, MA, BScN4, Alexander
Molassiotis, PhD, RN1,2, Catherine Walshe, PhD, RN3, 1The
Hong Kong Polytechnic University, Hung Hom, Kowloon,
HKSAR, Hong Kong, 2Hung Hom, Kowloon, HKSAR, Hong
Kong, 3Lancaster University, Lancaster, United Kingdom,
4University Health Network, Toronto, Ontario, Canada.
32
Dominique, RN, PhD1,2, 1Université de Sherbrooke, Longueuil,
Quebec, Canada, 2Charles Le-Moyne Hospital Research
Centre, Longueuil, Quebec, Canada.
I-05-B 10:00 AM - 10:30 AM
Lung Cancer Navigation Program: How the
Patients React to this New Model of Care
Delivery During the First Six Months?
Julie Dallaire, MScN, Andreanne Saucier, MScN, CON(C),
Andrea M. Laizner, PhD, Anita Mehta, PhD, CON(C), MarieClaire Richer, PhD, MUHC, Montreal, Quebec, Canada.
Developing and Implementing an
Interdisciplinary Team-Based Care
Approach for Patients with a Suspected
or Confirmed Thyroid Cancer Diagnosis
(ITCA-THYCA)
Gabrielle Chartier, RN1, Melissa Henry, PhD2, Christina
MacDonald, RN1, Magali Dewitte, MSc3, Martin Black, MD1,
Richard Payne, MD1, Alexander Mlynarek, MD1, Antoinette
Ehrler, MSc1, Carmen Loiselle, PhD2, Zeev Rosberger, PhD2, Saul
Frenkiel, MD4, Michael Tamilia, MD1, Michael Hier, MD1, 1Jewish
General Hospital, Montreal, Quebec, Canada, 2McGill University,
Montreal, Quebec, Canada, 3Lady Davis Institute, Montreal,
Quebec, Canada, 4Montreal University Health Centre, Montreal,
Quebec, Canada.
Health Break / Pause Santé
11:00 AM - 11:30 AM
Canadian Room
Helene Hudson Lectureship /
Conférence Helene Hudson
11:30 AM - 12:30 PM | Concert Hall
Becoming a Navigator: Building Core
Competencies
Sarah Champ, BScN, Nursing Education, Jennifer
Anderson, RN, MN, CON(C), Linda Watson, RN, PhD,
CON(C), Cancer Control, Alberta Health Services, Calgary,
Alberta, Canada.
Cancer Patient Navigation has been identified as a strategy
to improve person centredness, and to address the
challenges related to access, care coordination, and system
integration. As a result, a provincial navigation program
involving 15 rural and isolated urban cancer centres has
been implemented in our provincial cancer program. A robust
program evaluation, conducted two years post program
implementation, demonstrated the numerous positive effects
that the introduction of the navigator role has had on the
patient experience, system efficiencies, and health system
utilization. The need to develop new professional development
supports for both experienced and novice navigators became
apparent as our focus shifted from implementing a new
initiative to sustaining and growing an existing program. The
initial navigation orientation was built on existing national
competencies, in the domains of facilitating continuity of
care and patient and family empowerment. However, program
staff recognized that additional competency development
around providing supportive care in a rural and/or isolated
community was required. This presentation will explore both
the redevelopment of the navigation orientation program to
better reflect the realities of rural navigation practice, and the
development of on-going professional development supports
to ensure experienced navigators have support to continually
expand their competencies. Those in navigation, education or
program development roles will benefit from understanding one
province’s approach to developing a standard orientation and
competency framework for navigation.
L’orientation despatients en oncologie a été dégagée à titre
de stratégie permettant d’améliorer la prestation de soins
axés sur la personne et d’aborder les défis relatifs à l’accès et
à la coordination des soins et à l’intégration du système. Par
conséquent, un programme provincial d’orientation des patients
mettant en jeu 15 centres de cancérologie en milieu rural et en
région isolée a été mis en œuvre au sein de notre programme de
cancérologie provincial. Une vigoureuse évaluation du programme
réalisée deux ans après sa mise en place, a souligné les nombreux
effets positifs que l’implantation du rôle d’intervenant-pivot a
eus sur l’expérience des patients, le rendement du système et
l’utilisation du système de santé. La nécessité d’élaborer de
nouveaux services d’appui au perfectionnement professionnel
pour les intervenants-pivots chevronnés et débutants s’est
manifestée alors que notre priorité passait de la mise en œuvre
d’une nouvelle initiative au maintien et à la croissance d’un
programme existant. La formation initiale à l’orientation des
patients se basait sur des compétences nationales préexistantes
dans les domaines de la facilitation de la continuité des soins et
de l’autonomisation des patients et de leurs proches; toutefois,
le personnel du programme a convenu qu’il était nécessaire
de développer des compétences additionnelles au niveau
de la prestation de soins de soutien en milieu rural et/ou en
région isolée. Cette présentation explorera le remaniement du
programme de formation à l’orientation des patients afin de
mieux refléter la réalité de la pratique de l’orientation en milieu
rural et le développement de services permanents d’appui
au perfectionnement professionnel afin que les intervenantspivots chevronnés disposent du soutien nécessaire pour
développer régulièrement leurs compétences. Les intervenants
exerçant des rôles en orientation des patients, en éducation
ou en élaboration de programmes tireront parti de l’examen
de l’approche retenue par une province pour élaborer un cadre
normalisé de formation et de développement des compétences
pour l’orientation des patients.
33
Day One / Jour un
I-05-C 10:30 AM - 11:00 AM
Day One / Jour un
Janssen Lunch Symposium /
Dîner éducatif Janssen
12:45 PM - 2:15 PM
Concert Hall
Transforming Patient Care in Canada:
Practical Nursing Considerations with
Emerging Treatments in Malignant
Hematology
•
To explore the role of new targeted therapies in CLL and
emerging mechanisms of action in multiple myeloma to
address unmet patient needs
•
To provide practical insights on the role of nursing in
side-effect management with new targeted therapies
•
To develop patient support strategies for nursing to
ensure compliance to targeted therapies and optimizing
patient outcomes
II-01 2:15 PM - 4:15 PM | Confederation 3
II-01-C 3:15 PM - 3:45 PM
Assessing the Feasibility and Impact of
Providing Dignity Therapy to Patients
with Primary Malignant Brain Tumours
and Their Caregivers in an Adult
Ambulatory Oncology Care Setting
Claire Moroney, RN(EC)1, Denise Bilodeau, MS1, Janet Ellis,
MD1, Jennifer Moore, MD1, Hyla Okorofsky, BSN1, Margaret I.
Fitch, PhD2, 1Sunnybrook Health Sciences Centre, Toronto, Ontario,
Canada,2University of Toronto, Toronto, Ontario, Canada.
II-01-D 3:45 PM - 4:15 PM
Psychosocial Oncology Program: Perceptions of a CNS Telephone Triage Assessment
Anita Mehta, PhD1, Andrea M. Laizner, PhD1,
France Desrochers, BSc2, Erin Donivan, BScN2, 1McGill
University Health Centre, Montreal, Quebec, Canada,
2McGill University, Montreal, Quebec, Canada.
II-02 2:15 PM - 4:15 PM | Confederation 5&6
II-01-A 2:15 PM - 2:45 PM
Women’s Perceptions of Support
Received During Nurse-Led Teaching
About Vaginal Dilator Use
Karen Rezk, RN, BScN, MSc(A) candidate1, Alexa Bisaillon,
RN, BNI, MSc(A) candidate1,2, Renata Benc, RN, BA,
MSc(A), CON(C)2, Tara Jesion, RN, MSc(A), CON(C)2,1,
1McGill University, Montreal, Quebec, Canada, 2Jewish
General Hospital, Montréal, Quebec, Canada.
II-02-A 2:15 PM - 3:00 PM
Facilitating Advanced Care Planning
in Malignant Hematology: A Quality
Improvement Project
Leah M. Jodoin, RN(EC), MN, CON(C), St. Michael’s
Hospital, Toronto, Ontario, Canada.
II-01-B 2:45 PM - 3:15 PM
II-02-B 3:00 PM - 3:45 PM
Oncology Nurses Striving to Provide
Management of Death Rattle at the End of
Exceptional Care to the Complex Oncology Life: What Oncology Nurses Need to Know
Patient. What’s Next Mr. W.? Can You
Susan E. McClement, RN, PhD, CHPCN(C)1 2,
Identify the Oncology Emergencies?
,
Laurie Ann Holmes, BScN, CON(C), CHPCN(C),
The Ottawa Hospital, Ottawa, Ontario, Canada.
34
1College of Nursing, Winnipeg, Manitoba, Canada,
2CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Improving Access to Standardized Fertility What’s in a Name? The Impact of Obtaining
Preservation Information for Older
an Oncology Specialty Designation
Adolescents and Young Adults with Cancer Mary Jane Esplen, RN, PhD1 3, Jiahui Wong, PhD1 3,
Using a User-Centred Approach
Komal Patel, RN, MN, CON(C), CHPCN(C)1 2, Maureen Watt,2,
,2 ,
,
Seline Tam, BSc, Laura Mitchell, RN, MN, CON(C),
Abha Gupta, MSc, MD, FRCPC, Princess Margaret Cancer
II-03 2:15 PM - 3:45 PM | Tudor 7
Smit, RN, MN, CON(C)4, Donalda MacDonald, RN, CON(C)1,
Esther Green, RN, MSc5, 1de Souza Institute, Toronto, Ontario,
Canada, 2University Health Network, Toronto, Ontario,
Canada, 3University of Toronto, Toronto, Ontario, Canada,
4Grand River Hospital/Grand River Regional Cancer Centre,
Kitchener, Ontario, Canada, 5Canadian Partnership Against
Cancer, Toronto, Ontario, Canada.
II-04 2:15 PM - 4:15 PM | Tudor 8
II-03-A 2:15 PM - 2:45 PM
How Does Your Garden Grow? Stories of
Nursing Leadership in a Blossoming Team II-04-A 2:15 PM - 2:45 PM
Supportive Care for Cancer Survivors
Allison P. Filewich, BScN, CON(C), Andrea Knox,
in the Community: The Roles of Parish
BScN, CON(C), Tina S. Haayer, BScN, British Columbia
Cancer Agency, Kelowna, British Columbia, Canada.
Nurses and Nurse Pratictioners
II-03-B 2:45 PM - 3:15 PM
Accreditation Standards for Integrated
Cancer Care
Stephanie Carpenter, MA, Accreditation Canada,
Ottawa, Ontario, Canada.
II-03-C 3:15 PM - 3:45 PM
Navigation of Lung Cancer Patients
Through the Diagnostic Phase of Care:
Purposeful Early Engagement
Chantal Bornais, RN, BSN, Jennifer Smylie, BN, RN,
MHSM, The Ottawa Hospital, Ottawa, Ontario, Canada.
Krista Wilkins, PhD, RN, University of New Brunswick,
Fredericton, New Brunswick, Canada.
II-04-B 2:45 PM - 3:30 PM
The Development of a Nurse
Practitioner-Led Rapid Assessment
Clinic for Acute Leukemia
Alix J. Duck, NP, MN, BScN, BA, Kayla J. Madsen,
BScN, Nancy A. Pringle, RN, Nancy A. Wagg, RN, Princess
Margaret Cancer Centre, Toronto, Ontario, Canada.
II-04-C 3:30 PM - 4:15 PM
Palliative Care Referral, Triage, and Patient
Navigation: a Nurse-Led Quality Initiative
Cathy Kiteley, RN, MScN, CON(C), CHPCN(C),
Maria Rugg, MN, CHPCN(C), Robert Sauls, MD, Trillium
Health Partners, Mississauga, Ontario, Canada.
35
Day One / Jour un
II-02-C 3:45 PM - 4:15 PM
II-03-D 3:45 PM - 4:15 PM
Day One / Jour un
II-05 2:15 PM - 4:15 PM | Alberta
II-06 2:15 PM - 4:15 PM | British Columbia
II-05-A 2:15 PM - 2:45 PM
II-06-A 2:15 PM - 2:45 PM
Brain Fog: Is it All in Their Heads?
Anita Mehta, PhD, Andreanne Robitaille, MSN, McGill
University Health Centre, Montreal, Quebec, Canada.
A Mixed Method Study Exploring
Colorectal Cancer Screening Behaviors
Among South Asian Immigrants in Ontario
II-05-B 2:45 PM - 3:15 PM
Joanne Crawford, BScN, CON(C), MScN, PhD(c)1,2,
1University of Toronto, Toronto, Ontario, Canada, 2Brock
University, St. Catharines, Ontario, Canada.
Using an Interprofessional Team Approach Concurrent Session / Atelier simultané
to Enhance the Care of Patients with
II-06-B 2:45 PM - 3:15 PM
Complex Treatment Pathways
Health Care Teams Collaborating to Manage
Eirena N. Calabrese, BSN, RN, MN, Arlene Court, BSN,
Patients’ Pain at the Top of the Ladder
RN, CON(C), Glen Gonzales, BSc, MRT(T), Brian Liszewski,
BSc, MRT(T), Colin Myers, BA, Mark Pasetka, BSc, BScPharm.,
PharmD, R.Ph., Steve Russell, BSc, MRT(T), Yee Ung, MD,
Jackie Ezezika, BA, PEng, MEng, Yooj Ko, MD, Sunnybrook
Health Sciences Centre, Toronto, Ontario, Canada.
Laurie Ann Holmes, BScN, CON(C), CHPCN(C), The
Ottawa Hospital, Ottawa, Ontario, Canada.
II-06-C 3:15 PM - 3:45 PM
II-05-C 3:15 PM - 3:45 PM
The Breast & Bone Health Program:
A Transdisciplinary Model of Care to
Preparing the Specialized Oncology Nurse
Proactively Address Bone Health in
for International Partnerships: Reflections
Breast Cancer
from One Centre’s Experience
Samantha Mayo, RN, PhD, Pamela Savage, RN, MAEd,
CON(C), Justin Young, BA, MPA, University Health Network,
II-05-D 3:45 PM - 4:15 PM
Enhancing Purpose and Passion Through
the Work of Our Partnership Council
Kathryn McKay, RN, BScN, Linda Nixon, RN, Trillium
Garnet J. Lau, RN, MSc(A), MSc1, Julie Lapointe, PhD,
erg. OT(C)2, Mary-Ann Dalzell, MSc, PT1, Nadia Smirnow,
BSc, PT CLT1, Marize Ibrahim, MSc, PT CSLT1, Evan Beloff, BA,
ND1, Carole Séguin, BSc Inf.1, Nicole Tremblay, PhD3, Lindsay
Duncan, PhD2, Suzanne O’Brien, MA1, Carmen G. Loiselle, RN,
PhD1,2, 1Jewish General Hospital, Montreal, Quebec, Canada,
2McGill University, Montreal, Quebec, Canada, 3Université de
Montreal, Montreal, Quebec, Canada.
II-06-D 3:45 PM - 4:15 PM
An Interprofessional Approach to
Oral Anti-Cancer Management: The
Development, Implementation and
Evaluation of a Care Pathway for Patients
Eirena N. Calabrese, RN, BScN, MN, Alia Thawer,
BSc, BSc.Pharm, R.Ph, Sunnybrook Health Sciences
36
By invitation only.
2:15 PM - 4:15 PM | Quebec
Committee and SIG meetings /
Rencontre des comités et groupes
d’intérêts spéciaux
4:15 PM - 5:15 PM
Focus Group /
Panel de discussion
5:15 PM - 6:15 PM | Alberta
This session will be of interest for nurses engaged in the area
of hematology that play an active role in patient education.
• Gain insight into the specific needs of nurses as it relates
to their role in education and counselling of R-CLL and R-FL
patients, who are about to initiate therapy
• Gain feedback on select educational materials
Keynote Presentation I /
Conférence plénière I
6:15 PM - 7:15 PM | Concert Hall
With over 28 years experience in the health care industry and
as a registered nurse in the operating room, she understands
how your attitude affects those around you at home and in the
workplace environment. Meg is co-author of the book “From
the Stage to the Page - Life Lessons from Four Funny Ladies”.
She has appeared on the CBC Television Network, Women’s
Television Network and Prime TV, as well as being featured
in many radio programs and comedy festivals. Meg has a
tremendous ability to connect with her audience and take
every event to a higher level.
La conférencière professionnelle et comédienne Meg Soper est
considérée être l’une des meilleures motivatrices au Canada. Elle
combine un sens de l’humour remarquable avec une perspective
unique sur la vie afin de captiver son public et de lui offrir à chaque
fois une présentation pleine d’inspiration et de divertissement.
Meg a été conférencière d’honneur et interprète vedette lors de
conventions et de cérémonies de grandes sociétés d’Amérique du
Nord et d’un peu partout au monde. Elle a partagé la scène avec des
vedettes telles que Ray Romano et Ellen Degeneres.
Comptant plus de 28 ans d’expérience dans l’industrie des soins
de la santé et en tant qu’infirmière de salle d’opération, elle
comprend comment notre attitude affecte ceux qui sont autour de
nous à la maison et dans notre environnement de travail. Meg est
la co-auteure du livre « From the Stage to the Page - Life Lessons
from Four Funny Ladies ». Elle est passée aux réseaux de télévision
CBC, Women’s Television Network et Prime TV, en plus de sa
participation à de nombreux programmes de radio et de festivals
d’humour. Meg a la capacité formidable d’accrocher son auditoire
et d’élever chaque événement à un niveau supérieur.
Welcome Reception /
Réception de bienvenue
8:00 PM onwards | Canadian Room
Meg Soper, RN
Professional speaker and comedian
Meg Soper is recognized as one of the
premiere motivators in Canada. She
combines her remarkable sense of
humour with her unique perspective
of life to captivate her audience and
provide them with a presentation filled
with inspiration and entertainment.
Meg has appeared as a keynote speaker and feature
performer at conventions and corporate functions across
North America and internationally. She has shared the stage
with such celebrities as Ray Romano and Ellen Degeneres.
37
Day One / Jour un
CANO/ACIO’s International Strategic
Directions – Roundtable /
Table ronde : directions stratégiques
internationales de l’ACIO/CANO
Day Two /
Jour deux
Monday, October 5, 2015
Lundi 5 octobre 2015
Zumba Session / Séance de zumba
6:15 AM - 7:00 AM | Algonquin
Day Two / Jour deux
Pfizer Injectables Breakfast Symposium /
Déjeuner éducatif
Pfizer Injectables
Improving the Management of Patients
with Cancer Associated Thrombosis
Martha Louzada, MD, FRCPC, BSc, MSc, Assistant
Professor of Medicine, Hematology Consultant at the
University of Western Ontario/ London Health Sciences
Centre, London, Ontario
Adrienne Fulford, RN(EC), MScN, CON(C), Nurse
Practitioner-PHC, Hematology Oncology, Victoria Hospital,
London, ON
The goal of this session is to review the evidence in the
management of cancer associated thrombosis and explore what
can be done to improve patient compliance with their treatment.
• Critically appraise available evidence in the management
of cancer associated thrombosis using LMWH
• Gather insight on how to ensure patients are compliant
with their treatment
Merck Lectureship and Award
Presentation / Conférence Merck et
remise de prix
The Implementation of a Nurse-led
Subcutaneous Immunoglobulin (SCIG)
Program at CancerCare Manitoba
For individuals diagnosed with chronic lymphocytic leukemia
(CLL) or lymphoproliferative diseases, infectious complications
may occur at any time and may be life-threatening. Traditionally,
the standard treatment for hypogammaglobulinemia has been
hospital-based, intravenous immunoglobulin (IVIG) infusions. IVIG
is resource intensive and associated with systemic adverse events.
For patients, it is also a necessity. As the demand for cancerrelated services continues to rise, clinicians are challenged with
examining their current practice and identifying ways of utilizing
existing resources in new and innovative ways. Subcutaneous
immune globulin (SCIG) therapy is used to treat patients with
primary immune deficiency (PID) but there is growing interest for
its use in the CLL patient population. There are many benefits of
subcutaneous administration including improved quality of life
measures for patients.
The application of SCIG in oncology is relatively new and poorly
documented. Moreover, the management of patients within
oncology centres is not documented in the literature. An initial
analysis at our centre highlighted multiple opportunities for
improvement, patient engagement and change related to
immunoglobulin administration.
This presentation will highlight our nurse-led SCIG program
and show how an oncology nurse can examine current health
care practices and infuse passion and meaning to make
innovative changes that impact patient lives, bring meaning
and satisfaction to our work, and have an impact on the
delivery of cancer care.
Mise en œuvre, à CancerCare Manitoba,
d’un programme d’administration souscutanée d’immunoglobuline géré par le
personnel infirmier
Chez les personnes diagnostiquées de leucémie lymphoïde
chronique (LLC) ou de syndromes lymphoprolifératifs, des
complications infectieuses peuvent survenir en tout temps et
constituer un danger de mort. Habituellement, le traitement
standard de l’hypogammaglobulinémie consiste en des
perfusions d’immunoglobuline par voie intraveineuse en milieu
hospitalier. Ces dernières sont exigeantes en termes de ressources
et sont associées à des événements indésirables systémiques.
C’est également une nécessité pour les patients. Comme la
demande de services d’oncologie ne cesse d’augmenter, le
personnel clinique a pour défi d’examiner sa pratique actuelle
et de cerner des manières à la fois nouvelles et novatrices
d’utiliser les ressources existantes. L’administration souscutanée d’immunoglobuline sert à traiter les patients atteints
de déficit immunitaire primaire, mais on s’y intéresse de plus
en plus concernant son emploi auprès des patients atteints de
LLC. L’administration par voie sous-cutanée s’accompagne de
nombreux avantages dont de meilleures mesures de la qualité de
vie chez les patients.
Erin Streu, RN, MN, CON(C), Clinical Nurse Specialist,
CancerCare Manitoba.
38
Cette présentation tracera les grandes lignes de notre programme
d’administration d’immunoglobuline par voie sous-cutanée géré
par le personnel infirmier et montrera comment une infirmière en
oncologie peut examiner les pratiques actuelles liées aux soins
de santé et faire fond sur sa passion et sa réflexion pour générer
des changements novateurs ayant une incidence sur la vie des
patients et sur la prestation des soins contre le cancer et qui
rendent notre travail plus significatif et satisfaisant.
10:00 AM - 10:30 AM
Canadian Room
Posters Group 1 Canadian Room Foyer
Annual International Symposium:
CANO/ACIO, ONS, ISNCC /
Symposium international annuel :
ACIO/CANO, ONS, ISNCC
Precision Medicine: Emerging Ethical
Issues for Oncology Nurses
Stella Aguinaga Bialous, RN, DrPH, FAAN, President, ISNCC
Margaret Barton-Burke, PhD, RN, FAAN, President, ONS
Barbara Fitzgerald RN, MScN, President, CANO/ACIO
• Identify ethical issues of genomic-based oncology nursing
practice
• Describe the ethical foundations of oncology nursing practice
from a global perspective
• Discuss the ethical challenges that patients and providers
face when translating genomic information into practice
Oncology nursing practice is complex. No longer is there a “one
size fits all” approach to treatment. Over the past 10 years, the
ability to sequence the human genome expanded the horizon
for understanding many diseases, especially cancer. Precision
medicine takes many factors into consideration, including age,
tumor histology, as well as tumor genetics and proteomics.
The promise of precision medicine offers exciting possibilities,
yet bring challenging ethical issues such as informed decision
making, informed consent and genetic testing, maintaining
privacy and confidentiality, preventing genetic discrimination and
strengthening genomic care and access around the world.
Oncology nurses play a critical role in advocating, educating,
counseling, and supporting patients and their families who
are making gene-based healthcare decisions. Knowledge and
understanding of current and emerging ethical issues is an
essential component and underpinning of oncology nursing
practice in this rapidly evolving field. This session focuses on a
presentation and discussion on the ethics/ethical underpinnings
of genetics, genomics, and the decision-making process. This
session includes genomic-based exemplars and case studies to
help you explore your own ethical beliefs and concerns.
Boehringer Ingelheim Lunch
Symposium / Dîner éducatif
Boehringer Ingelheim
11:45 AM - 1:15 PM |
Concert Hall
Advances in the Treatment of Non-Small
Cell Lung Cancer (NSCLC): A Nursing
Perspective
Dr. Labib Zibdawi, Medical Oncology, Stronach
Regional Cancer Centre, Southlake Regional Health Centre,
Newmarket, Ontario
Massey Nematollahi, Clinical Coordinator, Clinical
Trials Stronach Regional Cancer Centre Southlake, Ontario
Lorraine Martelli, Nurse Practitioner - Cancer Distress
Screening and Response Initiative Hamilton Health
Sciences Corporation Hamilton, Ontario
• Better understand the evolution of treatment options for
patients with NSCLC
• Discuss how nurses can influence early biomarker testing to
optimize treatment decisions
• Review the pivotal role nurses play in working with patients to
help them manage the side effects of treatment
• Discuss how to incorporate palliative care and symptom
management into care of the patient affected by lung cancer
39
Day Two / Jour deux
L’application de l’administration sous-cutanée
d’immunoglobuline en oncologie est relativement nouvelle et
est mal documentée. De plus, la prise en charge des patients
dans les centres d’oncologie n’est aucunement documentée
dans la littérature. L’analyse initiale effectuée dans notre centre
a permis de cerner de nombreuses possibilités d’amélioration,
de promotion de la participation des patients et de changement
relativement à l’administration d’immunoglobuline.
Workshop / Atelier III-01
1:15 PM - 2:45 PM | Confederation 3
Supporting Practice: Canadian Virtual
Hospice Knowledge Tools Project
Jo-Ann Lapointe McKenzie, RN, BScN, MN, Shelly
Cory, MA, Brenda Hearson, BN, MN, CHPCN(C), Canadian
Virtual Hospice, Winnipeg, Manitoba, Canada.
• Increase the knowledge and utilization of the resources
and support available on the Virtual Hospice website
Day Two / Jour deux
• Discuss the challenges faced by marginalized patients and
families in accessing palliative care
• Make nurses aware of the new tools that will be available
on the Virtual Hospice website
• Participate in the dissemination and evaluation of the
tools and offer suggestions for future tool development
1:15 PM - 2:45 PM | Confederation 5&6
Medically Assisted Death in Canada:
Careful and Thoughtful Practice
Directions for Oncology Nurses
Barbara Fitzgerald, RN, MScN2, Barbara Russell, MBA,
PhD, Shari Moura, RN, MN, CON(C), CHPCN(C)1,
1Princess Margaret Cancer Centre - University Health Network,
Toronto, Ontario, Canada, 2CANO/ACIO President, BC Children’s
Hospital, Vancouver, British Columbia, 3Toronto General Hospital,
Women’s College Hospital, Toronto, Ontario, Canada.
In 1993, the Supreme Court of Canada ruled in a split decision
against Sue Rodriguez, a woman with advanced ALS wanting
medical assistance to end her life. Twenty-two years later, however,
the Court ruled unanimously in favour of Lee Carter, a woman with
progressive spinal stenosis, wanting medical assistance to die. The
Court’s ruling impacts federal and provincial/territorial legislation
as well as professional regulations. Recognizing that governments
and professional bodies may wish to write practice-guiding policies,
the Supreme Court instituted a 12-month waiting period before its
ruling takes effect.
This session will examine the ruling’s impact on oncology nurses’
work in hospital- or community-based, interprofessional settings.
Various ethical, legal, professional considerations are included in
the session’s 5 parts: (1) “pre-Carter” – a prototypical case of a
patient with advanced cancer and nurses’ usual responsibilities
in discussing aggressive treatment versus palliative care with
the patient and family as well as highlight typical physician and
pharmacist responsibilities, (2) key directions and reasons from the
Supreme Court’s Carter v. Canada ruling, (3) “post-Carter” – the case
40
re-examined to identify nursing responsibilities that likely will and
will not change when a patient is interested in medical assistance
to die, (4) “what to pay attention to” if legislative and professional
guidelines are written to help clarify certain criteria, institute
appropriate safeguards, and establish seamless procedures,
and (5) the audience’s insights and views of how their work with
oncology patients and interprofessional teams will benefit from or
be challenged by this pivotal change in Canadian healthcare and
society.
III-03 1:15 PM - 2:45 PM | Tudor 7
III-03-A 1:15 PM - 2:00 PM
Pursuit of Excellence in Chemotherapy
Management: The Evolution of a Chemo
Council
Eleanor A. Miller, BScN, MAEd, Linda Ramjohn,
BScN, MAEd, Candice McGaw, BScN, Sunnybrook Health
Sciences Centre, Toronto, Ontario, Canada.
III-03-B 2:00 PM - 2:45 PM
Understanding the Experience of
Individuals Who Attend a Breathing
Wellness Program to Address Dyspnea
Sahaana Rangarajan, BSc1, Cathy Kitelely, BScN,
MScN, CON(C), CHPCN(c)2, 1University of Toronto, Toronto,
Ontario, Canada, 2Trillium Health Partners, Mississauga ,
Ontario, Canada.
III-04 1:15 PM - 2:45 PM | Tudor 8
III-04-A 1:15 PM - 1:45 PM
To Evaluate the Use of a Comprehensive
Geriatric Assessment in Geriatric
Cancer Patients Undergoing Adjuvant
Chemotherapy
Manon A. Lemonde, RN, PhD, Rama Koneru, MD, Orit
Freedman, MD, Archit Malyala, BSc, Durham Regional
Cancer Center, Oshawa, Ontario, Canada.
III-04-B 1:45 PM - 2:15 PM
III-05-C 2:15 PM - 2:45 PM
Wendy L. Petrie, RN, BScN, MScN, CON(C) CHPCN(C),
Sylvie Bruyere, RN, BScN, CON(C) CHPCN(C), Lynn
Kachuik, RN, BA, MS, CON(C) CHPCN(C), The Ottawa
Hospital, Ottawa, Ontario, Canada.
III-04-C 2:15 PM - 2:45 PM
Pseudoprogression in Patients with a High
Grade Glioma: Nursing Implications for
Practice in the Context of Uncertainty
Catherine-Anne Miller, BScN, MHSc, Montreal
Neurological Hospital - McGill University Health Centre,
Montreal, Quebec, Canada.
III-06 1:15 PM - 2:45 PM | British Columbia
Measuring the Impact of Radiation
Therapy Treatment Using Patient Reported
Outcome Measures: BC’s Prospective
III-06-A 1:15 PM - 1:45 PM
Outcomes Support Initiative
Susan J. Curtis, RN, Kam Dosanjh, RN, Fraser Valley
Cancer Centre, Surrey, British Columbia, Canada.
III-05 1:15 PM - 2:45 PM | Alberta
III-05-A 1:15 PM - 1:45 PM
Bringing a Passion for Oncology to the
Generalist Nurse
Jessica Lam, BScN1, Anne Embleton, BScN, MN, OCN,
CON(C)2, 1University Health Network, Toronto, Ontario, Canada,
2Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
III-05-B 1:45 PM - 2:15 PM
Étude pilote /prétest d’un plan de soins de
suivi (PSS) pour des femmes atteintes du
cancer de l’endomètre avec traitements
adjuvants à la fin du traitement initial
Johanne Hébert, PhD1,2, Lise Fillion, PhD2,3, 1UQAR, Lévis,
Quebec, Canada, 2Université Laval, Québec, Quebec, Canada,
3Centre de recherche en cancérologie de l’Université Laval,
Québec, Quebec, Canada.
III-06-B 1:45 PM - 2:15 PM
Étude psychométrique de la version française
du WCCNRR-F adapté pour évaluer le degré
de sévérité de la stomatite chez les patients
recevant des traitements anti-cancéreux
Nicole Allard, PhD, MScN, MEd1, Séverine Garnier, PhD2,
1UQAR campus de Lévis, Lévis, Quebec, Canada, 2Université
Laval, Quebec, Quebec, Canada.
Achieving Integration for Nurse Practitioners
in Oncology: Research in Action
Tina S. Haayer, BScN, Lorelei Newton, PhD, RN, Maxine III-06-C 2:15 PM - 2:45 PM
Alford, PhD, RN, Lisa Henczel, NP, Denise Tarlier, PhD, NP,
BC Cancer Agency, Kelowna, British Columbia, Canada.
Aider les personnes atteintes de cancer
à faire face à la peur de la récidive
Christine Maheu, PhD1, Sophie Lebel, PhD2, 1McGill
University, Montreal, Quebec, Canada, 2University of Ottawa,
41
Day Two / Jour deux
Failing to Prepare Is Preparing to Fail ...
Implementing a Palliative Approach
2:45 PM - 3:15 PM |
Canadian Room
Workshop / Atelier IV-01
Passion and Politics: How Oncology
Nurses Can Influence Public Policy
Day Two / Jour deux
Heather Sinardo, BScN, MN1, Gabriel Miller, BA2,
Joelle Walker, BA, BSc, LLB2, 1Canadian Cancer Society,
Toronto, Ontario, Canada, 2Canadian Cancer Society,
IV-03-B 4:00 PM - 4:45 PM
Issues for the Young Adult with
Cancer: Increasing Access to Fertility
Preservation Information and Services
Laura Mitchell, RN, MN, CON(C)1,2, Eleanor
Hendershot, RN(EC), NP3,4,2, Abha Gupta, MD, MSc1,5,6,
1Princess Margaret Cancer Centre, Toronto, Ontario, Canada,
2University of Toronto, Toronto, Ontario, Canada, 4Hospital for
Sick Children, Toronto, Ontario, Canada.
IV-04 3:15 PM - 4:45 PM | Tudor 8
IV-04-A 3:15 PM - 3:45 PM
Pre-Operative Preparation for People
CANO/ACIO Research Committee Workshop: Undergoing Breast Cancer Surgery in
Kuwait: The Case of Passionate Nurses’
A World Café Approach to Getting Inspired
Initiative to Improve Patient Experience
About Oncology Nursing Research
Dawn Stacey, RN, PhD, CON(C)1, Aronela Benea, RN,
MScN2, Christine Maheu, RN, PhD3, Kristen Haase, RN,
PhD(c)1, Sally Thorne, RN, PhD4, Lorelei Newton, RN,
PhD5, Krista Wilkins, RN, PhD6, Jennifer Stephens, RN,
PhD(c)4, 1University of Ottawa, Ottawa, Ontario, Canada,
2Women’s College Hospital, Toronto, Ontario, Canada, 3McGill
University, Montreal, Quebec, Canada, 4University of British
Columbia, Vancouver, British Columbia, Canada, 5BC Cancer
Agency, Vancouver, British Columbia, Canada, 6University of
New Brunswick, Fredericton, New Brunswick, Canada.
IV-03 3:15 PM - 4:45 PM | Tudor 7
Ai Tanimizu, RN, BScN2, Kholoud Sourani, BN1, Bara’ah
Turkmani, BN1, 1Kuwait Cancer Control Centre, Shuwaikh,
Kuwait, 2University Health Network, Toronto, Ontario, Canada.
IV-04-B 3:45 PM - 4:15 PM
Living Beyond Cancer: A Passionate
Team Approach to Enhancing Recovery
and Survivorship
Terra A. Thibault, BScN, BSc, CON(C)1, Karen H.
Woodworth, BN, CON(C)2, 1Nova Scotia Cancer Centre,
Halifax, Nova Scotia, Canada, 2Queen Elizabeth II Health
Sciences Centre, Halifax, Nova Scotia, Canada.
IV-03-A 3:15 PM - 4:00 PM
Administration of Chemotherapy on Non- IV-04-C 4:15 PM - 4:45 PM
Oncology Units: Nurses’ Experience and
Nurse-Led Proactive Calls Provided
Barriers and Facilitators to Best Practice
to First Time Chemotherapy Patients
Virginia Lee, RN, PhD, Luisa Luciani Castiglia, RN,
MSc(A), CON(C), Louise Fullerton, RN, MSc(A), Sonia
Castiglione, RN, MSc(A), Myriam Skrutkowski, RN, MScN,
CON(C), McGill University Health Centre, Montreal,
Quebec, Canada.
42
with Gastrointestinal Cancers:
A Demonstrative Project
Allison Loucks, RN, BA, BScN, Jennifer Petronis, RN, CON(C),
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
IV-06-B 3:45 PM - 4:15 PM
IV-05 3:15 PM - 4:45 PM | Alberta
Joy Bunsko, BSN, CON(C), Amanda Bolderston, MSc, RTT,
FCAMRT, BC Cancer Agency, Surrey, British Columbia, Canada.
IV-06-C 4:15 PM - 4:45 PM
Safe Treatment and Care: Creation of a
IV-05-B 3:45 PM - 4:15 PM
Standard Nurse Initiated Symptom Follow Up
Integration of Palliative Care Early in
Program for Patients Receiving Ipilumumab
Advanced Cancer: Oncology Nurses Can Therapy in an Ambulatory Setting
Make It Happen!
Lynn Kachuik, RN, BA, MS, CON(C), CHPCN(C), The
Ottawa Hospital, Ottawa, Ontario, Canada.
Jen Rosychuk, BScN, Jeevan Dosanjh, BScN, Karen Janes,
MScN, BC Cancer Agency, Vancouver, British Columbia, Canada.
Concurrent Session / Atelier simultané Keynote Presentation II /
Conférence plénière II
IV-05-C 4:15 PM - 4:45 PM
Oncology Nurses Education Program:
TED TEAM
A New Treatment for Metastatic
Pancreatic Cancer
Mary Ferguson-Paré,
Michelle Forman, RN, CON(C)3, Shari Moura, RN, MN,
CON(C), CHPCN(C)1, Angela Whynot, RN, BScN, CON(C)2,
1Princess Margaret Cancer Centre, Toronto, Ontario,
Canada, 2Capital Health, Halifax, Nova Scotia, Canada,
3Burnaby Hospital, Vancouver, British Columbia, Canada.
IV-06 3:15 PM - 4:45 PM | British Columbia
IV-06-A 3:15 PM - 3:45 PM
Dépistage systématique de la détresse :
portraits et regards croisés sur les
perceptions des différents acteurs,
perspectives cliniques et de recherche
Nicole Tremblay, MSc inf., CSIO (C), ICSP(C), Odette
Roy, MSc inf., MAP, PhD, Louise Compagna, BSc inf., Caroline
Provencher, MSc inf., Claudine Tremblay, MSc inf., CSIO(C);
CIUSSS, Est-de-l’île de Montréal, Quebec, Canada.
CM, RN(NP), PhD, CHE
Dr. Ferguson-Paré recently retired as
Vice-President, Professional Affairs
and Chief Nurse Executive at University
Health Network, which comprises
Toronto General, Toronto Western and
Princess Margaret Hospitals as well as Toronto Rehabilitation
Institute. She was also the Vice-President, Nursing Services
at the Baycrest Centre for Geriatric Care; the Vice-President,
Professional Affairs, Human Resources and Organizational
Development at the Vancouver Hospital and Health Sciences
Centre and Vice-President Nursing at the Queen Elizabeth
Hospital, now Toronto Rehabilitation Institute in Toronto.
Her previous experience includes progressive senior nursing
management and executive positions in both the acute care and longterm care sectors; nursing education; and institutional and community
nursing experience in psychiatry, addictions therapy, Victorian
Order of Nurses, family practice and student health. She is an adjunct
faculty member at York and Trent University Schools of Nursing.
43
Day Two / Jour deux
Concurrent Session / Atelier simultané The Key to Iron Chelation in
Myelodysplastic Syndrome Patients:
IV-05-A 3:15 PM - 3:45 PM
Nurses Leading the Way
Driving Excellent Patient Education in
Outpatient Oncology: Are We Delivering Mary C. Doherty, BScN, MN, NP, PHC, Nancy A. Pringle,
RN, Cindy Murray, BScN, MN, NP, Adult, Princess
a ‘Cadillac’ or a ‘Jalopy’ Service?
Margaret Cancer Centre, Toronto , Ontario, Canada.
La docteure Ferguson-Paré a récemment pris sa retraite de son
poste de vice-présidente aux affaires professionnelles et de
chef de direction aux soins infirmiers du Réseau universitaire
de santé, qui englobe les hôpitaux Toronto General, Toronto
Western et Princess Margaret ainsi que l’Institut de réadaptation
de Toronto. Elle a également été vice-présidente aux services
infirmiers du Baycrest Centre for Geriatric Care, vice-présidente
aux affaires professionnelles, aux ressources humaines et au
développement organisationnel du Vancouver Hospital and
Health Sciences Centre et enfin, vice-présidente aux soins
infirmiers à l’Hôpital Queen Elizabeth, devenu maintenant
l’Institut de réadaptation de Toronto à Toronto.
Day Two / Jour deux
Son expérience antérieure inclut une suite évolutive de postes
de direction en soins infirmiers et de postes de cadre supérieur
dans les secteurs des soins aigus et des soins de longue durée;
de l’éducation infirmière; et de l’expérience en soins infirmiers
en institution et dans la communauté en psychiatrie, en thérapie
des toxicomanies, aux Infirmières de l’Ordre de Victoria du
Canada, en pratique familiale et en santé étudiante. Elle est
professeure adjointe aux écoles de sciences infirmières des
universités York et Trent.
Leslee Thompson,
RN, MScN, MBA
Leslee is President and CEO of Kingston
General Hospital and Assistant Professor
in the Faculty of Health Sciences at
Queens University. Starting out at the
bedside as a critical care nurse and then
oncology clinical nurse specialist, Leslee’s passion for improving
patient care has fueled a 30 year career that spans both public and
private sectors and multiple organizations. Prior to joining KGH in
early 2009, she held senior executive positions at Capital Health
Authority (Edmonton, AB), University Health Network, Sunnybrook
& Women’s Health Sciences Centre, Cancer Care Ontario and in the
private sector with Medtronic Canada.
Leslee has an MBA from the University of Western Ontario, a
Masters of Nursing from the University of Toronto, and a Nursing
degree from Queens. She is also a certified corporate director and
sat on the board of Shoppers Drug Mart for seven years. Leslee is
currently Chair of Council of Academic Hospitals of Ontario, Chair
of Foundation of Healthcare Improvement, and a board member of
Ontario Institute of Cancer Research.
Leslee Thompson est la présidente-directrice générale de
l’Hôpital général de Kingston (HGK) et est professeure adjointe
à la Faculté des Sciences de la santé de l’Université Queens. Elle
a commencé comme infirmière en soins intensifs au chevet des
malades puis a travaillé comme infirmière clinicienne spécialisée
en oncologie. La passion de Leslee pour améliorer les soins
aux patients a alimenté une carrière de 30 ans qui s’étend aux
secteurs publics et privés et à de multiples organismes. Avant
de se joindre à l’HGK au début de 2009, elle a occupé des postes
44
de haute direction à la Régie régionale de la santé Capital (à
Edmonton, en Alberta), au Réseau universitaire de santé, au
Sunnybrook & Women’s Health Sciences Center, à Action Cancer
Ontario et enfin, à Medtronic Canada, dans le secteur privé.
Leslee détient une MBA de l’Université Western en Ontario, une
maîtrise en sciences infirmières de l’Université de Toronto, et
un baccalauréat de Queens dans ce même domaine. Elle est
également administratrice de sociétés certifiée et a fait partie
du conseil d’administration de Pharmaprix/Shoppers Drug
Mart pendant sept ans. Leslee est présentement directrice du
Conseil des hôpitaux universitaires de l’Ontario, directrice de la
Fondation canadienne pour l’amélioration des services en santé
et membre du conseil d’administration de l’Institut ontarien de
recherche sur le cancer.
Annie Parker,
PhD, MBA, BCom, BA
In 1965, when Annie Parker was 14, she
lost her mother to breast cancer. Both her
older sister and first cousin also went on
to die from breast cancer.
In 1980, at age 29, Annie was diagnosed with breast cancer and
received a radical mastectomy. Nine years later, she was told she
had third-stage ovarian cancer. To Annie, this pattern was more than
just a fluke and she believed that there was a gene that carried the
disease from generation to generation, but others thought it was
just an eerie coincidence. Annie became obsessed about proving
her theory that the cause of her cancer lay in family genetics.
Annie Parker was one of the first Canadians to be tested and found
positive for Dr. King’s discovery of the BRCA1 mutation.
In 2005, Annie Parker was once again diagnosed with cancer,
this time with a tumor behind the liver. Currently, Annie is living
cancer-free with her second husband Michael Warby. Annie is also
a strong advocate for genetic testing and believes those who have
family members with breast cancer should get tested.
Annie’s inspirational book is the story of cancer, family, survival,
and change. Cinematographer Steven Bernstein turned her
manuscript into a feature film titled Decoding Annie Parker, which
has won awards at the Hamptons International Film Festival and
the Seattle International Film Festival.
En 1965, alors qu’elle n’avait que 14 ans, Annie Parker a perdu
sa mère d’un cancer du sein. Sa sœur aînée ainsi que sa cousine
germaine sont également mortes du cancer du sein.
En 1980, à l’âge de 29 ans, Annie a été diagnostiquée d’un cancer
du sein et a subi une mastectomie. Neuf ans plus tard, elle a appris
qu’elle avait un cancer de l’ovaire de stade 3. Pour Annie, ces
répétitions étaient plus bien qu’un hasard et elle croyait qu’il y avait
un gène qui transmettait la maladie d’une génération à l’autre;
mais pour les autres, ce n’était qu’une coïncidence sinistre. Annie
s’est entêtée à vouloir prouver sa théorie selon laquelle la cause de
son cancer résidait dans la génétique familiale.
En 2005, Annie Parker a été à nouveau diagnostiquée d’un
cancer, cette fois d’une tumeur située derrière le foie.
Présentement, Annie Parker vit sans cancer avec son second
mari, Michael Warby. Annie défend ardemment les tests
génétiques et croit que celles qui ont des membres de famille
atteints du cancer du sein devraient se faire tester.
Le livre inspirant d’Annie Parker raconte l’histoire du cancer,
de la famille, de la survie et du changement. Le cinéaste Steven
Bernstein a adapté son manuscrit pour en faire un long métrage
intitulé Decoding Annie Parker, qui a gagné des prix aux festivals
internationaux du film des Hamptons et de Seattle.
Council of Chapters Meeting /
Rencontre du conseil des sections
Roche Dinner Symposium /
Souper éducatif Roche
Day Three /
Jour trois/
Tuesday, October 6, 2015
Mardi 6 octobre 2015
Roche Breakfast Symposium /
Déjeuner éducatif Roche
The Oncology Nurse’s Role in Assessing
and Managing Catheter-Related
Thrombosis and Infection
Alana Campbell, RN, MN, CVAA(c), Foothills hospital,
Alberta, Inara Karrei, RN, BScN, M.Ed., CON(C), Ottawa
Hospital Cancer Centre, Ontario.
• Describe the best practices for assessment and
management of CVAD dysfunction
Administration of GAZVYA for the First Time
• Discuss the causes and consequences of CVAD
dysfunction, focusing on infection
Rebekah Conlon, RN, Research Coordinator in Hematology,
Nova Scotia Health, Halifax, NS.
• Understand the bi-directional relationship between CRT
and CRBSI
Carolyn Owen MD, FRCPC, Department of Medicine and
Oncology, University of Alberta, Edmonton, AB.
• Discuss preventative measures to decrease the incidence
and clinical consequences of CRT and CRBSI
• Describe an IRR and its grading
• Discuss steps to mitigate potential IRRs with GAZYVA
• Discuss with nurses, patients and caregivers what to
expect on the first infusion day
Yoga Session / Séance de yoga
9:10 PM - 10:00 PM | Algonquin
CANO/ACIO AGM / AGA de l’ACIO/CANO
CANO/ACIO Awards of Excellence
Ceremony / Cérémonie des prix
d’excellence de l’ACIO/CANO
10:00 AM - 10:30 AM
Canadian Room
45
Day Three / Jour trois
Annie Parker faisait partie des premières Canadiennes à être
testées et à se retrouver positives à la découverte de la Dre King,
la mutation BRCA1.
Workshop / Atelier V-01
10:30 AM - 12:00 PM | Confederation 3
V-03 10:30 AM - 12:00 PM | Tudor 7
Enhancing Nursing Passion to Use
Practice Guides for Informing Remote
(Telephone) Symptom Support: An
Interactive Workshop
V-03-A 10:30 AM - 11:00 AM
Dawn Stacey, RN, PhD, CON(C)1,2, Tracy L. Truant, RN,
MSN, PhD(c)3, Barbara Ballantyne, RN, MScN, CON(C),
CHPCN(C)4, Kim Chapman, RN, MScN, CON(C)5, Myriam
Skrutkowski, RN, MSc, CON(C)6, 1University of Ottawa,
Ottawa, Ontario, Canada, 2Ottawa Hospital Research Institute,
Ottawa, Ontario, Canada, 3University of British Columbia,
Vancouver, British Columbia, Canada, 4Health Sciences
North, Sudbury, Ontario, Canada, 5Horizon Health Network,
Fredericton, New Brunswick, Canada, 6McGill University
Health Centre Research Institute, Montreal, Quebec, Canada.
Fear of Cancer Recurrence: A Qualitative
Study of the Experience of Survivors of
Ovarian Cancer
Jamie Kyriacou, BSc1, Alexandra Black, BSc1, Christine
Maheu, PhD1, Nancy Drummond, MSc(A)2, Joanne Power,
MSc(A)3, 1McGill University, Montreal, Quebec, Canada,
2Jewish General Hospital, Montreal, Quebec, Canada, 3McGill
V-03-B 11:00 AM - 11:30 AM
Survivors of Childhood Brain Tumours:
V-02 10:30 AM - 12:00 PM |
A Qualitative Thematic Synthesis
Confederation 5 & 6
V-02-A 10:30 AM - 11:15 AM
Roberta L. Woodgate, PhD3, Ketan Tailor, MEd1,
Rochelle Yanofsky , MD2, Magimairajan Issai Vanan, MD2,
1Marquette University, Milwaukee, Wisconsin, United States,
2CancerCare Manitoba, Winnipeg, Manitoba, Canada,
3University of Manitoba, Winnipeg, Manitoba, Canada.
CANO/ACIO Radiation Oncology Nursing
Practice Standards and Competencies:
The Time Has Come!
V-03-C 11:30 AM - 12:00 PM
Maurene McQuestion, RN, BA, BScN, MSc, CON(C)1 ,2,
Christine Zywine, RN(EC), BScN, MN, CON(C)1,2,
Brenda C. Ross, RN, BScN3, Tracy L. Truant, RN, BN, MSN,
PhD(C)4, 1Princess Margaret Cancer Centre, Toronto, Ontario,
3BC Cancer Agency, Vancouver, British Columbia, Canada,
4UBC, Vancouver, British Columbia, Canada.
Wellness Beyond Cancer Program:
Empowering Patients to Meet Their
Survivorship Needs - Part 2 (Follow-Up
From Québec City Presentation)
V-02-B 11:15 AM - 12:00 PM
Carrie Liska, RN, BScN1, Robin Morash, RN, MHS1,
Lise Paquet, PhD2, Gail Larocque, NP-PHC1, 1The Ottawa
Hospital, Ottawa, Ontario, Canada, 2Carleton University,
Building an Integrated Survivorship
Pathway Between Cancer Care and
Primary Care: A Collaborative Approach
to Improve the Transition Experience
Post Cancer Treatment
Linda Watson, RN, PhD, CON(C), Shelley Currie, MS,
Debbie Lamb, RN, BN, Farah Kubba, BA, Heather Ebeling, RN,
BScN, MN, Alberta Health Services, Calgary, Alberta, Canada.
46
V-04 10:30 AM - 12:00 PM | Tudor 8
V-05-B 11:15 AM - 12:00 PM
Concurrent Session / Atelier simultané Improving Cancer Symptom Management
Through Knowledge Translation:
V-04-A 10:30 AM - 11:00 AM
Implications for Nursing Practice
Supporting Nurses with Purpose and
Denise E. Bryant-Lukosius, PhD1 2, Greta Cummings,
Passion: Development of an Online
PhD3, Nancy Carter, PhD2, Margaret I. Fitch, PhD4,
Margaret Forbes, RN, MN1, Esther Green, MSc5, Mark
Study Group for the CNA Oncology
Hartman, MBA6, Lynne Jolicoeur, RN, MN7, Wenonah
Certification Exam
,
V-04-B 11:00 AM - 11:30 AM
Becoming a Lean Leader: Reflections
and Practice
Joy Bunsko, BSN, CON(C), Stephanie Aldridge, BSc,
MEd, RT(T), Lori Rowe, MA, RT(T), AC(T), BCom, BC Cancer
Agency, Surrey, British Columbia, Canada.
V-06 10:30 AM - 12:00 PM | British Columbia
V-04-C 11:30 AM - 12:00 PM
V-06-A 10:30 AM - 11:00 AM
Enhancing Passion and Purpose: The
Factors Influencing the Effectiveness of
Trillium Project
Audit and Feedback: Nurses’ Perceptions
Charmaine Lynden, RN(EC), RN, MN, CON(C), Devi
Ahuja, RN(EC), RN, MN, CON(C), Cathy Kiteley, RN,
MScN, CON(C), CHPCN(C), Trillium Health Partners,
Mississauga, Ontario, Canada.
Kathryn Baldwin, BN1,2, Venessa Christina, BSc2,
Alain Biron, PhD2,3, Jessica Emed, MSc(A)1,2, Karine Lepage,
MScN1,2, 1Jewish General Hospital, Montreal, Quebec,
Canada, 2McGill University, Montreal, Quebec, Canada,
3McGill University Health Centre, Montreal, Quebec, Canada.
V-05 10:30 AM - 12:00 PM | Alberta
V-06-B 11:00 AM - 11:30 PM
Collaboration and Social Interaction
V-05-A 10:30 AM - 11:15 AM
Among Oncology Nurses
Electronic Nursing Documentation:
Jane Moore, RN, PhD, CCRN1, Dawn Prentice, RN, PhD1,
Creating a Standardized Documentation Maurene McQuestion, RN, MSN, CON(C), APN2, 1Brock university,
St Catharines, Ontario, Canada, 2University Health Network,
Tool for Oncology Nurses
Janelle L. Desjardins, BScN, MScN, Melissa Boonstra,
BScN, The Ottawa Hospital, Ottawa, Ontario, Canada.
47
Andrea Knox, RN, BScN, CON(C), Tina S. Haayer,
RN, BScN, Ava L. Hatcher, RN, BN, CON(C), BC Cancer
Agency, Kelowna, British Columbia, Canada.
Mahase, MBA8, Lorraine Martelli, NP, MN1, Carole Mayer,
PhD6, Gregory Pond, PhD1 ,2, Anne Snider, MEd1, Linda
Watson, PhD9, Jennifer Wiernikowski , NP, MN1, 1Juravinski
Cancer Centre, Hamilton, Ontario, Canada, 2McMaster
University, Hamilton, Ontario, Canada, 3University of
Alberta, Edmonton, Alberta, Canada, 4Sunnybrook Odette
Cancer Centre, Toronto, Ontario, Canada, 5Canadian
Partnership Against Cancer, Toronto, Ontario, Canada,
6Northeast Cancer Centre/Health Sciences North, Sudbury,
Ontario, Canada, 7Ottawa Hospital, Ottawa, Ontario,
Canada, 8Cancer Care Ontario, Toronto, Ontario, Canada,
9Alberta Health Services, Calgary, Alberta, Canada.
Concurrent Session / Atelier simultané Keynote Presentation III /
V-06-C 11:30 AM - 12:00 PM
Conférence plénière III
Implementation of Breast Cancer
Survivorship Guidelines by Primary
Health Care Nurse Practitioners in
Southeast Ontario: Results of a Mixed
Methods Study
Paul Alofs,
PhD, MBA, BCom, BA
Paul has four university degrees but he’s
not an academic. His friend, Dominic
Barton, world-wide head of McKinsey and
McKinsey, has endorsed his book “Passion
Capital”, but Paul is not a consultant.
Marian Luctkar -Flude, RN, BScN, MScN, PhD(c),
Alice Aiken, PhD, Mary Ann McColl, PhD, Joan Tranmer,
RN, PhD, Queen’s University, Kingston, Ontario, Canada.
Novartis Lunch Symposium /
Dîner éducatif Novartis
12:15 PM - 1:45 PM |
Concert Hall
Breaking News: Matters of the Heart in
MPNs Ph- and CML
Diego Delgado, MD, MSc, Associate Professor, Division
of Cardiology and Transplant, UHN Cardiologist, Toronto
General Hospital, Toronto, ON
Sabrina Fowlkes, BScN, Research nurse, Clinical
Research Unit Jewish General Hospital, Montreal, QC
Harold Olney, MD, FRCPC, Assistant Professor of
Medicine, University of Montreal, Chief Department of
Hematology-Transfusion Medicine, CHUM Montreal, QC
• Evaluate how risk factors can be used to guide therapeutic
approaches in the management of chronic myeloid leukemia (CML)
• Review the recent development in the molecular pathogenesis
of myeloproliferative neoplasms (MPNs) and their impact on
diagnosis algorithms
• Review the recent WHO revised criteria for diagnosis of
polycythemia vera (PV) and novel therapeutic approaches
What’s most interesting about Paul is
the diversity of his experience and his track record of success
in retailing, marketing, entertainment, technology, and social
enterprise. His bestselling book “Passion Capital” captures the
patterns of success and he is truly a Passion Capitalist.
Since joining The Princess Margaret Cancer Foundation as President
and CEO in 2003, Paul has helped raise over $850 million for cancer
research and clinical care. The Foundation raises and stewards
funds for The Princess Margaret Hospital, one of the top 5 cancer
research centres in the world. In April 2012, Paul helped launch the
Billion Dollar Challenge for Personalized Cancer Medicine.
Paul’s career has been on a skyward trajectory since university.
His resume includes Colgate-Palmolive Canada, The Marketing &
Promotion Group, HMV Music Canada, President of BMG Music
Canada, The Walt Disney Company, and President, Strategic
Business Units for the launch of MP3.com.
Paul Alofs a quatre diplômes universitaires mais ce n’est pas un
universitaire. Son ami, Dominic Barton, le directeur au niveau
mondial de McKinsey et McKinsey, a endossé son livre
« Passion Capital », mais Paul n’est pas consultant.
Ce qui fait l’intérêt particulier de Paul est la diversité de son
expérience et ses succès répétés dans les domaines de la
vente, du marketing, du divertissement, de la technologie et de
l’entreprise sociale. Son best-seller, Passion Capital, saisit fort
bien les modèles de succès. C’est un vrai capitaliste de passion.
Depuis qu’il s’est joint à la Fondation de l’Hôpital Princess
Margaret comme président directeur général en 2003, Paul a aidé
à recueillir plus de 850 millions de dollars pour la recherche sur le
cancer et pour les soins cliniques à l’Hôpital Princess Margaret. La
fondation recueille des fonds et les achemine à l’Hôpital Princess
Margaret, un des cinq meilleurs centres de recherche sur le cancer
au monde. En avril 2012, Paul a aidé à lancer le Défi d’un milliard
de dollars à l’appui de la médecine personnalisée en cancérologie.
La carrière de Paul est montée en flèche depuis l’université. Son
curriculum vitae inclut Colgate-Palmolive Canada, The Marketing
& Promotion Group, HMV Music Canada, son poste de président
de BMG Music Canada, de la compagnie Walt Disney et son
poste de président des unités de stratégie d’entreprise pour le
lancement de MP3.com.
48
Workshop / Atelier VI-01
CANO/ACIO 2015 Standards of Care
Invitational Workshop: Building a
Foundation for Oncology Nursing’s
Contribution to Person-Centred Care
By invitation only.
Tracy L. Truant, RN, MSN, PhD(c)1, Allyson Nowell, RN,
BScN, MSN3, Brenda C. Ross, RN, BScN2, 1UBC School of
Nursing, Vancouver, British Columbia, Canada, 2BC Cancer
Agency, Vancouver, British Columbia, Canada, 3Princess
3:30 PM - 5:00 PM | Confedertaion 5&6
Case Scenario-Concept Mapping
(CSCM): An Innovative Teaching/
Learning Strategy to Stimulate Critical
Thinking and Problem Solving in
Oncology Nursing
Marcia Flynn-Post, MHS, BA, CON(C), Leslie
Williams-Brennan, BSc, BScN, MN, CON(C), Princess
VI-03-B 4:15 PM - 5:00 PM
An Ethical Perspective in Cancer
Radiotherapy of Persons Who Are
Socioeconomically Disadvantaged
Siby Elizabeth J. Thomas, RN, MSN, BC Cancer
VI-04 3:30 PM - 5:00 PM | Tudor 8
VI-04-A 3:30 PM - 4:00 PM
Improving Emotional Support During
Cancer Treatment: Patients’ Perceptions
Keira Samson, BScN, Rachel Yee-Sui-Chun, BScN, Virginia
Lee, RN, PhD, McGill University Health Centre, Montreal,
Quebec, Canada.
VI-04-B 4:00 PM - 4:30 PM
Identifying Causes of Delays in Discharge
in Patients Diagnosed With High-Grade
Glioma on a Neuro-Surgical Unit
Karen Rezk, RN, BScN, MSc(A) candidate1, CatherineAnne Miller, BScN, RN, MScH.2, 1McGill University,
Montreal, Quebec, Canada, 2MUHC Montreal Neurological
Hospital, Montreal, Quebec, Canada.
VI-04-C 4:30 PM - 5:00 PM
VI-03 3:30 PM - 5:00 PM | Tudor 7
Empowering People with Purpose
and Passion: The Development of a
VI-03-A 3:30 PM - 4:15 PM
Lymphedema Program in Oncology
What’s New in the Management of
Martina Reddick, RN, Independent Consultant, Tors
Cove, Newfoundland, Canada.
Infusion Reactions? Patient Outcomes
Improved with New Pharmacological
Approaches
Jessica Culligan, BScN, Katlynn Schellenberger, BScN,
Margaret Mayer, MScN, CON(C), RN(EC), Sandra Ferris,
CON(C), GRRCC, Kitchener, Ontario, Canada.
49
3:00 PM - 3:30 PM
Canadian Room
VI-06 3:30 PM - 4:30 PM | British Columbia
VI-05 3:30 PM - 5:00 PM | Alberta
VI-06-A 3:30 PM - 4:00 PM
VI-05-A 3:30 PM - 4:00 PM
Oncology Nurses’ Attitudes Toward
Systematic Symptom Assessment Using
the Edmonton Symptom Assessment
System (ESAS): Results from a Large
Cancer Care Ontario Province-Wide Study
Esther Green, RN1, Dora Yuen, MPH2, Martin Chasen,
MBChB3, Christopher Klinger, PhD3, Michael Brundage, MD4,
Monika Krzyzanowska, MD5, Wenonah Mahase, MBA2, Sean
Molloy, MHSc7, Reena Tabing, MA2, Heidi Amernic, PhD(c)2,
Serena Kurkjian, MBA2, Zahra Ismail, MHA2, Omid Shabestari,
PhD2, José Pereira, MBChB3, 1Canadian Partnership Against
Cancer, Toronto, Ontario, Canada, 2Cancer Care Ontario,
Toronto, Ontario, Canada, 3University of Ottawa, Ottawa,
Ontario, Canada, 4Queen’s University, Kingston, Ontario,
7St. Joseph’s Health Centre, Toronto, Ontario, Canada.
People, Process, Product: Cancer
Information the Canadian Cancer
Society Way
Tracy Torchetti, MA, McMaster University, Hamilton,
Ontario, Canada.
VI-06-B 4:00 PM - 4:30 PM
Evaluating a New Process for Interstitial
Brachytherapy through Inter-professional
Collaboration and Patient Engagement
Dianne Hill-Mugford, RN, BScN, Lily Man, RN, MN, Anita
Long, RN, MSN/ED, CON(C), Barbara McArthur, BScN, CPNc,
Elaine Avila, RN, BScN, Sunnybrook Health Sciences Centre,
VI-05-B 4:00 PM - 4:30 PM
VI-06-C 4:30 PM - 5:00 PM
Patients Pushing the Boundaries of
Privacy and Support in the Digital Age – Heutagogy in Oncology Nursing: The
Good for Them, Good for You?
Experience of Nurses and the Factors that
Facilitate and Hinder Self-Determined Learning
Heather Sinardo, BScN, MN2, Colleen Young, BA1,
1Canadian Virtual Hospice, Toronto, Ontario, Canada,
2Canadian Cancer Society, Toronto, Ontario, Canada.
VI-05-C 4:30 PM - 5:00 PM
Charissa Cordon, BSc, BScN, MN, CON(C)2,1, 1Fielding
Graduate University, Santa Barbara, California, United
States, 2St. Joseph’s Health Centre, Toronto, Ontario, Canada.
Committee and SIG meetings /
A Passion for Setting a Plan: A Quality
Rencontre des comités et groupes
Improvement Initiative on Advance Care d’intérêts spéciaux
Planning
5:15 PM - 6:15 PM
Kelly McGuigan, RN, BScN, MN, CON(C), CHPCN(C)1,
Jocelyn Brown, RN, BScN, MN1, Robin Forbes,
RSW, MSW1, Judy Costello, RN, MScN1, Jennifer Bell, PhD2,
Kyle Anstey, PhD2, 1Princess Margaret Cancer Centre, Toronto,
Ontario, Canada, 2University Health Network, Toronto,
Ontario, Canada.
50
Social Event / Soirée sociale
7:00 PM onward | Concert Hall
Wednesday, October 7, 2015
Mercredi 7 octobre 2015
Merck Breakfast Symposium /
Déjeuner éducatif Merck
7:30 AM – 8:45 AM |
Concert Hall
Discover When Science Meets Art:
The PD-1 Era
Dr. Marcus Butler, MD, Medical Oncologist, Princess Margaret
Cancer Centre, Toronto, Ontario
Ms. Nancy Gregorio, BScN, MN, OCN, CONC, Oncology Specialized
Nurse, Princess Margaret Cancer Centre, Toronto, Ontario
• Summarize the key learnings from recent clinical trial data
on the safety and efficacy of the PD-1 inhibitors in malignant
melanoma
• Articulate the place in therapy of the PD-1 inhibitors in the
clinical management of patients with malignant melanoma
• Describe the occurrence and management of immune-related
side-effects of the PD-1 inhibitors relative to other immune
therapy
Keynote Presentation IV /
Conférence plénière IV
9:00 AM – 10:00 AM | Concert Hall
Hans Messner,
MD, PhD
Dr. Messner is Professor of Medicine
at the University of Toronto and
has spent most of his career at the
Princess Margaret Cancer Centre,
University Health Network. He focused
on the use of allogeneic stem cell
transplants in the management of patients with hematopoietic
malignancies, predominantly leukemia. He was the founding
president of the multidisciplinary Canadian Blood and Marrow
Transplant Group (CBMTG) and was a member of the task force to
develop the Canadian Standard of Cells, Tissues and Organs for
Transplantation. It remains his objective to improve the long-term
outcome of patients benefiting from a stem cell transplant.
Professeur de médecine à l’Université de Toronto, le Dr Messner
a passé la majorité de sa carrière au Centre de cancérologie
Princess Margaret, Réseau universitaire de santé. Il a dirigé
son attention sur l’utilisation des allogreffes de cellules
souches dans la prise en charge des patients atteints de
cancers hématopoïétiques, principalement la leucémie. Il a
été le président fondateur de la Société canadienne de greffe
de cellules souches hématopoïétiques (CBMTG), un organisme
multidisciplinaire et a fait partie du groupe de travail chargé
d’élaborer la norme canadienne pour cellules, tissus et
organes destinés à la transplantation. Il s’est fixé comme
objectif d’améliorer les résultats à long terme pour les patients
subissant une greffe de cellules souches.
10:00 AM – 10:30 AM
Canadian Room
Workshop / Atelier VII-01
Writing for Publication
Margaret I. Fitch, RN, PhD, University of Toronto,
10:30 AM - 12:00 PM | Confederation 5&6
Evidence-Based Strategies for the Design
and Effective Use of Advanced Practice
Nursing Roles in Cancer Control: Practice
Guideline Recommendations
Denise E. Bryant-Lukosius, RN, PhD1, Esther
Green, BScN, MSc(A)2, Barbara Fitzgerald, RN,
MScN1, 1Juravinski Hospital and Cancer Centre,
Hamilton, Ontario, Canada, 2Canadian Partnership
Against Cancer, Toronto, Ontario, Canada.
51
Day Four / Jour quatre
Day Four /
Jour quatre
VII-04-B 11:15 AM - 12:00 PM
VII-03 10:30 AM - 12:00 PM | Tudor 7
Concurrent Session / Atelier simultané Passionate People Coming Together for
a Common Purpose: Interdisciplinary
VII-03-A 10:30 AM - 11:00 AM
Oncology Palliative Care Rounds
Unwanted Encore 2.0: An Update on
Patricia Murphy-Kane, BScN, MN, CHPCN(C), BA,
the Lived Experience of Having Multiple Andrea Colagiacomo, BScN, Princess Margaret Cancer
Cancer Diagnoses
VII-05 10:30 AM - 12:00 PM | Alberta
VII-03-B 11:00 AM - 11:30 AM
VII-05-A 10:30 AM - 11:00 AM
Cancer Survivorship: Exploring
Structures and Contexts Shaping High
Quality Care for All
Multi-Day Treatment Model: Why Is this
a Better Way?
Tracy L. Truant, RN, MSN, PhD(c), Sally Thorne,
RN, PhD, Colleen Varcoe, RN, PhD, Carolyn Gotay,
PhD, University of British Columbia, Vancouver, British
Columbia, Canada.
Jodi Hyman, BScN, CON(C), RN, Cancer Care
Manitoba, Winnipeg, Manitoba, Canada.
Concurrent Session / Atelier simultané VII-05-B 11:00 AM - 11:30 AM
VII-03-C 11:30 AM - 12:00 PM
People, Purpose, Passion: The Role of
the Specialized Oncology Nurse as We
Using Neurofeedback to Manage LongTransition Patients Through Our Uniquely
Term Symptoms in Cancer Survivors:
Designed Rapid Assessment Clinic for
Results of a Survey of Neurofeedback
Newly Diagnosed Leukemia Patients
Providers
Dianne Groll, PhD, RN, Queen’s University, Kingston,
Ontario, Canada.
Nancy A. Pringle, RN, Nancy A. Wagg, RN, Princess
VII-05-C 11:30 AM - 12:00 PM
From the Line to the Lab: The Impact of Blood
VII-04 10:30 AM - 12:00 PM | Tudor 8
Collection Practice on Patient Outcomes
Concurrent Session / Atelier simultané Susan Csatari, RN, BD Canada, Mississauga, Ontario, Canada.
VII-04-A 10:30 AM - 11:15 AM
The Passion and Purpose of Hope When
Living with Pancreatic Cancer
Shari Moura, RN, MN, CON(C), CHPCN(C), Princess
Margaret Cancer Centre - University Health Network,
52
Concurrent Session / Atelier simultané Amgen Lunch Symposium / Dîner
VII-06 10:30 AM - 12:00 PM | British Columbia éducatif Amgen
12:15 PM - 1:45 PM |
Concurrent Session / Atelier simultané Concert Hall
VII-06-A 10:30 AM - 11:00 AM
Supporting Patients with Breast Cancer:
Building Capacity Within a Group of
Interdisciplinary Approaches to Optimize
Generalist Oncology Nurses to Create a Patient Outcomes
Seamless Transition to Care
Angela Leahey, Odette Cancer Centre/Sunnybrook Health
Charissa Cordon, BSc, BScN, MN, CON(C), Melissa Morey- Sciences, Toronto, Ontario
Hollis, BSN, MHSc, Victoria Crowder-Bansen, RN, BScN, MHSc,
Giancarla Curto-Correia, MHSc, PT, Edelgard Lenzo, RN, St.
• Discuss the importance of an interdisciplinary approach to
Joseph’s Health Centre, Toronto, Ontario, Canada.
managing patients with breast cancer
• Discuss the role of supportive care in optimizing patient outcomes
Concurrent Session / Atelier simultané • Address the importance of bone health in the adjuvant and
VII-06-B 11:00 AM - 11:30 AM
metastatic setting including diet, exercise and supportive care
Mommy Yelled at Me to Clean Up
My Room and Got Throat Cancer:
Supporting Children When a Parent or
Sibling Has Cancer
Andrea L. Warnick, BScN, MA, Andrea Warnick
Consulting, Toronto, Ontario, Canada.
Annual Canadian Cancer Society and
CANO/ACIO Joint Symposium /
Symposium joint annuel de la société
canadienne du cancer et de l’ACIO/CANO
Concurrent Session / Atelier simultané Shattering the Myths: Smoking
VII-06-C 11:30 AM - 12:00 PM
Cessation Is an Essential Element of
“Best Practice” Cancer Care!
Passionate Multidisciplinary Team
Members Committed to Implement and Andrew Pipe, CM, MD, Professor, Faculty of Medicine,
University of Ottawa, Chief, Division of Prevention and
Sustain the Enhanced Recovery After
Rehabilitation, University of Ottawa Heart Institute
Surgery (ERAS) Clinical Pathway Across John Atkinson, Director, Cancer Prevention and Tobacco
Control, Canadian Cancer Society, Ontario Division
the Surgical Program
With the number of new cases of cancer diagnosed in Canada
expected to rise by about 40 per cent in the next 15 years,
the need to address cancer prevention in cancer care couldn’t
be more important. An overview of recent and future cancer
statistics will be shared with a focus on preventative power
of smoking cessation. Smoking cessation is one of the most
important, and most powerful, interventions that can be
delivered in any clinical environment – and is particularly
important in the Cancer Care setting. Tobacco addiction is the
leading cause of preventable disease, death and disability
in Canada and a principal cause of many common cancers.
Approaches to smoking cessation have been impeded by
outdated concepts and prejudicial attitudes and, when
treating cancer, the misconception that cessation is “too late”.
There is clear and convincing evidence that smoking cessation
53
Barbara Fitzgerald, RN, MScN, President, CANO/ACIO
Rosemarie Rivera, MN, Amber Curry, MHSc, Susan
Bradbury, LPN, RPN, Minette McNeil, MEd, Lisa DeBeer,
BSc, RD, Rachel Meyer, BSc, FRCPC, Rouge Valley Health
Systems, Scarborough, Ontario, Canada.
at the time of cancer diagnosis and treatment extends lives,
improves treatment response, and greatly facilitates patient
comfort and well-being. In some instances smoking cessation
may be the most potent intervention of all! There are
remarkable opportunities to enhance “Best Practice” cancer
care by assisting patients with smoking cessation. Nursing
leadership is essential if we are to more effectively provide
the benefits of smoking cessation to our patients. Simple,
sensitive, strategic and systematic approaches to cessation
can dramatically enhance cessation success and will be
addressed in this discussion.
Workshop / Atelier VIII-01
Outpatient Management of Acute
Leukemia: Sharing Our Passion
Cindy Murray, NP, MN, Mary C. Doherty, MN, NP-PHC,
Shannon Nixon, MN, RN, Princess Margaret Cancer Centre,
Build capacity for managing acute leukemia patients in the
ambulatory setting by sharing our knowledge and skills around;
a) the clinical assessment and management of the transfusion
needs of acute leukemia patients, and;
b) the identification and management of common infections in
acute leukemia patients.
Strengthening the Care of Older Adults
with Cancer: Purpose and Passion in
Oncology Nursing for this SIGnificant
Group of People
Lorelei Newton, PhD, RN1, Fay J. Strohschein,
RN, MSc(A), PhD(c)2, Tina S. Haayer, RN, BSN,
MA (current)1, 1BC Cancer Agency, Victoria, British
Columbia, Canada, 2Jewish General Hospital, Montreal,
Quebec, Canada.
54
VIII-03 3:00 PM - 4:30 PM | Tudor 7
VIII-03-A 3:00 PM - 3:30 PM
Empowering Patients Through
Treatment for Head and Neck Cancers:
Implementation and Evaluation of an
Early-in-Treatment Group Educational
Intervention
Maurene McQuestion, RN, BA, BSc, MSc, CON(C),
Andrea Gomes, MHS, Reg-CASLPO, Joanne Pun, BSc, RD,
VIII-03-B 3:30 PM - 4:00 PM
Educating the Leukemia Population:
The Implementation and Effectiveness
of a Developed Educational Toolkit to
Support the Leukemia Patient Population
Throughout the Trajectory of Care
Katherine Lee, BScN, CON(C), Fatima Abdelmalek,
BScN, MN, CON(C), Christine Bent, BScN, Laura Olmi,
BScN, CON(C), Erin Saretz, BScN, Sandra Bolyki, BA,
Kaminiben Patel, BScN, CON(C), Anna Papizzo, BScN,
Eve Dimopoulos, BScN, Princess Margaret Cancer Centre,
VIII-03-C 4:00 PM - 4:30 PM
Group Medical Appointments: A Novel,
Collaborative Approach to Breast
Cancer Patient Education for Adjuvant
Endocrine Therapy
Ann Vlahadamis, RN, MN, NP1, Melanie Danilak,
BSc, Pharmacist1, Edith Pituskin, RN, MN, PhD2, Krista
Rawson, RN, MN, NP1, Karen King, MD1, 1Alberta Health
Services, Edmonton, Alberta, Canada, 2University of Alberta,
Edmonton, Alberta, Canada.
VIII-04 3:00 PM - 4:30 PM | Tudor 8
VIII-05 3:00 PM - 4:30 PM | Alberta
VIII-04-A 3:00 PM - 3:30 PM
VIII-05-A 3:00 PM - 3:45 PM
Empowering Patients and Caregivers with Designing Innovative Cancer Services:
Knowledge: The Development of a Nurse-Led Responding to the Unmet Supportive
Gynecologic Oncology Chemotherapy Class Care Needs of Patients with Newly
Diagnosed Advanced Colon Cancer
Lisa Ould Gallagher, RN, CON(C), Nazlin Jivraj, RN,
BScN, CON(C), Sarah E. Ferguson, MD, FRCSC, Nazek
Abdelmutti, MSc, Janet Papadakos MEd, PhD(c), Princess
Suganya Vadivelu, RN, MScN, CON(C), PGDHM1,
Denise E. Bryant-Lukosius, PhD2, 1Juravinski Cancer Centre,
Hamilton Health Sciences, Hamilton, Ontario, Canada,
2McMaster University, Hamilton, Ontario, Canada.
VIII-04-B 3:30 PM - 4:00 PM
VIII-05-B 3:45 PM - 4:30 PM
Timely Discharge Initiative: The
Exploring the Relationship Between
Patients’ Perspective
Social Determinants of Health and
Mary Glavassevich, MN, Rosemary Irish, MSN/
Symptom Burden in Cancer Populations:
ED, CON(C), Elaine Avila, BScN, Sunnybrook Health
Perspectives of Cancer Care Practitioners
Return to Work Questionnaire for
Cancer Survivors
Christine Maheu, PhD1, Andrea Vodermaier, PhD2,
Wolfgang Linden, PhD2, Katerina Rnic, MS2, Mina Singh,
PhD3, Lise Fillion, PhD4, 1McGill University, Montreal, Quebec,
Canada, 2University of British Columbia , Vancouver, British
Columbia, Canada, 3York University, Toronto, Ontario,
Canada, 4Université Laval, Quebec City, Quebec, Canada.
Anna Santos Salas, PhD, RN, University of Alberta,
Closing Ceremony and Abstract Award
Presentation / Cérémonie de clôture
et remise de prix pour abrégés
55
VIII-04-C 4:00 PM - 4:30 PM
Oral abstract presentations / Abrégés des présentations orales
Oral Abstract
Presentations /
Abrégés des
Présentations
Orales
Sunday, October 4, 2015
Dimanche 4 octobre 2015
9:30 AM - 11:00 AM | Conference 3
Designing a Small Manageable Qualitative
Study in Your Clinical Unit
Sally Thorne, RN, PhD, University of British Columbia,
Vancouver, British Columbia, Canada.
• Learn ways to draw on clinical wisdom to identify researchable
problems
• Articulate a workable research question
• Recognize the value of a logical study design, guided by a
nursing perspective
• Recognize implications of naming and framing the study approach
• Consider effective ways of dividing labour in collaborative projects
• Appreciate the role of a plan for analysis and knowledge
translation
Developing a team project can be a wonderful way to inspire
your unit and give your colleagues a shared experience in the
nursing research process. However, unless you have access to a
research mentor with time and skill to support you, it can seem a
daunting process. Applied qualitative research methods, including
interpretive description, are designed to serve the knowledge
needs of a professional practice discipline rather than a theoretical
enterprise. They follow a logical research design guided by nursing’s
“way of knowing” and can lend themselves to small, team-based
projects that produce useable and practice-relevant knowledge.
In this Workshop we will review the basics of a process by which
credible and publishable studies can be designed and conducted
by clinical teams informed by questions that arise from the patient
care context. We will address practical aspects of how to situate
your study within current knowledge, frame your research question,
decide on and select your study population and data sources,
gather and document data, and make sense of what you find in a
manner that “speaks” to other clinical practitioners. By setting your
aims at a manageable level, dividing up the task and capitalizing
on the available skills and dynamics within your clinical team,
56
you can design a project that is not only interesting and relevant
but also professionally satisfying. You can use this kind of small
study approach to open up new insights or to push forward on the
consideration of new questions or new angles of thinking about
a clinical problem from a nursing perspective. Since success all
hinges on keeping it manageable, and the textbooks often fall short
in telling you exactly how to do that, this Workshop is oriented
around practical tips to work with what you have, and optimize your
capacity to reach a truly satisfying outcome. Next year at this time,
you could be presenting your study findings at CANO/ACIO!
9:30 AM - 11:00 AM | Conference 5 & 6
The CALM Intervention Workshop: Taking
the Passion for Psychosocial Care in
Nursing to the Next Level
Maurene McQuestion, RN, BScN, MSc, CON(C), Patricia
Murphy-Kane, RN, BScN, MN, CHPCN (C), Kelly
McGuigan, RN, BScN, MN, CON(C) CHPCN(C), Carmine
Malfitano, MSW, RSW, Gary Rodin, MD, FRCPC, Sarah Hales,
MD, PhD, FRCP(C), Princess Margaret Cancer Centre, Toronto,
Ontario, Canada.
• Discuss and review the theoretical underpinnings and the four
domains of CALM therapy
• Explore how to integrate the CALM therapy skills into day to
day nursing practice
Individuals with advanced cancer have the challenge of making the
most of each day, while simultaneously facing the reality of their
death. In a large cancer centre, advanced practice nurses (APNs),
psychiatrists and other physicians, psychologists, and social
workers have been trained to provide a novel psychotherapeutic
intervention to help patients meet this challenge. Managing
Cancer And Living Meaningfully (CALM) is a brief, semi-structured,
individual, psychotherapeutic intervention rooted in several broad
theoretical traditions, including relational theory, attachment
theory and existential psychotherapy.
The intervention supports reflection and dialogue with patients
in four domains in 3-6 sessions over 3-6 months. These domains
are: symptom management and communication with health care
providers, changes in self and relations with close others, sense
of meaning and purpose, and mortality. Primary caregivers attend
one or more of the sessions.
This interactive Workshop will explore the theoretical
underpinnings of CALM and its four domains, using case
presentations, vignettes, and videos. The benefits and challenges
in adapting this therapy to nursing practice will be reviewed.
Participants in this Workshop will learn to build and enhance their
psychosocial skills and integrate this into day to day practice.
I-03-B 10:00 AM - 10:30 AM
Cancer Survivorship Nurse Practitioner:
Reflections on Implementation
I-03 9:30 AM - 11:00 AM | Tudor 7
simultané I-03-A 9:30 AM - 10:00 AM
Rooted in Optimal Care - Licensed
Practical Nurses in Oncology
Robin Moser, LPN, Tish Palfrey, LPN, Jackie Bergin, LPN,
Barbara Moore, LPN, Lizanne Clark, LPN, Tina S. Haayer, BScN,
LPN, Andrea Knox, BScN, CON(C), Allison P. Filewich, BScN,
CON(C), BC Cancer Agency, Kelowna, British Columbia, Canada.
The recent expansion of our ambulatory care team has seen the
integration of the licensed practical nurse (LPN), establishing
a full complement of nursing staff that includes nursing aides,
registered nurses, and nurse practitioners. Exploring dynamics
of the intradisciplinary nursing team through the LPN lens at
our centre may inform and contribute to enhanced nursing care
delivery at a provincial level.
The introduction of LPNs into systemic therapy has been the impetus
for reflection and evaluation of our current state of nursing practice
and skill mix. Initial focus groups identified common barriers, gaps,
and redundancies in the provision of nursing care and scopes of
practice. This understanding is imperative to building a stronger
nursing team which enables timely care by the most appropriate
nursing team member to meet the individual patient needs.
Patient experience, the driving force for determining optimal
models of care, is paramount. A literature review and additional
focus groups will inquire into patient perspectives of care received
by LPNs and glean insight from other organization’s experiences
using a similar model. Our objectives include understanding
patient experience, defining current state of nursing care delivery,
exploring advancement of LPN practice provincially, enhancing
collaboration among nurses and identifying opportunities for
strengthening oncology care delivery across the nursing discipline.
In efforts to better define roles and responsibilities, we will
need to liaise with professional bodies and the health authority
in developing guidelines for LPN practice in oncology. Through
collective efforts and creative ideas from patients and the cancer
care team, we hope to achieve a new benchmark for the provision
of care by LPNs in the adult oncology population.
Kristina Morrison, NP, Lisa McCune, MA, BC Cancer
Agency, Vancouver, British Columbia, Canada.
The Survivorship Nurse Practitioner (SNP) role was introduced in
British Columbia in 2013. Two years later, the speakers will share
key learnings about implementing this role in a complex and
complicated health care system. They will also share strategies for
change management and implementation as the program expands
to new locations.
When the SNP role was first introduced, oncology health
professionals had a limited understanding of how to integrate the
role into the cancer care system. The Survivorship and Primary Care
Program developed resources and strategies to generate awareness
of the role, drive referrals from oncologists and other health care
professionals, and support continuity of care. Two years later, the
SNP role is well-integrated into the cancer care system at two BC
Cancer Centres (Vancouver and Fraser Valley). The SNP case loads
are comprised of 170-250 patients with varied complexity.
The speakers will use a case-based presentation style to
illustrate the role of the survivorship nurse practitioner in a
patient’s cancer journey.
Working in small groups, participants will use change
management tools to explore, discuss and evaluate strategies that
support the integration of new roles in a complex and complicated
health care system.
I-03-C 10:30 AM - 11:00 AM
Adapting to Change: The Nurse’s Role in
Oral Chemotherapy Administration
Samantha Scime, BScN, RN, St. Michael’s Hospital,
OBJECTIVE: The purpose of this project is to collaborate with the
nursing team to identify needed resources and education that
will facilitate the provision of comprehensive care to individuals
receiving oral therapy.
BACKGROUND: Over the past ten years the use and development
of oral chemotherapy in cancer treatment has increased
exponentially. While these agents often provide the patient with
a greater sense of control and quality of life, there are unique
implications that can affect patient tolerance and safety of
administration. This progression in therapy has had a profound
57
Through this innovative therapy, the APNs have engaged in an
exciting and enriching learning experience that has redefined
their relationship with individuals living with advanced cancer.
impact on oncology practice settings and consequently calls for
a shift in the nursing role within these treatment centres. The
Canadian Association of Nurses in Oncology (CANO/ACIO) stresses
the importance of tailored patient assessments and education
pertaining to symptom management and medication adherence.
Furthermore, CANO/ACIO identifies the nurse’s responsibility to
advocate for processes that ensure quality and safety in patient
care. The hematology/oncology program at St. Michael’s Hospital,
a university affiliated tertiary care centre, is managing an increasing
number of patients receiving oral chemotherapy. As this trend
continues, it is imperative that nurses are supported in their
changing role and encouraged to participate in policy development.
METHODS: In collaboration with the multidisciplinary team, current
patient assessment, education and documentation processes
will be reviewed and revised in accordance with the CANO/ACIO
Statement on Cancer Chemotherapy Administration and Care.
RESULTS: Evaluation of this process, perspectives from nursing
and final results will be shared.
I-04 9:30 AM - 11:00 AM | Tudor 8
I-04-A 9:30 AM - 10:00 AM
Usability and Acceptability of Nevasic
Audio Program in Management of
Chemotherapy-Induced Nausea
and Vomiting
with a total of 15 participants were conducted. Results indicated
that recruitment targets were achieved. Issues of Nevasic
acceptability were highlighted as weaknesses of the program.
These findings indicate that patients do not have a strong
willingness to use Nevasic or listen to music after chemotherapy
to manage CINV. However, the results showed statistically
significant less use of anti-emetics (p = 0.003) and borderline
non-significant improvement in quality of life (p = 0.06). Further
studies are required to investigate the effectiveness of Nevasic
from perspectives such as anti-emetic use, as well as its overall
effect on the levels of nausea and vomiting.
I-04-B 10:00 AM - 10:30 AM
Nurse-Led Model for Oncology Patient
Follow-Up
Kathy Coskey, RN, BScN, CON(C), CCRP1, Margaret
F. Forbes, RN(EC), MN, CON(C), BScN1,2, 1Hamilton Health
Sciences, Hamilton, Ontario, Canada, 2McMaster University,
The incidence of cancer increases with age. This contributes to the
numbers of patients being seen at cancer centres. Although diagnosis
and treatment is the primary focus, there is a need post-treatment
to ensure patients receive ongoing surveillance and assistance in reintegrating into families, workplaces and social environments.
The Juravinski Cancer Centre (JCC) is an outpatient facility where
physician and nurse teams care for disease site specific groups
of patients. Once treatment is completed patients require
ongoing follow up for a timeframe, often directed by practice
Saeed Moradian, PhD, MA, BScN4, Alexander
guidelines. Until 2003 follow up care at the JCC was provided
Molassiotis, PhD, RN1,2, Catherine Walshe, PhD, RN3, 1The
by oncologists or general practitioners in oncology. In 2003 a
Hong Kong Polytechnic University, Hung Hom, Kowloon,
nurse practitioner clinic was established for breast cancer well
HKSAR, Hong Kong, 2Hung Hom, Kowloon, HKSAR, Hong
follow-up to see patients after treatment until transition back
Kong, 3Lancaster University, Lancaster, United Kingdom,
to family physician. Visits include assessment, focused physical
4University Health Network, Toronto, Ontario, Canada.
exam, and mammograms. In 2012 with increasing clinic volumes,
a registered nurse joined the team allowing enhancement of
Pharmacological therapy is only partially effective in preventing
services including more time to spend assessing for long term and
or treating chemotherapy induced nausea and vomiting
late side effects, emotional, spiritual and sexual needs, as well as
(CINV). Therefore, exploring the complementary role of nonhealth promotion and disease prevention. Self-management, goal
pharmacological approaches used in addition to pharmacological setting and empowerment are strongly encouraged. When patients
agents is important. Nevasic uses specially constructed audio
are self-managing, symptoms are controlled, and there is no need
signals hypothesized to generate an antiemetic reaction. The
for ongoing follow-up, patients are offered transition to family
aim of this study was to examine the feasibility of conducting a
physician. The patient and family physician are provided with a
randomized controlled trial (RCT) to evaluate the effectiveness
survivorship care plan that outlines patient specific cancer history,
of Nevasic to control CINV. A mixed method incorporating an RCT suggested surveillance per practice guidelines, symptoms that
and focus group interviews was designed. For the RCT, 99 female may suggest recurrence, and cancer related resources.
breast cancer patients were randomized to receive either Nevasic
Between 2012 and 2014 two successful projects that utilized this
plus usual care, music plus usual care, or usual care only. Data
model were carried out. There were high levels of patient and
were analysed using descriptive statistics and linear mixedprovider satisfaction to date. Based on this successful model, there
effects models. Also, to obtain participants’ views regarding the
are plans to expand this model into other disease sites at the JCC.
acceptability of the interventions in the trial five focus groups
58
Up Stream and Down the Road:
Introducing a Mobile Cancer Screening
Coach to Under- and Never-Screened
Populations in an Urban Setting
Patti-Ann Allen, RN, BScN, MScN, CON(C), Riley
Crotta, MHSc, Alyssa Higginson, BSc, MHSc, Britney
Martin, BSc, MHSc, Hamilton Health Sciences, Hamilton,
Ontario, Canada.
PEOPLE: In Ontario, someone is diagnosed with cancer every
eight minutes. With an aging population and increasing life
expectancy, more than 400,000 Ontarians will be living with
or have survived cancer by 2015. Cancer continues to be the
number one cause of premature death in Ontario. As Ontario’s
population ages and grows, the number of people diagnosed
with cancer will increase. Concern for the socially conscious
nurse is that those of lower socioeconomic status have lower
screening rates than those with higher education and income.
PURPOSE: While cancer screening rates have been increasing
across all three of the disease sites in which screening tests
are available (breast, cervical, colorectal), the rates of cancer
screening completeness for all three modalities is very low
despite survival rates of as high as 90% when cancer is
diagnosed early. Implementation of a mobile cancer screening
service is a complex, multifaceted process that includes the
careful planning and procurement of equipment, an extensive
plan to ensure that the facilities will be accessed by the targeted
audience and an evaluation that can measure satisfaction and
feedback to provide ongoing quality improvement.
PASSION: The major purpose of this presentation is to: discuss
why certain populations are under- or never-screened, examine
the strategies or implementation activities that can be used
to recruit and support clients to a targeted mobile screening
program, and the subsequent preliminary evaluation points used
to refine and tailor effective strategies. Recruitment and support
activities include community relationship building, incorporation
of client preferences, partnerships with community providers,
and most importantly the building of trust. Oncology nurses
should be inspired to be aware of the barriers that can face
clients and be challenged to find solutions to health seeking and
preventative health care initiatives.
I-05-A 9:30 AM - 10:00 AM
An Adaptation of a Purposeful
Nursing Framework to Understand
Interprofessional Patient-Centred
Practice in Oncology Teams: Usefulness
and Limitations
Karine Bilodeau, RN, PhD, CON(C)1,2, Tremblay
Dominique, RN, PhD1,2, 1Université de Sherbrooke, Longueuil,
Quebec, Canada, 2Charles Le-Moyne Hospital Research
Centre, Longueuil, Quebec, Canada.
Health professionals in the oncology context have to work
together to ensure quality patient care. Although many studies
explore interprofessional education and practice, interprofessional
knowledge is mostly related to teamwork and organizational
context and lack to explain how oncology teams are patientcentred. Some frameworks have included “patient-centred”
concepts to highlight the implication of the patient within
oncology team processes but give a limited description of their
contribution to the interprofessional practice. Nursing science
aims to develop extensive expertise related to patient-centred
approaches and its contribution can inspire new collaborative
approaches. For these reasons, an adaptation of the “PersonCentred Nursing (PCN) Framework” was achieved to support
the description of an interprofessional patient-centred (IPPC)
practice. The purpose of this presentation is to understand how
the PCN framework can help to highlight the IPPC practice in
oncology teams. We performed secondary qualitative analyses
from a larger multiple case study on interprofessional teamwork
in oncology teams in Québec. Data from four homogenous focus
groups (health professionals, patients) were analysed. An iterative
content analysis approach was used and framed within the
adaptation of PCN Framework. Findings suggest that IPPC practice
is variable within teams. Prerequisites and care environment
components have an important influence on the process of IPPC
practice. Also, the adapted version of PCN Framework seems to
be helpful to understand the IPPC practice in oncology. Finally,
nursing implications of the usefulness of this framework will be
discussed.
59
I-04-C 10:30 AM - 11:00 AM
I-05 9:30 AM - 11:00 AM | Alberta
I-05-B 10:00 AM - 10:30 AM
I-05-C 10:30 AM - 11:00 AM
Lung Cancer Navigation Program: How the Developing and Implementing an
Patients React to this New Model of Care
Interdisciplinary Team-Based Care
Delivery During the First Six Months?
Approach for Patients with a Suspected
or Confirmed Thyroid Cancer Diagnosis
Julie Dallaire, MScN, Andreanne Saucier, MScN, CON(C),
(ITCA-THYCA)
Andrea M. Laizner, PhD, Anita Mehta, PhD, CON(C), MarieClaire Richer, PhD, MUHC, Montreal, Quebec, Canada.
PURPOSE: Lung cancer is the most prevalent cancer for men
and woman combined, occurring with advancing age having
comorbidities. A Lung Cancer Navigation Program was developed
in 2009 to improve experience of care. Our research project was
initiated to characterize the population and potential outcomes
of the program such as level of distress, symptoms and level of
satisfaction during their trajectory of care. This presentation will
focus on the patient’s reported distress, symptoms and level of
satisfaction during first six months of contact with the program.
METHODS: Between May 2012 and March 2014, all adults
with suspicion of lung cancer were eligible for the study. They
completed the DT+CPCL, ESAS and EORTC-sat35 at three
different times during their care trajectory: first visit, 2 months
and 6 months.
RESULTS: Of 126 patients recruited at T1 with suspected lung
cancer, 47 completed questionnaires at T2 and 28 at T3. At
T1, 66.4 % had distress level 4 or greater; CPCL problems
most frequently identified: fears (58.7%), sleep (52.4%) and
understanding illness (51.6%). At T2, 53.5% had distress level
4 or greater; CPCL problems most frequently identified: fears
(53.2%), sadness (38.3%) and worry (38.3%); at T3, 42.9%
had distress level 4 or greater; CPCL problems most frequently
identified: sleep (48.3%), coping (37.9%) and meaning of life
(34.5%). ESAS symptoms were consistent with lung disease
trajectory. Overall satisfaction improved in regards to obtaining
information about treatment, whereas it remained problematic in
relation to information about community services, logistics such
as way-finding, parking and transportation.
CONCLUSION: There were differences across time periods in the
prevalence of distress and the problems or concerns contributing
to distress. Nurses need to be vigilant and assess for distress
at each encounter during the illness trajectory so that they can
provide appropriate intervention and referral.
Gabrielle Chartier, RN1, Melissa Henry, PhD2, Christina
MacDonald, RN1, Magali Dewitte, MSc3, Martin Black, MD1,
Richard Payne, MD1, Alexander Mlynarek, MD1, Antoinette Ehrler,
MSc1, Carmen Loiselle, PhD2, Zeev Rosberger, PhD2, Saul Frenkiel,
MD4, Michael Tamilia, MD1, Michael Hier, MD1, 1Jewish General
Hospital, Montreal, Quebec, Canada, 2McGill University, Montreal,
Quebec, Canada, 3Lady Davis Institute, Montreal, Quebec, Canada,
4Montreal University Health Centre, Montreal, Quebec, Canada.
BACKGROUND: No studies currently evaluate an interdisciplinary
team based care approach (ITCA-ThyCa) including a dedicated
nurse, as promoted by organizations worldwide, in patients with
a suspected or confirmed thyroid cancer. The goal of this clinical
research program is to evaluate the impact of such care.
METHODS: The clinical approach for the dedicated nurse
comprised of: 1) Screening for distress (ESAS;Canadian
Problem Checklist;PHQ-9 and GAD-7); 2) Nursing meetings
mapped on medical treatment course + previous research; 3)
Targeted interventions on clinical symptoms (ESAS>4); and 4)
Interdisciplinary communication and treatment planning. Our
program evaluation is ongoing and based on the Centers for
Disease Control and Prevention (2014) Framework and Canadian
Partnership Against Cancer (2012) guidelines.
RESULTS: Sixty-one patients are eligible for the program of which
30 (100%) were contacted and agreed to take part to receive
more information and emotional support; another 31 will be
contacted shortly. Patients were mostly female (73%); 52 years old
(s.d.=18.9;range=18-89) and early stage (68.8%).
Clinically important issues on pre-treatment ESAS (score>=4)
consisted of: tiredness(63%), anxiety(39%), well-being(29%), and
pain(21%). The nurse met with patients on average 3 times (range
1-25; 71% between 1-5), and initiated a total of 37 referrals and
184 interdisciplinary exchanges (x=7.5; 80% between 1-7). Clinical
cases will be presented to illustrate the interdisciplinary approach
and nursing work done in the context of our program, concretely
highlighting how patients benefited from the approach.
CONCLUSIONS: Overall, the data collected preliminarily indicates
that thyroid cancer patients have significant needs commanding
attention in the context of an interdisciplinary approach such as
ITCA-ThyCa. This study highlights how important it is to investigate
the mechanisms underlying symptoms of tiredness, anxiety, and
pain in this population.
60
II-01-A 2:15 PM - 2:45 PM
Women’s Perceptions of Support
Received During Nurse-Led Teaching
About Vaginal Dilator Use
Karen Rezk, RN, BScN, MSc(A) candidate1, Alexa Bisaillon,
RN, BNI, MSc(A) candidate1 ,2, Renata Benc, RN, BA,
MSc(A), CON(C)2, Tara Jesion, RN, MSc(A), CON(C)2 ,1,
1McGill University, Montreal, Quebec, Canada, 2Jewish
General Hospital, Montréal, Quebec, Canada.
Vaginal dilator use is recommended for the prevention of vaginal
stenosis after pelvic radiation therapy treatment. Although
women’s experiences with vaginal dilator use have been
previously studied, little is known about nurse-led teaching
sessions pertaining to these recommendations. This study
explored women’s perceptions of the support they received during
the nurse-led teaching about vaginal dilator use. We conducted a
retrospective qualitative study using semi-structured interviews
with a sample of 11 women with a history of gynecological cancer
who have attended a nurse-led teaching session about vaginal
dilator use. Themes that emerged from the data included: the
timing of the teaching did not make sense; the nurse put women
at ease; address the whole person; and tailoring the teaching
approach to facilitate support. Women’s perceptions of support
were influenced by the timing of and readiness to receive
information about vaginal dilator use. While nurses themselves
were important sources of support during the teaching, the
content they delivered should have addressed holistic implications
of dilator use. Ultimately, individualizing the teaching approach
is important for meeting women’s support needs. These findings
may help nurses and healthcare professionals improve the
provision of support during teaching sessions about vaginal
dilator use. This may lead to improved adherence and enhanced
recovery for women with gynecological cancer.
II-01-B 2:45 PM - 3:15 PM
Oncology Nurses Striving to Provide
Exceptional Care to the Complex Oncology
Patient. What’s Next Mr. W.? Can You
Identify the Oncology Emergencies?
Laurie Ann Holmes, BScN, CON(C), CHPCN(C),
In this presentation we will follow the adventures of Mr. W.,
a 71 year old male referred to the cancer clinic with a recent
diagnosis of small cell lung cancer. He presents with extreme
shortness of breath, significant edema in the upper extremities,
dilated veins in upper chest and neck. He is admitted to hospital
for symptom management. What is your diagnosis? Signs and
symptoms of superior vena cava obstruction will be discussed,
along with treatment options. A femeral line is inserted and Mr.
W. receives urgent chemotherapy. Ten days post chemotherapy
he is neutropenic, develops shingles, and suddenly his oxygen
requirements are increasing. As his respiratory demands escalate,
RACE is consulted, Mr. W. is intubated and transferred to ICU.
Sepsis is the most common non-coronary related death in the ICU.
The importance of early identification and treatment of sepsis will
be presented. While in ICU chest xray reveals a significant pleural
effusion; what are his risk factors and how should this be managed?
During his two week stay in ICU a feeding tube is inserted to
provide nutritional support and he is treated for an upper extremity
deep vein thrombosis. Related to continued issues with upper
extremity edema Mr. W. receives a short course of radiation therapy
to his sternal region. Finally, after seven weeks in hospital Mr.
W. is transferred to a rehabilitation unit and continues to receive
chemotherapy for the treatment of his lung cancer.
II-01-C 3:15 PM - 3:45 PM
Assessing the Feasibility and Impact of
Providing Dignity Therapy to Patients with
Primary Malignant Brain Tumours and
Their Caregivers in an Adult Ambulatory
Oncology Care Setting
Claire Moroney, RN(EC)1, Denise Bilodeau, MS1, Janet Ellis,
MD1, Jennifer Moore, MD1, Hyla Okorofsky, BSN1, Margaret I.
Fitch, PhD2, 1Sunnybrook Health Sciences Centre, Toronto, Ontario,
Canada,2University of Toronto, Toronto, Ontario, Canada.
AIM: To determine the operational feasibility and psychosocial
impact on patients and family caregivers of providing Dignity
Therapy (DT) in an ambulatory neuro-oncology care setting.
METHODS: Subjects are identified by members of the care team.
The intervention is offered by one of four trained co-investigators
all of whom have completed a 5 day Dignity Therapy Workshop.
The patient is asked a series of questions in the context of an
interview that is audio-recorded, transcribed, and edited to form
an easily readable “legacy document” that is then provided to
the patient for them to share with whomever they wish. Patients
and caregivers complete pre- and post-intervention evaluations
using the Patient Dignity Inventory (PDI), the Hospital Anxiety
and Depression Scale (HADS), and the Herth Hope Index (HHI).
61
II-01 2:15 PM - 4:15 PM | Confederation 3
They are also asked to qualitatively describe their reflections
on the experience of DT. Additionally, the co-investigators will
qualitatively describe their experiences of providing DT and their
thoughts on the feasibility and impact of this intervention.
RESULTS: Data will be analyzed through the study period by the
principal investigator.
CONCLUSIONS: Patients living with primary malignant brain
tumours (PMBTs) and their family caregivers commonly
experience psychosocial distress related to poor and
unpredictable prognoses. DT has been shown in other terminally
ill populations to decrease their psychosocial distress as well
as that of their caregivers by helping patients to document what
matters to them and how they wish to be remembered. DT has
not yet been examined in patients with PMBTs. Given the unique
aspects of PMBT patients and their journey, a formal study to
assess both the operational feasibility and psychosocial impact
of Dignity Therapy on patients and family caregivers of patients
with PMBTs is being conducted.
RESULTS: Three major themes emerged: 1) Triage as a bridge to
care: referring to the structure of the triage process and provided
a link to psychosocial services; 2) Supportive presence: referring
to the CNS’ actions to foster a therapeutic relationship; and 3)
Tailored care: referring to the individualized strategies targeted to
the participant’s unique needs. Each theme will be presented and
discussed using the participants’ descriptions of their experience.
CONCLUSION: Overall, the telephone-triage was able to address
concerns of these participants, suggest individualized coping
strategies and provide support. Further work is needed to
determine if such telephone assessment allows us to meet the
patient’s needs through the provision of nursing interventions
such as emotional support, normalization, validation of one’s
experience and referral to allied resources when appropriate.
II-02 2:15 PM - 4:15 PM | Confederation 5&6
Concurrent Session / Atelier simultané II-02-A 2:15 PM - 3:00 PM
II-01-D 3:45 PM - 4:15 PM
Facilitating Advanced Care Planning
Psychosocial Oncology Program:
in Malignant Hematology: A Quality
Perceptions of a CNS Telephone Triage Improvement Project
Assessment
Anita Mehta, PhD1, Andrea M. Laizner, PhD1,
France Desrochers, BSc2, Erin Donivan, BScN2, 1McGill
University Health Centre, Montreal, Quebec, Canada,
2McGill University, Montreal, Quebec, Canada.
BACKGROUND: The Psychosocial Oncology Program (PSO) at
the McGill University Health Centre (MUHC) receives over 700
consults a year. The importance of a triage process for assessing
psychosocial distress is documented as a minimal standard
of psychosocial care. The Clinical Nurse Specialist (CNS) on
the team is responsible for triaging each referral. Despite the
fact that nursing telephone assessments and interventions
are a growing focus of clinical care, there are few studies
exploring the perceptions of such care. Therefore, the purpose
of our study was to explore perceptions of cancer patients or
family members related to their psychosocial telephone-triage
assessment conducted by a CNS. This was deemed a critical step
in determining the success of the psychosocial triage process.
METHODS: A qualitative descriptive design was used to explore
the perceptions of 11 cancer patients and family members
triaged by the CNS for the PSO program. Audiotaped in-person
interviews were transcribed verbatim and analyzed for themes
and categories using a constant comparative method.
62
Leah M. Jodoin, RN(EC), MN, CON(C), St. Michael’s
Hospital, Toronto, Ontario, Canada.
OBJECTIVES: The goal of this presentation is to gain an understanding
of current knowledge, theories, and challenges to advance care
planning with patients who have hematologic malignancies.
Background: With advances in current therapy, people with
hematologic malignancies are seeing improved event free survival.
Many, however, will progress to a palliative state. Research shows
that patients with hematologic malignancies are less likely to
receive best practice palliative care than other malignancies (Harle
et al., 2008). Many patients die in acute care settings or shortly after
receiving chemotherapy – making advance care planning increasingly
important. Advance care planning is a process of reflection and
communication about personal care preferences in the event that an
individual becomes incapable of relaying their wishes.
METHODS: The interdisciplinary hematology/oncology team at a
Canadian university affiliated tertiary care centre has undertaken
a current state analysis as the first step in a quality improvement
project, to standardize advance care planning for patients who
have hematologic malignancies.
Impact: This initiative is in the development phase. Data collection
is ongoing for the current state analysis. Outcome measures will
be shared including how this process hopes to improve patient
outcomes, team relationships, staff engagement and resource use.
II-02-B 3:00 PM - 3:45 PM
Management of Death Rattle at the End of
Life: What Oncology Nurses Need to Know
Susan E. McClement, RN, PhD, CHPCN(C)1,2,
1College of Nursing, Winnipeg, Manitoba, Canada,
2CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Noisy respiratory secretions, commonly referred to as death
rattle, is a phenomenon experienced by many patients as death
draws near. In order to provide competent care for patients
experiencing death rattle and their families, nurses must have a
comprehensive understanding of its pathophysiology, assessment,
and management. Drawing on published empirical evidence, this
presentation will examine: i) the mechanisms of death rattle;
ii) the types of secretions believed to cause death rattle; iii)
pharmacological and non-pharmacological interventions; and
iv) education and support of family members. Areas requiring
additional research about death rattle will also be discussed.
II-02-C 3:45 PM - 4:15 PM
Improving Access to Standardized Fertility
Preservation Information for Older
Adolescents and Young Adults with Cancer
Using a User-Centred Approach
Seline Tam, BSc, Laura Mitchell, RN, MN, CON(C),
Abha Gupta, MSc, MD, FRCPC, Princess Margaret Cancer
Adolescent and young adult (AYA) cancer patients under 40
should be made aware of their fertility risks and options before
starting treatment. Current discussions by oncology providers
around fertility preservation (FP) are often inadequate due
to the lack of knowledge and resources needed to properly
support these conversations. Because of this, patients can have
increased levels of anxiety, depression and distress, if their
informational needs around fertility are unmet.
A user-centred approach can be used to develop fertility
preservation infographic brochures. Pamphlets can be beneficial
because it is common for patients to forget or incorrectly
remember information they are provided with at the time of
diagnosis. In addition, they can be used by staff to introduce the
fertility topic, and by patients to make well-informed decisions
about their fertility.
Two FP pamphlets are currently being developed, one for males
and one for females. They will be reviewed by AYA patients,
survivors and partners based on ease of understanding,
acceptability, and perceived utility. To evaluate its effectiveness,
they will complete questionnaires specific to each brochure.
We will define “effective” if the participant responds “agree” or
“strongly agree” to 17 of 20 assessment items. Then, they will
complete a Short Test of Functional Health Literacy in Adults
(STOFHLA), which will help us determine if health literacy affects
the perception of the pamphlet’s effectiveness. Upon review,
participants will help develop efficient FP tools that can ultimately
reduce decisional conflict and regret among patients and their
potential partners, improving their overall cancer journey.
II-03 2:15 PM - 4:15 PM | Tudor 7
II-03-A 2:15 PM - 2:45 PM
How Does Your Garden Grow? Stories of
Nursing Leadership in a Blossoming Team
Allison P. Filewich, BScN, CON(C), Andrea Knox,
BScN, CON(C), Tina S. Haayer, BScN, British Columbia
Cancer Agency, Kelowna, British Columbia, Canada.
Imperative to successfully transforming outpatient oncology care
to welcome a full complement of nursing disciplines is the role
of nursing leadership. Not only does the leadership role require
skills to facilitate relational dynamics or to navigate concurrent
change processes, leaders need a vision and they must nurture
the underlying values of oncology nursing.
Due to the growing complexity and care demands of the oncology
patient, models of nursing care delivery have seen continual
adaptation in order to remain effective and sustainable. Through
evolution of care models, leadership remains one constant
source of encouragement and grounding. Leadership influence
poses even more significance when the model of care includes
the integration of multiple nursing roles within one care team.
In the province of British Columbia, registered nurses (RNs) have
primarily provided the delivery of nursing care for oncology patients.
63
CONCLUSION: Within the multidisciplinary team, nurses
and nurse practitioners play a critical role in facilitating the
conversation around advance care planning. This presentation
will focus on current knowledge and best practices related to
advance care planning and end of life care for the malignant
hematology patient population. Case studies, processes and
outcomes of our initiative will be shared.
However, with the support of operations at one regional cancer
centre, integration of nurse practitioners (NPs) and licensed
practical nurses (LPNs) has achieved a full complement of
nursing care providers within the outpatient oncology setting.
This novel concept has raised questions concerning the current
care models and the expectations regarding multiple scopes of
nursing practice in oncology.
Successful integration and advancement of nursing practice
is dependent on the abilities of nursing leadership to elicit
dialogue, generate openness, navigate and respect political
landscapes and legislation, as well, be sensitive to the dynamics
and culture of local care teams.
Personal leadership inventories and stories of success can
help identify ways to establish stakeholder commitment and
resilience during times of change. Learning from the experiences
of those planting the seeds of true nursing collaboration in
oncology proves a rich source of knowledge.
II-03-B 2:45 PM - 3:15 PM
Accreditation Standards for Integrated
Cancer Care
Stephanie Carpenter, MA, Accreditation Canada,
Throughout 2014 and 2015 Accreditation Canada is revising
the cancer care standards in collaboration with the Canadian
Partnership Against Cancer (CPAC). The standards have
been revised to address the integrated nature of cancer care
delivery, with specific modules that address the safe delivery of
radiotherapy and systemic therapy within a context of providing
client- and family-centred care.
The cancer care standards were revised and new content was
developed under the guidance of a standards working group
composed of experts in the field with representation from the
Canadian Partnership for Quality Radiotherapy (CPQR). As well,
the standards were evaluated through a web-based national
consultation and pilot tested in Canadian organizations that
provide a range of care. The standards are designed to be
customizable in any organization that provides cancer care
services regardless of structure, complexity, and scope of services.
The presentation will address the background and motivation
for revising the cancer care standards, the development
process, and how these standards meet the quality and safety
needs of organizations providing cancer care. Issues core to
the standards include client- and family-centred services,
access to services, client education, team safety and education,
equipment safety, safe prescribing, safe preparation and
administration, and client transitions.
64
Accreditation Canada’s standards not only address the safety
needs of clients receiving cancer care, but provide a tool for
organizations to continuously improve their services through
national standards of excellence.
II-03-C 3:15 PM - 3:45 PM
Navigation of Lung Cancer Patients
Through the Diagnostic Phase of Care:
Purposeful Early Engagement
Chantal Bornais, RN, BSN, Jennifer Smylie, BN, RN,
MHSM, The Ottawa Hospital, Ottawa, Ontario, Canada.
The Canadian Cancer Society estimates that approximately 26,100
new lung cancer cases will be diagnosed in Canada in 2014. Of that
number, the CCS estimates an overwhelming majority, nearly 80%,
will die of their disease. Compared to other cancers in Canada,
lung cancer represents the leading cause of death among all
cancers, nearly double the mortality rate of the next most deadly
cancer.
As such, patients referred with a suspicion of lung cancer benefit
greatly from rapid assessment and diagnosis of their disease in
order to access treatment and supportive care. However, many
patients report feeling overwhelmed with the speed at which they
are experiencing diagnostic testing and may cancel procedures due
to a lack of understanding, anxiety or both. The Ottawa Hospital has
recently transformed the manner in which these patients and their
families experience the assessment and diagnostic phase of care.
Patients are contacted by a nurse within 24-48 hours of referral and
offered an opportunity to meet with a Nurse Navigator to review
their individualized plan of care and receive teaching and support.
This session offers the opportunity for patients and families to have
their questions answered and reassures them that they will be
cared for by an expert interprofessional team. Diagnostic testing is
also aligned with this visit thereby reducing the overall wait time to
treatment decision.
Feedback from patients and loved ones following this Navigation
Day visit indicates greater understanding of their plan of care,
improved satisfaction and significantly reduced anxiety. Other
benefits from this Navigation Day include earlier intervention
for smoking cessation and improved access to symptom
management. Nurse Navigators also report greater satisfaction
though an expanded role and timely identification of appropriate
resources to meet patient needs.
II-04 2:15 PM - 4:15 PM | Tudor 8
What’s in a Name? The Impact of Obtaining
an Oncology Specialty Designation
simultané II-04-A 2:15 PM - 2:45 PM
Mary Jane Esplen, RN, PhD1,2,3, Jiahui Wong, PhD1,2,3, Komal
Patel, RN, MN, CON(C), CHPCN(C)1,2, Maureen Watt-Smit, RN, MN,
CON(C)4, Donalda MacDonald, RN, CON(C)1, Esther Green, RN,
MSc5, 1de Souza Institute, Toronto, Ontario, Canada, 2University
Health Network, Toronto, Ontario, Canada, 3University of Toronto,
Toronto, Ontario, Canada, 4Grand River Hospital/Grand River
Regional Cancer Centre, Kitchener, Ontario, Canada, 5Canadian
Partnership Against Cancer, Toronto, Ontario, Canada.
A unique specialty designation was developed in Ontario to provide
a learning pathway that represents advanced knowledge and skills
in specialized oncology nursing. The designation builds further on
the CNA certification, and incorporates competency based CANO
standards across all domains of care. Not unlike the widely-known
MacMillan nurse in the UK, this designation offers recognition of
a comprehensive set of knowledge and skills that symbolize high
quality oncology care. Employers can apply the designation as their
hiring and performance evaluation criteria. The designation can
also be used to highlight the skills of the workforce for the public
and raise the awareness of the importance of oncology nursing
excellence. The designation is now available to support the nurse’s
journey from the initial training in a nursing school (an intern
designation) through to advanced practice levels, such as the APN
or PhD Scholar designation.
This presentation will utilize both qualitative and quantitative data
from the first twenty designates in Ontario to highlight a broad
range of approaches they used to complete the learning pathway.
Also included in the presentation is the scope of their clinical
fellowship projects and the impact of such learning on their clinical
experiences from diverse clinical areas. Examples will be used to
highlight the rationale for pursuing the designation, its meaning,
its outcomes and future impacts. Opportunities for management
buy in and methods for leaders to use the designation in building
work force capacities in a standardized and cost effective way will
also be discussed.
Supportive Care for Cancer Survivors
in the Community: The Roles of Parish
Nurses and Nurse Practitioners
The expanding cancer survivor population creates complexity for
the healthcare system. Cancer survivors experience a number of
physical and psychosocial issues as well as chronic health problems
that greatly affect quality of life, health and productivity. Communitybased care providers, including parish nurses and nurse practitioners,
are assuming greater responsibility for the ongoing supportive care
sought by cancer survivors. They offer a health promotion perspective
that may be useful in helping cancer survivors normalize their lives
and give them increased control of their health. Their perspectives
on their ability to provide supportive care to cancer survivors are
poorly understood. An interpretive, descriptive qualitative design
was adopted to better understand the care that is provided to cancer
survivors by parish nurses and nurse practitioners. This presentation
will describe these experiences of these community-based care
providers in taking care of cancer survivors in New Brunswick,
including their professional responsibilities and their informational
needs and preferences in caring for cancer survivors. Data were
captured through semi-structured interviews. Interviews were
transcribed and reviewed for common themes. While recognizing the
uniqueness of these experiences, the results of this research may
serve as a starting point for conversations about how to implement
best practices in delivering ongoing supportive care to cancer
survivors in community settings.
simultané II-04-B 2:45 PM - 3:30 PM
The Development of a Nurse
Practitioner-Led Rapid Assessment
Clinic for Acute Leukemia
Alix J. Duck, NP, MN, BScN, BA, Kayla J. Madsen,
BScN, Nancy A. Pringle, RN, Nancy A. Wagg, RN, Princess
Acute leukemia is a rapidly progressive malignancy that requires
timely intervention with specialized assessment, clinical
management, and chemotherapy. Over the last five years there
has been an increase in the incidence of acute leukemia cases.
65
II-03-D 3:45 PM - 4:15 PM
In the face of a growing aging population this rising trend is
predicted to continue and consequently, is producing significant
resource strains in a major oncology centre. In response to this
a nurse practitioner led rapid assessment clinic for suspected or
confirmed cases of acute leukemia was implemented to ensure
timely and adequate access to diagnosis, clinical monitoring,
therapy and supportive care, as well as patient and caregiver
education. This autonomous nursing led clinic now provides care
for over 350 patients a year and is able to provide diagnosis and
initial therapy planning within 48 hours from time of referral.
It has been identified in the literature that nursing-led outpatient
oncology clinics are proving to be a valuable, cost-effective and
comprehensive solution in meeting the increasing demand for
care in oncology. This presentation will share strategies used for
the successful adoption and advancement of a nurse practitioner
role in an outpatient oncology setting as well as the impact
of nurse-based care in meeting the complex needs of acute
leukemia patients. The discussion will include methods used in
the development of an advanced practice nursing model of care,
barriers and challenges encountered and outcomes achieved.
References:
Cancer Care Ontario (2011). Adult Acute Leukemia Services Plan for
the Greater Toronto Area.
Liego, M., Loomis, J., VanLeuven, K., Dragoo, S. (2014). Improving
Outcomes Through the Proper Implementation of Acute Care Nurse
Practitioners. The Journal of Nursing
Administration, 44 (1), 47-50.
Ruegg, T., A. (2013).
A Nurse Practitioner-Led Urgent Care Centre: Meeting the Needs
of the Patient with Cancer. Clinical Journal of Oncology Nursing, 17
(4), E52-E57.
II-04-C 3:30 PM - 4:15 PM
Palliative Care Referral, Triage, and Patient
Navigation: A Nurse-Led Quality Initiative
Maria Rugg, MN, CHPCN(C), Robert Sauls, MD, Trillium
The oncology program in our region has been very successful in
the goals of early identification of patients with palliative care
needs and referral to the advanced practice nurse in palliative
care and/or the palliative care clinic. As a result, the visit
volumes in the clinic have grown to among the highest of all the
provincial cancer centres. However, as the volumes of referrals
have grown, the waiting times for palliative care services has
also grown. In order to ensure that patients have early, timely
access to palliative care a new model of care was proposed in
April of 2014 that utilizes resources both in our centre and in
the community that matches the complexity of patient needs
66
to the most appropriate providers. We proposed that a more
sophisticated nurse led referral and triage-navigation system
that would include identification of complexity of patient needs,
communication and liaison with primary care providers (family
physicians), when patient needs can be met by that provider and
assessment by the most appropriate provider (APN or MD) within
the cancer centre when needs are complex would result in earlier
access to quality palliative care supports. It has been almost
one year since we piloted this new model and there are many
lessons learned. We have successfully reduced wait times to just
less than two weeks which is the provincial goal. There has been
tremendous uptake by primary health teams, and from chart
audits, ER visits have decreased substantially.
The presentation will outline the steps we undertook for this
quality improvement initiative including structures, processes
and outcomes. A case example will be provided to demonstrate
the role of the nurse in facilitating quality palliative care services
for patients and families with unmet needs. Data including
our pre- and post-experience will be shared along with our
sustainability plan and future ideas.
II-05 2:15 PM - 4:15 PM | Alberta
II-05-A 2:15 PM - 2:45 PM
Brain Fog: Is it All in Their Heads?
Anita Mehta, PhD, Andreanne Robitaille, MSN, McGill
BACKGROUND: It has been estimated that 15% to 70 % of cancer
patients experience slow mental processing, memory lapses, and
difficulty concentrating, and multitasking. These sometimes vague
yet distressing mental changes cancer patients notice are real,
and not imagined. Despite this fact, patients often report distress
related to the lack of acknowledgement of their symptoms by
healthcare professionals. Approximately 14% of cancer survivors
reported memory problems, compared with 8% of participants
without a prior cancer diagnosis, representing an approximately
40% increase in the likelihood of cancer survivors reporting
cognitive concerns. While the exact prevalence of ‘brain fog’ is
hard determine, it is clear that there is a considerable impact of a
patient’s quality of life, causing depression and anxiety in many
patients. This cluster of symptoms, often referred to as “chemo
brain” since 50 to 60 % of individuals experience these difficulties
during or after chemotherapy, is now increasingly being recognized
by the more formal term, post-cancer cognitive impairment (PCCI).
RESULTS: Preliminary results on the evaluation of these initiatives
will be highlighted, and participant feedback will be presented.
CONCLUSION: New research is showing that there are likely
other factors such as fatigue and worry that actually start
before treatments, and are then enhanced by the effects of
chemotherapy. Moreover, given that these symptoms may persist
for months, or even years after a patient has finished treatment, it
is imperative that patients are properly assessed and supported
as they cope with such cognitive changes.
3. Enhanced interprofessional communication through
our electronic systems (Mosaiq, SunnyCare) to overcome
departmental and electronic system silos.
Since the pilot launched there have been no errors/near misses
for patients who receive Xeloda chemotherapy and radiation
concurrently. There has also been a significant reduction in the
number of blood work and medical oncology appointments
missed by this patient population. This pilot illustrates
the benefits of an interprofessional approach when facing
complex treatment pathways to ensure patient safety through
communication amongst team members.
II-05-C 3:15 PM - 3:45 PM
Preparing the Specialized Oncology Nurse
Concurrent Session / Atelier simultané for International Partnerships: Reflections
II-05-B 2:45 PM - 3:15 PM
from One Centre’s Experience
Using an Interprofessional Team Approach Samantha Mayo, RN, PhD, Pamela Savage, RN, MAEd,
CON(C), Justin Young, BA, MPA, University Health Network,
to Enhance the Care of Patients with
Complex Treatment Pathways
Eirena N. Calabrese, BSN, RN, MN, Arlene Court, BSN,
RN, CON(C), Glen Gonzales, BSc, MRT(T), Brian Liszewski,
BSc, MRT(T), Colin Myers, BA, Mark Pasetka, BSc, BScPharm.,
PharmD, R.Ph., Steve Russell, BSc, MRT(T), Yee Ung, MD,
Jackie Ezezika, BA, PEng, MEng, Yooj Ko, MD, Sunnybrook
Health Sciences Centre, Toronto, Ontario, Canada.
Patients prescribed oral chemotherapy have unique needs which
are further complicated by the addition of concurrent radiotherapy.
An interprofessional team with representation from nursing,
pharmacy, physicians, radiation therapy, and support services
collaborated to tackle a 7.7% error/near miss rate for patients
who receive Xeloda chemotherapy and radiation concurrently.
These patients interact with multiple health professionals and
team members along their treatment journey and thus benefit
from an interprofessional team approach. The team utilized Lean
processes which provided opportunity to; clarify roles through
activities such as role shadowing, understand the patient
perspective through patient engagement, and identify new
processes and goals through shared decision making.
The group introduced the following strategies to enhance the
patient experience and patient safety:
1. Developed and implemented an interprofessional clinical care
pathway which clarifies health professional and support staff
responsibilities.
The global cancer burden is increasing at an alarming pace. An
important approach to mitigating this burden involves enhancing
the capacity of the global nursing workforce to contribute to
comprehensive cancer care. Various international organizations
have identified the important role of the specialized oncology
nurse in this effort, specifically by providing education and clinical
mentorship to international colleagues. However, the necessary
training or support that such nurses require to be effective in such
roles is unclear. In 2010, our organization, the University Health
Network in Toronto, Canada engaged in a 5 year contract with the
Kuwait Ministry of Health to improve cancer service delivery at the
Kuwait Cancer Control Center. The purpose of this presentation
is to describe the lessons learned through our experience of
preparing specialized oncology nurses for consultative roles
as part of this international partnership. Based on a review of
the literature and results of a semi-structured survey of staff
who participated in at least one international site visit, we
identify three major elements that should be addressed in the
preparation of nurses involved in international partnerships: (1)
a clear description of professional expectations and deliverables;
(2) strategies for negotiating cross-cultural differences; and (3)
cultivation of relevant leadership and relational skills. Practical
strategies for addressing each of these considerations will be
suggested, and the implications for enhancing the role of the
oncology nurse in global cancer care will be discussed.
2. Developed an interprofessional approach to ensure medication
adherence and monitor chemotherapy related toxicities.
67
METHODS: This presentation will focus on a brief description of
PCCI and describe individual and group interventions that can
help the patients recognize and manage their way through the fog.
In addition, a Workshop organized by CanSupport at the Cedars
Cancer Centre in Montreal, Canada will be discussed and the
content and tools used will be presented.
II-05-D 3:45 PM - 4:15 PM
Enhancing Purpose and Passion Through
the Work of Our Partnership Council
Kathryn McKay, RN, BScN, Linda Nixon, RN, Trillium
In the spring of 2014, inter-professional practice councils were
introduced to our organization as a means to promote grass
root creative ideas supported by evidence to facilitate change
and knowledge transfer. Practice councils create opportunities
for partnership, leadership and engagement of front line staff
to focus on improving patient care, quality and satisfaction.
Of the six practice councils within the oncology program, the
systemic and clinic council which is chaired by an expert RN
in medical oncology and an advance practice nurse is moving
towards achieving the goals set out in the terms of reference.
The journey began with an environmental scan and fishbone
analysis to assess gaps and opportunities. This was followed by
a survey monkey to determine priorities. Communication was
identified as a key gap and opportunity for us to affect change.
Four key communication themes were documentation, electronic
interfaces between services, communication processes to
support patients who receive combined therapies and principles
to guide inter-professional communication and team work.
This presentation will provide an overview on the development
of our practice base council and highlight the work we have
accomplished within the theme of team communication. We
will describe the process the council used to develop and
validate principles and key behaviours of effective teams. The
presentation will also highlight some of the benefits we have
seen with the implementation of our inter-professional council
including a greater understanding and appreciation of what each
profession brings to the care of the oncology patient and the
importance and benefits of team collaboration.
II-06 2:15 PM - 4:15 PM | British Columbia
II-06-A 2:15 PM - 2:45 PM
A Mixed Method Study Exploring
Colorectal Cancer Screening Behaviors
Among South Asian Immigrants in Ontario
Joanne Crawford, BScN, CON(C), MScN, PhD(c)1,2,
1University of Toronto, Toronto, Ontario, Canada, 2Brock
University, St. Catharines, Ontario, Canada.
68
Cancer screening for breast and cervical cancer are low among
South Asian immigrants in Canada. Low rates of colorectal cancer
screening have been reported in South Asian immigrants in
the US and UK. However, few studies have examined colorectal
cancer screening behaviors among South Asian immigrants in
the Canadian context. This study used an exploratory sequential
mixed methods design to explore colorectal cancer screening
among South Asian immigrants in Ontario. In phase one, a
scoping study was undertaken to map out the available evidence
on cancer screening among South Asian immigrants. Phase two
qualitatively explored South Asian immigrants’ perspectives of
colorectal cancer and screening. Phase three utilized findings from
the scoping study and qualitative study to inform development of
a quantitative instrument. The scoping study reported on factors
that influenced breast, cervical and colorectal cancer screening
including beliefs and attitudes, knowledge, barriers, and gender
differences. Qualitative findings revealed South Asian immigrant’s
beliefs and attitudes, knowledge and awareness, and support and
accessibility specific to colorectal cancer and screening. Findings
from both studies guided conceptual definitions of measures to be
included in the instrument. A subsequent literature search of preexisting measures was undertaken. Select measures were critically
appraised, and an advisory group was consulted on measures to be
included in the instrument. The instrument includes multiple scales
and will be pre-tested with 20 South Asian immigrants in the spring
using cognitive interviewing. The presentation will discuss findings
that informed instrument development, and outcomes of the pretesting with the South Asian immigrant population.
II-06-B 2:45 PM - 3:15 PM
Health Care Teams Collaborating to Manage
Patients’ Pain at the Top of the Ladder
Laurie Ann Holmes, BScN, CON(C), CHPCN(C), The
Ottawa Hospital, Ottawa, Ontario, Canada
Sixty percent of patients undergoing treatment for cancer
experience pain, seventy five percent of patients in the palliative
phase have unrelieved pain, and most patients have more than
one pain site. The World Health Organization in 1990 developed
guidelines to aid clinicians with pain management. The route and
modality is based on the patient’s pain requirements. Ideally pain
management is by mouth and by the clock. As we climb the pain
ladder, different strengths and modalities of pain medications may
be required. For those patients whom pain is not controlled by
the p.o. route a subcutaneous or intravenous patient controlled
pump will be initiated. When patients are admitted in pain crisis
the nurse, oncologist and palliative care team work together to
monitor and evaluate pain management. For neuropathic pain
and difficult pain syndromes, an anesthesiologist specialist is
consulted. Based on their assessment a port-a-cath may be
surgically inserted into the intrathecal space.
RESULTS and Clinical Implications: This program promotes
a transferable care model that offers timely transdisciplinary care
coordination and empowers women to engage in bone-healthy
practices at diagnosis and throughout survivorship.
II-06-D 3:45 PM - 4:15 PM
An Interprofessional Approach to
Concurrent Session / Atelier simultané Oral Anti-Cancer Management: The
II-06-C 3:15 PM - 3:45 PM
Development, Implementation, and
Evaluation of a Care Pathway for Patients
The Breast & Bone Health Program:
A Transdisciplinary Model of Care to
Eirena N. Calabrese, RN, BScN, MN, Alia Thawer,
BSc, BSc.Pharm, R.Ph, Sunnybrook Health Sciences
Proactively Address Bone Health in
Breast Cancer
Garnet J. Lau, RN, MSc(A), MSc1, Julie Lapointe, PhD,
erg. OT(C)2, Mary-Ann Dalzell, MSc, PT1, Nadia Smirnow,
BSc, PT CLT1, Marize Ibrahim, MSc, PT CSLT1, Evan Beloff, BA,
ND1, Carole Séguin, BSc Inf.1, Nicole Tremblay, PhD3, Lindsay
Duncan, PhD2, Suzanne O’Brien, MA1, Carmen G. Loiselle, RN,
PhD1,2, 1Jewish General Hospital, Montreal, Quebec, Canada,
2McGill University, Montreal, Quebec, Canada, 3Université de
Montreal, Montreal, Quebec, Canada.
BACKGROUND: Breast cancer treatment, most notably endocrine
therapy, interferes with bone metabolism and can lead to bone
fragility, osteoporosis, and fractures. Because this effect can
persist beyond active treatment, strategies are needed to sensitize
healthcare professionals and women. Breast cancer bone health
guidelines have been published; however, in Quebec there are no
programs to translate these into practice.
OBJECTIVES: The objectives of this pilot program are to:
1) raise patient, caregiver, and public awareness on the
effects of cancer treatment on bone health; 2) systematically
assess women with breast cancer and provide evidencebased preventive and/or management interventions; and 3)
improve practice through a transdisciplinary program of care
that explicitly includes bone health – such program being
provincially and nationally transferable.
APPROACH: The co-leadership of nursing and physiotherapy
is an innovative program feature which emphasizes an early
comprehensive bone health assessment. Women diagnosed with
breast cancer and undergoing treatment in an outpatient oncology
clinic are invited to participate. Over 3 years, 525 participants are
expected to enroll. The program nurse and physiotherapist consult
and work with members of the oncology team in the provision of
tailored evidence-based interventions (e.g. exercise prescriptions,
nutritional counselling, information provision, support for positive
lifestyle). Strategies to empower women to engage in bone health
self-management are integrated throughout.
Oral anti-cancer agents are a growing treatment option for
patients. With fewer visits to the cancer centre, opportunities
for education and symptom assessment are decreased and
becoming increasingly challenging. An interprofessional group
within the genitourinary site at a large cancer centre in Toronto,
Ontario developed and implemented a care pathway for patients
who are prescribed abiraterone or enzalutamide to improve
adherence, education, and toxicity management.
Patients are given instructions to pick up their medication, via
telephone, by a nurse. A pharmacist provides education when the
medication is dispensed, followed by a phone call to the patient
within 72 hours of starting the medication. The patient is then
informed to return to the clinic in two weeks to have blood work
and to be seen in the nursing clinic. Both the pharmacist and nurse
follow standardized assessments developed interprofessionally.
Assessments, interventions, and education are documented to
facilitate interprofessional communication.
On-going evaluation of the pilot continues, however early data
suggests that patients are extremely satisfied with the follow-up
model, and feel they are confident in their understanding’s of the
drug, how to take it, and toxicity reporting and management. Plans
to disseminate the pathway to include other oral medications are
under way. This model utilizes the expertise of different members
of the interprofessional team, promotes the optimization of scope
of practice, and allows the interprofessional team to provide safe,
excellent care for patients.
69
The goal of intrathecal pain management is to preserve
function and improve quality of life. Via the intrathecal route,
a combination of anesthetic agent plus opioid are infused
providing better pain control and less toxicity. Prior to discharge
the clinical nurse specialist works with community nurses to
ensure they have received adequate training on this therapy. In
this presentation the role of intrathecal pain management, the
benefits and risk will be discussed.
Annual International Symposium:
CANO/ACIO, ONS, ISNCC /
Symposium international annuel :
ACIO/CANO, ONS, ISNCC
Monday, October 5, 2015
Lundi 5 octobre 2015
Precision Medicine: Emerging Ethical
Issues for Oncology Nurses
Supporting Practice: Canadian Virtual
Hospice Knowledge Tools Project
Stella Aguinaga Bialous, RN, DrPH, FAAN, President,
ISNCC
Margaret Barton-Burke, PhD, RN, FAAN, President, ONS
Barbara Fitzgerald RN, MScN, President, CANO/ACIO
Jo-Ann Lapointe McKenzie, RN, BScN, MN, Shelly Cory,
MA, Brenda Hearson, BN, MN, CHPCN(C), Canadian
Virtual Hospice, Winnipeg, Manitoba, Canada.
Oncology nursing practice is complex. No longer is there a “one
size fits all” approach to treatment. Over the past 10 years, the
ability to sequence the human genome expanded the horizon
for understanding many diseases, especially cancer. Precision
medicine takes many factors into consideration, including age,
tumor histology, as well as tumor genetics and proteomics.
The promise of precision medicine offers exciting possibilities,
yet bring challenging ethical issues such as informed decision
making, informed consent and genetic testing, maintaining
privacy and confidentiality, preventing genetic discrimination and
strengthening genomic care and access around the world.
• Increase the knowledge and utilization of the resources
and support available on the Virtual Hospice website.
Oncology nurses play a critical role in advocating, educating,
counseling, and supporting patients and their families who
are making gene-based healthcare decisions. Knowledge and
understanding of current and emerging ethical issues is an
essential component and underpinning of oncology nursing
practice in this rapidly evolving field. This session focuses on a
presentation and discussion on the ethics/ethical underpinnings
of genetics, genomics, and the decision-making process. This
session includes genomic-based exemplars and case studies to
help you explore your own ethical beliefs and concerns.
70
• Discuss the challenges faced by marginalized patients and
families in accessing palliative care.
• Make nurses aware of the new tools that will be available
on the Virtual Hospice website.
• Participate in the dissemination and evaluation of the
tools and offer suggestions for future tool development.
Come learn about new free, online tools developed by Canadian
Virtual Hospice (CVH) to support individuals living with advanced
cancer and enhance your clinical practice. These educational tools
will be available regardless of where you live or work. CVH, serving
over 90,000 visitors a day, is the go-to website for evidenceinformed content & interactive support services for patients,
families, health care providers (HCPs), researchers and educators.
Funded by the Canadian Partnership Against Cancer and created
in collaboration with patients, families, health care providers
and pan-Canadian partners, our Knowledge Tools Project will
produce 4 major tools to address gaps in information and support
available to those living with advanced cancer as well as their
HCP’s. The First Nations, Inuit and Metis (FNIM) Empowerment
Tool will use the voices and art from FNIM communities to create
videos and print materials that address barriers and enablers to
culturally safe care; myths of palliative care; misunderstandings
of terms such as “treatable”; information that should be provided
by HCPs; and questions to ask, including the use of traditional
medicines. The Cultural, Spiritual and Religious Tool will target
cultural and/or religious groups through a set of videos that share
the voice and wisdom of respected leaders, patients and families
of these communities. The Loss and Grief Interactive Tool for
Patients and Families offers on-line psycho-educative modules
to provide an option for those who don’t or can’t access existing
in-person supports due to lack of availability, geography, timing,
choice, finances and other factors. The Methadone for Analgesia
Online Training Tool will provide core competencies in methadone
prescribing in palliative care, so that physicians in Canada have
access to the same comprehensive curriculum. After a brief ‘tour’
of Virtual Hospice & a ‘first look’ at these exciting new tools,
participants will be asked for feedback and suggestions.
III-03 1:15 PM - 2:45 PM | Tudor 7
Medically Assisted Death in Canada:
Careful and Thoughtful Practice Directions III-03-A 1:15 PM - 2:00 PM
for Oncology Nurses
Pursuit of Excellence in Chemotherapy
Barbara Fitzgerald, RN, MScN2, Barbara Russell, MBA, Management: The Evolution of a Chemo
PhD, Shari Moura, RN, MN, CON(C), CHPCN(C)1,
Council
1Princess Margaret Cancer Centre - University Health
Network, Toronto, Ontario, Canada, 2CANO/ACIO President,
BC Children’s Hospital, Vancouver, British Columbia,
3Toronto General Hospital, Women’s College Hospital,
Toronto, Ontario, Canada
In 1993, the Supreme Court of Canada ruled in a split decision
against Sue Rodriguez, a woman with advanced ALS wanting
medical assistance to end her life. Twenty-two years later,
however, the Court ruled unanimously in favour of Lee Carter,
a woman with progressive spinal stenosis, wanting medical
assistance to die. The Court’s ruling impacts federal and
provincial/territorial legislation as well as professional regulations.
Recognizing that governments and professional bodies may wish
to write practice-guiding policies, the Supreme Court instituted a
12-month waiting period before its ruling takes effect.
This session will examine the ruling’s impact on oncology nurses’
work in hospital- or community-based, interprofessional settings.
Various ethical, legal, professional considerations are included in
the session’s 5 parts: (1) “pre-Carter” – a prototypical case of a
patient with advanced cancer and nurses’ usual responsibilities
in discussing aggressive treatment versus palliative care with
the patient and family as well as highlight typical physician and
pharmacist responsibilities, (2) key directions and reasons from
the Supreme Court’s Carter v. Canada ruling, (3) “post-Carter”
– the case re-examined to identify nursing responsibilities
that likely will and will not change when a patient is interested
in medical assistance to die, (4) “what to pay attention to” if
legislative and professional guidelines are written to help clarify
certain criteria, institute appropriate safeguards, and establish
seamless procedures, and (5) the audience’s insights and views
of how their work with oncology patients and interprofessional
teams will benefit from or be challenged by this pivotal change in
Canadian healthcare and society.
Eleanor A. Miller, BScN, MAEd, Linda Ramjohn,
BScN, MAEd, Candice McGaw, BScN, Sunnybrook Health
The administration of safe chemotherapy is of utmost priority on
a Medical and Radiation Oncology unit. Given the complexity of
chemo regiments, the impact of technology, and the emphasis
on inter-professional collaboration, it is important to explore
innovative ways to effectively manage chemotherapy.
The chemo council evolved from a need to address recurring
issues and challenges such as, delivering chemotherapy to
patients who are located elsewhere in the hospital, prioritizing
patients for elective chemotherapy when there are few available
beds and communication challenges.
The vision of the council is to provide a collaborative
environment where team members can enquire, discuss, develop
and encourage safe practice for chemotherapy administration.
Our first meeting involved the development of the terms of
reference and a brain storming session to identify key priorities.
Over the past year and a half the council has implemented the
computerized Nursing Systematic Therapy Verification (STV)
system, developed a chemotherapy administration checklist
for nurses, collect and reviewed data on central lines for early
assessment of chemo patients. Reviewed the elective chemo
process, implemented a chemo distribution list as a means of
improving communication among team members. As well as
worked collaboratively with the outpatient chemo clinic to
facilitate consistency in practice and safe chemo for all patients.
The development of the chemo council has provided an
opportunity to improve practice, foster more effective
communication and improve collaboration for safer patient care.
71
III-03-B 2:00 PM - 2:45 PM
Ontario, Canada, 2Trillium Health Partners, Mississauga,
Ontario, Canada.
BACKGROUND: Dyspnea is defined as a subjective experience
of breathing distress and is derived from interactions among
multiple factors. Current literature suggests that educating
affected individuals about breathing management strategies
can lead to significant improvements in their ability to cope with
dyspnea related symptoms.
OBJECTIVE: To elucidate and understand patient experience
on managing shortness of breath 1 month after attending a
breathing wellness program.
METHODS: Data collection will be accomplished through semistructured interviews with individuals who have attended a
RESULTS: Through thematic analysis we hope to learn more
about how individuals are coping with dyspnea and what
strategies they continue to use on a daily basis.
FUTURE DIRECTIONS: Following data analysis results will be
used towards improving a breathing wellness program at a local
tertiary hospital. By incorporating current patient feedback the
program can be modified to help future patients more effectively
achieve dyspnea relief.
III-04 1:15 PM - 2:45 PM | Tudor 8
III-04-A 1:15 PM - 1:45 PM
To Evaluate the Use of a Comprehensive
Geriatric Assessment in Geriatric
Cancer Patients Undergoing Adjuvant
Chemotherapy
Manon A. Lemonde, RN, PhD, Rama Koneru, MD, Orit
Freedman, MD, Archit Malyala, BSc, Durham Regional
Cancer Centre, Oshawa, Ontario, Canada.
72
A comprehensive geriatric assessment in clinical oncology practice
would help to individualize care for geriatric cancer patients by
improving treatment selection, minimizing toxicity, and identifying
need for additional supports to optimise tolerance of chemotherapy.
However, the assessment has not been standardized and is often
not used in routine practice. Our study utilizes a pretest-post-test
design using Hurria et al comprehensive geriatric assessment scale
before and after adjuvant chemotherapy in geriatric patients with
lung, breast or colorectal cancers.
This comprehensive tool includes a self-administered patient
questionnaire and an assessment by healthcare professional,
addressing seven important domains: functional status,
comorbidity, psychological state, social support, nutritional
status, cognitive function, and medications as well as sociodemographic data.
Patients will first be introduced to the study by their oncologist.
Those interested in participating will be directed to the study
staff. Once informed consent is obtained, the patient would
be requested to complete the self-administered questionnaire
followed by the healthcare professional assessment questions.
The same comprehensive geriatric assessment would be
administered a second time two to six weeks after last
chemotherapy treatment. Data analysis will include descriptive
statistics for all patients. A one-way repeated measures ANOVA
test will track changes in patients’ scores prior to and after
treatment. There are no results available as data collection started
on January 28th, 2015 and continues until we recruit 30 patients.
III-04-B 1:45 PM - 2:15 PM
Failing to Prepare Is Preparing to Fail ...
Implementing a Palliative Approach
Wendy L. Petrie, RN, BScN, MScN, CON(C) CHPCN(C),
Sylvie Bruyere, RN, BScN, CON(C) CHPCN(C), Lynn
Kachuik, RN, BA, MS, CON(C) CHPCN(C), The Ottawa
Cancer therapies are intensive and complex, but many will
not provide long term cure. There may be a period of disease
stability fraught with distressing symptoms. Even with incurable
disease, many patients live for weeks or months ill-prepared for
the transition to palliative care.
In our model of patient-centred care, communication about
prognosis, goals of care and palliation must be integrated into
oncology care. However, multiple barriers related to patients,
families and health care providers affect this transition to
palliation including: difficulty in accepting futility/failure of
treatment, lack of advance care planning, and challenges in
addressing end of life.
We will discuss two cases that exemplify outcomes of early
versus late involvement of palliative care. These will be
supported by literature evidence as well as data from a recent
chart audit of oncology patients who died at our hospital.
Oncology and Palliative Care nurses, passionate about providing
high quality care, have key roles in collaborating to implement a
palliative approach to care early in the oncology disease trajectory
to promote excellent care for our patients and their families.
III-05 1:15 PM - 2:45 PM | Alberta
III-05-A 1:15 PM - 1:45 PM
Bringing a Passion for Oncology to the
Generalist Nurse
Jessica Lam, BScN1, Anne Embleton, BScN, MN, OCN,
CON(C)2, 1University Health Network, Toronto, Ontario, Canada,
2Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
III-04-C 2:15 PM - 2:45 PM
The combination of a lack of oncology focused education in
Canadian undergraduate nursing schools and general hospital
orientation have left many nurses unprepared to care for the
number of cancer patients that the generalist nurse encounters
on medical-surgical units.
Measuring the Impact of Radiation
Therapy Treatment Using Patient Reported
Outcome Measures: BC’s Prospective
Outcomes Support Initiative
Bridging the Gap in Oncology Nursing Care (BGONC) was a
project developed and implemented to reduce the knowledge
gap for nurses in cancer care, instill a sense of passion for
oncology and develop their leadership skills as general oncology
resource nurses for their colleagues.
Susan J. Curtis, RN, Kam Dosanjh, RN, Fraser Valley
Cancer Centre, Surrey, British Columbia, Canada.
The hospital is a large academic facility in an urban centre
with one site being entirely devoted to oncology. BGONC was
developed to provide an educational program for nurses in
the Nursing Resource Team (NRT) working on general medicalsurgical units across the hospital. This initiative was the first of
its kind at our facility and was tailored towards the NRT, which
is comprised of new graduate nurses. A needs assessment
demonstrated a lack of knowledge regarding carcinogenesis and
oncology care in general, which affected the nurses’ abilities to
manage the common symptoms and complications experienced
by cancer patients as well as their confidence in providing
patient education. Given the knowledge gap in cancer and its
care requirements, the goal of BGONC was to give NRT nurses
a deeper understanding of cancer and the patient’s cancer
trajectory from the time of diagnosis, through treatment, to
survivorship or end-of-life.
The BC Cancer Agency has a new way of providing care before
and after radiation therapy. The Prospective Outcomes and
Support initiative (POSI) is a provincial program intended
to collect Patient Reported Outcome Measures (PROMs) on
effectiveness of radiation therapy (RT). This initiative has been
designed to work on a pre/post RT model measuring the impact
of treatment on symptom management from the patient’s
perspective. This model allows health care professionals to
identify the positive and negative impacts of treatment on
patient’s function and quality of life.
Through calls by the Nursing Telephone Line following palliative
bone metastases RT, we are addressing any unmet needs.
As frontline healthcare Professionals, we continually strive
to improve patient care and as such, have found that POSI
effectively improves the level of post treatment care we provide
to our patients. Preliminary results demonstrate that this
multidisciplinary approach is improving patient outcomes.
Ultimately, POSI will expand to nurse-led follow up care
guided by tumour-specific questionnaires. Population-level
data collected from POSI will enable high quality comparative
research in the future.
Workshops developed by oncology trained nurse educators
provided NRT nurses with the knowledge and skills to care
holistically for cancer patients across the hospital. An
established knowledge translation framework and a program
evaluation model guided the development, implementation,
and evaluation of the program. Results were extremely positive,
with knowledge uptake and satisfaction clearly demonstrated.
Sustainability is currently being developed and will be discussed
in the presentation.
73
Evidence exists that palliative care, with its focus on patients’
quality of life, through expert symptom management,
psychosocial and spiritual support, assistance with decisionmaking, and mobilization of community resources, should be
initiated early, but it is often equated with end of life care.
III-05-B 1:45 PM - 2:15 PM
Achieving Integration for Nurse Practitioners
in Oncology: Research in Action
Tina S. Haayer, BScN, Lorelei Newton, PhD, RN, Maxine
Alford, PhD, RN, Lisa Henczel, NP, Denise Tarlier, PhD, NP,
BC Cancer Agency, Kelowna, British Columbia, Canada.
Increasing numbers of cancer diagnoses in combination with
limited availability of oncology specialists continues to present
inconsistencies in oncology care. Cancer care organizations are
compelled to look for innovative solutions and complementary
cancer care providers to strengthen access to oncology services.
The integration of the Nurse Practitioner (NP) role in oncology has
shown effectiveness in closing gaps and enhancing outcomes by
providing earlier access to comprehensive care and facilitating
referrals to patient support services. However, investigation of
organizational dynamics that lead to the successful addition of
NPs to the oncology care team remains imperative to achieving
these positive outcomes.
The role of the oncology NP in Canada, at both the provincial and
national levels, requires additional exploration and discussion.
Research and best practice approaches to NP integration currently
exists in the literature; however, extant findings may not always apply
to particular organizational contexts nor accurately reflect different
cancer care environments. Inquiring into approaches that enhance
NP integration into the specialty of oncology are essential and may
provide insight into additional opportunities for oncology NPs.
Recognizing and taking action on the potential for improvement in
oncology care by integrating the NP role is a powerful means for
creating positive change along the cancer trajectory. Objectives
to bridge historical knowledge, familiar literature, best practices,
and experiential learning will strengthen our understanding of
oncology NP integration. Establishing a strong foundation in this
information will also help identify avenues for advancing the
research focus beyond integration into discovering new meanings
for NP oncology care. In essence, this research can help lead us
towards a better understanding of how NP knowledge translates
into cancer care and improves outcomes for oncology patients.
III-05-C 2:15 PM - 2:45 PM
Pseudoprogression in Patients with a High
Grade Glioma: Nursing Implications for
Practice in the Context of Uncertainty
Catherine-Anne Miller, BScN, MHSc, Montreal
Neurological Hospital - McGill University Health Centre,
74
Glioblastoma Multiforme (GBM) is the most common primary brain
malignancy and has a limited prognosis (median of 14 months).
There has been significant progress with new treatment modalities.
On the other hand, the goal of care remains control through time,
and not ‘cure’. The standard treatment of patients with a GBM
includes combined chemotherapy and radiation therapy.
Pseudoprogression is a post radiation treatment effects and can be
described as the early apparent radiographic progression following
radiotherapy with subsequent improvement or stabilization through
time. Patients with pseudoprogression are told that their imaging
shows changes, but time is needed to determine whether it is
progression or not. Uncertainty and fear often characterize this
waiting period.
Although there is growing medical literature on the phenomenon
of pseudo-progression vs. real progression, there lacks nursing
research on the lived experience of patients faced with this
uncertain imaging result and how they cope.
This presentation will be an overview of what is known about
pseudoprogression in neuro-oncology from a nursing perspective
highlighting nursing interventions. Recent data from the
oncology literature on uncertainty will be discussed. Illustrations
and examples from clinical practice will be offered.
III-06 1:15 PM - 2:45 PM | British Columbia
III-06-A 1:15 PM - 1:45 PM
Étude pilote /prétest d’un plan de soins de
suivi (PSS) pour des femmes atteintes du
cancer de l’endomètre avec traitements
adjuvants à la fin du traitement initial
Johanne Hébert, PhD1,2, Lise Fillion, PhD2,3, 1UQAR, Lévis,
Quebec, Canada, 2Université Laval, Québec, Quebec, Canada,
3Centre de recherche en cancérologie de l’Université Laval,
Québec, Quebec, Canada.
Des défis substantiels sont liés aux conséquences du cancer et
des traitements qui affectent la qualité de vie des personnes
atteintes et des proches et augmente la complexité des soins
pour les soignants et le système de santé. La phase de transition
« fin de traitement / début de survie » est une phase distincte
de la trajectoire de soins et demeure problématique sur les
plans physique, psychologique et social. Les soins en période
de survie devraient comprendre la prévention et la surveillance
de la récidive ou de nouveaux cancers, l’intervention sur les
conséquences de la maladie et des traitements et la coordination
des soins entre les spécialistes et la première ligne. Cependant, la
phase de l’après traitement est une phase négligée du continuum
III-06-B 1:45 PM - 2:15 PM
Étude psychométrique de la version
française du WCCNRR-F adapté pour
évaluer le degré de sévérité de la
stomatite chez les patients recevant des
traitements anti-cancéreux
Nicole Allard, PhD, MScN, MEd1, Séverine Garnier,
PhD2, 1UQAR campus de Lévis, Lévis, Quebec, Canada,
2Université Laval, Quebec, Quebec, Canada.
Le cancer constitue un problème majeur de santé publique au
Canada. Selon les statistiques de la Société Canadienne du Cancer
de 2015, l’incidence du cancer a été estimée à 166 400 nouveaux
cas et 73 800 décès ont été attribuables à cette affection maligne.
La stomatite est une complication courante qui survient chez les
personnes qui reçoivent les traitements anticancéreux, notamment
la radiothérapie de la tête et du cou (Rubenstein, 2004; Sonis,
2004). Au moins les trois quart des patients vont présenter des
complications sérieuses incluant une douleur intense, la dysphagie,
les infections locales, voire même une septicémie qui réduisent leur
qualité de vie ou entraine la mort (Rubenstein, 2004).
Plusieurs auteurs s’accordent pour affirmer que la prise en
charge de la stomatite est loin d’être optimale. Une des raisons
fréquemment soulevées pour l’expliquer, réside en l’absence
d’outils cliniques adéquats pour l’évaluer. Or, l’évaluation physique
de la bouche a été identifiée comme étant l’intervention la plus
cliniquement significative et répond aux exigences de la loi 90.
L’objectif général de cette étude était de déterminer les qualités
psychométriques de la version traduite et adapté en français du
WCCNRR-F auprès d’une population francophone recevant des
traitements de radiothérapie de la tête et du cou. Ainsi, les qualités
psychométriques (consistance interne, fiabilité inter-juges, validité,
notamment sensibilité au changement) seront examinées. Les
implications pour la pratique, la formation et la recherche seront
également discutées.
III-06-C 2:15 PM - 2:45 PM
Aider les personnes atteintes de cancer
à faire face à la peur de la récidive
Christine Maheu, PhD1, Sophie Lebel, PhD2, 1McGill
University, Montreal, Quebec, Canada, 2University of Ottawa,
Dans cette présentation, Dr. ‘x’ va présenter les aspects
théoriques et pratiques de la peur de la récidive du cancer. En
s’appuyant sur ces travaux de recherche sur une intervention de
groupe cognitive-existentielle adressant la peur de la récidive,
elle présentera le modèle théorique de son intervention et ses
six objectifs et cibles thérapeutiques. À partir d’un exemple de
cas, elle va illustrer les stratégies et exercices utilisées afin de
cibler chacun de ces six objectifs.
OBJECTIFS :
• Comprendre ce qu’est la peur de la récidive du cancer,
son déroulement dans le temps, ses antécédents et ses
conséquences;
• Se familiariser avec un modèle théorique de la peur de la
récidive afin de développer ses connaissances sur les cibles
d’interventionl;
• Se familiariser avec les outils d’évaluation de la peur de la
récidive afin d’identifier les survivants qui ont probablement un
niveau clinique de cette peur; et
• Se familiariser avec une intervention et des outils et exercices
visant à mieux gérer la peur de la récidive du cancer.
Passion and Politics: How Oncology
Nurses Can Influence Public Policy
Heather Sinardo, BScN, MN1, Gabriel Miller, BA2,
Joelle Walker, BA, BSc, LLB2, 1Canadian Cancer Society,
Toronto, Ontario, Canada, 2Canadian Cancer Society,
• Increase oncology nurses’ understanding of their role in
influencing public policy, both individually and collectively
• Gain awareness of the role of the media in influencing
government decisions
• Learn best practices for meeting with elected officials
• Identify ways individuals can take action in the upcoming
federal election
75
de soins. L’IOM (2006) recommande la mise en place d’un plan
de suivi pour toutes les personnes qui terminent leur traitement
initial. L’infirmière en oncologie peut jouer un rôle clé dans le
développement et la mise en place d’un tel plan de suivi. La
présente étude comporte deux phases. La phase I permet le
développement d’un plan de suivi et la phase II permet de le prétester sur un petit échantillon. Pour la phase I, 29 professionnels
de la santé et 20 femmes atteintes du cancer de l’endomètre ont
été rencontrés en entrevue individuelle dans le but de connaître
leur perception quant à l’utilité et au contenu d’un tel outil et ont
permis le développement du plan de suivi.
Palliative care. Access to medications. Financial relief for
caregivers. Employment insurance restrictions. Tobacco control.
Indoor tanning. Asbestos.
Working with government and legislators to bring about healthy
public policies is a vital part of the fight against cancer. Changing
public policy is one of the most effective tools for preventing cancer
and helping those living with and beyond cancer.
This interactive session will focus on exploring the role oncology
nurses can play in shaping public policy, both individually and
collectively. It will assist the audience to gain awareness of political
realities and the role of the media, essential for influencing
government decisions. You’ll come away with knowledge of best
practices and tools to become effective advocates. There will be
substantial time allotted for questions and discussions with leaders
in the field of cancer advocacy - experts with a proven track record in
influencing government policy.
Interested in meeting with elected officials from local, provincial and
national governments to persuade them to make cancer one of their
top priorities? Join this session to find out how. A powerful way to
change public policy is for oncology nurses to speak up and make
your collective voice heard on behalf of your patients so they receive
the best possible oncology care.
BONUS: With just 3 weeks remaining until the federal election, the
Workshop will be sure to include some rapid fire suggestions so you
can take action and make a difference immediately! The candidates
want your vote, so let them know what they need to do to get it!
CANO/ACIO Research Committee
Workshop: A World Café Approach
to Getting Inspired About Oncology
Nursing Research
Dawn Stacey, RN, PhD, CON(C)1, Aronela Benea, RN,
MScN2, Christine Maheu, RN, PhD3, Kristen Haase, RN,
PhD(c)1, Sally Thorne, RN, PhD4, Lorelei Newton, RN,
PhD5, Krista Wilkins, RN, PhD6, Jennifer Stephens, RN,
PhD(c)4, 1University of Ottawa, Ottawa, Ontario, Canada,
2Women’s College Hospital, Toronto, Ontario, Canada, 3McGill
University, Montreal, Quebec, Canada, 4University of British
Columbia, Vancouver, British Columbia, Canada, 5BC Cancer
Agency, Vancouver, British Columbia, Canada, 6University of
New Brunswick, Fredericton, New Brunswick, Canada.
• To discuss common challenges with conducting oncology
nursing research.
• To support oncology nursing research by sharing experiences
and resources.
• To build networks with others conducting oncology
nursing research.
BACKGROUND: The research process begins with a researchable
problem and a sound research question stemming from clinical
practice. Thus, you are invited to bring your clinically-based
problems to be discussed within the context of conducting
research to view solutions and options in a new light.
OBJECTIVES: The overall aim is to provide an opportunity for
oncology nurses to discuss common clinical research issues,
share experiences, and establish networks with others either
interested in or conducting research.
DESCRIPTION: A ‘world café’ approach is used for this Workshop
to provide a structured conversational process to facilitate
open discussion, creative thinking, and link ideas to generate
collective wisdom. Following an introduction, a list of potential
topics will be generated for small group discussions. Examples
of discussion topics include: transforming clinical questions
into a research project, writing a research question, organizing a
journal club, working with a mentor, and tips for writing grants.
Subsequently, we will have small group discussions facilitated
by CANO/ACIO members who are experienced in generating
research and/or systematically implementing research evidence
into practice. Participants will spend about 20 to 30 minutes
at each table discussing a topic with a focus on solutions
for addressing and/or managing the clinical problems to be
assessed by research projects.
There will be opportunities for small group discussion in English
and French.
IV-03 3:15 PM - 4:45 PM | Tudor 7
IV-03-A 3:15 PM - 4:00 PM
Administration of Chemotherapy on NonOncology Units: Nurses’ Experience and
Barriers and Facilitators to Best Practice
Virginia Lee, RN, PhD, Luisa Luciani Castiglia, RN, MSc(A),
CON(C), Louise Fullerton, RN, MSc(A), Sonia Castiglione, RN,
MSc(A), Myriam Skrutkowski, RN, MScN, CON(C), McGill
76
PURPOSES: To understand the experience of nurses
administering chemotherapy to patients diagnosed with cancer
on non-oncology in-patient units. To identify the barriers and
facilitators to support best clinical practice.
METHODS: Using a mixed methods design, 36 nurses completed an
adapted questionnaire (Verity et al., 2008) to capture the education,
perceptions and practice of nurses administering chemotherapy.
Informed by survey results, eleven nurses participated in focus
groups to further discuss their experience, as well as barriers and
facilitators to best chemotherapy nursing practice.
An oncofertility program has been established at a large, urban
tertiary cancer centre with the following goals: 1) standardize
access to FP information for all patients 2) provide first-line
counseling regarding FP 3) create patient education tools 4)
facilitate referral to FP clinics and 5) provide education to health
care providers regarding FP.
The Advanced Practice Nurse (APN) plays a pivotal role in
this initiative by facilitating patient and provider access to
FP information and services. APNs endeavor to ensure that
all young patients have access to in-depth counseling on
fertility-related issues and have the opportunity to meet with
a fertility specialist. Provider knowledge on oncofertility has
been assessed and education modules have been developed
to meet the learning needs of these individuals. Concurrently,
fertility care pathways and patient education tools have been
implemented to further address this area of need.
The aims of this presentation are to 1. Provide education on FP
options available to male and female patients and 2. Highlight
three key components of the APN role in oncofertility: patient
counseling, provider education and resource development.
RESULTS: Although education and perceived support were
described as facilitators, inconsistencies in these became
barriers. Other influencing factors included: low frequency
Fertility programming is an important aspect of AYA care and
of chemotherapy administration and challenges with intershould be prioritized in cancer care institutions. Outcomes and
professional coordination. Nurses voiced feelings of distress
about how to reconcile their beliefs on providing the best care for next steps will conclude this presentation.
patients in the current practice context.
CONCLUSIONS: These findings are being used to guide decisionmaking around the re-organization of the model of care delivery
to meet CANO standards.
IV-03-B 4:00 PM - 4:45 PM
IV-04 3:15 PM - 4:45 PM | Tudor 8
IV-04-A 3:15 PM - 3:45 PM
Issues for the Young Adult with
Cancer: Increasing Access to Fertility
Preservation Information and Services
Pre-Operative Preparation for People
Undergoing Breast Cancer Surgery in
Kuwait: The Case of Passionate Nurses’
Initiative to Improve Patient Experience
Laura Mitchell, RN, MN, CON(C)1,2, Eleanor
Hendershot, RN(EC), NP3,4,2, Abha Gupta, MD, MSc1,5,6,
1Princess Margaret Cancer Centre, Toronto, Ontario, Canada,
2University of Toronto, Toronto, Ontario, Canada, 4Hospital for
Sick Children, Toronto, Ontario, Canada.
Ai Tanimizu, RN, BScN2, Kholoud Sourani, BN1, Bara’ah
Turkmani, BN1, 1Kuwait Cancer Control Centre, Shuwaikh,
Kuwait, 2University Health Network, Toronto, Ontario, Canada.
Adolescents and young adults (AYA) with cancer (defined as 15
to 39 years of age) have unique psychosocial and medical needs
in comparison to their older adult counterparts. A diagnosis of
cancer at a young age is specifically challenged as oncological
treatments can compromise fertility. The risk for infertility can be
as distressing as the cancer diagnosis and therefore AYA patients
value discussions around fertility preservation (FP) with their
healthcare providers.
Breast cancer is the leading cancer diagnosis for women living in
Kuwait similarly to other countries. Survey questionnaires were
distributed to post-operative patients and informal interviews
were conducted regarding surgery experience in a cancer centre
in Kuwait. Participants expressed that they did not feel ready for
their surgery and that more information regarding emotional and
physical needs would have been helpful to cope with the distress
associated with breast cancer surgery.
77
BACKGROUND: At our university health centre, although the vast
majority of chemotherapy is administered in oncology settings,
about one third of in-patient chemotherapy is delivered on nononcology units. The challenges to meet the recommendations
of the CANO Standards and Competencies for Chemotherapy
Nursing Practice presented an opportunity to conduct an integrated
knowledge translation study to optimize current practice.
This quality improvement initiative was lead by passionate
nurses who wanted to offer more education and support for
patients. To address patient issues, nurses were the driving force
in addressing the concern by developing an informational presurgery class. A Canadian hospital’s breast cancer pre-surgery
class model was adapted and implemented. Steps taken to
develop and deliver the class will be presented.
Through this initiative, regular meetings were organized for
the interdisciplinary team to communicate on the progress and
concerns of the development of class and any other concerning
patient issues.
different hospitals so that patients and families in the rural
areas also have access. The sessions provide information
on what they might expect as they transition from active
cancer treatment, to recovery, and then survivorship. This
class provides opportunity for patients to learn more about
what happens after cancer treatment, to ask the cancer
team questions, and to meet other cancer survivors. Topics
discussed at these sessions include: follow up care, short and
long term side effects of cancer treatment, the importance
of physical activity, eating well after cancer, coping and
adjustment, spirituality, and who to talk to if you have sexual
health or other concerns.
The scope of the development of pre-surgery class was
to offer more information and education to patients.
This initiative went beyond the scope and resulted in
increased communication and collaboration amongst
the interdisciplinary team, improved streamlined patient
education, and improved ambulatory patient experience.
This presentation will discuss the implementation process of this
initiative and the challenges we faced along the way. We will also
explore the formal evaluation of the initiative, feedback, and
impact this program has had on our patients and families.
Although this initiative focused on education class for breast
cancer, this concept can be applied to other cancer sites,
hospitals, and agencies in Canada.
IV-04-C 4:15 PM - 4:45 PM
IV-04-B 3:45 PM - 4:15 PM
Living Beyond Cancer: A Passionate
Team Approach to Enhancing Recovery
and Survivorship
Terra A. Thibault, BScN, BSc, CON(C)1, Karen
H. Woodworth, BN, CON(C)2, 1Nova Scotia Cancer
Centre, Halifax, Nova Scotia, Canada, 2Queen Elizabeth
II Health Sciences Centre, Halifax, Nova Scotia, Canada.
The lierature indicates that the transition from active treatment
to survivorship can be a distressing time for patients and
families. Patients often worry about the cancer coming back,
how their health will be monitored, whether they will recognize
signs of things going wrong or will they know what to do if that
happens (Katz, 2012). As well, studies demonstrate that cancer
survivors worry about memory loss, fatigue, financial concerns,
and return to work. (Filsinger,Burkhalter and Campbell, 2011).
“Living Beyond Cancer – What Happens Now?” is a patient
education initiative that began in our tertiary hospital in 2012
as a result of patients and families asking for more support and
education upon completion of treatment.
These monthly 2.5 hour interactive sessions are delivered in
person by an interprofessional team of health care providers
including nurses, radiation therapists, social workers,
physiotherapists, dietitians and spiritual care providers.
They are also delivered via telehealth across the province to
78
Nurse-Led Proactive Calls Provided
to First Time Chemotherapy Patients
with Gastrointestinal Cancers: A
Demonstrative Project
Allison Loucks, RN, BA, BScN, Jennifer Petronis,
RN, CON(C), Princess Margaret Cancer Centre, Toronto,
Ontario, Canada.
Specialized Oncology Nurses play a critical role with patients
who are newly diagnosed, vulnerable, and at transitional
points in their cancer journey. Research studies have examined
proactively providing nursing care to oncology patients at
targeted time points. Proactive phone calls to individuals after
receiving chemotherapy for the first time showed increased
patient satisfaction, lower incidence of drug errors, and less
serious toxicity; all of which have important implications
for patient safety and reduced risk of unplanned hospital
admissions (Craven, Hughes, & Burton, 2013).
Princess Margaret Cancer Centre has a large Ambulatory Care
setting with high volumes of patients receiving chemotherapy.
Proactive nurse-led phone calls aimed at providing support and
management to patients during specific high risk time points
were not currently in place in the Ambulatory Department. The
identification of potential patient care gaps prompted the need
to design a nurse-led program that will provide patients with
an early opportunity to ask questions and to address common
symptoms and side effects of treatment.
As part of a demonstration project, a Specialized Oncology
Nurse will provide proactive phone calls to all patients who
have started systemic chemotherapy for the first time. The
The goal of this presentation will be to provide an overview of
the project and its implementation. The project will be evaluating
the intervention looking at both the nursing role and the impact
on the patient experience. This presentation will also discuss the
possible implementation of the project across a large oncology
ambulatory population and strategies for sustainability.
IV-05 3:15 PM - 4:45 PM | Alberta
simultané IV-05-A 3:15 PM - 3:45 PM
Driving Excellent Patient Education in
Outpatient Oncology: Are We Delivering a
‘Cadillac’ or a ‘Jalopy’ Service?
Joy Bunsko, BSN, CON(C), Amanda Bolderston,
MSc, RTT, FCAMRT, BC Cancer Agency, Surrey, British
Columbia, Canada.
Patient education interventions are an essential component of
support for people undergoing cancer treatment to decrease
anxiety and stress, increase treatment compliance and selfefficacy. Oncology nurses are ideally positioned to meet the
education and informational needs of patients undergoing
treatment for cancer. Despite the known benefits, there is
a considerable variability in patient education services in
Canadian cancer centres. Many lack an identifiable patient
education program, institutional commitment, program
leadership, and financial resources. An interprofessional group
at the BC Cancer Agency has taken a multi-phased, mixedmethods approach to surveying the landscape of patient
education from the health care professional perspective.
After identification of key stakeholders within the agency, an
environmental scan was performed along with a comparison of
internal processes within the framework set by the Canadian
Partnership Against Cancer for patient education. Focus groups
were held followed by a provincial survey regarding staff
attitudes and perceptions related to patient education. This
presentation will discuss the process and findings, areas of
strengths and those requiring improvement at BCCA. It takes
people with a purpose of improving cancer information and
education and passion to deliver patient focused care.
simultané IV-05-B 3:45 PM - 4:15 PM
Integration of Palliative Care Early in
Advanced Cancer: Oncology Nurses
Can Make It Happen!
Lynn Kachuik, RN, BA, MS, CON(C), CHPCN(C),
There has been a lot of recent attention in the literature about
the need to integrate Palliative Care early in the disease
trajectory. The benefits of this model of concurrent care include
increased patient and family satisfaction, improved quality
of life, reduced overall health care system costs and even
improved survival for those with advanced disease. Cancer Care
Ontario, The American Society of Clinical Oncology, and the
World Health Organization have all recommended that Palliative
Care become a standard part of routine oncology care.
However, with few specialist palliative care resources and
more patients living longer with incurable disease, cancer
care programs cannot rely solely on those with expert
educational preparation in palliative care. Oncology nurses are
well positioned to work in collaboration with their palliative
care colleagues to provide the basics of palliative care by
incorporating “A Palliative Approach to Care” into their daily
practice. The basic tenets of this approach, patient and
family-centred care, a holistic assessment, basic symptom
management, therapeutic communication and system
navigation are integral to oncology nursing practice.
This presentation will define the components of “A Palliative
Approach”, how they can be incorporated into oncology nursing
practice and describe the inter-relationships with specialized
palliative care teams. We will outline specific educational
interventions, tools and infrastructure supports used to address
these knowledge gaps in our cancer program. We will also
report on challenges, successes and lessons learned.
79
Gastrointestinal Ambulatory Clinic was identified as an area with
large numbers of patients on chemotherapy who may benefit
from a proactive phone call. The program will address symptoms
and side effects which may have gone unmanaged between clinic
visits, and potentially reduce stress and anxiety.
IV-05-C 4:15 PM - 4:45 PM
Oncology Nurses Education Program:
A New Treatment for Metastatic
Pancreatic Cancer
Michelle Forman, RN, CON(C)3, Shari Moura, RN, MN,
CON(C), CHPCN(C)1, Angela Whynot, RN, BScN, CON(C)2,
1Princess Margaret Cancer Centre, Toronto, Ontario,
Canada, 2Capital Health, Halifax, Nova Scotia, Canada,
3Burnaby Hospital, Vancouver, British Columbia, Canada.
Pancreatic cancer (PC) is the fourth leading cause of cancerrelated deaths in Canada and projected to become the second
leading cause of cancer-related mortality by 2020. PC is
associated with a 5-year survival rate of less than 10%. Few
patients diagnosed with PC have identifiable risk factors or
symptoms and there are no reliable detection tools to diagnose
this disease in its early stage. About 80% of patients are
inoperable at the time of diagnosis, presenting with either
metastatic or unresectable locally advanced disease. Many
patients with PC present with a poor performance status and
a cluster of cancer related symptom which makes it even more
challenging to treat. Until recently, only a few of over 30 phase
III trials have demonstrated a significant survival benefit for
patients with advanced PC, including patients treated with
combination gemcitabine plusnab-paclitaxel.
Specialized oncology nurses have an enhanced role and
unique contribution in the delivery of PC care. Through an
interactive Workshop, a case-based educational program
was developed. The program developed will provide an upto-date overview of PC, review the new treatment option of
combination gemcitabine plus nab-paclitaxel, assess strategies
and interventions to assist with treatment-related toxicities
and disease-related symptoms, and provide information on
supportive care needs of patients with metastatic PC and their
families. This presentation will describe the process utilized to
build the educational program and share the final content.
Nicole Tremblay, MSc inf., CSIO (C), ICSP(C), Odette
Roy, MSc inf., MAP, PhD, Louise Compagna, BSc inf.,
Caroline Provencher, MSc inf., Claudine Tremblay, MSc inf.,
CSIO(C); CIUSSS, Est-de-l’île de Montréal, Quebec, Canada.
Le dépistage systématique de la détresse est considéré comme
le 6e signe vital chez la personne atteinte de cancer (Partenariat
canadien contre le cancer, 2009). C’est dans ce contexte que
le programme clientèle d’oncologie de l’Hôpital MaisonneuveRosemont (HMR) a débuté l’implantation de cette pratique, en
janvier 2012. Concomitamment, sous la gouverne du Centre
d’excellence en soins infirmiers de cet établissement, une équipe
d’infirmières a entrepris des travaux de recherche exploitant
différentes facettes cliniques autour du dépistage. Notre étude
à devis mixte séquentiel exploratoire a poursuivi cinq buts
pendant les deux dernières années, notamment : recueillir des
informations sur la détresse vécue par la clientèle ciblée (sein
et cancers hématologiques) (N=532) et mieux connaître les
perceptions infirmières (N=45) et clientèle (N=122) à l’égard du
dépistage systématique de la détresse en contexte de cancers
hématologiques, de greffe de cellules hématopoïétiques et de
cancer du sein. Nos résultats mettent en lumière des convergences
et des divergences dans les perceptions des différents groupes de
participants, lesquelles peuvent notamment modifier les discours
cliniques autour de l’implantation du dépistage. Par ailleurs,
notre équipe de recherche a utilisé diverses stratégies afin de de
vivre des succès à travers l’arrimage de deux objectifs précis : le
déploiement de l’outil ayant des retombées sur la qualité de vie
des patients d’une part et, d’autre part., la réalisation d’une étude
infirmière analysant les impacts du dépistage sur la clientèle et les
infirmières. Cette présentation se veut donc aussi une occasion de
partager notre expérience tant clinique que de recherche.
IV-06-B 3:45 PM - 4:15 PM
The Key to Iron Chelation in
Myelodysplastic Syndrome Patients:
Nurses Leading the Way
IV-06 3:15 PM - 4:45 PM | British Columbia
Mary C. Doherty, BScN, MN, NP, PHC, Nancy A. Pringle,
RN, Cindy Murray, BScN, MN, NP, Adult, Princess
IV-06-A 3:15 PM - 3:45 PM
Myelodysplastic syndrome (MDS) is a heterogeneous disorder
of the hematopoietic stem cell compartment characterized
by anemia and transfusion dependency. In patients with
low-risk MDS transfusion support can often be life-long. The
consequence of which is iron overload.
Dépistage systématique de la détresse :
portraits et regards croisés sur les
perceptions des différents acteurs,
perspectives cliniques et de recherche
80
As the body has no natural ability to excrete iron, its
accumulation leads to end-organ damage in the liver, heart
and endocrine tissues. However, symptoms do not manifest
themselves until it reaches a critical level; iron overload is
a silent killer. Nurses play an integral role in caring for MDS
Key objectives of the education module will include:
1. The pathophysiology of transfusional iron overload;
2. Its clinical consequences
3. Diagnosis
4. Current Canadian consensus guidelines
5. Treatment and its side effects
6. The central role of nurse in management
IV-06-C 4:15 PM - 4:45 PM
Safe Treatment and Care: Creation of
a Standard Nurse Initiated Symptom
Follow Up Program for Patients
Receiving Ipilumumab Therapy in an
Ambulatory Setting
Jen Rosychuk, BScN, Jeevan Dosanjh, BScN, Karen
Janes, MScN, BC Cancer Agency, Vancouver, British
Columbia, Canada.
Patients undergoing systemic therapy can experience serious
and potentially life threatening treatment side effects. The
BC Cancer Agency’s (BCCA) current model for symptom and
side effect support relies on the patient’s ability to identify
and promptly self-report via a Patient Care Nurse Telephone
Helpline (telehealth).
Nurses caring for patients receiving systemic therapy need to be
aware of the uniqueness of each treatment to properly assess
and provide appropriate patient care. In the case of Ipilumumab,
patient education and nurse awareness are paramount as there
is potential for immune mediated side effects which may require
urgent immune suppressing therapies. With the introduction of
Ipilumumab to the treatment options for melanoma at the BCCA,
nurse-initiated symptom follow up was identified as an option in
the care for patients.
The goal of the program is to keep medication related
adverse events to less than or equal to an NCI grading of
one for patients receiving Ipilumumab treatment in all six
regional BC Cancer Agency (BCCA) centres. Using various
quality improvement frameworks, components of the
program were developed and trialed to create a patientcentred system for prompt identification, response and
treatment of Ipilumumab side effects.
In the context of an ambulatory care unit, regular weekly
assessments were delivered in collaboration with the physician
team. Patient resources and timing of information sharing was
considered. Nurse education needs and support tools were
examined, developed, delivered and evaluated. And lastly,
documentation and continuity of care was implemented using
existing processes and evaluated for effectiveness.
This presentation will outline the quality improvement frameworks
used in the creation of a practical, province-wide interdisciplinary
approach to identification and management of immune mediated
side effects cause by treatment with Ipilumumab.
Tuesday, October 6, 2015
Mardi 6 octobre 2015
Workshop / Atelier V-01
Enhancing Nursing Passion to Use
Practice Guides for Informing Remote
(Telephone) Symptom Support: An
Interactive Workshop
Dawn Stacey, RN, PhD, CON(C)1,2, Tracy L. Truant, RN,
MSN, PhD(c)3, Barbara Ballantyne, RN, MScN, CON(C),
CHPCN(C)4, Kim Chapman, RN, MScN, CON(C)5, Myriam
Skrutkowski, RN, MSc, CON(C)6, 1University of Ottawa, Ottawa,
Ontario, Canada, 2Ottawa Hospital Research Institute, Ottawa,
Ontario, Canada, 3University of British Columbia, Vancouver,
British Columbia, Canada, 4Health Sciences North, Sudbury,
Ontario, Canada, 5Horizon Health Network, Fredericton,
New Brunswick, Canada, 6McGill University Health Centre
Research Institute, Montreal, Quebec, Canada.
• Be familiar with elements of evidence-informed remote
symptom support using the COSTaRS practice guides.
• Have enhanced knowledge, confidence, and skills
using the COSTaRS practice guides in conversation with
simulated patients.
• Explore ways to incorporate the COSTaRS practice
guides into their clinical practice and overcome barriers
interfering with their use.
BACKGROUND: The pan-Canadian Oncology Symptom Triage
and Remote Support (COSTaRS) practice guides are available
for use by oncology nurses when providing remote (telephone)
symptom management to oncology patients. The COSTaRS
practice guides summarize evidence from clinical practice
guidelines in easy to use, nurse-friendly formats and can help
nurses integrate best practices into their clinical practice.
81
patients who have, or are at risk for, the development of iron
overload. They possess a central role in patient education
on monitoring and treatment by tailoring the education to
individual patient’s needs, culture and values. They can
respond and clarify patient concerns or questions and provide
appropriate guidance to ensure optimal adherence to therapy.
OBJECTIVE: The objectives are: a) to enhance nurses’ knowledge,
skills, and confidence with using the COSTaRS practice guides; b)
to learn how to use the practice guides in a conversation with a
patient, and c) to tailor symptom self-care to patients’ needs.
DESCRIPTION: A 90-minute interactive Workshop is planned.
First we will provide an overview of COSTaRS. We will introduce
the content of specific practice guides and a case study
to be used for role play exercises. Discussion will provide
opportunity for nurses and ‘simulated patients’ to reflect on
their experiences with the practice guides. Next we will discuss
how the practice guides can be used with patients experiencing
symptom clusters. Finally, we will focus on steps for moving the
practice guides into clinical practice and problem solving how
to manage barriers perceived to interfere with their use. The
Workshop will include several activities for engaging nurses.
Workshop materials are available in English and French. The
Workshop will be conducted in English with some activities in
English or French.
V-02 10:30 AM - 12:00 PM |
Confederation 5 & 6
V-02-A 10:30 AM - 11:15 AM
CANO/ACIO Radiation Oncology
Nursing Practice Standards and
Competencies: The Time Has Come!
Maurene McQuestion, RN, BA, BScN, MSc, CON(C)1,2,
Christine Zywine, RN(EC), BScN, MN, CON(C)1,2,
Brenda C. Ross, RN, BScN3, Tracy L. Truant, RN, BN, MSN,
PhD(C)4, 1Princess Margaret Cancer Centre, Toronto,
Ontario, Canada, 2University of Toronto, Toronto, Ontario,
Canada, 3BC Cancer Agency, Vancouver, British Columbia,
Canada, 4UBC, Vancouver, British Columbia, Canada.
The Canadian Association of Nurses in Oncology/ Association
Canadienne des Infirmieres en Oncologie (CANO/ACIO) strives
to advance oncology nursing practice excellence through
practice, education, research and leadership for the benefit
of all Canadians. Radiation Oncology Nursing Practice (RONP)
standards and competencies, were selected by CANO/ACIO
members as a key knowledge product to be developed. The
need for this product was validated by the CANO/ACIO Radiation
Therapy Special Interest Group as a top priority. The vision for
this project is that “Every person across Canada, regardless
of geography, receives radiation oncology nursing care from
nurses who meet a predetermined standard of practice through a
comprehensive education program to ensure competency”.
82
Canadian nurses in geographically diverse clinical settings,
including cancer centers and general hospitals, urban and rural,
inpatient and ambulatory settings, care for people who receive
radiation therapy. They have identified variable access to practice
standards and competencies, and educational programs. In
Canada there has not been any standard coordinated process or
supporting structure for oncology nurses to develop, implement
and maintain RONP standards and competencies. CANO/ACIO
members have collaborated to gain clarity surrounding current
RONP, identify gaps, and share standards and competencies that
are currently available in Canada and internationally.
The resulting knowledge product, CANO/ACIO RONP Standards
and Competencies, will support excellence in RONP, enhance
patient safety, improve nurses’ work life and will enhance cancer
control in Canada. This paper will describe findings from the
literature review, environmental scan and Think Tank (2014)
and the process used to develop the draft document. Finally,
strategies planned to gain consensus will be discussed.
V-02-B 11:15 AM - 12:00 PM
Building an Integrated Survivorship
Pathway Between Cancer Care and
Primary Care: A Collaborative Approach
to Improve the Transition Experience
Post Cancer Treatment
Linda Watson, RN, PhD, CON(C), Shelley Currie, MS,
Debbie Lamb, RN, BN, Farah Kubba, BA, Heather Ebeling, RN,
BScN, MN, Alberta Health Services, Calgary, Alberta, Canada.
In Alberta, there is currently no consistent approach to posttreatment follow-up and prevention care for cancer survivors.
Practices regarding where patients receive post-treatment
follow-up care, and who provides it vary from physician to
physician, tumour group to tumour group, and from setting
to setting. This inconsistent approach creates a risk that
survivors may not receive the care and support they need
to optimize their wellness after cancer treatment, to prevent
secondary cancers, and to stay healthy. In an effort to mitigate
this risk and improve the post treatment transition experience
for survivors, a collaborative project team was struck with
representatives from the provincial cancer agency, primary
care and the provincial cancer prevention and screening
program. This collaborative approach allowed for the creation
of a multi-pronged quality improvement initiative focusing on
synergistic internal (cancer system) and external (primary care)
changes to ensure the cancer survivor’s experience through this
transition is improved, and a seamless and consistent approach
to transitioning care from cancer care to primary care post
treatment was created. In this presentation, the collaborative
approach utilized by the project team to engage, explore,
V-03-B 11:00 AM - 11:30 AM
V-03 10:30 AM - 12:00 PM | Tudor 7
Roberta L. Woodgate, PhD3, Ketan Tailor, MEd1,
Rochelle Yanofsky , MD2, Magimairajan Issai Vanan, MD2,
1Marquette University, Milwaukee, Wisconsin, United States,
2CancerCare Manitoba, Winnipeg, Manitoba, Canada,
3University of Manitoba, Winnipeg, Manitoba, Canada.
V-03-A 10:30 AM - 11:00 AM
Fear of Cancer Recurrence: A
Qualitative Study of the Experience of
Survivors of Ovarian Cancer
Jamie Kyriacou, BSc1, Alexandra Black, BSc1, Christine
Maheu, PhD1, Nancy Drummond, MSc(A)2, Joanne Power,
MSc(A)3, 1McGill University, Montreal, Quebec, Canada,
2Jewish General Hospital, Montreal, Quebec, Canada, 3McGill
BACKGROUND/PURPOSE: Ovarian cancer is the deadliest
of the cancers that exclusively affects women, with a 5-year
survival rate of 10-35%. Consequently, in ovarian cancer
survivors, the fear of experiencing a recurrence is high. There is
a near absence of studies that have investigated the experience
of fear of cancer recurrence (FCR) in women with ovarian cancer.
One model has been proposed to guide the conceptualization of
FCR and understand its impact in cancer survivors. The purpose
of this study is to better understand FCR through the reflections
of ovarian cancer survivors by using the FCR model.
METHODS: This study has a descriptive qualitative design
aimed at capturing the rich detail of the FCR topic. Twelve
participants were recruited from the gynecology oncology
clinics at two University teaching hospitals in Montreal.
Researchers conducted face-to-face, semi-structured interviews.
Content, transcribed verbatim, underwent content analysis.
RESULTS: FCR is a complex, multi-dimensional phenomenon
and its impact was found to fall on a spectrum. The first four
themes that emerged were moderators of the participants’
FCR experience: (a) varied beliefs and sources of worry; (b)
perception of risk of recurrence; (c) uncertainty surrounding
different facets of recurrence; (d) management of FCR. The fifth
theme spoke to the participants’ opinions of the FCR model.
CONCLUSIONS: The findings from this study offer a glimpse
into the fear of recurrence of an ovarian cancer survivor. Each
woman experienced it differently yet commonalities were found
in their narratives. The insightful themes will allow nurses to
intervene more effectively with their patients in the hopes of
decreasing distress and improving quality of life.
Survivors of Childhood Brain Tumours:
A Qualitative Thematic Synthesis
The multiple late-effects experienced by survivors of childhood
brain tumours, are not only a source of great distress for
survivors, but also for their families. Although there is
qualitative research discussing the experiences of survivors
of childhood brain tumours, further synthesizing the available
evidence derived from qualitative findings has the potential
to provide a more in-depth and coherent understanding of
the experiences of survivors of childhood brain tumours and
their families. The purpose of this study was to systematically
identify and synthesize qualitative evidence on how survivors
of childhood brain tumours and their families experience
life after surviving childhood brain tumours. Ten qualitative
studies published between 2004 and 2014 were included in the
synthesis based on an electronic search in seven databases.
This thematic synthesis revealed that life after surviving
childhood brain tumours was experienced as a paradox. While
survivors and their families celebrated making it through the
cancer experience, they nonetheless encountered a world with
loss and new challenges that included living with uncertainty,
intensification of the parenting role, a changing social world,
and a different way of being. This synthesis reinforces that
more needs to be done to help survivors of childhood brain
tumours and their families live with and manage the late-effects
associated with survival from childhood brain tumours. Nurses
and other health and social service personnel need to view the
completion of treatment for a childhood brain tumour as a point
on a continuum of living with a brain tumour.
V-03-C 11:30 AM - 12:00 PM
Wellness Beyond Cancer Program:
Empowering Patients to Meet Their
Survivorship Needs - Part 2 (Follow-Up
From Québec City Presentation)
Carrie Liska, RN, BScN1, Robin Morash, RN, MHS1,
Lise Paquet, PhD2, Gail Larocque, NP-PHC1, 1The Ottawa
Hospital, Ottawa, Ontario, Canada, 2Carleton University,
83
design, implement and evaluate this quality improvement
work will be discussed. The components of the innovative
post treatment transition model of care and the evaluation
framework will also be discussed in this presentation.
Cancer survivors require coordinated, interdisciplinary, and
supportive care to address their unique needs. Empowerment
is a central construct for the management of cancer survivors.
Oncology nurses have an opportunity to provide leadership in
research and clinical practices to improve survivor’s access to
appropriate care, empowerment and self-management, and the
overall collective understanding of cancer survivors’ needs. The
Wellness Beyond Cancer Program (WBCP) currently provides
survivorship care to colorectal and breast cancer patients. The
program’s purpose is to ensure that all patients, at the end of
their active treatment, have access to appropriate follow-up care
and resources to best meet their individual needs. A program
objective includes empowering patients to participate in their
self-care and wellbeing. An individualized survivorship care
plan facilitates the transition and coordination of follow-up care
between the cancer centre and primary care providers. Patients
are asked to complete a needs assessment and empowerment
questionnaire. Self-identified needs reported as moderate to
extreme are included on their individualized survivorship care
plan. Patients are then invited to attend a disease specific
survivorship class to promote empowerment and self-care. One
year after referral, patients are requested once again to complete
a needs assessment and empowerment questionnaire. This
presentation is the second in a two part series on empowerment
within the WBCP. A program update will be provided and three key
questions will be addressed:
1. Has the WBCP impacted the self-identified needs and perceived
empowerment levels of breast cancer survivors?
2. Is a change in empowerment linked to a change in the selfidentified needs of breast cancer survivors?
3. Is there a difference between the self-identified needs and
perceived empowerment levels between breast cancer survivors and,
as previously presented at CANO in 2014, colorectal cancer survivors?
V-04 10:30 AM - 12:00 PM | Tudor 8
V-04-A 10:30 AM - 11:00 AM
Supporting Nurses with Purpose and
Passion: Development of an Online
Study Group for the CNA Oncology
Certification Exam
Andrea Knox, RN, BScN, CON(C), Tina S. Haayer,
RN, BScN, Ava L. Hatcher, RN, BN, CON(C), BC Cancer
Agency, Kelowna, British Columbia, Canada.
84
Registered Nurses working in oncology engage in continuing
professional development activities to keep their skills and
knowledge current. Successful completion of the Canadian
Nurses Association (CNA) certification exam in oncology (CONc)
is one way to have their skill and expertise validated and
recognized nationally. Historically, exam applicants working
for the British Columbia Cancer Agency (BCCA) have been
supported through educator facilitated onsite study groups
provided there were enough registrants. In an effort to expand
support provincially, the BCCA Professional Practice Nursing
Team (PPNT) created a virtual study group that is managed
through the PHSA Learning Hub. This innovative approach to
supporting oncology nurses to prepare for the certification
exam is now available to all oncology nurses in BC. This includes
nurses from six BCCA regional centres, 54 Community Oncology
Network (CON) clinics and numerous inpatient oncology units
across the province’s six health authorities.
This presentation will explore the development of the study group
from concept to reality including lessons learned and reflections
from the facilitators. A review the content and format of the virtual
classroom program, evaluation data and plans for future direction
will also be shared. The commitment for continuing professional
development opportunities is one attribute shared by oncology
nurses nationally and highlights the sense of purpose and
passion that drives the provision of optimal care. Supporting
nurses to attain CON(c) designation through the innovative use of
online resources both elevates the standard of oncology nursing
care being delivered and supports further transformation of
nursing education in the technological age.
V-04-B 11:00 AM - 11:30 AM
Becoming a Lean Leader: Reflections
and Practice
Joy Bunsko, BSN, CON(C), Stephanie Aldridge, BSc,
MEd, RT(T), Lori Rowe, MA, RT(T), AC(T), BCom, BC
Cancer Agency, Surrey, British Columbia, Canada.
Oncology leaders face multiple challenges daily. Increasing
workload and new emerging cancer treatments; working within a
“resource neutral” environment while working towards a model
of care that is patient centred are a few of these challenges.
Lean Leadership methodology was introduced to our Regional
cancer centre in November 2013. Using the tools of Lean
Leadership we were able to focus on a process of purposeful
patient driven care, creating standard work to support an
identified high needs patient population. This presentation will
discuss the principles of Lean Leadership, the process taken
to improve nursing care delivery and plans to replicate this
process in the future. Engaging the interdisciplinary team to
eliminate waste, use tools and metrics to map current state and
V-04-C 11:30 AM - 12:00 PM
Enhancing Passion and Purpose: The
Trillium Project
Charmaine Lynden, RN(EC), RN, MN, CON(C),
Devi Ahuja, RN(EC), RN, MN, CON(C), Cathy Kiteley,
RN, MScN, CON(C), CHPCN(C), Trillium Health
Partners, Mississauga, Ontario, Canada.
The hallmark of the Advanced Practice Nurse (APN) is to
incorporate the domains of leadership, education and research
into clinical practice. Findings from an Ontario oncology APN
role assessment survey in 2006 revealed that APN’s perceived
that they were not prepared to fully embrace the research
component of their role (Bryant -Lukosius 2006). A follow up
survey in 2013 revealed that on average, APN’s spent less
than 20% in the research domain. To address the gap between
research knowledge and application, the Canadian Centre for
Advance Practice Nursing Research (CCAPNR) partnered with
Trillium Health Centre to develop “The Trillium Project”. The
goal of this innovative partnership is to improve patient care
by strengthening the capacity of APNs to lead and integrate
research into their daily practice.
The three APN’s in the Oncology program embraced the
opportunity to participate in this novel initiative. They believed
that enhancing their knowledge, skills, and confidence, through
the Trillium Project, would strengthen their ability to the design,
implement and evaluate their individual research projects.
Over the course of five months of structured sessions, the
participants identified a research question within their clinical
practice and with guidance and support of the CCAPNR team,
individual proposals were developed.
This presentation will focus on the APN’s experience in
completing the Trillium Project and their perceptions of the
value of this innovation.
V-05 10:30 AM - 12:00 PM | Tudor 8
V-05-A 10:30 AM - 11:15 AM
Electronic Nursing Documentation:
Creating a Standardized Documentation
Tool for Oncology Nurses
Janelle L. Desjardins, BScN, MScN, Melissa Boonstra,
BScN, The Ottawa Hospital, Ottawa, Ontario, Canada.
OBJECTIVE: This presentation will discuss the development of
a new standardized electronic documentation tool and share
lessons learned during its development, implementation and
ongoing evaluation.
DESCRIPTION: A new standardized electronic nursing
documentation tool was developed for use by specialized
oncology nurses to document comprehensive patient health
and supportive care needs assessments completed during
patient consult and follow-up visits in the outpatient setting.
A documentation working group comprised of specialized
oncology nurses, the Clinical Manager and the Oncology
Informatics Manager met on a weekly basis to develop a
standardized documentation tool that reflect nursing practice and
workflow. The standardized electronic nursing documentation
tool was also developed based on an extensive review of the
College of Nurses of Ontario’s Documentation Practice Standard,
the Canadian Association of Nurses in Oncology’s Practice
Standards and Competencies for the Specialized Oncology
Nurse, Cancer Care Ontario’s Oncology Nursing Documentation
Competencies and organizational documentation policies and
procedures. A collaborative approach included discussion
between nurses, nursing professional practice experts, risk
management and the management team at The Ottawa
Hospital Cancer Centre to develop a tool that met both legal
and professional obligations while reflecting oncology nursing
practice. The new standardized electronic nursing documentation
tool was piloted by 8 nurses that were part of the working group
in the summer and fall of 2014. Feedback was regularly gathered
and the documentation tool modified as deemed appropriate. All
nurses received individual training at the end of November 2014
when the standardized electronic nursing documentation tool
was officially implemented. Initial results show early adoption of
the new electronic nursing documentation tool and evaluation
using surveys and individual meetings is ongoing to further
increase adoption.
85
improve flow is a continuous work, often met with skepticism
and resistance. The author’s experience of becoming certified
as a Lean Leader will be offered with reflection on some of
the incongruence’s and internal conflict experienced. It has
taken a passionate group of health care professionals in our
organization with strong local mentorship, a consistent drive
to improve patient care delivery and modelling behavior of
efficiency and daily support that is leading to success.
V-05-B 11:15 AM - 12:00 PM
Improving Cancer Symptom Management
Through Knowledge Translation:
Implications for Nursing Practice
Denise E. Bryant-Lukosius, PhD1,2, Greta Cummings,
PhD3, Nancy Carter, PhD2, Margaret I. Fitch, PhD4, Margaret
Forbes, RN, MN1, Esther Green, MSc5, Mark Hartman, MBA6,
Lynne Jolicoeur, RN, MN7, Wenonah Mahase, MBA8, Lorraine
Martelli, NP, MN1, Carole Mayer, PhD6, Gregory Pond,
PhD1,2, Anne Snider, MEd1, Linda Watson, PhD9, Jennifer
Wiernikowski , NP, MN1, 1Juravinski Cancer Centre, Hamilton,
Ontario, Canada, 2McMaster University, Hamilton, Ontario,
Canada, 3University of Alberta, Edmonton, Alberta, Canada,
4Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada,
5Canadian Partnership Against Cancer, Toronto, Ontario,
Canada, 6Northeast Cancer Centre/Health Sciences North,
Sudbury, Ontario, Canada, 7Ottawa Hospital, Ottawa, Ontario,
Canada, 8Cancer Care Ontario, Toronto, Ontario, Canada,
9Alberta Health Services, Calgary, Alberta, Canada.
INTRODUCTION: Many patients with cancer have poorly
managed pain and symptoms, despite evidence to support
effective practice. To address this research to practice gap, the
Ontario Cancer Symptom Management Collaborative (OCSMC)
was established to promote uptake of symptom management
guidelines in regional cancer centres (RCCs) using a knowledge
translation (KT) approach.
PURPOSE: To provide the first evaluation of OCSMC KT strategies for
improving the use of pain and symptom management guidelines.
METHODS: A descriptive study was conducted using qualitative
and quantitative methods including document analysis of
KT plans, surveys and key informant interviews. Participants
included healthcare decision-makers and providers (i.e.
physicians, nurses, allied providers) from 14 RCCs.
RESULTS: Over one year, RCCs implemented about 8 KT
interventions every 6 months. RCC characteristics (e.g., size,
geography) did not impact on type or number of interventions.
Nurses were the target of 60% of all interventions. Most
(95%) interventions focused on provider receipt (51%) and
understanding (87%) of the guidelines. Lack of KT expertise and
resources were barriers to effective planning. Nurses and other
providers reported limited symptom management guideline use.
CONCLUSIONS: Nurses were pivotal targets for improving
cancer pain and symptom management. Substantive RCC
investments in KT planning and interventions did not result in
increased symptom management guideline use.
86
SIGNIFICANCE/IMPLICATIONS: Increased use of best practices
for pain and symptom management is essential for improving
quality of care and patient quality of life. Engaging patients,
nurses and other providers in KT planning is needed to address
behavioural, team and organizational barriers to symptom
management guideline use. Future KT interventions must
enable nurses to apply symptom guidelines in their practice
through guideline integration into organizational structures and
team processes of care delivery.
V-06 10:30 AM - 12:00 PM | Alberta
V-06-A 10:30 AM - 11:00 AM
Factors Influencing the Effectiveness of
Audit and Feedback: Nurses’ Perceptions
Kathryn Baldwin, BN1,2, Venessa Christina, BSc2,
Alain Biron, PhD2,3, Jessica Emed, MSc(A)1,2, Karine Lepage,
MScN1,2, 1Jewish General Hospital, Montreal, Quebec,
Canada, 2McGill University, Montreal, Quebec, Canada,
3McGill University Health Centre, Montreal, Quebec, Canada.
Audit and feedback (A&F) is widely recommended and used
in oncology nursing to promote evidence-based practice and
improve quality of care. Yet, the literature has shown that
A&F has limited to modest effectiveness at most, and it will
continue to be an unreliable approach until we learn how and
when it works best. Understanding the factors that influence
the effectiveness of A&F is therefore important to maximize the
benefits of A&F as a quality improvement strategy.
This qualitative study explored nurses’ perceptions on factors
influencing the effectiveness of A&F. Fourteen registered
nurses were recruited from Hematology-Oncology and Internal
Medicine units (7 participants from each) at a universityaffiliated hospital in Montreal, Quebec. Participant ages
ranged from their 20-40s, experience on the units ranged from
4 months-8 years, and the majority worked full-time. Through
one-on-one semi-structured interviews, the nurses shared their
feelings and opinions on their experiences with A&F.
Three major themes were identified: the relevance of A&F, the
A&F process, and individual factors. First, nurses reported
that for A&F to be effective, it needs to be relevant: nurses
need to understand the purpose of A&F and the criteria
audited need to fit with their priorities. Second, nurses
expressed that A&F process, particularly the timing of A&F and
feedback characteristics, influence their receptiveness to A&F.
Third, individual factors, such as personality and perceived
accountability, were also found to influence the way nurses
perceive A&F, and therefore, its effectiveness.
V-06-C 11:30 AM - 12:00 PM
V-06-B 11:00 AM - 11:30 AM
Implementation of Breast Cancer
Survivorship Guidelines by Primary
Health Care Nurse Practitioners in
Southeast Ontario: Results of a Mixed
Methods Study
Collaboration and Social Interaction
Among Oncology Nurses
Jane Moore, RN, PhD, CCRN1, Dawn Prentice, RN,
PhD1, Maurene McQuestion, RN, MSN, CON(C), APN2, 1Brock
university, St Catharines, Ontario, Canada, 2University
Health Network, Princess Margaret Cancer Centre, Toronto,
Ontario, Canada.
BACKGROUND: Collaboration has been described in the context
of healthcare as a complex process by which interdependent
professionals work together to provide high quality patient
care. Research has demonstrated that interprofessional
collaboration is influenced by organizational, professional,
personal, interpersonal factors, and social factors, yet little
is known about social interaction in relation to collaboration
among nurses. The purpose of this qualitative study was to
examine nurses’ perceptions of social interaction in relation to
collaboration in oncology settings.
METHODS: This exploratory, descriptive case study analyzed
telephone interviews and documentary data from fourteen
oncology nurses employed at one cancer centre in Canada.
Thematic analysis revealed two themes: Knowing you is trusting
you, and formal and informal opportunities.
RESULTS: Nurses reported that social interaction meant getting
to know someone personally as well as professionally. A key
facilitator of social interaction was having a long-term current
and/or previous professional and social relationship. Barriers
to social interaction included lack of time and workload issues,
and poor interpersonal skills.
CONCLUSIONS: Oncology nurses needed to socially interact
as a means of developing and maintaining trust and respect;
a foundation for successful collaborative relationships and
effective collaborative practice. Nursing leaders are in an ideal
position to support social interaction by providing optimal
staffing levels, facilitating opportunities for nurse-nurse
social interaction, and identifying strategies to improve the
interpersonal skills of nurses.
Alice Aiken, PhD, Mary Ann McColl, PhD, Joan Tranmer,
RN, PhD, Queen’s University, Kingston, Ontario, Canada.
BACKGROUND: Follow-up care for stable breast cancer patients
is moving to primary care. Breast cancer survivors may continue
to experience a broad range of physical and psychosocial health
care needs following primary treatment. Although clinical
practice guidelines on follow-up care of breast cancer survivors
are available, it is unclear which guidelines primary health
care nurse practitioners (PHCNPs) are currently implementing
in practice. This study will identify PHCNP implementation of
21 key guideline recommendations for post-treatment breast
cancer care and describe PHCNP perceptions of barriers and
facilitators to guideline implementation.
METHODS: A descriptive survey was administered to a
sample of primary care providers including PHCNPs to identify
knowledge and practice gaps related to 21 “need-to-know”
breast cancer survivorship guideline recommendations. Semistructured interviews were conducted to explore challenges
related to implementation of these guideline recommendations.
PRELIMINARY RESULTS: Surveys were completed by 20
PHCNPs who reported routinely implementing an average of
40.2% of the key guideline recommendations. Implementation
rates were higher for prevention and surveillance
recommendations such as mammography and weight
management. Knowledge and practice gaps were highest for
recommendations related to screening and management of
long-term effects such as fatigue and distress. Nine PHCNPs
were interviewed. Thematic analysis revealed numerous
barriers and facilitators to guideline implementation, some
which are general to the primary care setting and some which
are specific to the PHCNP role.
CONCLUSIONS: Results suggest there are knowledge and
practice gaps related to implementation of the key guideline
recommendations for breast cancer survivorship care in
the primary care setting which could be targeted through
knowledge translation interventions, however, the identified
contextual challenges suggest one-size may not fit all.
87
This study provides insight into nurses’ perceptions of A&F
and a better understanding of how best to use A&F as a quality
improvement strategy to promote evidence-based care.
CANO/ACIO 2015 Standards of Care
Invitational Workshop: Building a
Foundation for Oncology Nursing’s
Contribution to Person-Centred Care
By invitation only
Tracy L. Truant, RN, MSN, PhD(c)1, Allyson Nowell,
RN, BScN, MSN3, Brenda C. Ross, RN, BScN2, 1UBC School
of Nursing, Vancouver, British Columbia, Canada, 2BC Cancer
Agency, Vancouver, British Columbia, Canada, 3Princess
The revision of the 2001 CANO/ACIO Standards of Care is a
special initiative of CANO/ACIO and integral to achieving CANO/
ACIO’s vision as leaders in oncology care. All other CANO/ACIO
position statements, practice standards and competencies arise
from these Standards of Care and provide direction for nurses
striving to achieve excellence in person-centred care. As such,
it is essential that a thoughtful, reflective, and inclusive process
is used to engage CANO/ACIO members in their revision, to
validate and come to consensus. In this invitational Workshop,
approximately 20 national oncology nursing experts will be
brought together for a 90 minute Workshop to validate the edits
proposed, to identify gaps and amendments and to discuss
strategies to engage external stakeholders and the public. Invited
participants will have the opportunity to review the draft version
of the CANO/ACIO Standards of Care prior to the Workshop.
Outcomes of this Workshop will include recommendations for
further revision of the Standards as well as a process for building
consensus and engaging external stakeholders and the public.
3:30 PM - 5:00 PM | Confedertaion 5&6
Case Scenario-Concept Mapping (CSCM):
An Innovative Teaching/Learning Strategy
to Stimulate Critical Thinking and
Problem Solving in Oncology Nursing
Marcia Flynn-Post, MHS, BA, CON(C), Leslie
Williams-Brennan, BSc, BScN, MN, CON(C), Princess
• Participants will develop a clear understanding of case
scenario-concept mapping
• Participants will be able to demonstrate how CSCM is completed
88
• Participants will be able to understand how CSCM can
be utilized to demonstrate the application of theory to
practice for the purpose of oncology nursing orientation
• Participants will discuss other potential applications for
CSCM in oncology nursing practice
Oncology nursing care is multifaceted; requires strong critical
thinking and problem solving skills to elicit optimal patient care. To
date 13 clinical trials nurses at PM have completed case scenarioconcept mapping (CSCM) as part of their orientation pathway. All
participants strongly agreed that CSCM helped them to synthesize
relevant information and apply critical thinking and reflection skills
used during the exercise to real life clinical situations.
Drawing from Huang et al., (2012) oncology specific CSCM’s will
be presented. Participants will be placed into small groups to
complete the CSCM exercise, where they are required to provide
an outline of their nursing assessments, identify causality of
adverse reactions, rationale for priority nursing diagnoses and
interventions, a summary of their nursing documentation and
identifying patient teaching. Each group will then present their
CSCM to the large group, where immediate feedback will be
provided on any gaps in knowledge and positive reinforcement.
Each group member will complete a questionnaire to evaluate
the effectiveness of CSCM in enhancing their critical thinking and
problem solving skills and its potential use as teaching/learning
strategy in their own clinical setting, followed by the facilitators
presenting data on the application of this activity in a clinical
trials context. Time will be allotted at the end of the Workshop for
a group discussion around the additional uses of CSCM as part of
the nurse’s continued learning along the novice to expert trajectory.
This Workshop will provide the learning tools required for oncology
nursing practice leaders to develop and implement this activity
regardless of clinical setting or level of nursing competency. There
is potential to adapt the CSCM so that it can be used for assessing
ongoing proficiency, development of learning plans and to ensure
uptake of standards such as the CANO practice standards or in
Ontario, the Symptom Management Guidelines.
VI-03 3:30 PM - 5:00 PM | Tudor 7
VI-03-A 3:30 PM - 4:15 PM
What’s New in the Management of Infusion
Reactions? Patient Outcomes Improved
with New Pharmacological Approaches
Jessica Culligan, BScN, Katlynn Schellenberger,
BScN, Margaret Mayer, MScN, CON(C), RN(EC), Sandra
Ferris, CON(C), GRRCC, Kitchener, Ontario, Canada.
A retrospective chart review was conducted in 2014 at
GRRCC, an ambulatory community cancer centre, involving
375 antineoplastic treatments given during a 6 week period.
Treatments where Montelukast +/- ASA was administered
showed a considerable decrease in number and severity of IRRs,
resulting in improved patient outcomes, decreased hospital
admission rates, and a reduction in nursing overtime. As a
result, we feel that is imperative that oncology nurses are aware
of emerging evidence supporting the novel pharmacological
approach in both the prophylaxis and management of IRRs.
This case-based presentation will provide an overview of the
pathophysiology of IRRs. The pharmacokinetics of the standard
approach to IRR management and that of Montelukast/ASA
will be explained. An infusion reaction algorithm to guide
oncology nurses in early reaction identification, grading using
CTCAE criteria, and timely pharmacological interventions will
be presented. Lastly, data from the 2014 chart review on the
utilization of Montelukast +/- ASA in preventing and managing
IRRs will be reviewed.
VI-03-B 4:15 PM - 5:00 PM
to health care (CNA, 2008). When caring for persons known to
misuse substances such as alcohol, illicit drugs, and smoking as
well as persons who lack employment, housing and those who
are without social supports in an ambulatory setting, there may
be difficulty in following the plan of care. These socioeconomic
factors may contribute to the patient’s need for hospitalization to
treat the acute side-effects or in order to complete the course of
treatment (Freund et al., 2013). An oral presentation followed by
interactive discussion is planned to enhance the understanding
of related moral issues and distresses that healthcare providers
may experience when their best efforts do not affect significant
health outcomes. Patient education, support and counseling
through the collaborative multidisciplinary team approach in
oncology nursing will be highlighted with a focus on clinical
ethics. The presentation of a case study aims at using an ethical
framework to help resolve moral conflict in providing care. The
facilitation of the discussion is intended to increase awareness in
the provision of safe, ethical care in the ambulatory setting.
References:
Canadian Nurses Association (2008). Code of Ethics for
Registered Nurses. Retrieved from https://www.cna-aiic.ca/~/
media/cna/files/en/codeofethics.pdf
Freund, T., Campbell, S. M., Geissler, S., Kunz, C. U., Mahler, C.,
Peters-Klimm, F., & Szecsenyi, J. (2013). Strategies for Reducing
Potentially Avoidable Hospitalizations for Ambulatory Care–
Sensitive Conditions. Annals of Family Medicine, 11(4), 363–370.
doi:10.1370/afm.1498
Whitehead, M., & Dahlgren, G. (1991). Policies and strategies to
promote social equity in health. Background document to WHO–
Strategy paper for Europe 2007, 14.
VI-04 3:30 PM - 5:00 PM | Tudor 8
simultané VI-04-A 3:30 PM - 4:00 PM
An Ethical Perspective in Cancer
Radiotherapy of Persons Who Are
Socioeconomically Disadvantaged
Improving Emotional Support During
Cancer Treatment: Patients’ Perceptions
Siby Elizabeth J. Thomas, RN, MSN, BC Cancer
Keira Samson, BScN, Rachel Yee-Sui-Chun, BScN,
Virginia Lee, RN, PhD, McGill University Health Centre,
Clients diagnosed with cancer who are socioeconomically
disadvantaged, often present a “safety net” ethical dilemma
in ambulatory care. Dahlgren and Whitehead (1991) highlight
a causal relationship between individual life style choices,
social networks, living and working conditions and health.
Understanding that some individuals in society are socio
economically disadvantaged and or vulnerable, which may lead
to diminished health and wellbeing, nurses’ work to improve the
quality of lives of people and take action to overcome barriers
The literature provides an extensive array of interventions to buffer
the emotional distress associated with the active treatment phase
of a patient’s cancer experience. Yet there is documentation that
patients continue to report low satisfaction with the emotional
support aspects of care. Nurses, being the most accessible
frontline health care provider to patients, play a crucial role in
ensuring that patients receive the emotional support they need
within the oncology treatment setting.
89
It is well known in Oncology that all antineoplastic agents
have the potential to initiate infusion-related reactions (IRRs).
Moreover, with the introduction of new antineoplastics agents
each year, the incidences of IRRs have increased. Oncology
nurses who deliver systemic therapies therefore require expert
skill in emergency management of IRRs. The standard of care
includes the administration of steroids, H1 and H2 blockers.
Unfortunately there are patients who still fail to respond to
traditional management approaches. During an IRR, antigenstimulated mast cells release leukotrienes and prostaglandins
in addition to histamine and other factors. The addition of
Montelukast to block the leukotriene receptor and ASA to block
the effect of the prostaglandins offers additional support to avert
mast cell contribution for IRRs.
PURPOSE: This descriptive study seeks to understand the
patients’ perspective of the nurses’ provision of emotional support.
METHODS: Twelve patients participated in individualized
audio recorded interviews about the emotional support
received during treatment. Data analysis was guided by the
interpretive descriptive approach.
FINDINGS: Patient perceptions of helpful nursing approaches
changed as their emotional needs evolved over time. The provision
of information was perceived as a source of guidance and
reassurance when uncertainty was at its height. At the beginning
of treatment, concrete information was needed to bridge cancer
treatment as a new experience, correct misconceptions, and
navigate the health care system. During cancer treatment, nursing
approaches that conveyed competent, humanistic care and
therapeutic distraction became more important.
IMPLICATIONS FOR PRACTICE: Few studies have explored
the practice of nursing from the patients’ perspective. This
presentation will discuss how the type and timing of nursing
interventions can be purposefully tailored to patients’
emotional needs during the active treatment phase of cancer.
VI-04-B 4:00 PM - 4:30 PM
Identifying Causes of Delays in Discharge
in Patients Diagnosed With High-Grade
Glioma on a Neuro-Surgical Unit
Karen Rezk, RN, BScN, MSc(A) candidate1, CatherineAnne Miller, BScN, RN, MScH.2, 1McGill University,
Montreal, Quebec, Canada, 2MUHC Montreal Neurological
Hospital, Montreal, Quebec, Canada.
Discharge planning processes have implications for patients
and families, healthcare providers, administrators, and
organizations at large. As such, delays in discharge often
result in suboptimal patient outcomes, increased resource
utilization, increased healthcare costs, and overall disruptions
to patient flow due to bed block. Although delays in discharge
have been studied in trauma and psychiatric patients, little is
known about delays in discharge in the brain tumour patient
population. A quality improvement project was conducted
to identify causes of delays in discharge in newly diagnosed
patients with high grade glioma on a Neuro-Surgical Unit. A
Lean Six Sigma Framework was adapted to guide the process
for data collection and analysis. Specifically, the first three
stages of the DMAIC (define, measure, analyze, improve,
control) approach were implemented. Qualitative data was
collected using semi-structured interviews with seven members
of the multidisciplinary team; quantitative data pertaining to
lengths of stay were collected from the hospital database; a
90
process map of the current discharge planning process was
presented to the multidisciplinary team and an adapted Root
Cause Analysis was conducted to identify bottlenecks causing
delays in the discharge process. The main overarching theme
that emerged was communication. Subthemes underlying this
main theme included: communication during multidisciplinary
rounds; incongruent messages being delivered to patients
and families; and discrepancies between team members and
the neurosurgeon resulting in unclear plans. In collaboration
with the multidisciplinary team, strategies were proposed to
undertake some of the identified causes of delays. Findings
from this project may improve timely and safe discharge for
brain tumour patients while facilitating smooth transitions
into community settings. Consequently, this may also promote
better communication and may contribute to more efficient
healthcare expenditure.
VI-04-C 4:30 PM - 5:00 PM
Empowering People with Purpose
and Passion: The Development of a
Lymphedema Program in Oncology
Martina Reddick, RN, Independent Consultant, Tors
Cove, Newfoundland, Canada.
The provision of care for cancer related lymphedema is
inadequate in Canada. This is frequently a result of under
recognition of this chronic debilitating condition and the many
etiology’s associated with it. While working in oncology I too
underestimated this problem.
Working in an oncology out-patient centre the need for
management of post breast cancer related lymphedema became
evident. In the region where I worked there was one referral
source; a registered massage therapist trained in complete
decongestive therapy (CDT). A private clinic means the patient
or the insurer (if the person had insurance) was responsible for
the cost of treatment. I encountered many suffering silently with
lymphedema and the toll it was taking on their personal, family
and social life was evident.
Complete decongestive therapy course for management of
lymphedema is offered to all health care professionals. Health
care costs are high and funding can be difficult to secure
when starting a new program. An application to seek funding
was made to the Canadian Breast Cancer Foundation (CBCF),
Atlantic Chapter for a community health grant to support
this initiative. Funding was successful and the development
of a lymphedema program in cancer care began. As with
development of any program setting goals and objectives as
well as setting a timeline are the most important.
VI-05 3:30 PM - 5:00 PM | Alberta
VI-05-A 3:30 PM - 4:00 PM
Oncology Nurses’ Attitudes Toward
Systematic Symptom Assessment Using
the Edmonton Symptom Assessment
System (ESAS): Results from a Large
Cancer Care Ontario Province-Wide Study
Esther Green, RN1, Dora Yuen, MPH2, Martin Chasen,
MBChB3, Christopher Klinger, PhD3, Michael Brundage, MD4,
Monika Krzyzanowska, MD5, Wenonah Mahase, MBA2, Sean
Molloy, MHSc7, Reena Tabing, MA2, Heidi Amernic, PhD(c)2,
Serena Kurkjian, MBA2, Zahra Ismail, MHA2, Omid Shabestari,
PhD2, José Pereira, MBChB3, 1Canadian Partnership Against
Cancer, Toronto, Ontario, Canada, 2Cancer Care Ontario,
Toronto, Ontario, Canada, 3University of Ottawa, Ottawa,
Ontario, Canada, 4Queen’s University, Kingston, Ontario,
Canada, 5University of Toronto, Toronto, Ontario, Canada, 7St.
Joseph’s Health Centre, Toronto, Ontario, Canada.
PURPOSE: Patients with cancer have a high symptom burden,
and evidence suggests that the use of systematic symptom
screening may be beneficial for patients. The purpose of this
study was to examine the attitudes toward and perceived usage
of ESAS among oncology nurses, who took part in a larger
province-wide study including all cancer care professionals in
oncology care settings.
METHODS: An exploratory mixed methods study design was
used. An electronic survey was sent to oncology nurses at the
14 Regional Cancer Centres across Ontario. Nurses’ attitude
and perceived usage of ESAS was measured using a 21-item
investigator-developed questionnaire. Descriptive statistics and
Kendal Tau b or c test were used for data analyses.
RESULTS: A total of 353 surveys were returned and analyzed
(35% response rate). Most oncology nurses had positive
attitudes toward ESAS, with 85% of nurses viewing the ESAS
tool as a useful starting point to assess patients’ symptoms.
Overall, 93% of nurses considered symptom management
within their scope of clinical responsibilities. However, 32%
of nurses indicated that ESAS might not sufficiently cover the
most common patient symptoms. Findings from statistical
analyses revealed that oncology nurses with over 10 years of
experience were more likely to view: (i) the use of standardized
instruments as “best practice” (p=0.049), (ii) ESAS improves
symptom screening (p=0.013), and (iii) ESAS enables them
to better manage patients’ symptoms (p=0.014). There was
no statistically significant difference between certified RNs
and RNs on attitudes or perceived usage of ESAS. Qualitative
responses revealed some misconceptions about the use of a
standardized screening tool.
CONCLUSIONS: Although nurses are screening for distress, more
work is needed in the practice environments. Future research
needs to explore and provide strategies to enhance personcentred symptom management and the evaluation thereof.
VI-05-B 4:00 PM - 4:30 PM
Patients Pushing the Boundaries of
Privacy and Support in the Digital Age
– Good for Them, Good for You?
Heather Sinardo, BScN, MN2, Colleen Young, BA1,
1Canadian Virtual Hospice, Toronto, Ontario, Canada,
2Canadian Cancer Society, Toronto, Ontario, Canada.
Thanks to the social Web, people facing a new diagnosis,
undergoing treatment, or living with chronic illness can tap into
larger networks online. Patients and caregivers know things –
about themselves, about each other, about treatments – and
they want to share what they know to help other people and
ask questions. Increasingly patients and families participate
in online communities to connect with peers and health care
providers. Over 60% of Canadians search for health information
online and 40% use this information in discussions with their
healthcare providers (Statistics Canada, 2010).
In this presentation, we will discuss the evolving digital landscape
of connection and isolation, and the pros and cons of disclosing of
illness and cancer in the digital age. We will examine online patient
communities, what makes them work and why. You will learn
how to evaluate the quality of an online community where selfdisclosure discussions deepen the sense of community, and how
these stronger ties enhance the health and well-being of the online
community members and their community.
You will find out more about how online patient and caregiver
communities can support you in your practice and the families
you care for, using 2 large Canadian online communities for
cancer support to illustrate the concepts.
91
This presentation will guide the audience in developing a
successful lymphedema program in cancer care. The challenges,
the rewards and the process through to evaluation and follow
up will be highlighted.
VI-05-C 4:30 PM - 5:00 PM
VI-06 3:30 PM - 5:00 PM | British Columbia
A Passion for Setting a Plan: A Quality
Improvement Initiative on Advance
Care Planning
VI-06-A 3:30 PM - 4:00 PM
Kelly McGuigan, RN, BScN, MN, CON(C), CHPCN(C)1,
Jocelyn Brown, RN, BScN, MN1, Robin Forbes, RSW,
MSW1, Judy Costello, RN, MScN1, Jennifer Bell, PhD2, Kyle
Anstey, PhD2, 1Princess Margaret Cancer Centre, Toronto,
Ontario, Canada, 2University Health Network, Toronto,
Ontario, Canada.
Advance Care Planning (ACP) is the process of capable patients
taking steps to ensure that their wishes are known and
documented in the event that they become incapable and/or
unable to communicate these preferences in the future.
ACP is an integral part of providing quality and patient-centred
care. Patients and caregivers report improved quality of life and
less distress after discussions with their health care team about
end-of-life care. However 86% of Canadians have not heard of
advance care planning and of those who did make a plan only
30% had their wishes documented in their medical record.
Health care organizations face the challenge of implementing
a systematic approach for normalizing and incorporating
ACP conversations into everyday practice. We discuss the
organizational strategy used to implement ACP in a large urban
health care centre with a high percentage of oncology patients.
A quality improvement initiative was established to provide health
care providers with the tools they need to document, discuss and
act on their patients ACP. The interprofessional group leading this
initiative established two key goals: increase awareness of the
ACP initiative among health care providers (HCP) and build their
capacity in having these discussions with patients.
We will review the organizational strategy for implementing
the initiative, including standardization of documentation
and resources across practice sites. We review the feedback
received from the HCP and outline next steps for sustainability.
People, Process, Product: Cancer Information
the Canadian Cancer Society Way
Tracy Torchetti, MA, McMaster University, Hamilton,
Ontario, Canada.
People with cancer, survivors and caregivers consistently report
information as an unmet need. And evaluations consistently
show that the Canadian Cancer Society’s information products
and services have a positive impact on people’s cancer journey,
on their knowledge and their ability to cope. After members of
the healthcare team, the internet and print resources are the
most common sources of information about cancer. But are
people finding the right information at the right time?
Many Canadians see us as the trusted source of cancer
information in Canada. Why do so many Canadians turn to us
for information? In this presentation, you’ll learn about how we
develop information for people living with cancer – information
that is accurate, credible, up to date and easy to understand.
You’ll understand how we put our audience first, what goes
into our gold-standard development process, the importance
of medical experts in our process and how we know our
information is having an impact on patients and caregivers.
You’ll also hear about new directions in cancer information
provision, how to help patients find what they need and
how you may be able to use your knowledge to support the
development of new resources.
simultané VI-06-B 4:00 PM - 4:30 PM
Evaluating a New Process for Interstitial
Brachytherapy through Inter-professional
Collaboration and Patient Engagement
Dianne Hill-Mugford, RN, BScN, Lily Man, RN, MN,
Anita Long, RN, MSN/ED, CON(C), Barbara McArthur, BScN,
CPNc, Elaine Avila, RN, BScN, Sunnybrook Health Sciences
BACKGROUND: A large teaching hospital in Toronto, Canada,
was privileged to offer its patients interstitial brachytherapy,
a new option for gynecological patients receiving radiation
in its Ambulatory Cancer Centre. The treatment required an
unprecedented process of coordinating patient care between in- and
92
OBJECTIVE: To evaluate whether the process was delivered as
planned and to identify factors that influenced attainment of goals.
METHODS: The Centers for Disease Control and Prevention
(CDC) Framework for Program Evaluation was adopted to
guide the evaluation process. Two cross-sectional surveys
were created to assess for fidelity, satisfaction, facilitators
and barriers to the process. One survey was for the
interprofessional team; another one was for the patients. Face
and content validity were obtained.
RESULTS: The evaluative surveys enabled stakeholders to
identify opportunities for improvement. The surveys prompted
stakeholders to critically assess whether the care delivery process
was meeting the practice needs and patient expectations.
CONCLUSION: The systematic process evaluation played
a crucial role in promoting quality patient centred care and
excellent healthcare. The feedback was used to refine the
process and provided input for future planning to ensure a
positive patient experience and evidence-informed care.
PURPOSE: In order to learn more about this phenomenon, a
qualitative descriptive study was conducted to explore oncology
nurses’ engagement in heutagogy, learn from their perspectives
about the factors and barriers to self-determined learning, and
explore strategies to address the systemic barriers to selfdetermined learning.
METHOD: 13 point-of-care oncology nurses working in a
quaternary cancer institution participated in this study, through
semi-structured interviews. Participants worked in various practice
areas in oncology. Data was analyzed using constant comparative
method, and used Complexity Theory as a framework.
RESULTS: Participants indicated that most of their learning is
emergent. They also indicated that they engage in heutagogy
to provide safe care to patients, for professional development,
and to impart their knowledge onto others, such as with their
colleagues or preceptees. Participants identified having the
support of their employer, colleagues, and families as one factor
that helped with self-determined learning. They also identified
strategies to best support oncology nurses with self-determined
learning, and provided recommendations for nurse leaders,
educators, and researchers.
IMPLICATIONS: This study has implications for nursing practice,
education, and research.
VI-06-C 4:30 PM - 5:00 PM
Wednesday, October 7, 2015
Mercredi 7 octobre 2015
Heutagogy in Oncology Nursing:
The Experience of Nurses and the
Factors that Facilitate and Hinder SelfDetermined Learning
Charissa Cordon, BSc, BScN, MN, CON(C)2,1, 1Fielding
Graduate University, Santa Barbara, California, United
States, 2St. Joseph’s Health Centre, Toronto, Ontario, Canada.
BACKGROUND: In oncology, novel cancer treatments and best
practices require that nurses must keep their knowledge and
skills current in order to provide excellent care to their patients.
To do this, nurses must engage in heutagogy. Heutagogy is
defined as self-determined learning (Blaschke, 2012; Hase &
Kenyon, 2001). It is a new concept in the field of education.
Heutagogy is a learner-centred approach that blends various
concepts related to adult learning, double-loop learning,
reflective practice and complexity theory. Nurses are already
engaging in this type of learning, however, no research exists
that has explored heutagogy in nursing, using complexity
science as a framework.
Writing for Publication
Margaret I. Fitch, RN, PhD, University of Toronto,
The purpose of this Workshop is to help nurses who want to write
for professional publication purposes. The members of the Editorial
Committee of the CONJ will provide guidance for participants in the
process of writing and tips for achieving success. Both first time
and more seasoned writers are welcome. The session will have
both didactic instruction as well as an interactive portion to allow
questions and discussion. It is anticipated that participants will be
able to seek advice about ideas they have for manuscripts they wish
to write and discuss how to proceed.
93
out-patient settings over two days. To ensure high quality patient
centred care and excellence in practice, an interprofessional working
group came together and developed a process based on the concept
of Knotworking from the Activity Theory.
10:30 AM - 12:00 PM | Confederation 5&6
practice settings, funding policies). Through interactive dialogue
with participants, guideline implementation challenges and
solutions will be identified and explored.
Evidence-Based Strategies for the Design
and Effective Use of Advanced Practice
Nursing Roles in Cancer Control: Practice
Guideline Recommendations
SIGNIFICANCE and IMPACT: Compared to previous reviews, the
recommendations are uniquely based on synthesized evidence
addressing all stages of cancer care and are specific to CNSs and
NPs meeting international criteria for APN. The recommendations
have important implications for optimizing specialized and
advanced nursing roles and designing innovative cancer services
to improve access and quality of care, patient experiences and
health outcomes.
Denise E. Bryant-Lukosius, RN, PhD1, Esther
Green, BScN, MSc(A)2, Barbara Fitzgerald, RN,
MScN1, 1Juravinski Hospital and Cancer Centre,
Hamilton, Ontario, Canada, 2Canadian Partnership
Against Cancer, Toronto, Ontario, Canada.
• To outline practice guideline recommendations regarding the
effective use of clinical nurse specialist and nurse practitioner
roles across the continuum of cancer care
• To facilitate interpretation of practice guideline
recommendations about the effective use of clinical nurse
specialists and nurse practitioners in various cancer control
contexts (cancer continuum, patient population, practice
setting, funding arrangements, healthcare system)
• To identify barriers and solutions to promoting the uptake
of practice guideline recommendations for the effective use
of clinical nurse specialists and nurse practitioners in cancer
control amongst target users including nurses, healthcare
administrators, educators and researchers
INTRODUCTION: Despite substantive evidence about the
effectiveness of advanced practice nursing (APN) roles, optimal
use and full integration of these roles in the Canadian healthcare
system remains elusive.
PURPOSE: This presentation aims to promote understanding and
uptake of new practice guideline recommendations on the effective
use of APN roles in cancer control amongst target users including
nurses, healthcare administrators, educators and researchers.
CONTENT and APPROACH: The guideline focuses on two types
of APN roles, the clinical nurse specialist (CNS) and nurse
practitioner (NP). Evidence-based recommendations, informed
by a systematic review of international studies evaluating the
effectiveness of CNS and NP roles in cancer control, will be
presented. Recommendations address each stage of cancer care
from prevention to end-of-life care. A guideline implementability
framework and case-based small group activities will be used to
discuss key issues and strategies for using the recommendations
to make decisions about introducing, designing, and evaluating
CNS and NP roles to improve the delivery of cancer services.
Strategies include how to adapt, individualize, communicate,
accommodate, implement and evaluate the guideline
recommendations in various contexts (e.g., provincial healthcare
systems, local/regional cancer care needs, patient populations,
94
VII-03 10:30 AM - 12:00 PM | Tudor 7
VII-03-A 10:30 AM - 11:00 AM
Unwanted Encore 2.0: An Update
on the Lived Experience of Having
Multiple Cancer Diagnoses
An estimated one in nine Canadians will have two or more
primary cancer diagnoses in their lifetime. It is expected that
the incidence of multiple primary cancer diagnoses (MPCD) will
increase as the number of cancer survivors increases. There is
some indication that MPCD negatively impact survivors’ mental
and physical status, and quality of life. Further, research indicates
that the illness burden of MPCD is cumulative and exceeds that of
survivors of a single cancer diagnosis. Despite this, both cancer
survivors and healthcare providers often assume that having
MPCD is the same as having cancer once. This is not the case. In
a qualitative study, 14 participants (5 men, 9 women), each with
an average of 3 cancer diagnoses in their lifetime, provided data
from participant-generated photographs and audio-recorded
interviews (individual and group). This lived experience was
described as an unwanted encore. Themes that capture the
essence of this unwanted encore include: (1) From Backdrop
to Center Stage, (2) It’s Familiar but Different, (3) There’s Life
After Cancer (Again), and (4) You Gotta have Faith. This study
provided an avenue for cancer survivors to reflect upon and
make meaning from their lived experiences of MPCD. What is
clear from this study is that recognition of the differences in each
cancer experience by cancer survivors, healthcare providers and
decision-makers is likely to enhance supportive care. Increased
knowledge about the lived experience of having MPCD may well
enhance supportive care offered to cancer survivors.
VII-03-C 11:30 AM - 12:00 PM
Cancer Survivorship: Exploring
Structures and Contexts Shaping High
Quality Care for All
Using Neurofeedback to Manage LongTerm Symptoms in Cancer Survivors:
Results of a Survey of Neurofeedback
Providers
Tracy L. Truant, RN, MSN, PhD(c), Sally Thorne,
RN, PhD, Colleen Varcoe, RN, PhD, Carolyn Gotay,
PhD, University of British Columbia, Vancouver, British
Columbia, Canada.
Dianne Groll, PhD, RN, Queen’s University, Kingston,
Ontario, Canada.
BACKGROUND: Health and social disparities rarely are
considered in the development of cancer survivorship models of
care (MoC), limiting access to high quality survivorship care for
many. To ensure survivors’ needs rather than social privileges
guide opportunities for quality survivorship care and optimal
health, it is imperative to understand how disparities influence
survivorship MoC.
BACKGROUND: Neurofeedback is a non-invasive, drug-free form of
brain training reported to help with a variety of conditions including
pain, fatigue, depression, anxiety, sleep disorders and cognitive
decline. However, it is unknown to what extent cancer survivors are
using neurofeedback for management of long-term symptoms.
PURPOSE: To explore and explain how the layering and
intersection of social, political, economic and personal factors,
and health experiences and health management strategies shape
the development of and access to high quality survivorship care
for Canadians with cancer. Recognizing the complexities inherent
in survivorship care, recommendations to foster high quality
survivorship MoCs are described.
OBJECTIVES: The purpose of this study is to explore current
use of neurofeedback by cancer survivors to manage long-term
symptoms and to identify safe and effective neurofeedback
modalities and protocols for this population.
METHODS: Using qualitative interpretive description methods,
this three-phased study includes 1) secondary analysis of the
Canadian Communication in Cancer Care database, 2) critical
textual analysis (e.g., survivorship guidelines, policies), and 3)
survivor and system stakeholder interviews.
FINDINGS: A beginning interpretive description of the study
findings is presented offering insights into the structures and
contexts that may shape survivors’ experiences and engagement
with the survivorship care system. Major themes include
communication within the health care environment, experiences
accessing survivorship resources, and ongoing unmet needs.
Gaps and inconsistencies in current survivorship care structures
and contexts are discussed, and preliminary recommendations to
achieve high quality survivorship care for all are presented.
CONCLUSIONS: This study offers insights into how survivorship
MoC may unwittingly reduce opportunities for survivor health
and makes recommendations to improve how we communicate
about, shape and enact equitably high quality survivorship MoCs.
METHODS: This exploratory quantitative study employed
a descriptive online survey administered to neurofeedback
providers to identify: (1) use of neurofeedback by cancer
survivors; (2) types/protocols of neurofeedback used; (3)
types of symptoms addressed; (4) success of training; and (5)
incidence/nature of side effects.
RESULTS: Seventy-nine neurofeedback providers completed an
online survey. Of these, 37 (46%) have provided neurofeedback
to an average of 6 cancer survivors (range=1-50). A variety of
approaches were used: NeurOptimal (42), HEG (20), QEEGbased (16), LENS (8), and other (36). Neurofeedback training
was reported to eliminate/reduce symptoms including fatigue
(12%/50%), cognitive impairment (17%/46%), sleep problems
(15%/69%), stress (20%/65%), anxiety (26%/60%), depression
(34%/50%), and pain (9%/36%). Transient side effects reported
included fatigue (9%), headache (7%), spaciness (6%), anxiety
(4%), insomnia (3%), and dizziness (3%).
CONCLUSIONS: Results suggest neurofeedback may be a
safe and effective complementary and alternative therapy
for management of long-term symptoms in cancer survivors.
Interviews with neurofeedback providers and cancer survivors
are in progress to further explore this, and to inform development
of a protocol for a pilot study to evaluate effectiveness in a
sample of cancer survivors.
95
VII-03-B 11:00 AM - 11:30 AM
VII-04 10:30 AM - 12:00 PM | Tudor 8
it explains the effectiveness of an interdisciplinary team approach
to provide comprehensive patient and family care. Although this is
what we all strive for in practice it can be challenging to achieve.
VII-04-A 10:30 AM - 11:15 AM
An acute palliative care unit in a large cancer centre has
successfully implemented interdisciplinary rounds. These weekly
rounds are led by the oncology palliative care nurses using a
number of patient screening tools to guide the discussion and
ensure the patient’s voice is present in the rounds. The results
include increased patient and staff satisfaction, decreased length
of stay and advancing clinical practice.
The Passion and Purpose of Hope When
Living with Pancreatic Cancer
Shari Moura, RN, MN, CON(C), CHPCN(C), Princess
Margaret Cancer Centre - University Health Network,
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer death in both men and women and has an overall
five year survival of eight percent. Eighty percent of people
with PDAC are diagnosed with unresectable locally advanced
or metastatic disease. The five year survival post-surgical
intervention for PDAC is less than twenty percent.
Recent clinical experience in a tertiary cancer centre’s dedicated
clinic caring for patients and families with pancreatic cancer
has observed that most patients and their families dealing with
a new diagnosis of PDAC appear to focus on hope for a cure,
remission of their cancer, and/or living for decades despite the
reported evidence related to survival. McClement and Chochinov
(2008) defined hope in patients with advanced cancer as a coping
mechanism, protecting patients from distress and suffering.
Bridging the concepts of hope and preparing patients and their
families for reality of having advanced cancer can be challenging
for specialized oncology nurses.
This presentation will review salient literature examining the
concept of hope in advanced cancer. Specific strategies utilized
to understand and sustain patients and their families hope when
living with pancreatic cancer will be shared. Discussion on how to
link conversations of hope with the introduction of early palliative
care and advanced care planning will be highlighted.
VII-04-B 11:15 AM - 12:00 PM
Passionate People Coming Together for
a Common Purpose: Interdisciplinary
Oncology Palliative Care Rounds
Patricia Murphy-Kane, BScN, MN, CHPCN(C), BA,
Andrea Colagiacomo, BScN, Princess Margaret Cancer
The challenges faced in coordinating these rounds included time
constraints, overlapping approaches, differences in opinion and
lack of structure.
This presentation will explore how the rounds were developed
using provincial and national guidelines and tools, the evolution to
date and the positive outcomes.
This approach to patient centred care directly improves use of
resources between professions, supports effective communication
within staff and provides a forum where staff can support each
other in caring for this very complex patient population. Overall,
it is an effective method in supporting and caring for the diverse
needs of patients and their families.
VII-05 10:30 AM - 12:00 PM | Alberta
VII-05-A 10:30 AM - 11:00 AM
Multi-Day Treatment Model: Why Is this
a Better Way?
Jodi Hyman, BScN, CON(C), RN, Cancer Care
Manitoba, Winnipeg, Manitoba, Canada.
The Canadian Association of Provincial Cancer Agencies (CAPCA),
The Institute for Safe Medication Practices (ISMP) Canada, and five
provincial cancer care organizations worked together to improve
safety with IV chemotherapy administration. One aspect they looked
at was the same day treatment model (not best practice) versus
multi-day treatment model (best practice).
The analysis revealed that although the same day model may seem
more consistent with patient-centred care, there are safety and
workload issues that affect all areas of the chemotherapy treatment
facility. In comparison to the same day treatment model, centres
using a multi-day model experienced many benefits and improved
patient safety.
Collaboration between various disciplines is the most desirable
and effective way to practice and meet the needs of patients and
their families. In the Model to Guide Hospice Palliative Care (2002)
96
VII-05-C 11:30 AM - 12:00 PM
This presentation will focus on the most current evidence that
supports the multi-day treatment model, tools and methods used
to promote change, lessons learned, and results that measured the
long term uptake of the multi day treatment model by the 16 CCP’s.
Susan Csatari, RN, BD Canada, Mississauga, Ontario, Canada.
VII-05-B 11:00 AM - 11:30 AM
People, Purpose, Passion: The Role of
the Specialized Oncology Nurse as We
Transition Patients Through Our Uniquely
Designed Rapid Assessment Clinic for
Newly Diagnosed Leukemia Patients
Nancy A. Pringle, RN, Nancy A. Wagg, RN, Princess
Acute leukemia is a rapidly progressive disease requiring timely,
intensive and complex treatment. This prompted a need for
specialized oncology nurses in an acute care setting to develop
a clear and concise pathway for a day in the life of a newly
diagnosed leukemia patient.
This presentation will discuss the patient’s journey from a
nursing perspective as we transition patients through our
rapid response clinic.
It is important to understand how patients proceed through the
care delivery system. Establishing the logical flow of the patient
through the clinic is key to reducing the length of the journey. The
value must be in the right order and can be re-ordered if necessary.
We will examine the process map and determine where there
are problem areas. Functional bottlenecks that obstruct flow and
cause delays (radiology, pathology) will also be discussed.
By standardizing the approach, providers will feel confident
patients are receiving the same information no matter which
team member is delivering it.
The challenges faced, opportunities identified and the resources
developed to support the nursing staff will be highlighted. The
collaboration and key contributions of all members of the team
will also be addressed.
From the Line to the Lab: The Impact
of Blood Collection Practice on Patient
Outcomes
It is vital for good patient outcomes that nurses are knowledgeable
about blood collection practice, to ensure optimal specimen
quality for accurate results. Between 80 and 85% of all clinical
decisions are based on laboratory results; studies have shown
that 68% of all specimen errors occur in the preanalytical phase
– before the blood is analyzed in the lab. Nurses routinely collect
blood samples, yet little formal training is available to them as
to how they can deliver the best quality specimen possible. A
specimen which is an accurate reflection of the patient’s “in vivo”
status should be the goal every time blood is drawn.
Best practice in blood collection from vascular access devices
improves laboratory test result accuracy, increases patient safety
and decreases time lost to re-draws. This presentation addresses
the key issues pertaining to specimen quality and promotes
understanding of the factors which contribute to hemolysis and
contamination or dilution of the specimen, as well as providing
the rationale for Lab requirements for patient identification, order
of draw, filling and mixing of tubes, and labeling of specimens.
Nurses draw blood from central vascular access devices in
many practice settings: critical care, acute and long term
care, ambulatory clinics, and community and home care. It is
essential for good patient outcomes, therefore, that they have
the knowledge required for best practice to reduce errors in the
preanalytical phase of specimen collection.
VII-06 10:30 AM - 12:00 PM | British
Columbia
VII-06-A 10:30 AM - 11:00 AM
Building Capacity Within a Group of
Generalist Oncology Nurses to Create a
Seamless Transition to Care
Charissa Cordon, BSc, BScN, MN, CON(C), Melissa
Morey-Hollis, BSN, MHSc, Victoria Crowder-Bansen, RN, BScN,
MHSc, Giancarla Curto-Correia, MHSc, PT, Edelgard Lenzo,
RN, St. Joseph’s Health Centre, Toronto, Ontario, Canada.
97
CancerCare Manitoba had adopted this model of care in 2013,
but the multi-day treatment model was not being used in the 16
rural community cancer programs (CCP’s) in Manitoba. In keeping
with the most current evidence based practice the community
cancer programs network was able to educate, guide and assist in
changing the way patient assessment, bloodwork and the timing of
chemotherapy administration took place in the 16 rural CCP’s.
“Seamless care” means that patients consistently receive the
highest quality of care from their healthcare providers regardless
of geographical location. In one community teaching health centre,
a new model of care was introduced in the oncology program
to ensure that oncology patients receive the highest quality of
care not only from the specialized oncology nurses working in
the chemotherapy clinic, but also from nurses working in the
general medicine inpatient unit. To facilitate this, the health centre
partnered with the de Souza Institute to support generalized
oncology nurses with their knowledge and skills in oncology.
Over a period of six months, 80% of nurses working in the
general medicine unit completed the Standardized Provincial
Chemotherapy and Biotherapy Course, and the Foundations in
Oncology Course. In order for nurses to maintain their knowledge,
skills, and competencies in chemotherapy administration and
practices, a group of nurses from the general medicine unit
rotated in the chemotherapy clinic. The Kirkpatrick 4-Level Training
Evaluation Model (1954), was used to evaluate the project.
We measured the participants’ reaction to the program, their
knowledge and behavior changes, and broad outcomes, which
include both process and patient outcome measures. The nurses’
attitudes, perspectives, and confidence in providing holistic care
to oncology patients were also measured.
Following completion of the courses, nurses felt an ignited passion
for oncology nursing. They worked together to implement tools
they learned from the courses to enhance their practice, and
improve the care they provide to oncology patients.
In this presentation, we will provide a description of project
activities, implemented practice changes, and findings from our
evaluation. Results from staff satisfaction surveys, participants’
pre and post test scores, and findings from documentation audit
reviews to determine changes in nursing practice and patient
outcomes will be presented.
VII-06-B 11:00 AM - 11:30 AM
Mommy Yelled at Me to Clean Up
My Room and Got Throat Cancer:
Supporting Children When a Parent or
Sibling Has Cancer
Andrea L. Warnick, BScN, MA, Andrea Warnick
Consulting, Toronto, Ontario, Canada.
Children and youth have an extraordinary capacity to understand
and live with issues related to the cancer diagnosis of a family
member. As a result, children and youth of all ages benefit from
receiving honest information in a simple and concrete manner
regarding the cancer diagnosis and prognosis for a parent or
sibling. However, out of a fear of saying the wrong thing many
98
nurses are often reluctant to advise families on this topic,
unintentionally leaving many families uncertain of how to best
support their children.
This session will identify four of the main concerns children
experience when a parent or sibling has cancer, as well as
techniques that nurses can use to support children with these
concerns. Strategies to help facilitate children’s understanding of
the illness will be explored, as will ways to increase their sense of
security and inclusion when a family member has cancer.
VII-06-C 11:30 AM - 12:00 PM
Passionate Multidisciplinary Team
Members Committed to Implement and
Sustain the Enhanced Recovery After
Surgery (ERAS) Clinical Pathway Across
the Surgical Program
Rosemarie Rivera, MN, Amber Curry, MHSc, Susan
Bradbury, LPN, RPN, Minette McNeil, MEd, Lisa DeBeer,
BSc, RD, Rachel Meyer, BSc, FRCPC, Rouge Valley Health
Systems, Scarborough, Ontario, Canada.
BACKGROUND: A clinical pathway called Enhanced Recovery
After Surgery (ERAS) was implemented across a Surgical
Program of a two-site community hospital for elective bowel and
colorectal cancer surgeries. Implementation of ERAS involved a
multidisciplinary approach that engaged numerous committed and
passionate health care professionals and leaders which played a
pivotal role in implementing this initiative.
The purpose of implementing ERAS was to enhance the overall
delivery and receipt of quality care for patients, families and health
care professionals by utilizing a set of best practice guidelines
and standards impacting the overall perioperative care of patients
to achieve earlier recovery time, better patient outcomes and
improved length of stay. This presentation will highlight the
implementation strategies undertaken by the team, the successes,
challenges and outcomes.
METHOD/FINDINGS: An ERAS committee and champions were
established to promote, implement and evaluate the effectiveness
of the clinical pathway. The team consisted of nurses, surgeons,
anesthetists, dietitians, allied health members, clinical practice
leaders, managers and directors. Achievements included the
development of an ERAS order set and clinical documentation
based on the pathway, establishment of weekly and bi-weekly
preoperative classes for patients and their families, ongoing chart
audits as well as telephone follow-ups after discharge. Several
challenges that hindered the implementation and sustainability
of ERAS included the lack of physician engagement, completion
of clinical pathway documentation by staff and referrals to preoperative ERAS classes.
Annual Canadian Cancer Society and
CANO/ACIO Joint Symposium /
Symposium joint annuel de la
société canadienne du cancer et
de l’ACIO/CANO
Shattering the Myths: Smoking
Cessation Is an Essential Element of
“Best Practice” Cancer Care!
Andrew Pipe, CM, MD, Professor, Faculty of
Medicine,University of Ottawa, Chief, Division of
Prevention and Rehabilitation, University of Ottawa
Heart Institute.
John Atkinson, Director, Cancer Prevention and
TobaccoControl, Canadian Cancer Society, Ontario Division.
Barbara Fitzgerald, RN, MScN, President, CANO/ACIO.
With the number of new cases of cancer diagnosed in Canada
expected to rise by about 40 per cent in the next 15 years, the
need to address cancer prevention in cancer care couldn’t
be more important. An overview of recent and future cancer
statistics will be shared with a focus on preventative power
of smoking cessation. Smoking cessation is one of the most
important, and most powerful, interventions that can be
delivered in any clinical environment – and is particularly
important in the Cancer Care setting. Tobacco addiction is the
leading cause of preventable disease, death and disability
in Canada and a principal cause of many common cancers.
Approaches to smoking cessation have been impeded by
outdated concepts and prejudicial attitudes and, when treating
cancer, the misconception that cessation is “too late”. There
is clear and convincing evidence that smoking cessation at the
time of cancer diagnosis and treatment extends lives, improves
treatment response, and greatly facilitates patient comfort
and well-being. In some instances smoking cessation may
be the most potent intervention of all! There are remarkable
opportunities to enhance “Best Practice” cancer care by assisting
patients with smoking cessation. Nursing leadership is essential
if we are to more effectively provide the benefits of smoking
cessation to our patients. Simple, sensitive, strategic and
systematic approaches to cessation can dramatically enhance
cessation success and will be addressed in this discussion.
Outpatient Management of Acute
Leukemia: Sharing Our Passion
Cindy Murray, NP, MN, Mary C. Doherty, MN, NP-PHC,
Shannon Nixon, MN, RN, Princess Margaret Cancer
Build capacity for managing acute leukemia patients in the
ambulatory setting by sharing our knowledge and skills around;
a) the clinical assessment and management of the transfusion needs of acute leukemia patients, and;
b) the identification and management of common infections
in acute leukemia patients.
The acute leukemia program at our institution is one of the
largest in North America providing care for more than 300 new
patients each year. These patients, who typically receive highintensity chemotherapy treatments, have historically remained
hospitalized. Increased attention to health care costs, use of
resources and patient quality of life has contributed to a shift to
outpatient management. A nurse-led ambulatory clinic has been
established in our institution to address the highly specialized
and complex care needs during the chemotherapy and
myelosuppressive phases. Successful outpatient management
is highly dependent on expert nursing care, thorough patient
education, and empowerment of patient self-care. Key issues for
nurse practitioners and registered nurses include blood product
assessment and administration, and management of infections
including febrile neutropenia.
A clinically-focused Workshop will be offered for nurse
practitioners and registered nurses who currently manage
patients diagnosed with acute leukemia. The goal is to share
knowledge and skills, and build capacity for acute leukemia
nursing care in the ambulatory setting. The following topics will
be addressed using a case-based approach:
1) Assessment and management of transfusion needs and
complications,
2) Identification and management of common infections in
patients with prolonged neutropenia, and
3) High-risk febrile neutropenia.
99
CONCLUSION/IMPLICATIONS: Overall, research and evaluation
reveals that utilizing ERAS has shown to improve patient
outcomes, length of stay and patient satisfaction. To ensure
the sustainability of this initiative, ongoing evaluation, active
participation of committed, passionate and engaging team
members are needed.
Strengthening the Care of Older Adults
with Cancer: Purpose and Passion in
Oncology Nursing for this SIGnificant
Group of People
Lorelei Newton, PhD, RN1, Fay J. Strohschein, RN,
MSc(A), PhD(c)2, Tina S. Haayer, RN, BSN, MA
(current)1, 1BC Cancer Agency, Victoria, British Columbia,
Canada, 2Jewish General Hospital, Montreal, Quebec, Canada.
• Provide an overview of Geriatric Oncology: Older People with
Cancer (25 minutes/5 minute break)
a) Discuss and consider the particular set of needs and
concerns that are not only under-recognized but also understudied in the geriatric oncology population
b) Review/outline how oncology nurses are uniquely positioned
to significantly improve care and outcomes for this population
• Discuss the unique Concerns: What is the purpose of geriatric
oncology as a sub-specialty? (25 minutes/5 minute break)
a) Introduce and discuss the two overarching factors that play
a significant role in the suboptimal care of the older adult with
cancer: ageism and health literacy
b) Explore the topic of ageism in oncology
c) Highlight the impact health literacy has in this patient
population and discuss how to address/mitigate the impact
• Sharing our Passion: Creating a Geriatric Oncology Special
Interest Group (25 minutes/5 minute break)
a) Assesssing interest/feasibility of sub-specialty
b) Building on contributions of participants from the first two
sections, continue discussion of a geriatric oncology SIG while
also collating comments, ideas and suggestions into draft
Statements of Purpose and Terms of Reference
c) Brainstorm action items for next steps.
In Canada, 43% of new cancer cases and 62% of cancer deaths
occur amongst Canadians 70 years of age and older. However, older
adults with cancer and their families present particular needs and
concerns that often remain under-recognized, unmet, and understudied. As the number of older Canadians is expected to double
by 2034, it is time to address the distinct strengths and needs of
this group by integrating oncology and aging to develop optimal,
appropriate approaches to care through practice, education,
policy, and research. This Workshop will provide an overview of
the emerging field of geriatric oncology and outline how oncology
nurses are uniquely positioned to significantly improve care and
outcomes. It will consist of two presentations and an interactive
discussion that will contribute to the development of a new Geriatric
Oncology Special Interest Group (SIG).
100
First, we will consider an overview of older people with cancer. The
ways in which older adults experience cancer and its treatment are
shaped by vast variation in terms of the biological, psychological
and social aspects of aging. Geriatric oncology is a specialty that
calls for collaboration to ensure appropriate care, and highlights
the limitations of existing evidence. Secondly, we will consider the
purpose of geriatric oncology as a sub-specialty in addressing the
unique concerns of older adults with cancer. In particular, clear
patterns of suboptimal treatment have been identified and are
underpinned by issues such as ageism and health literacy. Finally,
we will facilitate an interactive discussion to explore the challenges
and successes in caring for older adults with cancer, while
identifying needs, concerns, and future actions to integrate into
the purpose of the developing Geriatric Oncology SIG. Our ultimate
goal is to inspire passion in contributing to a model of oncology
nursing care that integrates understanding of oncology and aging
to optimize the care of older adults with cancer.
VIII-03 3:00 PM - 4:30 PM | Tudor 7
VIII-03-A 3:00 PM - 3:30 PM
Empowering Patients Through Treatment
for Head and Neck Cancers: Implementation
and Evaluation of an Early-in-Treatment
Group Educational Intervention
Maurene McQuestion, RN, BA, BSc, MSc, CON(C),
Andrea Gomes, MHS, Reg-CASLPO, Joanne Pun, BSc, RD,
Treatment for head and neck cancers (HNC) can be particularly
debilitating. Patients can suffer a host of short and long term
problems. Delivering timely supportive information in a meaningful
context can be challenging at the beginning of treatment. A disease
specific group education class was developed in 2012 and taught
by the Clinical Nurse Specialist, Speech Language Pathologist and
Registered Dietitian. Brief psychoeducational interventions have
been shown to reduce fear of the unknown, feelings of uncertainty,
psychological distress, improve knowledge and enhance coping
(Boesen, et. al., 2005; Halket, et. al., 2013).
The class was designed for patients starting radiation +/chemotherapy, as a supplement to the individualized patient
education. Content focused on support resources, managing
side effects, preventing swallowing dysfunction and maintaining
nutrition and hydration. Printed materials were provided in a
package for each participant. Patients were booked into the
class within their first two weeks of starting radiation, ensuring
that the class was part of their standard of care. Evaluations
were collected at the end of each session from both patients and
others attending the class.
In the pilot phase, ongoing feedback will then be obtained from
patients and key stakeholders at various points in the trajectory
of care to evaluate the effectiveness of the toolkit and its delivery.
This presentation will describe the implementation process of the
LEAP toolkit, and more specifically, will discuss the pilot phase of
this initiative in detail.
This presentation will focus on the program implementation
and evaluation results. Differences between patient and
family/caregiver and gender as well as changes in perceived
preparedness pre and post class will be presented. Successful
strategies for implementing a program for patients and families
living with HNC will be shared.
VIII-03-C 4:00 PM - 4:30 PM
VIII-03-B 3:30 PM - 4:00 PM
Educating the Leukemia Population:
The Implementation and Effectiveness
of a Developed Educational Toolkit to
Support the Leukemia Patient Population
Throughout the Trajectory of Care
Katherine Lee, BScN, CON(C), Fatima Abdelmalek,
BScN, MN, CON(C), Christine Bent, BScN, Laura Olmi,
BScN, CON(C), Erin Saretz, BScN, Sandra Bolyki, BA,
Kaminiben Patel, BScN, CON(C), Anna Papizzo, BScN,
Eve Dimopoulos, BScN, Princess Margaret Cancer Centre,
Navigating a cancer diagnosis can often be overwhelming and
frustrating. In our experiences, these feelings were exacerbated
with the abundance of information provided to newly diagnosed
acute leukemia patients before and during hospitalization. It
was also evident that many leukemia patients felt rushed and ill
prepared to transition into the community due to inconsistent
information being conveyed, as well as inadequate health
management education. This led to increased anxiety levels in
patients and families and a potential for poor health management
strategies. A needs assessment survey was conducted to
patients in an outpatient setting and through informal interviews
in the inpatient setting in order to evaluate the effectiveness
of the health teaching tools and strategies currently in place.
An analysis of the information gathered provided a foundation
for the implementation of the Leukemia Awareness Education
Package (LEAP) toolkit. LEAP was created in a modular format to
help increase the patient’s knowledge retention, build capacity
for survival-level knowledge, and provide a forum for open
communication between the patient and nurse. The overall goal
of the LEAP toolkit is to promote patient empowerment through
sound education. Currently in the pre-pilot phase, the developers
of the LEAP toolkit are in the process of educating front-line
nurses the purpose and importance of this change in practice.
Group Medical Appointments: A Novel,
Collaborative Approach to Breast
Cancer Patient Education for Adjuvant
Endocrine Therapy
Ann Vlahadamis, RN, MN, NP1, Melanie Danilak,
BSc, Pharmacist1, Edith Pituskin, RN, MN, PhD2, Krista
Rawson, RN, MN, NP1, Karen King, MD1, 1Alberta Health
Services, Edmonton, Alberta, Canada, 2University of Alberta,
BACKGROUND: Group medical appointments (GMA) are
currently practiced for a wide range of medical conditions such
as diabetes, hypertension, asthma, and cardiovascular disease.
Previously, postmenopausal estrogen receptor positive breast
cancer patients (ERBCP) in our cancer centre attended individual
physician clinic appointments to learn about their options for
adjuvant endocrine therapy. This resulted in variation of the
education provided to patients, lengthy medical oncologist (MO)
clinic visits and significant wait-lists to attend clinic. Accordingly,
we embarked on a pilot program to determine the feasibility and
acceptability of GMA in this patient population.
METHODS: Since 2010, ERBCP requiring endocrine therapy
were referred and scheduled in the biweekly GMA program run
in collaboration between a Nurse Practitioner and Pharmacist.
Education regarding choices, risks, benefits and side effects of
endocrine therapy were provided by a nurse practitioner (NP)
and/or pharmacist (RX). After questions were solicited from the
group, individual ERBCP were provided with prescriptions and
scheduled for guideline-based follow-up.
RESULTS: Approximately 900 ERBCP have attended GMA, with
100% of MOs referring eligible patients. Surveys indicate high
levels of satisfaction with the information provided and the
GMA format.
CONCLUSIONS: GMA provided by NP and RX is feasible and
acceptable to both ERBCP and MOs. Health system benefits may
include increased efficiency and reduced costs, with MO clinic
reserved for complex patient needs. Patient benefits include
timely access to care and high levels of reported satisfaction.
Future work will examine the effects of GMA on patient
compliance and medication reconciliation with endocrine therapy.
101
An initial feasibility pilot was conducted in 2012 followed by a
quality improvement program evaluation between October 2013
and December 2014. Demographic data, process evaluation and
an adapted Perceived Preparedness for Re-entry Scale (PPRS)
was used, focusing on how well prepared patients felt about
coping with side effects from treatment. 280 evaluations were
completed, including 231 patients and 47 family/caregivers.
VIII-04 3:00 PM - 4:30 PM | Tudor 8
VIII-04-B 3:30 PM - 4:00 PM
VIII-04-A 3:00 PM - 3:30 PM
Timely Discharge Initiative: The
Patients’ Perspective
Empowering Patients and Caregivers
with Knowledge: The Development of
a Nurse-Led Gynecologic Oncology
Chemotherapy Class
Mary Glavassevich, MN, Rosemary Irish, MSN/
ED, CON(C), Elaine Avila, BScN, Sunnybrook Health
Lisa Ould Gallagher, RN, CON(C), Nazlin Jivraj, RN,
BScN, CON(C), Sarah E. Ferguson, MD, FRCSC, Nazek
Abdelmutti, MSc, Janet Papadakos MEd, PhD(c), Princess
Princess Margaret Cancer Centre is a leader in oncology, however
rising patient volumes have made it increasingly difficult to
provide quality chemotherapy teaching in a clinical setting. The
challenge for nurses to provide comprehensive teaching in a
short period of time, led to the development of a chemotherapy
class specific to our patient population and protocols. This was a
nurse-led initiative that involved a multidisciplinary team.
The Gynecology Oncology group has had success since the
implementation in 2012 of the patient chemotherapy class. The
class empowers patients and caregivers with knowledge, and
decreases anxiety around treatment. The purpose of the class
is to provide education about the chemotherapy routine, side
effects and coping strategies.
Further development in 2014 of education materials has
enhanced the efficacy of the course. Materials reflect what is
taught to help patients and caregivers understand the typical
routine, side effects, medications and when to contact your
nurse or visit the emergency department. The class also allows
patients to bond with each other, and has thus created lasting
relationships. To date 379 patients and 345 caregivers have
attended the class. Our evaluations have shown that the class
has eased their fears by knowing what to expect with the
possible side effects of treatment. The class is unique because it
is taught by our team of specialized oncology nurses who have a
passion for empowering patients through education.
102
Within our organization there is an ongoing push to decrease
occupancy and increase efficiency by initiating early discharge
planning of patients. In our busy surgical oncology unit, patients
are being discharged throughout the day. Anecdotal evidence
from the interprofessional team indicates that patients are not
always aware of their expected date of discharge and time of
discharge. Hence, they may not be ready to leave by the specified
time. An interprofessional team initiated a quality improvement
process to explore the reasons for the delay in discharge.
The purpose of this initiative was to (1) determine if patients are
aware of their discharge date, (2) determine if patients received
information about their discharge time, and (3) explore the
barriers to patients being discharge before 1100.
A five-item questionnaire was developed to guide the telephone
interviews. Patients were contacted 7-10 days following discharge
home. Results were collated and themed.
This initiative provided useful information and understanding
of the barriers faced by patients and families. The findings
were used to implement strategies through interprofessional
collaboration that engages the patients and families in early
discharge planning and timely discharge. The authors believed
that the data and strategies utilized can be applied to similar
units within the organization and others.
VIII-05 3:00 PM - 4:30 PM | Alberta
Return to Work Questionnaire for
Cancer Survivors
VIII-05-A 3:00 PM - 3:45 PM
Christine Maheu, PhD1, Andrea Vodermaier, PhD2,
Wolfgang Linden, PhD2, Katerina Rnic, MS2, Mina Singh,
PhD3, Lise Fillion, PhD4, 1McGill University, Montreal, Quebec,
Canada, 2University of British Columbia , Vancouver, British
Columbia, Canada, 3York University, Toronto, Ontario,
Canada, 4Université Laval, Quebec City, Quebec, Canada.
Designing Innovative Cancer Services:
Responding to the Unmet Supportive
Care Needs of Patients with Newly
Diagnosed Advanced Colon Cancer
PURPOSE: As a result of reduce depilating treatment effect and
improved survival rates, a greater number of cancer survivors
are returning to work after treatment completion. In order to
assess patients’ experiences with return to work, we constructed
a questionnaire to explore several relevant domains. Phase I
consisted of the development of a clear 4-factor structure with
subscales addressing symptoms experienced at work, workplace
accommodation, meaning of work, work as a means to cope with
cancer, and external motivations. Aim of Phase II is to examine
the number of survivors that RTW, the time interval in which
they do so, and any changes that may occur at the workplace.
Furthermore, we are investigating whether or not return to work
is associated with physical and emotional distress.
METHODS: Phase II questionnaire development is being
assessed via an online questionnaire. Inclusion criteria include all
cancer survivors who are in working age. Recruitment is through
the Princess Margaret Cancer Centre Cancer Registry and with
Cancer Organizations across Canada. We currently have 150
cancer survivors who have completed the online RTW survey and
are aiming for 600.
RESULTS: One hundred patients under the age of 65 participated
in Phase I. The PCA suggested a 4-factor solution that accounted
for 67% of the variance labeled symptoms experienced at work
(6 items; α=.85), workplace accommodation (4 items; α=.76),
meaning of work (2 items; α=.70), and work as a means to cope
with cancer (2 items; α=.68). Subscales showed the expected
correlations with depressive symptoms, illness intrusiveness, and
fatigue, thus supporting construct validity. Phase II will analyze
results from the current 150 patient recruited and descriptive
data from each 4 factors will be presented.
CONCLUSION: Considering the absence of scales assessing
the multifactorial impact of RTW for cancer survivors, there is
an urgent need to complete the development of this scale and
publish the results.
Suganya Vadivelu, RN, MScN, CON(C), PGDHM1,
Denise E. Bryant-Lukosius, PhD2, 1Juravinski Cancer Centre,
Hamilton Health Sciences, Hamilton, Ontario, Canada,
2McMaster University, Hamilton, Ontario, Canada.
BACKGROUND: Colorectal cancer (CRC) is the second most
common cancer among Canadians and about 56% of them are
diagnosed with advanced stage disease. Little is known about
the supportive care needs (SCNs), healthcare services use and
costs associated with a new diagnosis of advanced colon cancer.
PURPOSE: To inform healthcare planning and the design
of new services, we examined the fit between patient
reported SCNs and their use of healthcare services during
the diagnostic phase for advanced colon cancer. Healthcare
service costs were also determined.
METHOD: A descriptive cross-sectional survey was conducted in
two cancer centres. Patient completed a self-report questionnaire
that included the SCNs Survey-Short Form, Functional
Assessment of Cancer Therapy-Colorectal and the Health Service
Utilization Questionnaire.
RESULTS: Ninety-four patients completed the questionnaire
(response rate =77.5%). ‘Fears about the cancer spreading’ was
the most prevalent unmet SCN (84%). Unmet SCNs experienced
by 65% or more of patients related to lack of control about
treatment outcomes, the uncertain future, and concerns about
family members well-being. The most severe CRC-specific
concerns were related to body appearance and bowel control.
About 55% of participants had visited the emergency department
and less than 12% used existing supportive care services.
CONCLUSION: Prevalent and priority unmet needs were related
to psychosocial support and information. Recommendations for
designing colon cancer-specific services are provided along with
strategies to improve patient use of existing resources. Factors
associated with healthcare use and costs will be reported.
103
VIII-04-C 4:00 PM - 4:30 PM
VIII-05-B 3:45 PM - 4:30 PM
Exploring the Relationship Between
Social Determinants of Health and
Symptom Burden in Cancer Populations:
Perspectives of Cancer Care Practitioners
Anna Santos Salas, PhD, RN, University of Alberta,
BACKGROUND: In cancer care, disparities are a rising concern
that affects Canadians from low socio-economic status, rural
and remote areas, and ethnic minorities. Disparities in pain and
symptom relief in specific cancer populations exist although this
knowledge is limited in Canada.
PURPOSE: To present preliminary results of a qualitative study
underway with an interdisciplinary pain and symptom control
team at a cancer institution. The study explores practitioners’
perspectives of social disparity and symptom burden in cancer
populations. A related aim is to identify practice strategies to
enhance symptom relief. This study builds on a qualitative study
near completion that explored palliative care practitioners’
perspectives concerning symptom complexity. A systematic
review and meta-analysis recently completed of the effect of
cancer pain interventions in populations with social disparities
also informs the study.
METHODS: A combination of both interpretive inquiry and
critical theory. A sample size of approximately 10 practitioners is
anticipated. Van Manen’s thematic analysis and Freire’s critical
reflection are followed in the analysis.
Poster presentations / Séance d’affichage
Research activities: in-depth interviews and follow up
conversations. Participants share their practice knowledge of how
conditions of daily living relate to complex symptom experiences.
They also discuss strategies to enhance symptom relief.
Research findings: To date, four cancer care practitioners have
participated in the study. Data analysis is underway. Research
data reveals participants’ comprehensive understanding
of symptom complexity in cancer populations and points
to a number of strategies to enhance symptom relief. A
compassionate approach to support individuals to the best of
their ability is reflected in participants’ stories.
CONCLUSION: This research study advances a critical
understanding of symptom burden in cancer populations and
outlines clinical strategies to further support vulnerable groups.
Poster
Presentations
Séance d’affichage
Sponsored by / Sponsorisées par:
Group 1 / Groupe 1
Monday, October 5 / Lundi 5 octobre
10:00 AM – 10:30 AM | Foyer
P-01 | Nicole Allard, PhD, MSc
Vers une utilisation des données probantes :
problèmes rencontrés et suggestions proposées
P-02 | Matthew Barlow, BScN, BSc2
Barriers and Facilitators to Enrolling Patients in
an Educational Program as Experienced Amongst
Healthcare Professionals Working with Outpatients
at a Local Tertiary Hospital
P-03 | Debbie Lawrie, RN, BScN, CON(C)
Improving Assessments and Interventions for Seniors
with Cancer: A Late Career Initiative Project
P-04 | Colleen P. Campbell, NP-PHC, MN, CON(C)
Improving Patient Safety and Confidence with Oral
Cancer Therapy Utilizing a Nurse Navigator-Led,,
Patient-Centred Education Program
P-05 | Colleen J. Colville, BScN, RN
Skin Care During Radiation Therapy: Maritime
Multidisciplinary Consensus... A Canadian First!
P-06 | Janelle L. Desjardins, BScN, MScN
Maintaining the Nurse-Client Therapeutic
Relationship When Using Technology at the Point
of Care in the Chemotherapy Treatment Unit
104
P-07 | Margaret F. Forbes, RN(EC), MN, CON(C)
One-Stop Comprehensive Lymphedema
Assessment and Treatment Planning
Group 2 / Groupe 2
Monday, October 5 / Lundi 5 octobre
2:45 PM - 3:15 PM | Foyer
P-08 | Marie-Laurence Fortin, MScN, CHPCN(C)
Soulager la souffrance en fin de vie : diffusion de
l’expertise au-delà des milieux de soins palliatifs
P-09 | Jessica Holmes, BScN, CON(C)
Pain Diaries: Do Patients Use Them and Are They
Helpful?
Group 3 / Groupe 3
Tuesday, October 6 / Mardi 6 octobre
10:00 AM – 10:30 AM | Foyer
P-15 | Roger M. Lyons, MD
Relationship Between Chelation and Clinical
Outcomes in Lower-Risk Patients with
Myelodysplastic Syndrome (MDS): Registry
Analysis at Five Years
P-16 | Isabella Petti, BScN, RN, CON(C),
Ruth Jenkins, RN, CON(C)
Acute Myeloid Leukemia Consolidation Therapy:
Nurses Championing Outpatient Care
P-17 | Tracy L. Powell, BScN, RN, MN
Developing a Community of Practice for Student
Nurses Interested in Oncology
P-10 | Emilie Hudson, RN
Piloting a Nurse-Led Cancer Survivorship
Educational Session
P-18 | Corrin N. Primeau, BA, BScN
A Pledge of Safety
Orientation Programs: Retaining and Easing the
Transition into the Practice of Oncology Nursing
P-12 | Olga Levina, BScN, CON(C), CHPCN(C),
Stephanie Chadwick, BScN, CETN(C), MCIScWHCNS, Diana Arones, RN
Providing Holistic Cutaneous Management
Alternatives for Amyloidosis Patients
P-13 | Aisha Winn, RN, Mary Ann Gamboa,
RN, Mary-Jo Rhodes, RN, Harmeet Sidhu, RN,
Nithu Thonichalil, RN, BScN, Sharon Greene,
RN, BScN
Oncology Nurses with a Passion for Improving
Inpatient Skin Assessments
P-14 | Melissa L. Lot, BScN, CON(C)
P-19 | Sahaana Rangarajan, BSc
Understanding the Experience of Individuals Who
Attend a Breathing Wellness Program to Address
Dyspnea
P-20 | Cherie C. Severson, RN, MN, CON(C),
BMTCN
Promoting Professional Development Through the
Initiation of a Hematology/BMT Special Interest
Group
P-21 | Cherie C. Severson, RN, MN, CON(C),
BMTCN
The Role of Biosimilar GC SF (Zarzio) for Progenitor
Cell Mobilization and the Treatment of Therapy
Induced Neutropenia in a Hematopoietic Stem Cell
Transplant Setting
Increasing Patient Safety: A Chemotherapy Quality
Improvement Project
105
P-11 | Marilyn L. Landry, BA, BN, MEd, BEd, RN
Group 4 / Groupe 4
Tuesday, October 6 / Mardi 6 octobre
3:00 PM - 3:30 PM | Foyer
P-22 | Jennifer M. Smylie, BN, RN, MHSM
Passion Leads to Innovation, People Sustain
Change: Rapid Access Diagnostic and Support for
Women Undergoing Assessment for Breast Cancer
P-23 | Dawn Stacey, RN, PhD, CON(C)
Implementation of Guideline-Informed Telephone
Support Protocols for Managing Cancer TreatmentRelated Symptoms: The COSTaRS Mixed Methods
Study
P-24 | Ethlyn Ferdinand, RN
Addressing Lymphoma and Multiple Myeloma
Patient Concerns by Telephone Triage in an
Outpatient Setting
P-25 | Roanne Thomas, PhD
Transitions to Breast Cancer Survivorship:
Generating Knowledge and Support Via Reflective
Writing
P-26 | Theresa Whiteside, BN,
Gisele Sarbacher, BN
Outpatient Administration of Dose- Adjusted
R-EPOCH (DA-R-EPOCH) for Aggressive Lymphomas
P-27 | Stacey Wu, BSN
Compassion Fatigue, Burnout, and Compassion
Satisfaction Among Oncology Nurses within an
International Setting
Monday, October 5/
Lundi 5 octobre
10:00 AM – 10:30 AM | Foyer
Group 1 / Groupe 1
P-01
Vers une utilisation des données
probantes : problèmes rencontrés et
suggestions proposées
Nicole Allard, PhD, MSc, UQAR campus de Lévis, Lévis,
Quebec, Canada.
La récente préoccupation des milieux cliniques à utiliser
des pratiques exemplaires issues de données probantes est
grandissante. Nous voyons apparaître différentes formations
et ressources pouvant être utilisées par les infirmières en
oncologie. Cette étude met en relief, à l’aide d’un devis à
séries temporelles, qu’après une intervention sous forme
d’une présentation formelle PowerPoint et de cartables
distribués aux infirmières sur les données probantes,
l’utilisation véritable des données probantes dans la pratique
est inchangée. Il en ressort que très peu d’infirmières s’y
intéressent et que celles qui les utilisent sont celles qui le font
dans le cadre de leurs fonctions (cadre conseil, cliniciennes).
Des recommandations pour la pratique, la formation et la
recherche sont suggérées.
P-02
Barriers and Facilitators to Enrolling
Patients in an Educational Program
as Experienced Amongst Healthcare
Professionals Working with Outpatients
at a Local Tertiary Hospital
Matthew Barlow, BScN, BSc2, Cathy Kitelely, RN,
MSc, CHPCN(C), CON(C)1, 1Trillium Health Partners,
Mississauga, Ontario, Canada, 2University of Toronto,
Mississauga, Ontario, Canada.
BACKGROUND: Breathlessness is a common symptom
associated with lung cancer and other advanced cancers
and if left unmanaged, has significant impact on quality
of life. There is good evidence that non-pharmacological
interventions should be utilized to help patients manage
and cope with the symptom. Despite this evidence, patient
enrollment to our patient educational program to teach these
strategies remains modest.
106
METHODS: Data collection will occur through the analysis of
two focus group sessions with clinicians who are able to refer
patients to the educational program.
RESULTS: Using thematic analysis, we hope to learn about
factors which may enable or impede the ability of clinicians
to refer patients to educational programs which teach nonpharmacological symptom management strategies.
FUTURE DIRECTIONS: Results from data analysis will be used
to suggest improvements in the referral process for a breathing
wellness program at a local tertiary hospital. Through improving
the referral process, attendance to the educational program may
be increased and a higher number of patients may benefit from
learning about non-pharmacologic strategies for the management
of their dyspnea.
P-03
Improving Assessments and Interventions
for Seniors with Cancer: A Late Career
Initiative Project
Debbie Lawrie, RN, BScN, CON(C), Eirena N.
Calabrese, RN, BScN, MN, Sunnybrook Health Sciences
In North America, the majority of people who are diagnosed
with cancer are aged 65 and older. This cancer diagnosis is
complicated by the various co-morbidities and psychosocial
issues that present during the aging process. Geriatric
oncology nursing is a specialized area that requires unique
knowledge and assessment skills to facilitate excellent care.
Currently at a large cancer centre in Toronto, there are no
geriatric specific resource tools or education available to
patients or staff. Although recently a fall risk and frailty
assessment were implemented, there is a lack of focused
resources available to address specific concerns. A late
career initiative application was submitted and accepted by
the Ministry of Health and Long Term Care to address some
of these needs. The goal of this initiative was to increase
and promote the identification of high-needs seniors within
the oncology population, increase targeted resources, and
facilitate access to community resources. An education
series about the specific and unique needs of the geriatric
oncology population was developed and presented and
education sessions for the nursing team. A survey assisted
in the development of this education session, and pre and
post quizzes were administered. Education resources for the
patient were developed with members of the interprofessional
team, including pharmacists and the occupational therapist.
These resources were implemented centre wide with feedback
from members of the interprofessional team and patients.
By utilizing an interprofessional approach to developing and
implementing education materials and increasing awareness
and knowledge of the nursing team, patients over the age of
65 are able to be appropriately assessed and be provided with
appropriate interventions.
P-04
Improving Patient Safety and
Confidence with Oral Cancer Therapy
Utilizing a Nurse Navigator Led,
Patient-Centred Education Program
Colleen P. Campbell, NP-PHC, MN, CON(C), Mary
Gorr, RN, CON(C), Patricia MacIsaac, RN, CON(C), Karen
Robins, RN, Ann Agar, RN, CON(C), Simcoe Muskoka
Regional Cancer Program, Barrie, Ontario, Canada.
Oral cancer therapy continues to challenge historical
practices within cancer programs. Health care providers have
little control over individual adherence and safety issues
met by patients and their caregivers outside the cancer
clinic. Infusional chemotherapy classes address symptoms
of pancytopenia that may have no relevance to patient’s
receiving targeted oral anticancer agents. Patients need
appropriate information related to their specific treatment and
reliable contact information for potential issues.
The aim of our quality improvement project was to
demonstrate that a specialized oncology Registered Nurse
oral therapy navigator can improve patient knowledge and
satisfaction through individualized classes utilizing adult
education principles and evidence based tools.
Education classes modified to each oral agent have been
developed. Evidence based tools such as MOATT (MASCC Oral
Agent Teaching Tool), symptom diaries, CCO monographs and
drug specific teaching kits when available, are used. Adult
education principles modified for psychosocial and physical
limitations are utilized.
Indicators of success included; improved patient knowledge
regarding possible adverse effects of treatment, medication
safety, and available supports. Data was collected utilizing
a pre-post questionnaire at the education session. Patient
satisfaction was measured utilizing a questionnaire following
three months of therapy. The education class is part of a
larger nurse navigator initiative for patients receiving oral
cancer therapy that has demonstrated fewer reported adverse
effects, improved documented adherence and improved
patient/provider satisfaction.
107
OBJECTIVE: To explore barriers and facilitators experienced by
clinicians when referring outpatients to an educational program
which teaches strategies for the self-management of dyspnea.
Systems impacted include patient wellbeing, patient safety
and provider satisfaction. We conclude that a dedicated
oncology certified oral cancer therapy nurse navigator
providing passionate, purposeful education improves patient
knowledge and satisfaction.
P-05
Skin Care During Radiation Therapy:
Maritime Multidisciplinary Consensus...
A Canadian First!
Colleen J. Colville, BScN, RN1,2,3,4, 1Nova Scotia Cancer
Centre, Halifax, Nova Scotia, Canada, 2Mount Saint
Vincent University, Halifax, Nova Scotia, Canada, 3Cancer
Care Nova Scotia, Halifax, Nova Scotia, Canada, 4Capital
Health, Halifax, Nova Scotia, Canada.
Radiodermatitis (skin change related to Radiation treatment)
is a known potential toxicity of external beam radiotherapy.
Ninety five percent of patients experience some degree of
skin alteration, ranging from erythema, pruitis, dry or moist
desquamation, to ulceration. Consequently impacting self
care activities, quality of life and potentially have a dose
limiting impact.
Canada’s Maritime provinces have five radiation treatment
centres. Historically, significant variation in skin care
teaching and practice occurred between these sites, even
within individual clinics. Some practices were not always
evidence informed. As a result, patients received inconsistent
information about caring for their skin depending on the
centre they received treatment, or the individual preferences
of the treating Radiation Oncologist. Confusion for patients
and risk for greater skin toxicities resulted.
Individually, some centres began to review information
they provided patients and started work to standardize
practice within their institutions. Professional passion and
resourcefulness rapidly transformed what began as isolated
centres working independently; to a multidisciplinary,
collaborative, inter-provincial working group seeking to
standardize patient education, and advance clinical practice
for the entire Maritime region.
Using the MASSC (2013) guidelines as reference, one patient
education booklet, “Skin care during Radiation Therapy” was
developed for use by all five cancer centers within the three
provinces; a Canadian first!
This clinical poster presents highlights of the evidenceinformed patient guide, clinician feedback received
throughout it’s development, and practice changes resulting
from the work.
108
P-06
Maintaining the Nurse-Client
Therapeutic Relationship When Using
Technology at the Point of Care in the
Chemotherapy Treatment Unit
Janelle L. Desjardins, BScN, MScN, The Ottawa
GOAL: This poster’s aim is to increase awareness on how the
use of technology at the point of care in the chemotherapy
treatment unit can have negative impacts on the development
of the nurse-client therapeutic relationship. Practical
strategies that oncology nurses can use to limit these possible
negative impacts will also be discussed.
SUMMARY: Technology use at the point of care continues
to increase with the advances in scientific and technical
knowledge. Various forms of technology are used on a daily
basis in the chemotherapy treatment unit by specialized
oncology nurses including (but not limited to) the use of
infusion pumps, vital sign machines, electronic documentation
tools and mobile devices. The literature shows however
that using technology at the point of care can have negative
impacts on the nurse-client therapeutic relationship as it
changes the communication and interaction patterns between
the nurse and the patient. The information provided in this poster
is based on an educational intervention that was completed
with specialized oncology nurses working in the Chemotherapy
Treatment Unit at The Ottawa Hospital Cancer Centre to increase
their awareness of these possible negative impacts and to provide
practical strategies to minimize these negative impacts on the
development of the nurse-client therapeutic relationship. The
College of Nurses of Ontario’s Practice Standard on the Therapeutic
Nurse-Client Relationship served as the framework to identify how
each element of the nurse-client therapeutic relationship can be
negatively impacted by the use of technology at the point of care.
P-07
One-Stop Comprehensive Lymphedema
Assessment and Treatment Planning
Margaret F. Forbes, RN(EC), MN, CON(C), Kathy
Coskey, RN, BSN, CON(C), Hamilton Health Sciences,
Lymphedema after lymph node surgery or radiation for cancer
treatment is common. To address this a NP at the Juravinski
Cancer Centre developed a clinic to assess, diagnose and
develop a treatment plan for cancer related lymphedema.
Monday, October 5/
Lundi 5 octobre
2:45 PM - 3:15 PM | Foyer
Group 2 / Groupe 2
P-08
Soulager la souffrance en fin de vie :
diffusion de l’expertise au-delà des
milieux de soins palliatifs
Marie-Laurence Fortin, MScN, CHPCN(C), Kim Sadler,
BSc Inf., Hôpital Général Juif, Montréal, Quebec, Canada.
Au Québec, la très grande majorité des patients meurent sur des
unités à visée curative, où les infirmières n’ont généralement
pas reçu de formation spécifique sur les soins de fin de vie, n’ont
pas de lignes directrices quand aux pratiques recommandées
et recoivent très peu de soutien (Fillion et al. 2011; Fillion et al.
2005 ; Fortin et Bouchard, 2009; Lambert et Lecompte, 2002).
Dans notre hôpital, nous avons élaboré un projet visant à
développer la formation infirmière en soins palliatifs. Ce projet
a reçu le 1er prix du Conseil des Infirmières et Infirmiers de
l’hôpital – Nursing Innovation Award 2012. Le projet consiste
en de courtes sessions de formation, d’environ 30 minutes,
portant sur différents thèmes liés aux soins palliatifs. Depuis
le début du projet, 163 infirmières travaillant sur des quarts de
jour, de soir et de nuit ont reçu la première session de formation
portant sur le soulagement de la douleur. Nos résultats
préliminaires nous montrent que ces sessions de formation
améliorent les connaissances des infirmières. Le récent rapport
du sénat du Canada (2010) sur la situation des soins palliatifs
souligne le besoin urgent de mobiliser le leadership de tous
les professionnels de la santé, de tous les milieux et de tous
les niveaux, afin d’assurer à la population canadienne l’accès à
des soins palliatifs de qualité. Nous pensons que notre projet
s’inscrit dans cette mission, et pourrait avoir un impact positif
s’il était implanté dans d’autres centres hospitaliers.
P-09
Pain Diaries: Do Patients Use Them and
Are They Helpful?
Jessica Holmes, BScN, CON(C)1, Kristy Dillon, BScN,
CON(C), CHPCN(C)1, Ingrid Harle, MD, FRCS(C), CCFP, FCFP,
ABHPM (cert)1,2, Janet Cory, RN, CHPCN(C)1, 1Kingston
General Hospital, Kingston, Ontario, Canada, 2Queen’s
University, Kingston, Ontario, Canada.
An interprofessional team at the Cancer Centre of
Southeastern Ontario developed a series of pain diaries to
improve education and communication between patients
(including family members and caregivers) and the health care
team. These diaries were piloted with patients consulted in
the ambulatory palliative care clinic. Normally, our palliative
care providers encourage patients and families to journal pain
medication usage as well as pain levels using the Edmonton
Symptom Assessment Tool (ESAS). Prior to this initiative,
our centre did not have standardized tools to guide this
information collection. Each patient tracked their medication
usage using their own method. The pain diaries created
were piloted on 32 patients. Each patient was given verbal
education on the diary by their palliative care nurse or doctor.
At the follow-up appointment, the patient could voluntarily
participate in a survey to evaluate whether the pain diary was
a) used and b) perceived as helpful, as well as provide helpful
feedback. 18 patients completed the survey. 83% of patients
used their pain diary. 92% of patients surveyed agreed or
strongly agreed that their pain diary was helpful. Anecdotal
feedback from patients included positive comments, such as
“the diaries helped us stay on track”. Recommendations for
improvements mentioned better space for notes and inclusion
of a reminder system. Anecdotal feedback from palliative
care providers included completed diaries provided a more
efficient and standardized way of assessing patients’ pain
management at home. This initiative aligns with CANO’s 2015
theme because this interprofessional group recognized a need
and drove it with a passion for improving communication with
patients in order to improve symptom management.
109
To enhance the services provided, a nurse and advanced
certified fitter were added to the team. After a comprehensive
consult, a treatment plan is devised. Patients who require
manual lymphatic drainage therapy are resourced closer
to their homes. The clinic sees between 3-5 new patients
and 12-15 follow-up patients per week. Patients commonly
have limb but may have truncal or breast lymphedema. The
NP, RN and advanced certifed fitter collaborate to develop
a treatment plan. Patients are provided with lymphedema
related education pamphlets and a individualized treatment
plan that incorporates skin care principles, exercise,
health body weight, some form of compression with or
without manual lymphatic drainage therapy. Patients are
followed on a 4-monthly basis until they are self-managing
their lymphedema and accessing lymphedema resources
independently. Within this model collaboration with
lymphedema therapists and other lymphedema related
health care providers in the surrounding communities within
our catchment area have been established and fostered.
Expansion of this model is aimed at the prevention aspect of
lymphedema. A lymphedema teaching class will be offered to
patients who are at the start of their cancer journey so they
can begin to engage in risk reduction strategies.
P-10
P-11
Piloting a Nurse-Led Cancer
Survivorship Educational Session
Orientation Programs: Retaining and
Easing the Transition into the P ractice
of Oncology Nursing
Emilie Hudson, RN1, Kristin Hendricks, MPH, BScN1,
Andreanne Robitaille, MSN, BSc Inf.2, Olivia Yu, BA, MA2,
Genevieve Chaput, MA, MD, BA2, 1McGill University, Montreal,
Quebec, Canada, 2MUHC, Montreal, Quebec, Canada.
CONTEXT: There are currently over 1 million cancer survivors
(CS) in Canada. Unfortunately, 1 in 2 CS experiences late
effects after treatment is over. An MUHC team conducted a
needs assessment of family physicians (FP), and identified
the need to improve communication with specialists and
to educate FP about survivorship (SP) issues. In turn, an
education session (FP ES) targeted at FPs was developed
to increase their SP knowledge. This intervention supports
current literature, which suggests that FP benefit from
increased SP education.
FPs and nurses collaborate in CS’s care, and numerous studies
validate the importance of the nurse’s role in SP care. Nurseled knowledge translation methods have been identified in SP,
but must be adapted to Canadian healthcare. To address this,
a nurse-led pilot ES containing common SP issues has been
created and will be delivered to patients upon completion
of treatment. This ED was designed based on the FP ES,
which reflects current guidelines and has received MAINPRO
accreditation.
METHODS: The ES will be delivered to CS within 4-6 weeks of
treatment completion, and is anticipated to begin in Spring
2015. It will be given bi-monthly for 6 consecutive months.
Outcome measures include assessment of CS satisfaction, SP
knowledge, and readiness to participate in their SP care. Preand post-tests will be completed by CS at the ES to assess
knowledge and satisfaction. The PAM, a validated tool used
to evaluate one’s ability to take charge of their own health
will be utilized to assess CS readiness to participate SP care.
Sample size has been set at 90. Inclusion criteria will consist
of any CS who has finished treatment at the MUHC. Ethics
approval has already been submitted for this pilot.
CONCLUSION: This intervention aims to improve the transition
of care of CS by empowering them through enhancing their
knowledge of SP issues. This nurse-led ES will further explore
the ever-growing benefits of nurses in SP care.
Marilyn L. Landry, BA, BN, MEd, BEd, RN, Queen Elizabeth
Health Sciences Centre, Halifax, Nova Scotia, Canada.
In 2012 the Cancer Program in Halifax initiated a project to
consolidate solid tumour and hematology systemic cancer
treatment areas. One goal is to develop orientation programs for
staff. This includes new graduate nurses and registered nurses
with none or limited oncology experience. The focus is to seek
best practice for retaining and easing the transition into the
practice of oncology nursing.
Interviews were conducted with nurses working 2 years or less
to record and validate their experiences. For nurses working
more than 2 years interviews took place to discuss their role as
an experienced nurse in the orientation of new staff and what
supports they require to fulfill this role. The data collected is
setting the foundation for developing an orientation program
for our Systemic Therapy Unit. We have discovered asking
oncology nurses, opens the door to significant information to
move forward in our goal. We are learning to ask and listen, to
validate experiences, to collect qualitative data, to enrich our
understanding of the current orientation, to focus on what works
well and what does not, to recognize one size does not fit all and
to move forward in develop successful orientation experiences.
Our experiences will be shared during the presentation. These
steps can be used by facilities seeking to improve orientation
programs to increase retention, and maintain competent oncology
nursing staff crucial to quality patient care.
P-12
Providing Holistic Cutaneous
Management Alternatives for
Amyloidosis Patients
Olga Levina, BScN, CON(C), CHPCN(C)1, Stephanie
Chadwick, BScN, CETN(C), MCISc-WHCNS2, Diana Arones,
RN1, 1Princess Margaret Cancer Centre, Toronto, Ontario,
Canada, 2University Health Network, Toronto, Ontario, Canada.
Amyloidosis is characterized by deposition of insoluble fibroid
amyloid protein in extracellular spaces of any tissue causing
impaired organ functioning (Cannon, Pullen, Rushing, 2004;
Nisbit et al, 2005). While this disease most frequently affects the
heart, kidneys, gastrointestinal tract, skin involvement remains
one of the most characteristic manifestations and accounts for
approximately 50% of all cases.
110
Improving quality of care for individuals that have cutaneous
manifestations of amyloidosis is a quality initiative that requires
investigation. Topical(s); such as, glucocorticoids and urea cream
(Hung et al., 2003) have been recommended in the past; however,
we need to determine what other measures may be utilized to
improve care.
It is important for the oncology nurse to assess and identify
when skin integrity is compromised, and be able to provide
patient and his/her family with recommendations for suitable
skin care. Patient education and ability to listen to patient’s
concerns are driven by nursing passion to provide best care.
Based on anecdotal experiences for treating amyloidosis patients
at Princess Margaret Cancer Centre some recommendations are
offered to promote skin integrity; however, gaps in evidence based
literature are unmet.
Oncology nurses play an important role in assisting patients
in guidance for holistic skin care. Our goal is to search data
bases to formulate improved quality initiatives to endorse skin
improvements for the amyloidosis patient.
P-13
Oncology Nurses with a P assion for
Improving Inpatient Skin Assessments
Aisha Winn, RN, Mary Ann Gamboa, RN, Mary-Jo
Rhodes, RN, Harmeet Sidhu, RN, Nithu Thonichalil, RN,
BScN, Sharon Greene, RN, BScN, Sunnybrook Health
Science Centre, Toronto, Ontario, Canada.
The Oncology Inpatient setting population have many comorbidities. At our teaching hospital the Inpatient oncology
nurses felt that the completion of the Braden Skin Assessment
Tool within the first 12 hours of the patient being admitted to
the unit would be an important thing to do. These patients
are at a higher risk for developing pressure ulcers because of
their changing nutritional requirements often as a result of the
treatment that they are receiving (chemotherapy, radiation, and
surgery). Their cognitive abilities and past experience we have
found to be a common challenge. We worked with our nursing
colleagues to ensure that the wounds or potential for wounds
were identified and steps put in place to minimize the risk for the
patient. Stage 2 pressure ulcers are a concern for the oncology
patient. Assessing the patient and ensuring that they are on an
appropriate bed surface is important. Identifying what the goals of
care for the wound are based on the goals of care for the patient
is crucial too. Identifying chronic wounds to new wounds from
positioning during the OR time, post surgical and wounds on
palliative patients is important. When we gave this challenge to
our colleague’s we found a decrease of pressure ulcer incidents
with our evidence collection through chart audits. We found
through education, encouragement positive reinforcement (i.e.
monthly update graphs showing each unit improvement) we have
been able to continue with our progress in promoting skin integrity
and a reduction in complicated pressure ulcers.
P-14
Increasing Patient Safety: A Chemotherapy
Quality Improvement Project
Melissa L. Lot, BScN, CON(C), Windsor Regional
Hospital, Windsor, Ontario, Canada.
The Chemotherapy Quality Improvement Project arose from a
chemotherapy incident which identified gaps in care and patient
safety concerns. A mapping process was completed, which
identified potential process improvements. Of the identified
improvements, 6 priority projects were identified. A team was
formed to develop and implement these priorities.
It was identified that there was limited access to the patient’s
record for all healthcare providers that were involved in the
patient’s journey. With access being provided, team members are
able to have a complete picture of the plan of care for the patient.
For chemotherapy administration, a checklist was implemented
for all first-time chemotherapy treatments or when a regimen
is changed due to a change in patient condition or disease
progression. This checklist is utilized by an RN one day prior to
treatment and is then double checked by the patient’s RN on the
day of treatment. CPOE generated chemotherapy orders were also
evaluated and additional documentation fields were added to
increase patient safety and provided traceable data.
Starting with the breast disease site, guidelines were developed,
which outline the minimum diagnostic testing to be completed
for all breast cancer patients undergoing active treatment with
a Systemic Funding Treatment Model (STFM) chemotherapy
regimen, outlined by Cancer Care Ontario (CCO). The results
of these tests will be reviewed by the ordering physician,
pharmacists and nurses prior to chemotherapy as part of the
double check process. This ensures that all patients receive the
minimum clinical monitoring that is required for their specific
chemotherapy regimen, therefore, increasing patient safety and
improving patient outcomes. The goal is to have standardized,
minimum clinical monitoring guidelines for each disease site.
Finally, the Patient Navigation Tool was developed to provide the
patient with the information they need to flow easily through the
treatment journey.
111
Cutaneous manifestations of this disease present as dryness
with waxy thickening and fragility; ecchymosis, periorbital and
facial purpura, skin papules and plaque, and severe pruritis
(Gorevic, 2014). Currently treatment of cutaneous manifestations
are limited; therefore, causing poor quality of life for individuals.
Management of the skin locally lacks scientific evidence based
support leaving clinicians and the individual to trial comfort
measures to manage cutaneous issues.
Tuesday, October 6/
Mardi 6 octobre
10:00 AM – 10:30 AM | Foyer
Group 3 / Groupe 3
P-15
Relationship Between Chelation
and Clinical Outcomes in LowerRisk Patients with Myelodysplastic
Syndrome (MDS): Registry Analysis at
Five Years
Roger M. Lyons, MD1,2, Billie J. Marek, MD2,3, Carole
Paley, MD4, Jason Esposito, MHS4, Katie McNamara, MHS,
CCRA4, Lawrence Garbo, MD2,5, Nicholas DiBella, MD2,6,
Guillermo Garcia-Manero, MD7,1Cancer Care Centers of
South Texas/US Oncology, San Antonio, Texas, United
States, 2The US Oncology Network, The Woodlands, Texas,
United States, 3Texas Oncology-South Texas Cancer Center,
McAllen, Texas, United States, 4Novartis Pharmaceuticals
Corporation, East Hanover, New Jersey, United States, 5New
York Oncology Hematology, Albany, New York, United States,
6Rocky Mountain Cancer Centers, Aurora, Colorado, United
States, 7The University of Texas, MD Anderson Cancer Center,
Houston, Texas, United States.
INTRODUCTION: We prospectively collected data from lowerrisk patients with MDS in an ongoing US registry to assess the
association between chelation and clinical outcomes, including
overall survival (OS), and report outcomes at 5 years.
were significantly greater in chelated versus nonchelated patients
(P<0.0001 for both). Patients with ≥6 months of chelation had
fewer deaths and longer OS, time to death, and time to AML
transformation versus nonchelated patients.
CONCLUSIONS: After 5 years of follow-up, iron chelation
therapy appears to be associated with improved OS and
longer time to AML transformation in lower-risk patients with
MDS. Causation has not been established. Limitations include
variation in time from diagnosis, duration of chelation, impact
of patient clinical status on decision to chelate, and optional
conduct of clinical assessments.
P-16
Acute Myeloid Leukemia Consolidation
Therapy: Nurses Championing
Outpatient Care
Isabella Petti, BScN, RN, CON(C), Ruth Jenkins,
RN, CON(C), Shannon Nixon, MN, RN, Cindy Murray,
MN, NP, Mary C. Doherty, MN, NP-PHC, Princess Margaret
Cancer Centre, Toronto, Ontario, Canada.
Patients diagnosed with acute myeloid leukemia (AML) have
traditionally received high-intensity consolidation chemotherapy
as an inpatient. The shift to outpatient management is increasingly
becoming more common due to health care costs, resource
utilization, and consideration of patient quality of life. Our centre
has been supporting over 200 patients yearly with outpatient
consolidation chemotherapy in a nurse practitioner-led clinic for
over 15 years.
There is a great amount of planning necessary in order
to successfully and safely treat patients from the start of
chemotherapy administration, through their nadir until
blood count recovery. Nurse practitioners and registered
METHODS: 600 adult patients with transfusional iron overload
nurses work together alongside a multidisciplinary team
from 107 US centers were enrolled. Patients were analyzed by
including physicians, social workers, pharmacists, home
iron chelation status: chelated or never chelated; a subgroup
care case managers, and spiritual care providers. Expert
of chelated patients had ≥6 months of chelation. Patients were
nursing care and patient education is provided for the
evaluated every 6 months for 5 years or until death for survival,
transfusion of blood products, central venous catheter care,
disease status, comorbidities, cause of death, and MDS therapy.
medication management, preventative oral care, bowel
RESULTS: Chelated patients (n=271) had a greater median number regimens, and the use of ambulatory infusion pumps. Unit
of lifetime units transfused at enrollment versus nonchelated
developed educational handouts are provided and include
patients (n=328): 38.5 vs 20.0. At baseline, cardiac and vascular
a communication tool for potential community emergency
comorbidity rates were significantly higher in nonchelated versus
department visits. Urgent care issues such as febrile
chelated patients (52.4% vs 34.3%, P<0.0001; 59.8% vs 48.0%,
neutropenia are often treated in the ambulatory setting.
P=0.0039, respectively). As of May 1, 2014, 538 patients had
We are passionate about supporting patients to stay in
discontinued (400 died, 66 lost to follow-up, 46 completed study,
the comfort of their homes while undergoing intensive
and 26 discontinued for other reasons). Of the 271 chelated
treatments. Our poster will highlight the specialized nursing
patients, 187 were chelated with deferasirox, 40 with deferasirox
care provided for outpatient management of consolidation
and deferoxamine, 32 with deferoxamine alone, and 1 with EDTA;
therapy for patients diagnosed with AML.
in 11 patients, the name of the chelator was not provided. OS
from diagnosis of MDS and time to acute myeloid leukemia (AML)
112
Developing a Community of Practice for
Student Nurses Interested in Oncology
Tracy L. Powell, BScN, RN, MN, Mount Royal
University, Calgary, Alberta, Canada.
Following consultation with the local Canadian Association of
Nurses in Oncology (CANO) chapter and practicing oncology
nurses at the local cancer centre, Students Interested in
Oncology Nursing (SION) was developed in collaboration with
a 4th year nursing student and a faculty member as part of
a leadership project in a Bachelor of Nursing (BN) program
at a western Canada university. As the BN curriculum had a
broad focus on oncology and cancer care, it was identified
that there was a need for nursing students to have access to
more specialized knowledge and information related to this
area of practice. SION was developed to provide students with
an opportunity to further explore their interest in oncology
that may have occurred as a result of life experience, through
exposure to cancer care during clinical placements, and from
mentorship opportunities while in undergraduate studies. As
a result of this awareness, the only criteria established for
joining SION was a genuine interest and passion in oncology
and cancer care.
SION focuses on the students’ interest as a way to connect
with and foster their desire for additional learning. Since SION
launched in the spring of 2013, it has continued to grow in its
membership. The facilitators of SION believe that one of the
reasons for SION’s continued appeal with students has been
a result of the use of innovative strategies for knowledge
transfer and information dissemination including an annual,
joint education session with the local CANO chapter.
The implications for this initiative on nursing practice are
only beginning to be explored but include mentorship and
modeling of the role of oncology nurses, as well as fostering
both new and continuous learning in oncology. Moreover, it
is hoped that student members continue to connect with the
area of oncology both while in their novice role and after they
graduate and become leaders in the nursing profession.
In an effort to maximize patient engagement, improve quality of
care, reduce adverse events and create a culture of accountability,
a safety pledge was created based on core corporate indicators/
expectations and centered on patient safety. It was piloted on a 28
bed inpatient oncology/medicine unit. The pledge addresses fall
safety, hand hygiene practices, medication administration safety
and safe practices for infection control. At the beginning of every
shift nurses pledge safe practices to their patients and/or families
and encourage patients to remind them if they have forgotten,
making them active participants in safe care. This same pledge, in
poster format, is prominently hung at the foot of every patient’s
bed as a constant reminder that patient safety is our number one
priority. Additionally, the nurse’s picture is affixed to the poster to
support familiarity of the nurse for the patients and or their families.
Daily leadership rounding by the clinical practice educator and
the program manager ensures staff compliance and patient/
family engagement. Rounding includes interacting with patients
and families with the purpose of establishing confirmation and
understanding of the pledge. In addition, an environmental scan
is conducted to ensure a safe surrounding. Patient participation
in safe practices is reinforced by management, strengthening the
idea that patients are equal partners in creating a culture of safe
patient care.
P-19
Ontario, Canada, 2Trillium Health Partners, Mississauga ,
Ontario, Canada.
BACKGROUND: Dyspnea is defined as a subjective experience
of breathing distress and is derived from interactions among
multiple factors. Current literature suggests that educating
affected individuals about breathing management strategies
can lead to significant improvements in their ability to cope
with dyspnea related symptoms.
OBJECTIVE: To elucidate and understand patient experience
on managing shortness of breath 1 month after attending a
P-18
A Pledge of Safety
Corrin N. Primeau, BA, BScN, Colette Clarke, RN, MScN,
Windsor Regional Hospital, Windsor, Ontario, Canada.
If we assume that nurses are ethical beings, whose practices are
driven by altruistic motives, then one can assume that a nurse’s
promise or pledge to provide a certain level of care to their
patients brings with it a high likelihood of compliance.
METHODS: Data collection will be accomplished through
semi-structured interviews with individuals who have
attended a breathing wellness program.
RESULTS: Through thematic analysis we hope to learn more
about how individuals are coping with dyspnea and what
strategies they continue to use on a daily basis.
113
P-17
FUTURE DIRECTIONS: Following data analysis results will
be used towards improving a breathing wellness program
at a local tertiary hospital. By incorporating current patient
feedback the program can be modified to help future
patients more effectively achieve dyspnea relief.
P-20
Promoting Professional Development
Through the Initiation of a Hematology/
BMT Special Interest Group
Cherie C. Severson, RN, MN, CON(C), BMTCN, ACBTBCC, Calgary, Alberta, Canada.
BACKGROUND: Professional development is a requirement
for Registered Nurses by provincial regulatory bodies,
certification associations, healthcare leaders, educators and
colleagues. Connecting through an online special interest
group (SIG) allows RNs to network, share expertise, ignite
passion in the specialty and further improve on research,
education, leadership and clinical practice.
METHOD: An online Hematology/BMT SIG has been
developed on the CANO website to promote professional
development and spark interest in the specialty of
hematology and blood and marrow transplant (BMT) The
SIG was advertised in the CONJ. An online needs survey
was conducted. Narratives have been developed to allow
novice to expert nurses to increase their knowledge related
to hematology and BMT. Each narrative poses questions
to foster critical thinking and salience. Unique articles of
interest are posted to expand the available literature. An
events page is available to advertise dinner meetings or
conferences. A quarterly newsletter is created highlighting
events and issues in hematology and BMT. Plans for a blog
and webinars have been discussed.
RESULTS: Members of the Hematology/BMT SIG have
expressed interest in discussing research, education,
leadership and clinical practice setting issues. An online
survey monkey indicates 80% of the respondents wish
to increase their awareness of upcoming events in the
specialty. Subjective data indicate novice and expert nurses
are faced with challenges in professional development.
Themes identified include lack of: knowledge, time, support
for furthering their education, and difficulty with role
delineation. Baseline membership has increased 10 times
in addition to another 50 potential members expressing
interest. Conclusion: The developing online Hematology/BMT
SIG is an opportunity for RN’s to network, ignite passion,
share knowledge and express concerns related to leadership,
research, education and clinical practice.
114
P-21
The Role of Biosimilar GC SF (Zarzio)
for Progenitor Cell Mobilization and
the Treatment of Therapy Induced
Neutropenia in a Hematopoietic Stem
Cell Transplant Setting
Cherie C. Severson, RN, MN, CON(C), BMTCN,
ACB-TBCC, Calgary, Alberta, Canada.
BACKGROUND: Neupogen is used to mobilize PBSCs and treat
therapy induced neutropenia in HCT settings. A more cost
effective biosimilar GCSF(Zarzio) is in use in Europe since
2009 and is now approved in the USA for all 5 indications
as Neupogen. Thesis: Zarzio is reported as safe, equally
efficacious and more cost effective. Summary: Schmitt et al
reviewed 23 published studies on the use of biosimilar GCSF
for mobilization in auto and allo HCT(17; 6 respectively). 904
pts (hematologic malignancies and healthy donors) underwent
mobilizaton using a biosimilar GCSF. The median CD34+ count
is 3-10.2x106/kg(range 1-23x106/kg). Median # of apheresis
collection is 1 with few 2nd & 3rd collections. Median time to
ANC(>0.5G/L) and PLT engraftment(>20G/L) is 11-15(range
7-23) and 12-14 days(d)(range 6-33) respectively. In allo
HCT ANC engraftment is similar but median PLT recovery is
25d(range 0-33). The SE profile is comparable(H/A, bone and
muscle pain, flu like symptoms and mild fever). Schmitt et al
report biosimilar GCSF is safe and effective as Neupogen. The
authors state EBMTA does not recommend biosimilar GCSF
use in healthy donors. Bassi et al performed a retrospective
study with 56 auto HCT pts to assess the safety and efficacy
of biosimilar GCSF starting on day 5 post HCT with BEAM.
Median # of days biosimilar GCSF was administered is 7(range
4-9). Median CD34+ cells infused is 2.2-7.76X 106/kg. Median
time to ANC and PLT recovery is10(range 8-11)and 12d(range
8-23) respectively. Again the SE profile is comparable with
some febrile neutropenia. The cost of Zarzio is $13.50US/vial
compared to $96.65US/vial for Neupogen. Aapro et al report
across European G5 countries the cost(converted from €)
incurred for one pt during one cycle of tx 1-14d is: Neupogen
300ug $169.52/d CDN to $2373.40/14d CDN vs. Zarzio 300ug
$126.27/d CDN to $1767.80/14d CDN. Conclusion:The use of
Zarzio in auto HCT is safe, comparable, equally efficacious
and more cost effective than Neupogen.
3:00 PM - 3:30 PM | Foyer
Group 4 / Groupe 4
P-22
Passion Leads to Innovation, People
Sustain Change: Rapid Access Diagnostic
and Support for Women Undergoing
Assessment for Breast Cancer
Jennifer M. Smylie, BN, RN, MHSM, Antonella
Iaderosa, BScN, CON(C), The Ottawa Hospital, Ottawa,
Ontario, Canada.
The diagnostic phase of care is an extremely anxietyprovoking and stressful experience for the potential breast
cancer patient. Early detection and treatment are the
best options for improving outcomes in breast cancer. In
2011, a multidisciplinary team of breast cancer specialists
embarked on a new initiative to improve care by setting up
a Rapid Access Diagnostic and Support (RADS) program to
coordinate the diagnostic imaging work up, needle biopsy and
pathological diagnosis for women with suspicious diagnostic
mammogram findings. Our quality initiative was implemented
and coordinated by nursing in a high volume breast centre.
This service delivery model was awarded the Ontario Ministry
of Health’s Novel Advances in Cancer Care Delivery for its
success in demonstrating reduced wait times and enhancing
each patient’s overall breast care experience.
While the pilot was very successful in achieving target goals,
sustaining change in a busy centre is always an ongoing
challenge. This presentation will focus on the implementation
of the RADS clinic from a nursing perspective, highlighting the
results of the initial pilot including improved diagnostic wait
times and overall patient experience. In addition, current wait
time data and overall patient experience will be reviewed to
determine if initial improvements have been sustained several
years later. The RADS initiative can serve as an innovative
service delivery model for other breast centres.
P-23
Implementation of Guideline-Informed
Telephone Support Protocols for
Managing Cancer Treatment-Related
Symptoms: The COSTaRS Mixed
Methods Study
Dawn Stacey, RN, PhD, CON(C)1,2, Meg E. Carley,
BSc2, Myriam Skrutkowski, RN, MSc, CON(C)3, Barbara
Ballantyne, RN, MScN, CON(C), CHPCN(C)4, Brenda Sabo,
RN, MA, PhD5, 1University of Ottawa, Ottawa, Ontario,
Canada, 2Ottawa Hospital Research Institute, Ottawa,
Ontario, Canada, 3McGill University Health Centre
Research Institute, Montreal, Quebec, Canada, 4Health
Sciences North, Sudbury, Ontario, Canada, 5Dalhousie
University, Halifax, Nova Scotia, Canada.
BACKGOUND: The pan-Canadian Oncology Symptom Triage and
Remote Support (COSTaRS) team used the CAN-IMPLEMENT(c)
methodology to develop 13 protocols on cancer treatment-related
symptoms. Protocols were informed by clinical practice guidelines
and formatted to narrow the know-do gap. The study aim was to
build an effective and sustainable approach for implementing
COSTaRS protocols for nurses providing telephone symptom
support to cancer patients.
METHODS: Comparative case study with mixed-methods
guided by the Knowledge to Action Framework in 3 ambulatory
oncology programs. Researcher-knowledge user teams: (a)
assessed factors influencing nurses’ use of protocols; (b)
adapted protocols for local use; (c) intervened to address
barriers; (d) evaluated protocol use; and (e) monitored
changes in barriers. Analysis was within and across settings.
RESULTS: At baseline, 50%, 39%, 3% nurses used protocols at
sites 2, 3, and 1. Over 85% rated protocols positively but 20%
indicated too complex across all 3 sites. To overcome barriers,
nurses were trained and received reinforcement sessions.
Protocol adaptations included adding logos, more space
to document, obtaining health records approval, creating
pocket guides, and/or distributing with telephone messages.
Twenty-two 30-60 minute workshops with 107 nurses reached
90%, 85%, 97% of eligible nurses. Compared to pre-, nurses
post-training improved their confidence in supporting patients
with symptom management (p<0.01) and using COSTaRS
protocols (p<0.01). 94% recommended the workshop.
Protocol use identified by chart audit was 11%, 32%, 47%
and self-reported as 79%, 67%, and 82%. Several barriers
continued to interfere with protocol use.
CONCLUSIONS: Implementation of evidence-based protocols
in nursing requires a systematic process. Interventions resulted
in varied use of the protocols. Nurses were satisfied and felt
more confident after attending training. Strategies are needed to
address remaining barriers and support protocol use.
115
Tuesday, October 6/
Mardi 6 octobre
P-24
Addressing Lymphoma and Multiple
Myeloma Patient Concerns by Telephone
Triage in an Outpatient Setting
Diane E. Taylor, RN, BA, CON(C), CCRP,
Ethlyn Ferdinand, RN, Shelley Hoeg, RN, Luisa Del
Rizzo, RN, CCRP, Sabrina Bennett, BScN, Princess
Telephone Triage was implemented in our Hematology
Ambulatory Care Clinic in March 2014.
The rationale was to provide prompt telephone advice by
Specialized Oncology Registered Nurses to address patient
concerns. Patients with Multiple Myeloma and Lymphoma are
required to manage complex therapy regimens as outpatients.
Protocols are varied and patients may be elderly, have comorbidities or social barriers such as language, mobility
limitations or inadequate support systems.
The triage line is intended to provide a real time connection
with a specialized Oncology RN for symptom management,
counselling and on-going education. In collating outcomes of
the triage line data, we will address issues to enhance quality
of care, assess patient information needs and how to best
utilize telephone triage. Secondly, we would like to consider
the future direction of telephone triage and other tools of
communication.
Our poster will demonstrate the types of calls and concerns
received since implementation. We will focus on primary
patient concerns. We will propose ideas on how to facilitate
improving information and educational tools for Myeloma and
Lymphoma patients in the ambulatory care setting.
P-25
Transitions to Breast Cancer
Survivorship: Generating Knowledge
and Support Via Reflective Writing
Roanne Thomas, PhD, Wendy Gifford, RN, PhD,
Chad Hammond, PhD, University of Ottawa, Ottawa,
Ontario, Canada.
BACKGROUND: The transition to breast cancer survivorship
can be difficult. Long-term physical challenges, such as arm
morbidity from lymphedema, pain, and loss of range of motion,
may be underdiagnosed and rehabilitation is limited. Emotional
distress may remain, particularly if not addressed during acute
care. Yet, few community-based interventions exist to support
the critical transition to survivorship.
116
METHODS: Our interdisciplinary team developed reflective
writing workshops to support women in breast cancer
survivorship transitions. The intervention was delivered, in
partnership with a professional writer, to 11 breast cancer
survivors in Ottawa in a compressed format (14 hours over
2 days). Qualitative data included audiorecordings of the
workshops, copies of participants’ journal entries, and
photographs of collages created during the workshops. Our team
also collected and analyzed data pertaining to workshop content,
tools, and delivery, using surveys and telephone interviews.
FINDINGS: Participants were 43-75 years of age and 6 months
to 9 years post breast cancer diagnosis. All indicated that the
intervention addressed various survivorship concerns. While
physical challenges represented a significant issue, most
indicated that the emotional dimensions of survivorship were
left unaddressed. Participants discussed feelings of isolation
and stated that they did not have opportunities to express
what they perceived as negative emotions. The women also
shared that they felt they needed permission to engage in
self-care related to survivorship. Conclusions: Despite cancer
survivorship discourse indicating otherwise, transitions
associated with breast cancer survivorship can be difficult
and complex. Thus, women may benefit from interventions
grounded in holistic nursing practices. Our findings also
advance the emerging evidence base that supports reflective
writing as an arts-based intervention for women throughout
the survivorship trajectory.
P-26
Outpatient Administration of DoseAdjusted R-EPOCH (DA-R-EPOCH) for
Aggressive Lymphomas
Theresa Whiteside, BN, Gisele Sarbacher, BN,
Marc Geirnaert, BSc, BSc.Pharm, CancerCare Manitoba,
Winnipeg, Manitoba, Canada.
DA-R-EPOCH is a regimen that was traditionally given
in hospital due to continuous infusion delivery of three
chemotherapy agents in this protocol. A recent publication
demonstrated that this regimen is effective for Burkitt’s
lymphoma on an outpatient basis. This regimen has been
used in the treatment of other aggressive lymphomas (i.e.
HIV-related, Gray Zone Lymphoma - double or triple HIT,
mediastinal gray zone lymphoma). We adopted the DA-REPOCH regimen for outpatient administration using a smart
infusion pump (CADD SOLIS VIP).
Prior to implementing, the purchase of CADD SOLIS VIP was
required. The authors met to develop checklists for nursing
and pharmacy to ensure all of the necessary training and
safety be performed with staff: (i.e. items on checklists,
selection of patients, patient and staff education, blood work
On day 1 of the DA-R-EPOCH cycle (given every 21 days), the
patient receives rituximab. Once rituximab infusion is complete,
the patient is connected to the CADD-SOLIS VIP pump and remains
in the treatment room for a minimum of 30 minutes to ensure
proper understanding of the infusion pump. The patient returns
to the treatment room every 24 hours on days 2, 3 and 4 to have
a new infusion bag connected. On day 5, the patient’s infusion
pump is disconnected and then receives cyclophosphamide
intravenously. Outpatient prescriptions including prednisone and
supportive care are explained to the patient prior to day 1 by clinic
staff(physician, nurse and pharmacist).
DA-R-EPOCH has safely been adopted for outpatient
administration at our centre.
P-27
Compassion Fatigue, Burnout, and
Compassion Satisfaction Among Oncology
Nurses within an International Setting
Stacey Wu, BSN, Savitri Singh-Carlson, PhD, California
State University - Long Beach, Long Beach, California, United
States.
PURPOSE: This study explored the oncology nurse’s experience
of CF, BO, and CS and was conducted with oncology nurses in the
United States (U.S.) and Canada in order to examine the various
levels of CF, BO, and CS within the international setting. The study
answered the following questions: 1) What demography, health,
and work-related characteristics contributes to the risk for CF
and BO among oncology nurses in United States when compared
to those in Canada? 2) What is the relationship between CF, BO,
and CS among oncology nurses in United States in comparison
to nurses in Canada given the differing health care systems and
organization of health care delivery?
METHODS: The Professional Quality of Life Scale, Version 5 was
used to measure the risk for compassion fatigue and burnout and
likelihood for compassion satisfaction among 486 conveniently
sampled members of the Oncology Nursing Society (ONS) and 63
members of the Canadian Association of Nurses (CANO) utilizing
web data collection tool Fluid Surveys. The modified Abendroth
Demographic Questionnaire gathered demographic, health, and
work-related factors. Chi-square tests of independence was used
to determining association between demography, health, and
work-related factors and risk for CF, BO, and CS.
RESULTS: The risk for CF and BO was comparable between U.S.
and Canadian participants despite different health care systems.
Demography, health and work related factors all had impact
on the risk for developing CF and BO among U.S. nurses while
health and work related factors impacted Canadian nurses.
Sacrificing personal and psychological needs for patients, history
of headaches, and stress of maintaining a financial budget in both
cohorts were linked to moderate to high risk for CF and BO.
Exhibitor Listing /
Liste des exposants
ABBOTT NUTRITION
Abbott Nutrition is a leader in nutritional products to help adults
maintain an active, healthy lifestyle. We pioneered the market for
adult nutritionals more than 30 years ago with the introduction of
Ensure, a leading source of complete, balanced nutrition. In addition
to these well-known consumer brands, we also offer enteral
nutrition products as well as nutritional products for patients with
special dietary needs due to food allergies or diseases that affect
the body’s metabolism such as cancer, respiratory conditions and
gastrointestinal impairment. We focus on combining the science
of nutrition with state-of-the-art technology and design to offer
nutritional products that are easy to use and meet the changing
nutritional needs of people at each stage of life.
ADVANCED INNOVATIONS INC. BIO OIL
Bio-Oil is the #1 physician and pharmacist recommended product
for scar therapy. It helps patients with surgery scars and radiation
burns. Bio-Oils unique blend of natural plant oils and vitamins is
non-greasy, rapidly absorbed, and suitable for all skin types. BioOil is effective against other skin concerns like uneven skin tone,
aging and dehydrated skin.
ALBERTA HEALTH SERVICES
At Alberta Health Services (AHS) we are committed to putting
our patients first; empowering and enabling Albertans to be at
the center of their health care team, improving their own health
and wellness. CancerControl Alberta is focused on reducing the
impact of cancer on all Albertans and provides expert care and
support for patients from their first symptom to survivorship.
Our goal is to be to be a leader in cancer prevention, diagnosis,
treatment, survivorship and palliative care, all on a foundation of
world-class research.
At AHS we offer interesting, meaningful, and challenging work
with plenty of opportunities to learn and grow. There are great
employment opportunities at facilities in both rural and urban
Alberta. With excellent wages, flexible hours, and our commitment
to work life balance you will have plenty of time to juggle your
other passions and enjoy the great lifestyle Alberta has to offer.
Visit www.albertahealthservices.ca/careers to find career
opportunities and join us in making a meaningful difference to the
lives of Albertans.
117
monitoring as well as nurse assessments throughtout the cycle,
determination of KVO rates, infusion rates and reservoir volumes).
Clinic nurses who work with the physicians treating lymphoma
as well as the chemotherapy treatment room nurses (those who
connect and disconnect the infusion pump from the patient)
were trained on all necessary steps required for the delivery of
outpatient DA-R-EPOCH.
AMGEN
Amgen is committed to unlocking the potential of biology
for patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen has
reached millions of patients around the world and is developing a
pipeline of medicines with breakaway potential.
Amgen s’engage à libérer le potentiel que recèle la biologie
pour les patients souffrant de maladies graves en découvrant,
en mettant au point, en fabriquant et en offrant des
traitements innovants destinés aux êtres humains. Pionnière
en biotechnologie depuis 1980, Amgen a joint des millions de
patients partout dans le monde et développe une pépinière de
médicaments au potentiel avant-gardiste.
ASTELLAS
Astellas Pharma Canada, Inc. is a Canadian affiliate of Tokyo based
Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated
to improving the health of people around the world through the
provision of innovative and reliable pharmaceutical products. The
organization is committed to becoming a global category leader
in focused areas by combining outstanding R&D and marketing
capabilities. In Canada, Astellas has an intense commercial focus
on five therapeutic areas – urology, immunology, infectious disease,
dermatology and oncology. Visit: www.astellas.ca
BAYER
At Bayer, we put science to work in the areas of health, nutrition
and high-tech materials. Across Canada and around the world, we
develop products that improve quality of life for people, animals
and communities. We bring these values to life every day in the
way we work. Bayer Science for a Better Life.
and interventional procedures; improving drug delivery; aiding
anesthesiology and respiratory care; advancing cellular research
and applications; enhancing the diagnosis of infectious diseases
and cancers; and supporting the management of diabetes. We are
more than 45,000 associates in 50 countries who strive to fulfill
our purpose of “Helping all people live healthy lives” by advancing
the quality, accessibility, safety and affordability of healthcare
around the world. In 2015, BD welcomed CareFusion and its
products into the BD family of solutions. For more information on
BD, please visit www.bd.com.
BOEHRINGER INGELHEIM
The Boehringer Ingelheim group is one of the world’s 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany,
Boehringer Ingelheim operates globally with 146 affiliates and
a total of more than 47,700 employees. The focus of the familyowned company, founded in 1885, is researching, developing,
manufacturing and marketing new medications of high therapeutic
value for human and veterinary medicine.
Our drug discovery focuses on four major research areas
with high unmet medical need: immunology and respiratory
diseases, cardiometabolic diseases, central nervous system
diseases, and oncology.
Social responsibility is an important element of the corporate
culture at Boehringer Ingelheim. This includes worldwide
involvement in social projects, such as the initiative “Making
more Health” and caring for the employees. Respect, equal
opportunities and reconciling career and family form the
foundation of the mutual cooperation. In everything it does, the
company focuses on environmental protection and sustainability.
The Canadian headquarters of Boehringer Ingelheim was
established in 1972 in Montreal, Quebec and is now located in
Burlington, Ontario. Boehringer Ingelheim employs more than 550
people across Canada.
For more information please visit www.boehringer-ingelheim.ca.
BEAUTY GIVES BACK
Beauty Gives Back is the charitable foundation of the Canadian
beauty industry; The Cancer Blues is the name we’ve given to
the emotional fallout from cancer and its treatment. While there
are steady advances being made in the way cancer is treated,
the Cancer Blues is an often-ignored consequence of the disease
that can affect a woman’s ability to fight and endure through this
difficult ordeal. Counting more than 95% of women as customers
in their lifetime, the beauty industry is highly attuned to how
women feel about themselves, making us well poised to lead the
charge against the Cancer Blues.
For more than 20 years, Beauty Gives Back has supported tens
of thousands of women through the Cancer Blues with programs
such as Look Good Feel Better and FacingCancer.ca. Visit
beautygivesback.ca for more information about our free support
programs and to learn more about the Cancer Blues.
BRISTOL-MYERS SQUIBB
Bristol-Myers Squibb Canada is an indirect wholly-owned
subsidiary of Bristol-Myers Squibb Company, a global
biopharmaceutical company whose mission is to discover, develop
and deliver innovative medicines that help patients prevail
over serious diseases. For more information, please visit www.
bmscanada.ca
Bristol-Myers Squibb Canada est une filiale indirecte détenue
en propriété exclusive de Bristol-Myers Squibb, une société
biopharmaceutique d’envergure mondiale dont la mission est de
découvrir, mettre au point et fournir des médicaments novateurs
ayant pour but d’aider les patients à combattre des maladies
graves. Pour plus d’information, visitez le www.bmscanada.ca
BIOSYENT PHARMA INC.
BECTON DICKINSON (BD) CANADA
BD is a leading medical technology company that partners with
customers and stakeholders to address many of the world’s most
pressing and evolving health needs. Our innovative solutions are
focused on improving medication management and patient safety;
supporting infection prevention practices; equipping surgical
118
Listed on the TSX Venture Exchange (TSXV:RX) BioSyent is a
profitable growth-oriented specialty pharmaceutical company
which searches the globe to in-license or acquire innovative
pharmaceutical products that have been successfully developed,
are proven safe and effective, and have track records of improving
the lives of patients and supporting the healthcare professionals
that treat them. www.biosyent.com.
En pleine croissance, BioSyent, inscrit à la bourse de
croissance TSX (TSXV:RX) est une entreprise pharmaceutique
spécialisée dans l’approvisionnement et la commercialisation
de produits novateurs destinés à améliorer la vie des patients
et à supporter les professionnels de santé dans leurs fonctions.
www.biosyent.com
CALMOSEPTINE
Calmoseptine Inc. was founded June 1988 and markets
Calmoseptine Ointment in all 50 states and Canada, Australia and
the Philippines. Calmoseptine Ointment is Calmoseptine Inc.’s sole
product, which has allowed the company to be more innovative,
flexible and diverse in marketing. Health care professionals
recommend Calmoseptine Ointment because of its unique
properties not offered by its competitors.
Calmoseptine Ointment is an effective, multi-purpose moisture
barrier that protects and helps heal skin irritations. People who
benefit from Calmoseptine Ointment are those needing protection
or those with impaired skin integrity related to urinary and fecal
incontinence, feeding tube site leakage, fecal or vaginal fistula
drainage, moisture/perspiration, diaper dermatitis, and minor
scrapes and burns. It also temporarily relieves discomfort and
itching. Visit: www.calmoseptineointment.com
CANADIAN VIRTUAL HOSPICE
Canadian Virtual Hospice is the most comprehensive bilingual
online knowledge management centre on advanced illness,
palliative and end of life care, loss and grief in Canada. Accessed
by more than 3,000 people daily, it serves information and support
needs of the public, health care providers, researchers and
educators. The team, including interdisciplinary clinical experts,
curates develops evidence-informed text-based and multi-media
content. Information to support clinical practice is aggregated
in a “For Professionals” portal. The Ask a Professional feature
gives every Canadian equal access to a clinical team of experts
and is heavily used by care teams across the country. Peer-topeer support is provided to the public through professionally
moderated discussion forums. Facebook, Twitter, YouTube,
Vimeo and Pinteret channels are leveraged to disseminate latest
research, clinical best practice knowledge tools, news and
inspiration. Virtual Hospice is a not-for-profit fully funded by
government. All services are provided free of charge.
CANADIAN ASSOCIATION OF NURSES IN
ONCOLOGY / ASSOCIATION CANADIENNE
DES INFIRMIÈRES EN ONCOLOGIE
The Canadian Association of Nurses in Oncology (CANO/ACIO)
is the national organization that supports Canadian nurses to
promote and develop excellence in oncology nursing pratice,
education, research and leadership. CANO/ACIO’s mission is to
advance oncology nursing excellence through practice, education,
research and leadership for the benefit of all Canadians.
Fondée en 1985, l’Association canadienne des infirmières en
oncologie (ACIO/CANO) est un organisme d’envergure nationale qui
vise à promouvoir l’excellence de la pratique infirmière en oncologie
au profit de l’ensemble des Canadiens par le biais de la pratique, de
la formation, de la recherche et du leadership.
La mission de l’ACIO consiste à developer l’excellence infirmière
dans le domaine de la lutte contre le cancer pour le bénéfice de
la population canadienne ; sa vision est de devenir un leader
international dans le domaine des soins infirmiers en cancérologie.
Nous constituons une association dirigée pas ses membres qui suit
les orientations de ces derniers lors de l’élaboration des activités et
des initiatives.
CANADIAN NURSES ASSOCIATION
The Canadian Nurses Association (CNA) is the national professional voice
of Canada’s registered nurses (RNs). We help drive the profession forward
by offering RNs education, guides, tools and a speciality certification
programs. Together, CNA and the 135,000 RNs we represent are working
to improve Canada’s health-care system by advocating for improved
access to community-based care, better prevention and management
of chronic illnesses and disease, and enhanced high-quality, safe
patient care. Our strength lies in the knowledge, skills and experience
of RNs — Canada’s largest group of health-care providers.
L’Association des infirmières et infirmiers du Canada (AIIC) est la voix
professionnelle nationale des infirmières et infirmiers autorisés du
Canada. Nous contribuons à la progression de la profession en offrant
au personnel infirmier autorisé de la formation, des guides, des outils
et un programme de certification dans des spécialités. L’AIIC et les
135 000 membres qu’elle représente travaillent en collaboration pour
améliorer le système de soins de santé du Canada en militant pour un
meilleur accès aux soins de santé communautaires, pour la prévention
et la prise en charge accrues des maladies chroniques, ainsi que pour
des soins sûrs, de grande qualité et renforcés aux patients. Notre force
repose sur les connaissances, les compétences et l’expérience des
infirmières et infirmiers autorisés, soit le groupe le plus important de
fournisseurs de soins de santé au Canada.
CELGENE
Celgene Inc. is part of a global, integrated, biopharmaceutical
company engaged in the discovery, development and
commercialization of innovative therapies designed to improve the
lives of patients dealing with hematological disorders, cancer and
immune-inflammatory related diseases.
COLD COMFORT CANADA LTD.
A revolution in the Prevention of Chemotherapy related Hair Loss
has started in Canada.
No longer do cancer patients receiving chemotherapy treatment
have to suffer the trauma of hair loss.
We are the exclusive importer and distributor of Paxman Scalp
Coolers in Canada. Paxman is the World Leader in Scalp Cooling
for the Prevention of Chemotherapy-related Hair loss. Paxman
Scalp Cooling Systems have been used by hundreds of thousands
of patients in the UK , where it is offered as the standard of care to
the majority of patients undergoing chemotherapy. Scalp cooling
is widely used in the UK and Europe and has been proven to be
safe and effective. Paxman Scalp Coolers are now available in
Canada for use by patients wanting to preserve their hair and selfesteem during chemotherapy.
*Systems are available for sale or lease to patients and institutions.
119
CSL BEHRING
Biotherapies for Life
At CSL Behring, we are passionate about improving the quality
of life for people with rare diseases such as primary immune
deficiencies, hemophilia, von Willebrand disease and genetic
emphysema, and to advancing critical care treatments and
wound healing worldwide. As a global leader in the plasma
protein biotherapeutics industry, we research, develop,
manufacture and market biotherapies used to treat serious
diseases. Users of our therapies rely on them for their quality
of life and, in many cases, for life itself. Our products truly are
biotherapies for life.
Chez CSL Behring, notre préoccupation constante est
d’améliorer la qualité de vie des personnes atteintes de
maladies rares, comme les déficits immunitaires primaires,
l’hémophilie, la maladie de von Willebrand et l’emphysème
héréditaire, et de faire progresser le traitement des soins
critiques et des plaies dans le monde entier. En tant que leader
mondial de l’industrie des biothérapies à base de protéines
plasmatiques, CSL Behring mène des activités de recherche
et de développement, de fabrication et de commercialisation
de produits biothérapeutiques utilisés dans le traitement
des maladies graves. Les patients qui utilisent nos produits
thérapeutiques comptent sur ces derniers pour améliorer leur
qualité de vie et, dans plusieurs cas, pour sauvegarder leur vie.
Nos produits sont vraiment des biothérapies pour la vie.
DE SOUZA INSTITUTE
Established in 2008, de Souza Institute, in partnership with
University Health Network, Cancer Care Ontario and funded
by Ontario’s Ministry of Health and Long-Term Care, provides
ongoing educational support, professional development and
career counseling to nurses and other healthcare professionals
caring for patients along the hospice palliative and cancer care
continuum.
Lilly est un chef de file mondial dans le domaine des soins de
santé, alliant empathie et recherche dans le but d’offrir une vie
meilleure aux citoyens du monde entier. Notre entreprise a été
fondée il y a plus d’un siècle par le colonel Eli Lilly, qui était voué
à la mise au point de médicaments de grande qualité répondant
aux besoins de la population. Aujourd’hui, les employés de Lilly
s’efforcent de créer des médicaments révolutionnaires et d’en
faire profiter ceux qui en ont besoin. Ils cherchent également à
améliorer la compréhension et la prise en charge des maladies
et à contribuer au bien-être de nos communautés grâce à la
philanthropie et au bénévolat. www.lilly.ca
EISAI LIMITED
Eisai Limited was established in Canada on April 1, 2010. Our
corporate mission involves giving first thought to patients and
their families and to increasing the benefits health care provides,
a concept called human health care (hhc). Eisai strives to find
and develop new compounds that help to improve the lives of
people. Approved products in Canada: Aloxi® (palonosetron HCl),
which prevents chemotherapy-induced nausea and vomiting,
Halaven® (eribulin mesylate), a chemotherapy used for metastatic
breast cancer, Fycompa®, adjunctive therapy for the management
of partial onset seizures, and Banzel®, adjunctive treatment of
seizures associated with Lennox-Gastaut syndrome.
GILEAD
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas
of unmet medical need. The company’s mission is to advance
the care of patients suffering from life-threatening diseases.
Gilead has operations in more than 30 countries worldwide, with
headquarters in Foster City, California. Gilead Sciences Canada,
Inc. is the Canadian affiliate of Gilead Sciences, Inc. and was
established in Mississauga, Ontario in 2005.
Visit www.desouzainstitute.com for more information on
courses, registration, and learning pathways.
Gilead Sciences est une compagnie biopharmaceutique vouée
à la découverte, au développement et à la commercialisation
de médicaments novateurs dans des domaines où les besoins
médicaux ne sont pas satisfaits. Sa mission est d’améliorer les
soins aux patients souffrant de maladies menaçant le pronostic
vital. La société Gilead, dont le siège est installé à Foster City, en
Californie, est présente dans plus de 30 pays. Gilead Sciences
Canada, Inc. est la société affiliée canadienne de Gilead Sciences,
Inc., établie à Mississauga en Ontario depuis 2005.
ELI LILLY CANADA
INNOVATIVE ONCOSOLUTIONS INC.
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world.
We were founded more than a century ago by Colonel Eli
Lilly, who was committed to creating high quality medicines
that meet people’s needs, and today Lilly employees work
to discover and bring life-changing medicines to those who
need them, improve the understanding and management
of disease, and contribute to our communities through
philanthropy and volunteerism. www.lilly.ca
Innovative OncoSolutions Inc. is proud to be the exclusive distributor of
Equashield II®, a second generation closed system drug transfer device
(CSTD), in Canada. Our mission is to provide cost effective technologies
and solutions for use in cancer care providing institutions and/or sterile
compounding facilities. We strive to improve accessibility of cancer
drugs to patients in need. Our solutions enhance the safety and health
of patients and healthcare providers.
de Souza Institute offers courses with the best practices and
latest information, using webcasts, in-person workshops and
innovative online learning to support excellence in cancer care.
The Institute was named in honour of Anna Maria de Souza, a
distinguished Toronto philanthropist and volunteer who lost her
life to cancer in 2007.
120
IPSEN BIOPHARMACEUTICALS CANADA INC.
LUNDBECK CANADA
Ipsen Biopharmaceuticals Canada Inc. is the Canadian affiliate of
Ipsen, a global specialty driven pharmaceutical company created
in 1920 in Dreux, France.
Montreal-based Lundbeck Canada, proud sponsor of CANO/ACIO
2015, is a subsidiary of H. Lundbeck A/S, a leading international
research-based pharmaceutical company. For more than a decade,
Lundbeck has been a respected leader in developing and bringing
central nervous system disorder treatments to Canadians in a way
that reflects our Danish origins of respecting every individual and
taking care of one another. It is with this mindset that Lundbeck
is bringing new oncology treatments to Canada, wishing to give
hope, strength and humanity to Canadian cancer patients. Visit us
at lundbeck.ca
Improving the lives of patients is what drives us. The search for
innovative solutions to disabling conditions is at the heart of
everything we do. Increased life expectancy is making the pursuit
of our inspiring vocation more vital than ever: finding effective
therapeutic solutions to cure disease, relieve suffering and bring
value to the community. www.ipsen.com
JANSSEN INC.
LYMPHOMA CANADA
Our purpose: Make a difference.
As a member of the Janssen Pharmaceutical Companies of Johnson
& Johnson, Janssen Inc. is dedicated to addressing and solving the
most important unmet medical needs of our time. Driven by our
commitment to the passionate pursuit of science for the benefit of
patients, we work together to bring innovative ideas, products and
services to patients across Canada and around the world.
Nous mettons la science au service des patients.
À titre de membre du groupe des enterprises pharmaceutiques
Janssen de Johnson & Johnson, Janssen Inc. s’emploie à répondre
aux besoins non satisfaits les plus importants de notre temps.
Poussés par notre passion de mettre la science au service des
patients, nous collaborons à de nouvelles solutions, produits et
services pour le bien des patients dans le monde entier.
KIDNEY CANCER CANADA
We are the only national Canadian health charity dedicated to
improving the lives of those affected by kidney cancer. Kidney
Cancer Canada was formed in 2006 by patients, for patients.
We work closely with leading Canadian and international
experts, health providers, doctors and patients to:
• Provide information and support,
• Advocate for access to quality care and necessary
treatments, and
• Promote and support vital research that will help prevent
and treat kidney cancer.
Go to KidneyCancerCanada.ca to learn more about how we can
help and how you can support our work.
Lymphoma Canada is Canada’s only national organization focused
entirely on lymphoma. Guided by our scientific and nursing
advisory boards, our mission is to empower patients and the
lymphoma community through education, support, and research.
Together we are promoting early detection, finding better
treatments, helping patients access those treatments, learning
lymphoma’s causes, and finding a cure. Lymphoma Canada
provides, at no cost and in both official languages: electronic and
print materials on Hodgkin lymphoma, non-Hodgkin lymphoma
and chronic lymphocytic leukemia; peer and caregiver support
groups; educational forums; and advocacy on behalf of patients.
For more information about this registered charity, please visit
lymphoma.ca or call 1-866-659-5556.
MERCK
Today’s Merck is a global healthcare leader working to help
the world be well. Through our medicines, vaccines, biologic
therapies, and consumer and animal products, we work with
customers and operate in more than 140 countries to deliver
innovative health solutions. For more information about our
operations in Canada, visit www.merck.ca
La société Merck d’aujourd’hui est un chef de file mondial
dans le domaine des soins de santé qui vise à aider le monde
à vivre mieux. Grâce à nos médicaments, vaccins, traitements
biologiques, produits de santé grand public et de santé
animale, nous collaborons avec nos clients et oeuvrons à
procurer des solutions de santé novatrices dans plus de 140
pays. Pour de plus amples renseignements à propos de nos
activités au Canada, visitez le site www.merck.ca
Cancer du rein Canada a été fondée en 2006 par des patients
pour les patients. Nous sommes le seul organisme sans but
lucratif dont la mission est d’améliorer la vie des gens touchés
par le cancer du rein. Nous travaillons étroitement avec
des chercheurs et des experts canadiens et internationaux,
des professionnels de la santé, des médecins ainsi que des
patients et notre mission consiste à :
• offrir du soutien et de l’information ;
• militer en faveur de l’accès à des traitements de qualité et
efficaces ;
• encourager l’essor de la recherche afin de prévenir et de
guérir le cancer du rein.
Pour en savoir plus sur l’aide que nous sommes en mesure
d’apporter aux patients et à leurs familles et sur les différentes
manières de nous aider en retour, visitez notre site Web à
CancerduRein.ca.
121
NOVARTIS ONCOLOGY
When science and passion connect, innovation happens.
The oncology community shares a common mission: to transform
the way patients live with cancer and related diseases. At
Novartis Oncology, we are passionate about the discovery and
development of innovative medicines. We seek to provide a
broad range of new therapies as well as practical solutions to
advance the care of patients.
With over 9,000 oncology employees worldwide operating in 85
countries, Novartis Oncology has a truly global reach. We have
the advantage of extraordinarily talented and globally diverse
employees who, through shared goals and different perspectives,
are dedicated to transforming the lives of patients living with
cancer around the world. We have developed eight new practicechanging medicines in the past decade, addressing unmet medical
needs in patients worldwide. Our broad pipeline includes over 25
new molecular entities in development, targeting key molecular
pathways in cancer biology.
ONCOLOGY NURSING SOCIETY
The Oncology Nursing Society (ONS) is a professional organization
of more than 35,000 registered nurses and other healthcare
providers dedicated to excellence in patient care, education,
research, and administration in oncology nursing. The overall
mission of ONS is to promote excellence in oncology nursing and
quality cancer care. ONS is also a full-service publisher, with book
titles in symptom management, chemotherapy administration,
and survivorship, and will provide a bookstore for CANO/ACIO
members in the exhibit hall.
PFIZER CANADA INC.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of
the world’s leading biopharmaceutical companies. Our diversified
health care portfolio includes some of the world’s best known and
most prescribed medicines and vaccines. Every day, Pfizer Canada
employees work to bring therapies to patients that significantly
improve their lives. The company is a major contributor to health
research in Canada. We apply science and our global resources
to improve the health and well-being of Canadians at every
stage of life. Our commitment is reflected in everything Pfizer
does, from our disease awareness initiatives to our community
partnerships, to our belief that it takes more than medications to
be truly healthy. To learn more about Pfizer’s More than Medication
philosophy and programs, visit www.morethanmedication.ca. To
learn more about Pfizer Canada, visit pfizer.ca or you can follow
us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/
Pfizer.Canada).
RETHINK BREAST CANCER
Rethink Breast Cancer’s mission is to empower young people
worldwide who are concerned about and affected by breast cancer.
Rethink supports the unique needs of young women with breast
cancer by empowering them with age-appropriate information,
resources and community. The numbers are small but the needs are
real. We advocate on their behalf and create compelling campaigns
that fill the gaps in care and result in positive changes. We offer
inspirational digital resources and accessible information that
speaks to young women and their loved ones.
122
Rethink also educates millennials about breast cancer and motivates
them to take charge of their breast health. We develop bold and
engaging awareness campaigns that help young people be proactive
about their health. And we do all of this with style and sass.
No pink ribbons required.
ROCHE
From our approach to clinical trials for new drug therapies, to industry
partnerships and community involvement, Roche Canada is a leader
in providing pharmaceutical and diagnostic solutions that make a
profound difference in people’s lives.
Our innovative approach improves the effectiveness and
efficiency of the healthcare system in the diagnosis, treatment
and management of acute and long-term disease. Roche Canada
employs approximately 1,000 people across the country, with its
pharmaceuticals head office located in Mississauga, Ontario and
diagnostics division based in Laval, Quebec. We serve a broad base
of healthcare facilities and practitioners across the country, working
in partnership with them to ensure that the diagnostics and therapies
we deliver meet the medical needs of today and of the future. For
more information, please visit www.rochecanada.com
TAKEDA
Better Health, Brighter Future
Our way to better health is by advancing science to develop new
medicines to meet the needs of Canadians.
Takeda has been developing health solutions for more than 230
years as Japan’s leading pharmaceutical company. To find out more
about Takeda Canada and our commitment to Canadians, visit www.
takedacanada.com.
THERAKOS
Therakos is an immunotherapy company focused on providing
innovative treatment platforms that harness the power of each
individual patient’s immune system to fight disease. We are the
global leader in autologous immunotherapy delivered through
extracorporeal photopheresis (ECP).
Our therapeutic platforms, including the latest generation THERAKOS®
CELLEX® Photopheresis System, are the world’s only approved, fullyintegrated systems for administering autologous immunotherapy
through ECP. Our systems are used by academic medical centers,
hospitals, and treatment centers in more than 30 countries and
have already delivered over one million treatments globally.
TRUDELL MEDICAL MARKETING LIMITED
Trudell Medical Marketing Limited (TMML) is a leading specialty sales
and marketing company, supporting the Canadian hospital market
with its national reach and clinically knowledgeable staff. TMML
is committed to selling, servicing and distributing technologically
advanced critical care and respiratory product solutions and state
of the art operating room equipment to hospitals across Canada.
Our reputation is based on innovation, service and the experience
to provide our customers with specialized healthcare solutions. We
are dedicated to provide our customers with specialized health care
solutions. We are dedicated to the continuous improvement of our
products and services and take comfort in knowing our products
make a difference to the delivery of superior patient care.
WILLOW BREAST & HEREDITARY CANCER
SUPPORT
Willow Breast & Hereditary Cancer Support, founded in 1994,
is a national not-for-profit organization that provides free
support, insight and information to anyone, including those
at high risk, affected by breast and hereditary cancer.
Willow is about helping everyone, from the individual
diagnosed to their family and caregivers, cope with breast
and hereditary cancer. We appreciate that every person’s
experience is unique, so our efforts are tailored to each
individual. Our Support Team, which includes a Health
Librarian, works with our clients to address their unique
concerns: from interest in breast health to diagnosis,
treatment and on to survivorship, as well as the specific
needs of those living with metastatic breast cancer.
How to access Willow’s services:
• call our national, toll-free helpline 1.888.778.3100, with an
interpretation service available in 150 languages
• email our Support Service Team at [email protected]
• visit our website willow.org to access information, an
online community or request a call
• visit us at our Toronto office or North York General
Hospital onsite program
• attend one of Willow’s nationwide community-based peer
support groups
Willow is also the national coordinator for Breast
Reconstruction Awareness Day (BRA Day, which takes place
on the third Wednesday of October in communities across
Canada. BRA Day aims to empower women to make informed
choices about breast reconstruction through information and
the opportunity to connect with medical professionals, and
each other. Visit www.bra-day.com for more information.
We all have
commitments
OURS ARE TO CANADIANS
FA C I N G S E R I O U S D I S E A S E S
At Bristol-Myers Squibb Canada, we are committed to
helping Canadians prevail over serious diseases such as
cancer, HIV/AIDS, heart disease, rheumatoid
arthritis, hepatitis and psychiatric disorders.
We’re a long-established and experienced company
in research and development that has been helping
Canadians for more than 85 years, working to meet
today’s health challenges with the agility, innovation
and spirit of a young biotech company, discovering
and developing vital new treatments.
That’s why we call ourselves
3M
3M is fundamentally a science-based company. We produce
thousands of imaginative products, and we’re a leader in
scores of markets – from health care and highway safety to
office products and abrasives and adhesives. Our success
begins with our ability to apply our technologies – often in
combination – to an endless array of real-world customer
needs. 3M Health Care is committed to providing the health
care community with innovative solutions, based on 3M
diversified technologies, that help improve the quality of
life. 3M is a leading global supplier in single use medical
products ranging from skin and wound care, to peri-operative,
sterilization, infection control and diagnostics.
THE NEXT-GENERATION BIOPHARMA LEADER.
We’re committed to delivering the new
medicines Canadians need, to research
and to the newest technology.
We’re meeting
our commitments
to Canadians.
Find out more about us
Visit www.bmscanada.ca
Sunday, October 4 - Wednesday,
October 7, 2015 CANO/ACIO Annual Conference2015-07-20
15-0326-Publicité_BMS_AN_v1.indd 1
123 9:12 AM
Toronto Map
Carte de Toronto
Koreatown
Bathurst
Bay
St George
Spadina
51
Bloor-Yorkville
The Annex
tie
The Fairmont Royal York Hotelv
100 Front St W, Toronto, ON M5J 1E3
CastleFrank
Sherbourne
Bloor Yonge
21
Mirvish
Village
Museum
PARLIAMENT
JARVIS
Church-Wellesley
Village
ST
GEORGE
SPADINA
32
Wellesley
University
of Toronto
Cabbagetown
COLLEGE ST W
Little Italy
Queen’s Park
Kensington
Market
College
CARLTON
Downtown
Yonge
Discovery District
Ryerson
University
DUNDAS ST 1
Chinatown
Queen West
15
4
QUEEN ST W
St
St.PPatrick
Dundas
DUNDAS ST E
Osgoode
Queen
QUEEN ST E
53
Financial
District
Entertainment District
Fashion
District
KING ST W
St
ew
St. Andrew
KING ST E
7
BAY
YORK ST
Union
30
Distillery
Historic
District
YONGE
SPADINA
FRONT ST
King
FAIRMONT HOTEL
GARDINER EXPRESSWAY
QUEEN
GARDINER EXPRESS WAY
124
Waterfront
Queen’s Quay
Y
’S QUA
54
CANCER TAKES.
BAYER GIVES.
Our hope is that through research,
we will be able to help those with cancer enjoy their lives to the fullest.
www.bayer.ca
® Bayer and Bayer Cross are registered trademarks of Bayer AG, used under licence by Bayer Inc.
Our passion
ignites progress
At Eisai, human health care (hhc) is our goal. We give our
first thought to patients and their families and to increase
the benefits that healthcare provides. Our passionate
commitment to patient care is the driving force behind
all of our efforts. This dedication is born from deep within
our soul – an innate desire to find innovative solutions
that help address unmet needs and contribute to the
well-being of patients worldwide.
Sunday,
October 4of
- Wednesday,
October
7, 2015 CANO/ACIO
Annual Conference
Proud bronze
sponsor
the 2015
CANO
conference
125
Inspire your patients to lead healthier lives.
Visit morethanmedication.ca
Inspire your patients to lead healthier lives.
Visit morethanmedication.ca
FRAGMIN ® Pfizer Health AB, owner/Pfizer Canada Inc., licensee
® Pfizer Inc., used under license
© 2015 Pfizer Canada Inc. Kirkland, Quebec H9J 2M5
FRAGMIN ® Pfizer Health AB, owner/Pfizer Canada Inc., licensee
® Pfizer Inc., used under license
© 2015 Pfizer Canada Inc. Kirkland, Quebec H9J 2M5
FR-CANO-ACIO-8.5x5.5-ad-150527-E.indd 1
2015-05-27 4:42 PM
®
DOCKET #
DATE
2015-07-23
Hizentra
®
The first 20% subcutaneous
immunoglobulin intended for
self-infusion
FINAL OUTPUT
Printed with Ve
PRINT TYPE
Offset
ART SIZE
100%
DIMENSIONS
Hizentra® is indicated for
patients with Primary and
Secondary Immunodeficiency*
126
CSL Behring Canada,Conférence
Inc.
annuelle de l’ACIO/CANO
2015 | Toronto,
Ontario
*For more information
and a complete
risk/benefit profile, please contact Customer
Ottawa, On K1P 6L5
www.cslbehring.ca
Hiz 2015-07-001-EN
Service at 1-866-773-7721 ext. 2386 or refer to the Product Monograph available
on our website at www.cslbehring.ca.
FINAL: 8.5” x 5
COORDINATOR
Julie Beaulieu
®
Start Strong with Nutrition
Stay Strong through Treatment
Early nutrition intervention can help:1-6
• prevent lean body mass
and weight loss
• increase patient
quality of life (QOL)
• minimize treatment disruptions
• improve survival rates
Recommend Ensure® Plus Calories as part of a nutrient-rich diet
2 bottles of Ensure® Plus Calories provide:
• 710 calories
• 28 g protein
• 26 vitamins and minerals, including iron, zinc, and vitamin B12
1 National Cancer Institute: Nutrition Therapy. http://www.cancer.gov/cancertopics/pdq/supportivecare/nutrition/HealthProfessional/
page4. Last modified: 02/26/2014. Accessed March 13, 2014. 2 National Cancer Institute: Tumor-induced Effects on Nutritional
Status. http://www.cancer.gov/cancertopics/pdq/supportivecare/nutrition/HealthProfessional/page2. Last modified: 02/26/2014.
Accessed March 13, 2014. 3 Ravasco P et al. Head and Neck 2005;27:659-68. 4 Odelli C et al. Clinical Oncology 2005;17:639·45.
5 Ravasco P et al. J Clin Oncol 2005;23:1431-8. 6 Bosaeus I et al. J. Nutr. 2002;132:3465S–6S.
© Abbott Laboratories, Limited
ENS/956A08-July 2015 - 00610
00610 - ANI2015-07-23 - Ensure Oncology CANO Print Ad Update v2.indd 1
# 00610 - ANI2015-07-23
DESIGNER
APPROVALS
Client
FILE NAME
STEPHANE B. Ensure Oncology CANO Print Ad Update
Coordinator
T
VENDOR NAME
CMS
endor
N/A
N/A
R
Graphic Designer Colour Break
# OF COLOURS
COLOURS
4
4-Colour Process (CMYK)
INVENTORY CODE
MATERIAL COLOUR
N/A
White
5.5”
2015-07-23 4:20 PM
ADDITIONAL INFORMATION
N/A
CLIENT
Antoinette Dacoulis
Protecting
Anna the nurse…and
Anna the art curator.
COLOUR BREAK BOX
Date
TYPE OF COMMODITY:
N/A
Date
Date
DELTA VALUE (
PROCESS
L
A
B
PMS
L
Cyan
55
-37
-50
N/A
N/A
N/
Magenta
48
74
-3
N/A
N/A
N/
89
-5
93
N/A
N/
16
0
0
N/A
N/
Nurses
are equal parts expertise, dedication
PROOF VERSION
Yellow
N/A
and compassion—traits
that serve your
Black
N/A
patients, and everyone
in your life, well.
We ask just one thing: Please take care
of your health, too. Studies connect
Vendor must not change file
prior approval
from
hazardous drug without
exposure
to serious
Abbott Graphic Designer
health risks for nurses. We’re helping to
change that, by protecting thousands
of nurses every day from the hazardous
drugs they handle. We can’t do what you
do, but we can help you do it safely.
2
NOTE: LAB colour values will ONLY be used by Vendors
to match Abbott colours on press sheet.
N/A: Not Applicable
127
A
TOUTES NOS FÉLICITATIONS À L’ACIO/CANO
À L’OCCASION DE SON 30E ANNIVERSAIRE
e
anniversaire
128
Novartis Pharmaceuticals Canada Inc. is one of the country’s leading healthcare
companies committed to improving the health of Canadians.
We strive to discover and develop medicines that make a real difference.
There can be no delay.
Patients are waiting.
129
www.novartis.ca
GIOTRIF (afatinib) is indicated as monotherapy for the treatment
of Epidermal
GrowthisFactor
Receptor
(EGFR) tyrosine
GIOTRIF (afatinib)
indicated
as monotherapy
for the kinase
treatment
of Epidermal
Growth Factor
Receptor (EGFR)
tyrosine
kinase
inhibitor
naïve patients
with metastatic
(including
cytologically
GIOTRIF (afatinib) is indicated as monotherapy for the treatment
inhibitor
naïve
patientsadenocarcinoma
with metastatic (including
cytologically
proven
pleural
effusion)
of the lung
with
of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase
1
proven pleural
effusion) adenocarcinoma
of the lung with
activating
EGFR mutation(s).
inhibitor naïve patients with metastatic
(including cytologically
1
activating EGFR mutation(s).
proven pleural effusion) adenocarcinoma of the lung with
Available for oral administration as
1
activating EGFR
mutation(s).
for mg
oral
administration
as
20,Available
30, and 40
film-coated
tablets.
20, 30, and 40 mg film-coated tablets.
Available for oral administration as
For any medical inquiries, contact
20,For
30,any
and
40 mginquiries,
film-coated
tablets.
medical
contact
Boehringer Ingelheim (Canada) Ltd.
Boehringer Ingelheim (Canada) Ltd.
Medical
at
For
any Information
medical
inquiries,
Medical
Information
at contact
1-800-263-5103
x 84633.
Boehringer
Ingelheim
(Canada) Ltd.
1-800-263-5103
x 84633.
Medical Information at
To To
enrol
your
patient
into
enrol
your
patient
intothe
the
1-800-263-5103
x 84633.
HeadStart™
Patient
Assistance
HeadStart™ Patient AssistanceProgram,
Program,
please
callyour
1-800-987-9080
Toplease
enrol
patient into thefor
call
1-800-987-9080
for
more
information.
more
information.
HeadStart™
Patient Assistance Program,
please call 1-800-987-9080 for
more information.
Consult
Product
Monographatatwww.giotrif.ca/pm_english
www.giotrif.ca/pm_english for
precautions,
Consult
thethe
Product
Monograph
for contraindications,
contraindications,warnings,
warnings,
precautions,
adverse
reactions,
interactions,
dosing,and
andconditions
conditionsof
of clinical
clinical use.
is is
also
available
adverse
reactions,
interactions,
dosing,
use. The
TheProduct
ProductMonograph
Monograph
also
available
by calling 1-800-263-5103 x 84633.
by
callingthe
1-800-263-5103
x 84633.at www.giotrif.ca/pm_english for contraindications, warnings, precautions,
Consult
Product Monograph
adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available
1. GIOTRIF Product Monograph,
by Reference:
calling
1-800-263-5103
x 84633.
Reference:
1. GIOTRIF
Monograph,
Boehringer
IngelheimProduct
(Canada)
Ltd., July 31, 2014.
®
®
Boehringer Ingelheim (Canada) Ltd., July 31, 2014.
© 2015 Boehringer Ingelheim (Canada) Ltd.
CANO/ACIO
Annual
2015 | Toronto, Ontario
Ontario
5H4 Conference
130Burlington,
©Reference:
2015
Boehringer
Ingelheim
Ltd.
® L7L (Canada)
1.
GIOTRIF
Product
Monograph,
Conférence
annuelle
de l’ACIO/CANO 2015 | Toronto, Ontario
Burlington,Ingelheim
Ontario L7L
5H4
Boehringer
(Canada)
Ltd., July 31, 2014.
At Gilead Canada,
business as usual isn’t.
That’s because
That’s because we approach the world a bit differently.
Wewe approach the world a
bit differently. We don’t start from the status
don’t start from the status quo. We prefer a more collaborative
quo. We prefer a more collaborative style –
style – with physicians, with patients and with all of with
those
who with patients and with all of
physicians,
those who have an interest in our work. We
have an interest in our work. We welcome new perspectives,
welcome new perspectives, fresh ideas and
fresh ideas and novel challenges. We offer groundbreaking
novel challenges. We offer groundbreaking
therapeutics, and we realize that they are only
part of
therapeutics,
and we realize that they are
onlybring
part of the
the solution. The medications we develop and
to solution. The medications
we develop and bring to market improve
market improve patients’ health, but the way wepatients’
behave
– but the way we behave –
health,
thoughtfully, respectfully
and proactively
thoughtfully, respectfully and proactively
–
– is what really redefines expectations.
is what really redefines expectations.
Contact us at [email protected]
Contact us at [email protected]
131
We share your commitment to improving the lives of
cancer patients and are proud to be a sponsor of the
2015 CANO Annual Conference.
Nous partageons avec vous notre engagement pour
améliorer la vie des patients atteints du cancer et
sommes un fier partenaire de l’ACIO 2015.
Pr
Pr
lenalidomide capsules
pomalidomide capsules
Pr
thalidomide capsules
®
132
2015 Celgenede
Inc.l’ACIO/CANO
REVLIMID, POMALYST,
THALOMID,
VIDAZA, ISTODAX
and ABRAXANE are registered trademarks of Celgene Corporation.
Conférence©annuelle
2015
| Toronto,
Ontario
© 2015 Celgene Inc. REVLIMID, POMALYST, THALOMID, VIDAZA, ISTODAX et ABRAXANE sont des marques déposées de Celgene Corporation.
Notes
133
Tens of thousands of
PATIENTS ENROLLED
More than 10
YEARS OF PATIENT SUPPORT
Only 1
NUMBER TO CALL…FOR THE
VICTORY® PROGRAM
1-888-706-4717
VICTORY Program
®
Patient Assistance Program
134
VictoryAssist.ca
Password: Victory
135

Final Program Programme Final - CANO-ACIO

Transcription

Documents pareils

Print this article - Canadian Oncology Nursing Journal

Billing for Prenatal Screening

Upper Gap Archaeological Site

18-ciho-13/05/08-rocker au coeur tendre 21 morceaux, 1,7 heures

Here - National Magazine Awards

Gazette Summer 2009 - Law Society Gazette

invitation

Winter - FarmNorth

Canadian Conference for Fisheries Research Conférence

15 - Chapleau Express

Adopting a Business Model View to Study Industry Change: The

A nosocomial outbreak of 2009 pandemic influenza A (H1N1) in a